<S:Envelope xmlns:S="http://schemas.xmlsoap.org/soap/envelope/">
    <S:Body>
        <ns2:searchStudyResponse xmlns:ns2="http://services.ctep.nci.nih.gov/">
            <Documents>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:45">
                    <nciDocumentNumber>E6293</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E6293</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of tomudex in advanced colorectal cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:46">
                    <nciDocumentNumber>POG-8625/26</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-8625/26</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Combined therapy and restaging on the treatment of stages I, IIA, and IIA, Hodgkin's disease in Pediatric patients: A Pediatric Oncology Group Phase III study</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:46">
                    <nciDocumentNumber>GOG-LAP2</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-LAP2</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III randomized clinical trial of Laparoscopic Pelvic &amp; Para -aortic Node Sampling with Vaginal Hysterectomy &amp; BSO vs. Open Laparotomy with Pelvic &amp; Para-aortic Node Sampling &amp; Abdominal Hysterectomy &amp; BSO in Endometrial Adenocarcinoma and Uterine Sarcoma, Clinical Stage I, IIA, Grade I, II, III</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:46">
                    <nciDocumentNumber>P9650</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9650</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Vinblastine and Methotrexate in children with Desmoid Tumor (aggressive fibromatosis) which is recurrent or not amenable to surgical resection or irradiation- A Pediatric Oncology Group Phase II study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:46">
                    <nciDocumentNumber>S9709</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S9709</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study to Evaluate Transoral CO2 Laser Supraglottic Laryngectomy and Irradiation in Stage I, II and III Squamous Cell Carcinoma of the Supraglottic Larynx</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:46">
                    <nciDocumentNumber>P9423</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9423</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Cooperative Agreement Pediatric Trial of Mitoxantrone, Etoposide and PSC-833 (PSC-ME) Therapy in Patients with Relapsed and Refractory Acute Leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:46">
                    <nciDocumentNumber>POG-9620</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9620</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Autologous Bone Marrow transplantation for patients with recurrent AML using Busulfan and Melphalan as preparative therapy: A Pediatric Oncology Group Phase II study</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:46">
                    <nciDocumentNumber>POG-7631</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-7631</localDocumentNumber>
                        <localDocumentNumber>SWOG-7631</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>The evaluation of combined chemotherapy for metastatic Neuroblastoma (stageIV) (Phase I , II protocol)</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:46">
                    <nciDocumentNumber>JHD06</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>JHD06</localDocumentNumber>
                        <localDocumentNumber>JHD06</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III study of radiotherapy or abvd plus radiotherapy versus abvd alone in the treatment of early stage hodgkin's disease</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:50:46">
                    <nciDocumentNumber>T96-0034</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DM 96-101</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of intravenous ci-958 (nsc 635371) in patients with metastatic adenocarcinoma of the colon or rectum</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:46">
                    <nciDocumentNumber>POG-7607B</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-7607B</localDocumentNumber>
                        <localDocumentNumber>SWOG-7607B</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Evaluation of Lithium Carbonate in the amelioration of Hematopoietic toxicity following cancer chemotherapy in children with solid Tumors being treated with Ad-Con-Fu, Phase II</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:47">
                    <nciDocumentNumber>POG-9201</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9201</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>ALINC #16: treatment for patients with lesser risk AcuteLymphoblastic Leukemia - Phase III</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:47">
                    <nciDocumentNumber>CCG-0933</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCG-0933</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of continuous infusion Mercaptopurine followed by continuous infusion cytosine Arabinoside in children with refractory all, AML, and Non-Hodgkins Lymphoma with Marrow involvement</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:48">
                    <nciDocumentNumber>CCG-3951</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCG-3951</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Pilot Study of Multiple Cycles of High Dose Chemotherapy with Peripheral Blood Stem Cell Infusions in Advanced Stage Neuroblastoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:48">
                    <nciDocumentNumber>POG-9436</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9436</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of Cyclophosphamide, Vincristine, and Carboplatin for children with progressive Astrocytoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:48">
                    <nciDocumentNumber>CCG-2961</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCG-2961</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Study in Children with Untreated Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:49">
                    <nciDocumentNumber>EST-7887</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-7887</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Phase III Evaluation of Pelvic Lymphadenectomy Plus Hormonal Therapy Versus Pelvic Lymphadenectomy and Expectant Management in Patients with Pelvic Nodal Metastases (Stage D1) Adenocarcinoma of the Prostate</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>JBR10</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>JBR10</localDocumentNumber>
                        <localDocumentNumber>JBR10</localDocumentNumber>
                        <localDocumentNumber>JBR10</localDocumentNumber>
                        <localDocumentNumber>JBR10</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III prospective randomized study of adjuvant chemotherapy with vinorelbine and cisplatin in completely resected non-small cell lung cancer with companion tumour marker evaluation</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>INT-0137</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-9313</localDocumentNumber>
                        <localDocumentNumber>CALGB-9394</localDocumentNumber>
                        <localDocumentNumber>S9313</localDocumentNumber>
                        <localDocumentNumber>NCCTG-93-30-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Comparison of Adjuvant Chemotherapy with High-Dose Cyclophosphamide Plus Doxorubicin (AC) Versus Sequential Doxorubicin Followed by Cyclophosphamide (A->C) in High-Risk Breast Cancer Patients with 0-3 Positive Nodes</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>SWOG-9328</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-9328</localDocumentNumber>
                        <localDocumentNumber>S9328</localDocumentNumber>
                        <localDocumentNumber>P9328</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Autologous Stem Cell Transplantation for Patients with Acute Myeloid Leukemia Beyond First Remission: A Randomized Trial of Post-Transplant Therapy with Interleukin-2 Versus Observation: A Phase III Study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>E1695</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E1695</localDocumentNumber>
                        <localDocumentNumber>E1695</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>An evaluation of the immunologic mechanism of GM2-KLH/QS-21 vaccination in the context of ECOG trial E1694: a Phase III comparison of GM2-KLH/QS-21 vaccination and high-dose interferon Alfa-2B therapy for high-risk lymph node-metastatic..</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>NCCTG-89-32-53</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-89-32-53</localDocumentNumber>
                        <localDocumentNumber>ET-9110</localDocumentNumber>
                        <localDocumentNumber>89-32-53</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III evaluation of Somatostatin Analogue and Tamoxifen both alone and in combination in women with metastatic breast cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>INT-0058</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-8693</localDocumentNumber>
                        <localDocumentNumber>CALGB-8792</localDocumentNumber>
                        <localDocumentNumber>EST-4786</localDocumentNumber>
                        <localDocumentNumber>ISS-3</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Adjuvant therapy of primary osteosarcoma: a Phase III randomized intergroup study</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 00:00:00">
                    <nciDocumentNumber>INT-0125</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ID 91-025</localDocumentNumber>
                        <localDocumentNumber>CALGB-9293</localDocumentNumber>
                        <localDocumentNumber>EST-91025</localDocumentNumber>
                        <localDocumentNumber>NCCTG-91-24-52</localDocumentNumber>
                        <localDocumentNumber>RTOG-91-01</localDocumentNumber>
                        <localDocumentNumber>SWOG-9221</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase iii double-blind randomized trial of 13-cis retinoic acid (13-cra) to prevent second primary tumors (spts) in stage i non-small cell lung cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:52">
                    <nciDocumentNumber>GOG-81B</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-81B</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III trial of high vs intermediate dose Medroxyprogesterone Acetate (MPA) in patients with Advanced or Recurrent Endometrial Carcinoma positive for Estrogen and Progesterone Receptors</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:53">
                    <nciDocumentNumber>POG-9323</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9323</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Interferon-Alpha 2B Plus Hydroxyurea and Ara-C for Chronic Phase ACML in Children</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:55">
                    <nciDocumentNumber>NCCTG-89-42-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-89-42-51</localDocumentNumber>
                        <localDocumentNumber>89-42-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of sequential systemic 5-FU + Leucovorin and Intrahepatic FUDR for treatment of metastatic colorectal cancer confined to the liver</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:56">
                    <nciDocumentNumber>E1493</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E1493</localDocumentNumber>
                        <localDocumentNumber>ACTG 252</localDocumentNumber>
                        <localDocumentNumber>CALGB-9450</localDocumentNumber>
                        <localDocumentNumber>RTOG-94-16</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II of sequential Chemotherapy and Radiotherapy for AIDS-related primary Central Nervous System lymphoma; laboratory correlate: Epstein-Barr virus in Cerebrospinal fluid</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:57">
                    <nciDocumentNumber>SWOG-8903</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-8903</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Trial of Promace-Cytabom with GM-CSF for Treatment of Refractory Non-Hodgkin's Lymphoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:59">
                    <nciDocumentNumber>GOG-0076W</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-76W</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Limited Access Phase II Trial of CPT-11 (Irinotecan) (NSC #616348) in Patients with Advanced, Persistent or Recurrent Squamous Cell Carcinoma of the Cervix</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:00">
                    <nciDocumentNumber>T97-0103</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DM 97-182</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Irinotecan for the Treatment of Relapsed or Refractory Non-Hodgkin'sLlymphoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:00">
                    <nciDocumentNumber>T93-0191</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DM 93-151</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Simultaneous Homoharringtonine (NSC # 141633) and Alpha Interferon (IFN-a) Therapy in Chronic Myelogenous Leukemia (CML)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:01">
                    <nciDocumentNumber>POG-9779</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9779</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial of Tomudex in Children with Leukemia</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:01">
                    <nciDocumentNumber>NCCTG-98-32-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-98-32-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of Dolastatin-10 in Patients with Advanced Breast Cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:01">
                    <nciDocumentNumber>A09717</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCG-09717</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A PHASE  I study of THROMBOPOIETIN (RHTPO) plus G-CSF in children receiving IFOSFAMIDE, CARBOPLATIN, and ETOPOSIDE (i.c.e.) chemotherapy for recurrent or refractory SOLID TUMORS</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:02">
                    <nciDocumentNumber>W83-0753</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>OSU-8303</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Homoharringtonine, Phase I evaluation</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:03">
                    <nciDocumentNumber>W81-0205</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>80-C-98</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of 2'deoxycoformycin and ara in all</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:03">
                    <nciDocumentNumber>T90-0027</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>198-90-2</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of acivicin(nsc 163501) in the treatment of patients with recurrent or persistent glioma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:03">
                    <nciDocumentNumber>EST-1490</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-1490</localDocumentNumber>
                        <localDocumentNumber>305</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A randomized placebo-controlled Phase III study of Granulocyte-Macrophage colony stimulating factor (RHU-GM-CSF) in adult patients (>55-70 years) with acute non-lymphocytic Leukemia:  Protocol 305</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:04">
                    <nciDocumentNumber>NCOG-9L-82</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCOG-9L-82</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of Prednimustine in all over 60, smouldering Leukemia and refractory acute Leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:04">
                    <nciDocumentNumber>T83-1468</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CO-8192</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II study of local hyperthermia and electron-beam irradiation in the treatment of superficial human tumors(recurrent or metastatic)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:04">
                    <nciDocumentNumber>T83-1342</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CO-8231</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of interferon for glioblastoma multiforme</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:04">
                    <nciDocumentNumber>CALGB-8941</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-8941</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II rifn-alpha-2b (NSC# 377523) Modulation Study of ERP and PRP Content and Tamoxifen Sensitivity in Advanced Breast Cancer: A Limited Access Phase II</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:04">
                    <nciDocumentNumber>NCCTG-87-32-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-87-32-51</localDocumentNumber>
                        <localDocumentNumber>87-32-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of VP-16 and Cisplatin chemotherapy in Breast Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:04">
                    <nciDocumentNumber>EST-P-Z289</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-P-Z289</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of 5-Fluorouracil and rifn-alpha 2A in patients with advanced Colorectal carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:05">
                    <nciDocumentNumber>T88-0055</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>88-C-42</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial with suramin in patients with metastatic carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:05">
                    <nciDocumentNumber>T87-0270</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UH8789</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of 6-thioguanine in patients with metastatic Breast cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:05">
                    <nciDocumentNumber>T87-0271</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>84-03-02-03A</localDocumentNumber>
                        <localDocumentNumber>84-35</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of trimetrexate</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:05">
                    <nciDocumentNumber>T87-0194</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>OI-87-1</localDocumentNumber>
                        <localDocumentNumber>0I-87-1</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of continuous infusion recombinant il-2 in refractory lymphomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:06">
                    <nciDocumentNumber>T87-0016</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>87-850</localDocumentNumber>
                        <localDocumentNumber>UMCC-8702</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of pala in combination with 5-fluorouracil in unresectable adenocarcinoma of the pancreas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:06">
                    <nciDocumentNumber>T83-1055</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>OTT-84-01</localDocumentNumber>
                        <localDocumentNumber>NCIC-83-05</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I evaluation of intracarotid infusion of pcnu</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:06">
                    <nciDocumentNumber>T83-0995</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CO-8294</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study protocol for Taxol administered daily x 5 as a bolus injection, each 28 days</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:06">
                    <nciDocumentNumber>T83-1006</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CO-8394</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of cbdca and cddp</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:06">
                    <nciDocumentNumber>T83-0892</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>OSU-8311</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Evaluation of 2'deoxycoformycin (dcf) in refractory lymphoma - a Phase II study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:08">
                    <nciDocumentNumber>D79-006-0216</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>HIC-1971</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Dibromodulcitol Phase II in metastatic malignant melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:08">
                    <nciDocumentNumber>T85-0281</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>86-C-78</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II study of intrathecal 6-mercaptopurine</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:09">
                    <nciDocumentNumber>SEG-GI-77-223</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-GI-77-223</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II evaluation of adriamycin plus bleomycin in the treatment of primary liver carcinoma (hepatocellular and cholangiocellular), gallbladder carcinoma and bile duct carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:10">
                    <nciDocumentNumber>B83-0016</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>OI-83-11</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of recombinant Interferon-Beta</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:10">
                    <nciDocumentNumber>T85-0021</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>85-04-17-01</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of menogaril in patients with advanced Breast cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:10">
                    <nciDocumentNumber>INT-0015</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-GU-82-271P</localDocumentNumber>
                        <localDocumentNumber>MAOP-4383</localDocumentNumber>
                        <localDocumentNumber>UMCC-8303</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of cis-platinum, bleomycin, vinblastine and etoposide in massive disseminated testicular cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:11">
                    <nciDocumentNumber>T90-0130</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>90-C-209</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I trial of suramin in patients with advanced malignancies</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:11">
                    <nciDocumentNumber>T90-0158</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>90-080</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I trial of etanidazole (sr-2508) and radiotherapy in children with brain stem gliomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:11">
                    <nciDocumentNumber>T91-0045</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                        <localDocumentNumber>90-33</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of anti-b4 blocked ricin immunoconjugate in the therapy of hiv associated non-hodgkin's lymphoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:12">
                    <nciDocumentNumber>SWOG-9242</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-9242</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Evaluation of Taxotere in Small Cell Lung Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:12">
                    <nciDocumentNumber>POG-9377</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9377</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of N901-br for patients with CD56+ Malignancies</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:12">
                    <nciDocumentNumber>T94-0041</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DM-94-030</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II evaluation of topotecan (skf 104864) in non- hodgkin's lymphoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:12">
                    <nciDocumentNumber>T94-0129</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>93-C-0105</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II study of isolated hepatic perfusion with tumor necrosis factor and melphalan</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:13">
                    <nciDocumentNumber>T84-0488</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>OSU-8509</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I clinical and pharmacokinetic investigation of benzisoquinolinedione (bida)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:13">
                    <nciDocumentNumber>113-66N</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>73-22-01</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of dianhydrogalactitol and icrf-159 in patients with advanced Breast cancer previously exposed to cytotoxic chemotherapy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:16">
                    <nciDocumentNumber>T90-0103</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>90-017</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of chlorambucil plus ethacrynic acid in patients with refractory chronic lymphocytic leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:17">
                    <nciDocumentNumber>N82-0522</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>78-C-145</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III observation plus palliative radiotherapy vs. intensive chemotherapy for nodular Lymphomas and diffuse well-differentiated Lymphocytic Lymphomas (all stages)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:18">
                    <nciDocumentNumber>T90-0056</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of carboplatin/cytoxan/etanidazole in advanced ovarian cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:21">
                    <nciDocumentNumber>W78-0168</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PDC-591</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>3-deazauridine master protocol Phase II clinical trial in adv neoplastic disease</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:22">
                    <nciDocumentNumber>RTOG-90-02</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-90-02</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A randomized Phase III research study using irradiation alone or combined with hyperthermia for treatment of localized chest wall recurrences of Breast carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:23">
                    <nciDocumentNumber>T84-0207</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>84-C-20</localDocumentNumber>
                        <localDocumentNumber>BRMP-8505</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II studies of the adoptive immunotherapy of cancer with lymphokine activated killer cells</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:23">
                    <nciDocumentNumber>T89-0185</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>90-C-62</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase ib evaluation of interleukin-1 beta</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:24">
                    <nciDocumentNumber>T84-0139</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-ST-P28</localDocumentNumber>
                        <localDocumentNumber>ST-P-28</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Acnu and high dose intermittent 6-thioguanine - Phase I and preliminary Phase II observations</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:24">
                    <nciDocumentNumber>CALGB-8983</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-8983</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I trial of high dose doxorubicin plus recombinant granulocyte macrophage colony stimulating factor (gm-csf) plus dexrazoxane (adr-529,icrf-187, nsc # 169780) in solid tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:24">
                    <nciDocumentNumber>T89-0140</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>89-C-170</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with pala (n-phosponacetyl-l-aspartate) in metastatic gastrointestinal carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:26">
                    <nciDocumentNumber>INT-0106</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9048</localDocumentNumber>
                        <localDocumentNumber>CCG-8891</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Treatment of children with localized malignant germ cell tumors: a Phase II study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:26">
                    <nciDocumentNumber>T89-0070</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                        <localDocumentNumber>4/89-5H</localDocumentNumber>
                        <localDocumentNumber>89-05-122</localDocumentNumber>
                        <localDocumentNumber>889-5011-316</localDocumentNumber>
                        <localDocumentNumber>89051</localDocumentNumber>
                        <localDocumentNumber>H6042-04472-01</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of patients with renal cell carcinoma treated with high dose il-2 and roferon-a in combination with autologous lymphokine activated killer cells</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:26">
                    <nciDocumentNumber>T89-0065</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>89-C-125</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II study of monoclonal antibody in combination with interleukin-2 and cyclophosphamide for the treatment of metastatic malignant melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:26">
                    <nciDocumentNumber>NCCTG-87-81-52</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-87-81-52</localDocumentNumber>
                        <localDocumentNumber>87-81-52</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of 13-Cis-Retinoic Acid or Danazol in the treatment of favorable Myelodysplastic Syndromes</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:26">
                    <nciDocumentNumber>NCCTG-83-43-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-83-43-51</localDocumentNumber>
                        <localDocumentNumber>83-43-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A prospective Phase II /III randomized comparison of 5-Fu alone vs. 5-Fu plus adriamycin plus Cis-Platinum vs. the Mallinson regimen in the treatment of Advanced Pancreatic Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:27">
                    <nciDocumentNumber>INT-0108</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-3189</localDocumentNumber>
                        <localDocumentNumber>CALGB-9193</localDocumentNumber>
                        <localDocumentNumber>SWOG-8931</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III comparison of cyclophosphamide, doxorubicin, and 5-fluorouracil (caf) and a 16-week multi-drug regimen as adjuvant therapy for patients with hormone receptor negative, node-positive Breast cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:27">
                    <nciDocumentNumber>T89-0017</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>89-C-103</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase ib trial of intraperitoneal recombinant human gm-csf for patients with cancer limited to the peritoneal cavity</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:27">
                    <nciDocumentNumber>NCCTG-88-24-53</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-88-24-53</localDocumentNumber>
                        <localDocumentNumber>88-24-53</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III study of observation versus adjuvant therapies in completely resected Stage II and IIIA Non-Small Cell Carcinoma of the Lung</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:27">
                    <nciDocumentNumber>T88-0224</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DM-88-128</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of tpdc-fuhu chemotherapy for the treatment of tumors metastatic to the brain</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:28">
                    <nciDocumentNumber>GOG-8807</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-8807</localDocumentNumber>
                        <localDocumentNumber>T88-0125</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I evaluation of Intraperitoneal 131I labeled B72.3 monoclonal antibody in patients with Advanced Intraperitoneal Epithelial Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:28">
                    <nciDocumentNumber>T88-0079</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>88-C-122</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I and pharmacokinetic study of 4-ipomeanol (nsc # 3494381) in lung cancer patients</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:29">
                    <nciDocumentNumber>T88-0005</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>88-C-101</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase ib trial of poly iclc in combination with interleukin-2 in patients with cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:29">
                    <nciDocumentNumber>T87-0226</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>5 Phase I trial of the radiosensitizer sr2508 (etanidazole) combined with radiotherapy and chemotherapy for treatment of localized carcinoma of the esophagus</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:29">
                    <nciDocumentNumber>T87-0176</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>87-C-100</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of thiotepa (triethylenethiophosphoramide) in pediatric patients</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:29">
                    <nciDocumentNumber>T87-0180</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DM-89-039</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of high dose melphalan (hdm) and gm-csf in refractory multiple myeloma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:30">
                    <nciDocumentNumber>T87-0092</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CIC-87-117</localDocumentNumber>
                        <localDocumentNumber>86-133</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase ii, clinical, pharmacology, cell and molecular biology study of hexamethylene (hmba) in patients with myelodysplastic syndromes (mds) and acute myelogenous leukemia (aml)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:30">
                    <nciDocumentNumber>T87-0075</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHI-87-01</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I trial of carboplatin (cbdca, nsc 241240) combined with fixed doses of cyclophosphamide and bcnu with autologous marrow support for patients with refractory tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:30">
                    <nciDocumentNumber>T86-0256</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>87-C-24</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I and pharmacology study of 1-b-d-arabinofuranosyl-5-azacytidine (nsc-281272, ara-ac)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:31">
                    <nciDocumentNumber>T83-1061</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II study of continuous infusion of lymphoblastoid interferon in patients with metastatic Breast or renal carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:31">
                    <nciDocumentNumber>T83-1071</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CO-8392</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of acodazole hcl given intravenously on a weekly x 4 schedule</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:31">
                    <nciDocumentNumber>T83-1046</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>823-05-213</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I testing of new anticancer agent menogaril</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:31">
                    <nciDocumentNumber>SWOG-8746</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-8746</localDocumentNumber>
                        <localDocumentNumber>ECOG-PPI-188</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I trial of dose intensive chemotherapy combined with granulocyte-macrophage colony stimulating factor in advanced Breast cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:32">
                    <nciDocumentNumber>SWOG-8412</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-8412</localDocumentNumber>
                        <localDocumentNumber>NCOG-5O-84-2J</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Carboplatin/cyclophosphamide vs. cisplatin/cyclophosphamide in patients with measurable and non-measurable (sub-optimal) disease stages iii and iv ovarian cancer: phase iii</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:33">
                    <nciDocumentNumber>SEG-ST-77-219</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-ST-77-219</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Anguidine Phase II study of Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:33">
                    <nciDocumentNumber>SEG-ST-78-250</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-ST-78-250</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of hemi-body irradiation in Disseminated Metastatic Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:33">
                    <nciDocumentNumber>SEG-OVC-P21</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-OVC-P21</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II pilot study of combination hexa-cap and second look Laparotomy in Ovarian Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:33">
                    <nciDocumentNumber>SEG-OVCA-76-204</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-OVCA-76-204</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of BCNU and Cyclophosphamide followed by Adriamycin in patients with Ovarian Adenocarcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:33">
                    <nciDocumentNumber>SEG-MS-102</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-MS-102</localDocumentNumber>
                        <localDocumentNumber>V85-0187</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase Ia/Ib adjuvant study of Vaccina Oncolysate at the 2mg dose level in high risk malignant Melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:33">
                    <nciDocumentNumber>SEG-LEU-203</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-LEU-203</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of Mithramycin and Hydroxyurea in the therapy of blast phase of Chronic Myeloid Leukemia: exploration of two dose schedules</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:34">
                    <nciDocumentNumber>EST-7177</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-7177</localDocumentNumber>
                        <localDocumentNumber>N81-0979</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III evaluation of systemic treatment of advanced Breast cancer: Tamoxifen versus CMF in the elderly (age > 65)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:34">
                    <nciDocumentNumber>EST-3278</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-3278</localDocumentNumber>
                        <localDocumentNumber>N81-0986</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II - III studies in Chemotherapy of Islet Cell carcinoma: evaluations of Streptozotocin plus 5-Fluorouracil, Streptozotocin plus Adriamycin and Chlorozotocin alone</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:34">
                    <nciDocumentNumber>EST-2879</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-2879</localDocumentNumber>
                        <localDocumentNumber>N81-0991</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III study of Chemotherapy of advanced Ovarian cancer using low or high dose Cis-platinum with Hexamethylmelamine</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:34">
                    <nciDocumentNumber>EST-1179</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-1179</localDocumentNumber>
                        <localDocumentNumber>N81-0977</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III combination chemohormonotherapy for patients with metastatic Breast cancer who have received prior systemic therapy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:34">
                    <nciDocumentNumber>EST-P-Z386</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-P-Z386</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of Interferon alpha in locally recurrent or metastatic Head and Neck cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:35">
                    <nciDocumentNumber>EST-P-A884</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-P-A884</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of Poly Iclc (an interferon inducer) on the course of Renal Cell carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:35">
                    <nciDocumentNumber>EST-P-A386</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-P-A386</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study for the evaluation of Spiromustine in primary Brain Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:37">
                    <nciDocumentNumber>T86-0064</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>LAK-RENAL</localDocumentNumber>
                        <localDocumentNumber>EST-P-X887</localDocumentNumber>
                        <localDocumentNumber>IL2/LAK-#1</localDocumentNumber>
                        <localDocumentNumber>\</localDocumentNumber>
                        <localDocumentNumber>SWOG-8602</localDocumentNumber>
                        <localDocumentNumber>856-5011-104A</localDocumentNumber>
                        <localDocumentNumber>6116</localDocumentNumber>
                        <localDocumentNumber>CSU-389</localDocumentNumber>
                        <localDocumentNumber>804802-01-A</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of patients with metastatic or unresectable renal cell carcinoma with high dose il-2 and autologous lak cells</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:37">
                    <nciDocumentNumber>SEG-GU-P47</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-GU-P47</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II chemotherapy of Non-Resectable Germinal Cancer failing initial drug treatment:  VP-16, Platinum, Adriamycin, and Bleomycin</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:39">
                    <nciDocumentNumber>T85-0173</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CIC-85-54</localDocumentNumber>
                        <localDocumentNumber>UMCC-8519</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of ifosfamide and mesna in patients with epidermoid carcinoma of the esophagus</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:41">
                    <nciDocumentNumber>SEG-BRE-83-307</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-BRE-83-307R-T</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III comparison of CTX, ADR, and 5-FU vs CTX, MTX, and 5-FU both given to maximal tolerated dosage as adjuvant therapy after Masectomy for Carcinoma of the Breast w/1-3 +Axillary Nodes</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:47">
                    <nciDocumentNumber>CALGB-8321</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-8321</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A comparative study of two remission induction regimens of ARA-C for Acute Myelocytic Leukemia* A Phase III study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:47">
                    <nciDocumentNumber>B83-0018</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CO-8391</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I trial of human Lymphoblastoid Interferon with whole body Hyperthermia in advanced cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:47">
                    <nciDocumentNumber>RTOG-84-15</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-84-15</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II dose-searching randomized study of fast neutrons for tumors located in the extremities and extra-thoracic, extra-abdominal trunk</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:48">
                    <nciDocumentNumber>RTOG-81-03</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-81-03</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of Isotopic Immunoglobulin in the treatment of Non-Resectable Epidermoid and Large Cell Undifferentiated Adenocarcinoma of the Lung</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:48">
                    <nciDocumentNumber>T85-0039</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>OSU-8517</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Evaluation of 2'Deoxycoformycin (DCF) in Metastatic Malignant Melanoma - A Phase II Study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:48">
                    <nciDocumentNumber>INT-0078</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-5886</localDocumentNumber>
                        <localDocumentNumber>SEG-GU-305</localDocumentNumber>
                        <localDocumentNumber>SWOG-8594</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III trial of cisplatin alone or in combination with doxorubicin, vinblastine and methotrexate in advanced bladder cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:48">
                    <nciDocumentNumber>INT-0063</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-85-22</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A joint protocol between the radiation therapy oncology group and the medical research council: a Phase III protocol to study neutron therapy in squamous cell carcinoma of the upper aerodigestive tract</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:48">
                    <nciDocumentNumber>INT-0052</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-82</localDocumentNumber>
                        <localDocumentNumber>NCOG-5O-85-3J</localDocumentNumber>
                        <localDocumentNumber>RTOG-85-17</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III trial comparing combination chemotherapy (cap) with whole abdominal radiation therapy for stage iii optimal epithelial ovarian cancer with no gross residual disease</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:48">
                    <nciDocumentNumber>INT-0053</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                        <localDocumentNumber>DS-86-2</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Study of the effects of 13-cis retinoic acid, 1,25-dihydroxyvitamin d3 and recombinant interferon on proto-oncogene expression in vivo in the marrow and blood cells of patients w/anll, or the accelerated phase of blastic crisis of cml</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:49">
                    <nciDocumentNumber>INT-0038</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-85-15</localDocumentNumber>
                        <localDocumentNumber>NCOG-5C-84-1J</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II non-randomized study using infusion chemotherapy and radiation for advanced carcinoma of the cervix</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:49">
                    <nciDocumentNumber>B81-0534</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>81-C-112</localDocumentNumber>
                        <localDocumentNumber>BRMP-81-03</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I trial of Lymphoblastoid Interferon by intravenous infusion</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:49">
                    <nciDocumentNumber>POG-8775</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-8775</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of Interleukin-2 (IL-2) in the treatment of children with refractory Acute Leukemia: a POG single-institution study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:50">
                    <nciDocumentNumber>GOG-44</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-44</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Evaluation of Adjuvant Vincristine, Dactinomycin and Cyclophosphamide therapy in Malignant Germ Cell Tumors of the Ovary after resection of all Gross Tumor-Phase II</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:50">
                    <nciDocumentNumber>GOG-47</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-47</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III randomized study of Adriamycin plus Cytoxan versus Adriamycin plus Cytoxan plus Cis-Platinum in patients with Advanced Ovarian Adenocarcinoma - Suboptimal satge III, stage IV and recurrent</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:50">
                    <nciDocumentNumber>SWOG-9112</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-9112</localDocumentNumber>
                        <localDocumentNumber>T90-0141</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of the combination of high dose chemotherapy, Granulocyte-Macrophage stimulating factor, and Interleukin-2</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:50">
                    <nciDocumentNumber>T90-0142</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MOBILIZATION 91-12</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A randomized Phase II Study of the effect of Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) on mobilization of peripheral blood stem cells by high-dose Cyclophosphamide plus VP-16</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:50">
                    <nciDocumentNumber>EST-P-C488</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-P-C488</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of Autologous Bone Marrow Transplantation of 4HC purged marrow followed by GM-CSF infusions as consolidation therapy for patients with low-grade Non-Hodgkin's lymphoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:51">
                    <nciDocumentNumber>T90-0217</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>91-C-53</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Study of oral Clarithromycin Granules for suspension, in combination with Zidovudine or Dideoxyinosine, in the treatment of disseminated Mycobacterium Avium Complex infections in pediatric patients with AIDS</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:51">
                    <nciDocumentNumber>EST-P-A490</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-P-A490</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of Taxol in relapsed and refractory acute Non-Lymphocytic leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:51">
                    <nciDocumentNumber>EST-P-X990</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-P-X990</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I trial of Interleukin-1 Alpha and Cyclophosphamide in patients with Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:51">
                    <nciDocumentNumber>T91-0119</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>91-C-192</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I pharmacokinetic study of IL-2 encapsulated in liposomes</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:51">
                    <nciDocumentNumber>NCCTG-91-41-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-91-41-51</localDocumentNumber>
                        <localDocumentNumber>91-41-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of 5FU and Levamisole in patients with advanced Gastric cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:52">
                    <nciDocumentNumber>T91-0215</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>92-C-0087</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of intravenously administered (i.v.) 177Lutetium (177LU) labeled CC49 Monoclonal Antibody (MAB) in patients with Advanced Adenocarcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:52">
                    <nciDocumentNumber>EST-P-A491</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-P-A491</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I trial of Ril-3 + Zidovudine in HIV positive patients with Neutropenia, and Phase I trial of Ril-3 + Zidovudine + Standard Chop Chemotherapy in patients with HIV-related intermediate and High-Grade Non-Hodgkin's Lymphomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:52">
                    <nciDocumentNumber>T91-0268</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>92-C-0190</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of Taxol, Cyclophosphamide, and Granulocyte Colony-Stimulating Factor (G-CSF) in refractory or recurrent Ovarian Cancer patients</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:53">
                    <nciDocumentNumber>B92-0003</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UAC2129</localDocumentNumber>
                        <localDocumentNumber>T92-0159</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of the Murine Monoclonal Antibody D612 combined with Recombinant Human Macrophage Colony Stimulating Factor (RHM-CSF) in patients with Colorectal and Gastric Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:54">
                    <nciDocumentNumber>T93-0041</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>93-C-0153</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A prospective randomized, Phase III trial of Flac (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) chemotherapy with GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) versus PIXY 321 in advanced Breast Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:54">
                    <nciDocumentNumber>B93-0009</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DM 90-102</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I trial of Chimeric Monoclonal Antibody 14.18 (CH14.18) and Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor (RHGM-CSF) (Sargramostim) in metastatic melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:55">
                    <nciDocumentNumber>POG-9410</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SIMAL 8</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Simal 8 limited institution pilot: A study of Bone Marrow Transplantation after first marrow relapse of Non-T, Non-B ALL: A Pediatric Group Phase II /III pilot study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:55">
                    <nciDocumentNumber>T94-0149</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DM94-094</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of Biochemotherapy with Cisplatin, Vinblastine, Dacarbazine plus Interleukin-2 for Metastatic Melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:55">
                    <nciDocumentNumber>T94-0155</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of 9-Aminocamptothecin in patients with refractory Breast Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:56">
                    <nciDocumentNumber>T98-0009</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>98039</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Dolastatin-10 for Advanced Melanoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:56">
                    <nciDocumentNumber>T92-0250</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UPCC-7397</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Radiation Therapy with Concomitant Continuous Infusion Taxol for Glioblastoma Multiforme,  A Phase I Study</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-12-1999 11:01:42">
                    <nciDocumentNumber>T98-0041</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>IRB#:  98-095</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Pharmacokinetic-Guided Phase II Trial of the Rebeccamycin Analog NSC #655649 in Pediatric Patients with Relapsed/Refractory Neuroblastoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-29-1999 18:06:17">
                    <nciDocumentNumber>T98-0030</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>98-C-0162</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of MGI-114 in Patients with Recurrent or Persistent Epithelial Ovarian Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:18">
                    <nciDocumentNumber>T99-0005</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHI-25</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Oxaliplatin in Combination with Capecitabine in Metastatic/Recurrent Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-29-1999 18:06:18">
                    <nciDocumentNumber>T98-0065</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>99-C-0043</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial of Oral Perifosine with Different Loading Schedule in Patients with Refractory Neoplasms</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-29-1999 18:06:18">
                    <nciDocumentNumber>WLT-26</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>WLT-026</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Icrf-159 phase ii in renal carcinoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:18">
                    <nciDocumentNumber>T83-1326</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>85-233</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase 2 Study Of Intracavity Cisplatin With Thiosulfate Protection For Malignant Mesothelioma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>T95-0029</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase ii study of 9-aminocamptothecin (nsc 603071) in chronic lymphocytic leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>T95-0089</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase 2 Treatment of Adults and Children with Primary Brain Tumors with Irinotecan (CPT-11) (NSC# 616348)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>T96-0001</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>96-019</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial Of Krn5500 In Patients With Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>T97-0014</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>9023</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A phase ii trial of 9-aminocamptothecin (9-ac) as a 120-hour infusion in patients with advanced non-small cell lung cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>NCCTG-97-46-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-97-46-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Patients with Unresectable Hepatic Metastases from Metastatic Adenocarcinoma of the Colon or Rectum</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>RTOG-99-04</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-99-04</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Preoperative Chemotherapy and Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Stomach</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>T99-0038</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UPCI 99-020</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial of Weekly 17-Allylamino-17Demethoxygeldanamycin</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>W83-0836</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>83-C-39</localDocumentNumber>
                        <localDocumentNumber>85-7</localDocumentNumber>
                        <localDocumentNumber>83-16</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I-Ii Study Of Intrathecal Azq (Diaziquone 2.5 Diaziridinyl-3.6 - Biscarboethoxyamide- 1,4 Benzoquinone (Nsc-182986)</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:20">
                    <nciDocumentNumber>T92-0070</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A phase ii study of leucovorin, fluorouracil, and iododeoxyuridine (lif) combination chemotherapy for advanced colorectal cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:21">
                    <nciDocumentNumber>T94-0022</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ICC 1994</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Trial of O6 Benzylguanine and BCNU: A Biochemical Modulation Trial Based Upon Depletion of O6-Alkylguanine DNA Alkyltransferase Directed DNA Repair</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:22">
                    <nciDocumentNumber>T94-0136</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>IDD 94-32</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Rebeccamycin (NSC 655649) Given by Bolus Infusion Every 21 Days</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:22">
                    <nciDocumentNumber>T95-0054</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Trial Of Dexrazoxane (Zinecard), Doxorubicin (Adriamycin) And Escalating Doses Of Paclitaxel (Taxol) Plus Granulocyte Colony-Stimulating Factor In Advanced Breast Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:22">
                    <nciDocumentNumber>T95-0099</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I And Pharmacologic Study Of Cyclophosphamide Followed By Topotecan (Nsc# 609699) In Patients With Refractory Acute Leukemias And Advanced Chronic Myelogenous Leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T96-0058</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>96-C-0139</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study Of CARCINOEMBRYONIC Antigen Peptide 1 (CAP) with DETOX PC In Adult Patients with  ADENOCARCINOMAS  of the GASTROINTESTINAL TRACT, BREAST or LUNG</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T97-0011</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MCC 9612-2E</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of Bryostatin 1 (NSC 339555) and High-Dose 1-B-D-Arabinofuranosylcytosine (HiDAC) in Patients with Refractory Leukemia or Lymphoblastic Lymphoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T97-0012</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>9024</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of 9-AMINOCAMPTOTHECIN (9-AC) As A 120-Hour Infusion in Patients with advanced BREAST CANCER</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T97-0071</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>45333</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of 5-Fluorouracil, Recombinant Alfa-2a-Interferon and Intravenous Hydroxyurea with Filgrastim support in patients with refractory GI Malignancies</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T97-0100</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>IND 6170</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A randomized phase ii trial of a vaccine combining tyrosinase/gp100 peptides emulsified with montanide isa 51 alone or with gm-csf for patients with resected stages iia and iib melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T97-0123</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>97-53</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study Of Intraperitoneal Administration Of 9-Amino-20(S)-Camptothecin To Patients With Cancer Predominantly Confined To The Peritoneal Cavity</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:24">
                    <nciDocumentNumber>NCCTG-97-24-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-97-24-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Randomized, Double-Blind Study of CAI and Placebo in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:24">
                    <nciDocumentNumber>E8597</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E8597</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Pilot Trial of Adenovirus p53 and Radiotherapy on Nonsmall Cell Lung Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:24">
                    <nciDocumentNumber>NABTT-9806</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTT-9806</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Study To Evaluate Safety And Tolerance Of Escalating Doses Of RSR13 (Efaproxiral) Administered With BCNU Every Six Weeks In Patients With Recurrent Malignant Glioma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:24">
                    <nciDocumentNumber>T98-0074</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ID98-270</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Thalidomide in Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:24">
                    <nciDocumentNumber>T99-0015</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>9901</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase IB Trial of the Combination of Bryostatin-1 and Low Dose Interleukin-2: Evaluation of the Functional and Molecular Status of Human Monocytes as Antigen Presenting Cells</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:24">
                    <nciDocumentNumber>T99-0023</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>1199904138</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Oxaliplatin in Combination with 5-Fluorouracil and Gemcitabine in Patients with Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:24">
                    <nciDocumentNumber>RTOG-99-03</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-99-03</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III Trial to Assess the Effect of Erythropoietin on Local-Regional Control in Anemic Patients Treated with Radiotherapy for Carcinoma of the Head and Neck</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:24">
                    <nciDocumentNumber>T99-0035</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>99-037</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Trial of 17-N-Allylamino-17-Demethoxy Geldanamycin (17-AAG, NSC# 330507) in Patients with Advanced Cancer Therapeutic Protocol</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="05-04-1999 14:35:37">
                    <nciDocumentNumber>S9904</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S9904</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Thrombopoietin (RH-TPO) with High Dose Cytarabine (HDAC) and Idarubicin (IDA) Induction and Consolidation Therapy Followed by Autologous Peripheral Blood Stem Cell Transplant (APBSCT) and Post-APBSCT Interleukin-2 (IL-2) for Adult Patients of Age &lt; 56 with Previously Untreated De Novo, Non-M3 Acute Myeloid Leukemia (AML)</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="05-25-1999 09:39:11">
                    <nciDocumentNumber>GOG-0129K</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-129K</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Evaluation of Oxaliplatin (IND #57004, NSC #266046) in the Treatment of Recurrent or Persistent Endometrial Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="05-25-1999 10:57:33">
                    <nciDocumentNumber>GOG-0180</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-0180</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Danazol in Advanced or Recurrent Endometrial Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="06-17-1999 09:44:10">
                    <nciDocumentNumber>E2898</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E2898</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Randomized Trial of Interferon Alpha-2b Alone Versus Interferon Alpha-2b Plus Thalidomide in Patients with Previously Untreated Metastatic or Unresectable Renal Cell Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="06-18-1999 11:23:19">
                    <nciDocumentNumber>P9761</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>P9761</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of Irinotecan in Children with Refractory Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="08-16-1999 10:52:24">
                    <nciDocumentNumber>RTOG-99-10</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-99-10</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Supression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="08-19-1999 16:25:46">
                    <nciDocumentNumber>T99-0102</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>10M-99-1</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II  Trial of a MART-1/gp100/Tyrosinase Peptide-Pulsed Dendritic Cell Vaccine Treated with CD40 ligand/ Gamma Interferon with Subcutaneous IL-2 for Patients with Metastatic Melanoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="08-24-1999 14:48:01">
                    <nciDocumentNumber>T99-0111</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UC#10325</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of O6-Benzylguanine (NSC 637037) and BCNU (Carmustine) in Patients with Metastatic Melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="08-27-1999 08:29:56">
                    <nciDocumentNumber>52</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of SU5416 (NSC# 696819) in Patients with Advanced Colorectal Cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="09-07-1999 10:51:06">
                    <nciDocumentNumber>T96-0079</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial  of 9-AMINOCAMPTOTHECIN  in the treatment of patients with Metastatic  (D2),  Androgen-Independent Prostate Carcinoma.</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="09-23-1999 09:22:30">
                    <nciDocumentNumber>NABTT-9903</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>IL13PEI-001-R03</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma: Phase I/II Study</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="11-29-1999 16:36:43">
                    <nciDocumentNumber>S9927</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S9927</localDocumentNumber>
                        <localDocumentNumber>S9927</localDocumentNumber>
                        <localDocumentNumber>S9927</localDocumentNumber>
                        <localDocumentNumber>S9927</localDocumentNumber>
                        <localDocumentNumber>S9927</localDocumentNumber>
                        <localDocumentNumber>S9927</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Trial of Post-Mastectomy Radiotherapy in Stage II Breast Cancer in Women with One to Three Positive Axillary Nodes; Phase III</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-23-1999 10:29:19">
                    <nciDocumentNumber>POG-9906</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9906</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>ALinC 17: Protocol for Patients with Newly Diagnosed High Risk Acute Lymphoblastic Leukemia (ALL) - Evaluation of the Augmented BFM Regimen: A Phase III Study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="01-10-2000 12:00:04">
                    <nciDocumentNumber>E5597</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ECOG-E5597</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Chemoprevention Trial of Selenium Supplementation in Persons with Resected Stage I Non-Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="01-27-2000 12:53:41">
                    <nciDocumentNumber>1053</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>00-C-0123</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Gene Induction Mediated by Four-hour Intravenous Depsipeptide (FR901228/NSC 630176) Infusion in Lung Cancer Patients</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="05-02-2000 11:43:28">
                    <nciDocumentNumber>S0019</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0019</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III Trial of Ice Chemotherapy with or without Rituximab for the Treatment of Relapsed or Refractory CD20 Expressing Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients Not Suitable for High-Dose Therapy and PBSCT</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="05-16-2000 11:32:35">
                    <nciDocumentNumber>S0009</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0009</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Evaluation of Neoadjuvant Chemotherapy, Interval Debulking Followed by Intraperitoneal Chemotherapy in Women with Stage III and IV Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="05-18-2000 11:22:09">
                    <nciDocumentNumber>NABTT-9910</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTT-9910</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Evaluation of the Safety of PS-341 in the Treatment of Recurrent Gliomas</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="07-25-2000 09:42:31">
                    <nciDocumentNumber>2791</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>J0253</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Clinical - Laboratory Study of the Histone Deacetylase (HDA) Inhibitor MS-275 in Adults with Refractory and Relapsed Hematologic Malignancies</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="08-14-2000 12:14:45">
                    <nciDocumentNumber>RTOG-P-0011</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-P-0011</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Randomized Study of Adjuvant Therapy for High Risk  pT2-3NO Prostate Cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="10-24-2000 15:50:50">
                    <nciDocumentNumber>RTOG-S-0121</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-S-0121</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A PHASE I/II STUDY OF NEOADJUVANT CHEMOTHERAPY, ANGIOGENESIS INHIBITOR SU5416 (NSC #696819; A TK INHIBITOR ANTI-ANGIOGENESIS COMPOUND), AND RADIATION THERAPY IN THE MANAGEMENT OF HIGH-RISK, HIGH-GRADE, SOFT TISSUE SARCOMAS OF THE EXTREMITIES AND BODY  WALL</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="10-25-2000 14:54:58">
                    <nciDocumentNumber>2722</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CWRU 3100</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase II Study of Bevacizumab in Combination with Docetaxel in Locally Advanced Breast Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="11-02-2000 13:25:28">
                    <nciDocumentNumber>2712</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHII-30</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Randomized Trial of Bevacizumab Versus Bevacizumab and Thalidomide for Relapsed/Refractory Multiple Myeloma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="11-20-2000 14:58:44">
                    <nciDocumentNumber>4751</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHI-33</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Trial of R115777 (NSC 702818) in Advanced Malignant Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-07-2000 10:03:10">
                    <nciDocumentNumber>GOG-0189</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-0189</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Phase III Crossover Trial of Chemotherapy (Doxorubicin/Cisplatin/Paclitaxel and G-CSF) Versus Hormonal Therapy (Tamoxifen/Megestrol Acetate) in Patients with Stage III &amp; IV or Recurrent Endometrial Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="01-09-2001 12:37:09">
                    <nciDocumentNumber>2630</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Bevacizumab (Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor) in Addition to Fluorouracil and Hydroxyurea as Initial Chemotherapy with Concomitant Radiotherapy (B-FHX) for Poor Prognosis Head and Neck Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="02-20-2001 15:54:01">
                    <nciDocumentNumber>GOG-0146N</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-0146-N</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Evaluation of Bortezomib (Velcade, PS-341, NSC #681239, IND #58443) in the Treatment of Persistent or Recurrent Platinum-Sensitive Epithelial Ovarian or Primary Peritoneal Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="02-20-2001 16:20:19">
                    <nciDocumentNumber>5331</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>01-028</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Pharmacokinetic Study of STI571 in Patients with Advanced Malignancies and Varying Levels of Liver Dysfunction</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="02-21-2001 15:05:49">
                    <nciDocumentNumber>5150</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Clinical Trials of FTI Radiosensitization/A Phase I Trial of the Farnesyltransferase Inhibitor, R115777 (NSC# 702818) and Radiotherapy in Patients with Non-Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-02-2001 08:38:10">
                    <nciDocumentNumber>GOG-0170C</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-0170-C</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of ZD1839 (IRESSA) (NSC #715055, IND #61187) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-02-2001 09:56:28">
                    <nciDocumentNumber>CALGB-50002</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-50002</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Thalidomide (NSC #66847, IND #48832) for Patients with Relapsed or Refractory Low Grade Non-Hodgkin's Lymphoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-08-2001 12:07:56">
                    <nciDocumentNumber>NABTC-01-01</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTC-01-01</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II Trial of CCI-779 in Patients with Malignant Glioma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-15-2001 12:28:25">
                    <nciDocumentNumber>4470</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NYU00-57</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Epothilone B Analog BMS-247550 (NSC# 710428) in Stage IV Malignant Melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-23-2001 13:55:44">
                    <nciDocumentNumber>GOG-0230B</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-0230B</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Evaluation of Thalidomide (NSC #66847, IND 48832) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-05-2001 15:39:56">
                    <nciDocumentNumber>4553</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>03-C-0194</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of the Efficacy and Toxicity of Campath-1H in the Therapy of Adult T-Cell Leukemia</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-20-2001 12:46:16">
                    <nciDocumentNumber>2675</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>11255B</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Bevacizumab (NSC# 704865) Plus Gemcitabine in Patients with Advanced Pancreatic Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="05-30-2001 10:47:34">
                    <nciDocumentNumber>S0116</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0116</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of a D1/3-MAGE3-His Fusion Protein (NSC-719274) with Adjuvant SB-AS02B (NSC-719275) for Patients with Selected Stage IV, M1a, or M1b Metastatic Melanoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="06-06-2001 12:38:25">
                    <nciDocumentNumber>GOG-0126N</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-0126-N</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Evaluation of Weekly Paclitaxel (NSC #673809) in the Treatment of Recurrent or Persistent Platinum and Paclitaxel - Resistant Ovarian or Primary Peritoneal Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="08-08-2001 09:22:23">
                    <nciDocumentNumber>5411</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>11432B</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of OSI-774 (NSC# 718781) Based Multimodality Therapy for Inoperable Stage III Non-Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="08-13-2001 14:59:04">
                    <nciDocumentNumber>5522</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of UCN-01 in Advanced Renal Cell Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="08-14-2001 11:44:49">
                    <nciDocumentNumber>S0127</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0127</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of OSI-774 (NSC #718781) in Unresectable or Metastatic Adenocarcinoma of the Stomach and Gastroesophageal Junction</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-30-2001 14:18:03">
                    <nciDocumentNumber>5642</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>6042-04-7R0</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of the Antiangiogenic Agent Bevacizumab in Combination with 5-Fluorouracil and External Beam Radiation Therapy in Rectal Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="11-26-2001 16:27:02">
                    <nciDocumentNumber>S0200</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0200</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Randomized Study of Pegylated Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients with Recurrent Epithelial Ovarian or Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-07-2001 10:34:25">
                    <nciDocumentNumber>ADVL0211</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ADVL0211</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial of G3139 (Bcl-2 Antisense, NSC# 683428, IND# 58842) Combined with Cytotoxic Chemotherapy in Relapsed Childhood Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-07-2001 15:02:38">
                    <nciDocumentNumber>NABTT-2116</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTT-2116</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial to Evaluate Repetitive Intravenous Doses of Gadolinium-Texaphyrin as a Radiosensitizer in Patients with Glioblastoma Multiforme</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-12-2001 10:48:57">
                    <nciDocumentNumber>CALGB-30106</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-30106</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>ZD1839 (NSC #715055, IND #61187) with Induction Paclitaxel and Carboplatin Followed by Either Radiation or Concomitant Radiation with Weekly Paclitaxel and Carboplatin in Stage III Non-Small Cell Lung Cancer, A Phase II Study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-03-2002 10:53:00">
                    <nciDocumentNumber>S0218</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0218</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Oral EGFR Tyrosine Kinase Inhibitor OSI-774 (NSC-718781) in Patients with Malignant Pleural Mesothelioma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-08-2002 07:27:09">
                    <nciDocumentNumber>5701</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>11956A</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Study of Bevacizumab (rhuMab VEGF) in Combination with OSI-774 for Patients with Recurrent or Metastatic Cancer of the Head and Neck</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-08-2002 12:13:06">
                    <nciDocumentNumber>NCIC-BR.19</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CIRB:  02-012</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Prospective Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Antagonist, ZD1839 (IRESSA) in Completely Resected Primary Stage IB, II and IIIA Non-Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-19-2002 11:33:40">
                    <nciDocumentNumber>5611</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>1002-532</localDocumentNumber>
                        <localDocumentNumber>03-41</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Bevacizumab (RhuMAB-VEGF) in Hepatocellular Cancer for Patients with Unresectable Tumor (without Invasion of the Main Portal Vein or Metastatic Disease): A Phase II Study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-04-2002 09:54:56">
                    <nciDocumentNumber>5943</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>04-C-0142</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for Treatment of CD25 Positive Cutaneous T-Cell Lymphomas</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-04-2002 13:50:23">
                    <nciDocumentNumber>5856</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHI-40</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of PS-341 in Combination with Gemcitabine and Carboplatin in Selected Stage IIIB or IV Non-Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-04-2002 14:11:12">
                    <nciDocumentNumber>5750</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>03-C-0038</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of HeFi-1 in Refractory CD30-Positive Malignancy</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-12-2012 10:41:39" createdDate="05-28-2002 11:17:24">
                    <nciDocumentNumber>5913</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>11965B</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Epothilone B Analog BMS-247550 (NSC 710428) in Patients with Relapsed Aggressive Non-Hodgkin's Lymphomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="07-09-2002 16:21:46">
                    <nciDocumentNumber>S0221</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0221</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Trial of Continuous Schedule AC + G vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-18-2002 12:09:54">
                    <nciDocumentNumber>NANT N2002-01</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NANT N2002-01</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of High-Dose Pyrazoloacridine (PZA) (NSC 366140) Supported with Autologous Hematopoietic Stem Cell Rescue in Children with Recurrent or Resistant Neuroblastoma (IND #36325)</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-29-2002 16:32:23">
                    <nciDocumentNumber>5789</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHII-45</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Clinical Trial of Bevacizumab (IND 7,921; NSC 704865) and Low Dose Oral Cyclophosphamide in Recurrent Ovarian Cancer, Primary Peritoneal Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-26-2002 09:35:38">
                    <nciDocumentNumber>S0317</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0317</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of OSI-774 (NSC-718781) in Patients with Locally Advanced or Metastatic Papillary Histology Renal Cell Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-31-2002 14:58:49">
                    <nciDocumentNumber>6062</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CTRG P18/02</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of Fenretinide in Patients with Hormone Refractory Prostate Cancer</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-14-2003 08:56:38">
                    <nciDocumentNumber>6051</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial of Gemcitabine Followed by a Short Infusion of Flavopiridol in Patients with Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-16-2003 15:11:38">
                    <nciDocumentNumber>CALGB-90202</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-90202</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Double-Blind, Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men with Prostate Cancer Metastatic to Bone</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="02-03-2003 12:18:34">
                    <nciDocumentNumber>6021</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ID02-636</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Multi-Institutional Phase II Trial of Neoadjuvant Capecitabine (Xeloda) and Oxaliplatin (Eloxatin) for Resectable Colorectal Metastases in the Liver</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="02-04-2003 08:50:36">
                    <nciDocumentNumber>N9943</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>N9943</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II Trial of Gemcitabine and ALIMTA in Patients with Measurable or Evaluable, Unresectable or Metastatic Biliary Tract Carcinoma (Intrahepatic, Extrahepatic, Ampulla of Vater) and Gallbladder Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="02-25-2003 14:07:05">
                    <nciDocumentNumber>5907</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>03-105</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of G3139 (Genasense ) in Patients with Merkel Cell Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="02-27-2003 09:44:43">
                    <nciDocumentNumber>CALGB-80203</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-80203</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with and without Cetuximab (C225) for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-18-2003 10:47:10">
                    <nciDocumentNumber>E1302</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E1302</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Randomized, Placebo Controlled, Trial of Docetaxel Versus Docetaxel Plus ZD1839 (Iressa, Gefitinib) in Performance Status 2 or Previously Treated Patients with Recurrent or Metastatic Head and Neck Cancer</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="05-16-2003 10:19:37">
                    <nciDocumentNumber>6135</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>03-042</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II and Pharmacodynamic Study of PS-341 in Patients with Unresectable or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="08-12-2003 08:33:13">
                    <nciDocumentNumber>6293</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC0345</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Triapine for Advanced Adenocarcinoma of the Pancreas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="08-20-2003 15:57:26">
                    <nciDocumentNumber>S0339</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0339</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Gemcitabine, Carboplatin and PS-341 (NSC-681239) in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-17-2003 14:14:21">
                    <nciDocumentNumber>E1603</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E1603</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of Depsipeptide (NSC 630176) in Advanced Malignant Melanoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-02-2003 09:26:22">
                    <nciDocumentNumber>6447</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>04-021</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Multicenter, Open-Label, Phase II Study of Irinotecan, Cisplatin, and Bevacizumab in Patients with Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="11-24-2003 12:38:12">
                    <nciDocumentNumber>CALGB-60301</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-60301</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Pharmacokinetic and Phase I Study of Sorafenib (BAY 43-9006, NSC 724772, IND 69896) for Solid Tumors and Hematologic Malignancies in Patients with Hepatic or Renal Dysfunction</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="11-24-2003 13:07:57">
                    <nciDocumentNumber>6319</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCCWFU 71103</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Single Agent Depsipeptide (FK228) in Metastatic or Unresectable Soft Tissue Sarcomas</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-23-2003 11:18:30">
                    <nciDocumentNumber>6810</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>2004-0727</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of Capecitabine (Xeloda) and Peginterferon Alfa-2a (Pegasys) for Recurrent or Progressive Brain Metastasis from Breast and Colorectal Carcinoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-21-2004 16:39:43">
                    <nciDocumentNumber>6619</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UCI 04-04</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of CCI-779 in Combination with Imatinib Mesylate in Chronic Myelogenous Leukemia</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="02-10-2004 13:12:50">
                    <nciDocumentNumber>NABTC-03-03</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTC-03-03</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Trial of Depsipeptide in Patients with Recurrent High-Grade Gliomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-11-2004 12:55:09">
                    <nciDocumentNumber>NSABP-B-38</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NSABP-B-38</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III, Adjuvant Trial Comparing Three Chemotherapy Regimens in Women with Node-Positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide Followed by DD Paclitaxel (DD AC-P); DD AC Followed by DD Paclitaxel Plus Gemcitabine (DD AC-PG)</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-08-2004 09:01:25">
                    <nciDocumentNumber>6544</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>04-C-0218</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) with Evaluation of Hsp90 Client Proteins in Patients with Solid Tumors and Lymphomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-27-2004 13:42:39">
                    <nciDocumentNumber>6814</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>13327A</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Decitabine in Myelofibrosis</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="06-21-2004 15:04:51">
                    <nciDocumentNumber>S0307</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0307</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-12-2012 10:41:39" createdDate="07-08-2004 08:19:13">
                    <nciDocumentNumber>6936</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>2004-0792</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of 17-AAG in Patients with Relapsed/Refractory CD30+ Anaplastic Large Cell Lymphoma (ALCL), Relapsed/Refractory Mantle Cell Lymphoma (MCL), and Relapsed/Refractory Classical Hodgkin's Lymphoma (HL)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="07-19-2004 09:26:39">
                    <nciDocumentNumber>6992</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL032</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of UCN-01 in Combination with Topotecan in Patients with SCLC Who Relapsed or Progressed >= 3 Months After Completing First-Line Platinum-Based Chemotherapy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="07-27-2004 12:14:44">
                    <nciDocumentNumber>GOG-0076DD</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-0076DD</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Limited Access Phase II Trial of Cetuximab (C225,NSC #714692) in Combination with Cisplatin (NSC #119875) in the Treatment  of Advanced, Persistent , or Recurrent Carcinoma of the Cervix</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="08-10-2004 12:30:54">
                    <nciDocumentNumber>6996</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>07-0571</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II Clinical, Pharmacological, and Biological Study of Sorafenib (BAY 43-9006) in Combination with Cetuximab and Irinotecan in Patients with Advanced Colorectal Cancer</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="08-12-2004 09:12:47">
                    <nciDocumentNumber>6954</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>J04110</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial Oral Etoposide in Combination with the Farnesyltransferase Inhibitor R115777 (Zarnestra, Tipifarnib, NSC #702818, IND #58,359) in Elderly Adults with Newly Diagnosed Acute Myelogenous Leukemia (AML)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="09-08-2004 13:45:35">
                    <nciDocumentNumber>NSABP-B-40</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NSABP-B-40</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimens</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-05-2004 14:09:11">
                    <nciDocumentNumber>7002</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>OSU 04100</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Study of Flavopiridol Administered as a 30-Minute Bolus Followed by a 4-Hour Infusion in Lymphomas and Multiple Myeloma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-03-2004 15:18:15">
                    <nciDocumentNumber>6952</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>04-0336</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Multi-Center Phase Ib Study of Oxaliplatin (NSC #266046) in Combination with Fluorouracil and Leucovorin in Pediatric Patients with Advanced Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-16-2004 14:30:22">
                    <nciDocumentNumber>S0435</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0435</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of BAY 43-9006 (NSC-724772) in Patients with Platinum-Treated Extensive Stage Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-06-2005 13:45:39">
                    <nciDocumentNumber>S0509</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0509</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Novel Oral Anti-Angiogenic Agent AZD2171 (NSC-732208) in Malignant Pleural Mesothelioma</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-13-2005 12:04:43">
                    <nciDocumentNumber>7084</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>13850A</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of BMS 247550 (Ixabepilone) in Advanced Renal Cell Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-12-2012 10:41:39" createdDate="03-17-2005 14:34:19">
                    <nciDocumentNumber>6977</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>05-C-0229</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Pilot Phase II Study of Docetaxel Alone or in Combination with PANVAC(TM)-V (Vaccinia) and PANVAC(TM)-F (Fowlpox) in Adults with Metastatic Breast Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-18-2005 12:57:36">
                    <nciDocumentNumber>N0426</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>N0426</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Pemetrexed Disodium (ALIMTA) Plus Bevacizumab in Patients with Stage IIIB Pleural Effusion or Stage IV Non-Small Cell Lung Cancer (Second-Line Treatment)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="07-19-2005 09:49:25">
                    <nciDocumentNumber>7378</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>2006-011</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 1 Study of AFP464 (Aminoflavone Prodrug) in Patients with Advanced Solid Tumors</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="08-09-2005 15:18:08">
                    <nciDocumentNumber>7542</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>P6702</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Evaluation of Peptide Immunization and LMB-2 in Metastatic Melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-07-2005 10:44:48">
                    <nciDocumentNumber>7306</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MMC-14796</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Dose-Escalation Study of R115777 (Tipifarnib) Plus PS-341 (Bortezomib) in Relapsed or Refractory Acute Leukemias</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-20-2005 14:07:26">
                    <nciDocumentNumber>E5204</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E5204</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-21-2005 12:18:38">
                    <nciDocumentNumber>7285</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>14510A</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of PXD101 in Combination with Azacitidine (5-Aza) for Advanced Hematologic Malignancies</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="09-27-2005 11:26:34">
                    <nciDocumentNumber>S0521</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0521</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Trial of Maintenance Versus Observation for Patients with Previously Untreated Low and Intermediate Risk Acute Promyelocytic Leukemia (APL), Phase III</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-16-2005 15:23:55">
                    <nciDocumentNumber>7416</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>06-C-0164</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of BAY 43-9006 (Sorafenib) in Combination with Cetuximab (ErbituxTM) in EGFR Expressing Metastatic Colorectal Cancer (CRC)</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-12-2012 10:41:39" createdDate="01-11-2006 13:01:29">
                    <nciDocumentNumber>7565</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>2005-0977</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of AZD0530 (NSC 735464) in Patients with Previously Treated Metastatic Colorectal Cancer</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-24-2006 16:22:54">
                    <nciDocumentNumber>7437</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHII-74</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of the Halichondrin B Analog E7389 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Previously Treated with a Taxane</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="01-25-2006 10:30:05">
                    <nciDocumentNumber>7552</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-052</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of AZD0530 in Patients with Metastatic or Locally Advanced Gastric Carcinoma</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="02-24-2006 13:59:56">
                    <nciDocumentNumber>7627</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC057H</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of GW 786034 (Pazopanib) in Advanced Thyroid Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="03-20-2006 08:31:59">
                    <nciDocumentNumber>PBTC-022</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PBTC-022</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Bevacizumab Plus Irinotecan (Camptosar(TM)) in Children with Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="03-29-2006 15:18:23">
                    <nciDocumentNumber>7718</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-063</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Sunitinib Malate (Sutent; SU11248) in Patients with Intermediate-2 or High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-12-2006 15:09:16">
                    <nciDocumentNumber>7395</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>07-C-0059</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of AZD2171 in Metastatic Androgen Independent Prostate Cancer</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="05-08-2006 10:59:57">
                    <nciDocumentNumber>WFU-91105</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>WFU-91105</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Double Blind, Placebo Controlled Study of Donepezil in Irradiated Brain Tumor Patients</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="06-02-2006 09:09:27">
                    <nciDocumentNumber>7853</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>OSU-07022</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 1/2 Study of Reovirus Serotype 3 - Dearing Strain (Reolysin) (NSC 729968) in Patients with Ovarian, Primary Peritoneal and Fallopian Tube Carcinoma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="06-21-2006 08:41:54">
                    <nciDocumentNumber>7844</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>07-C-0081</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Study of Flavopiridol in Relapsed or Refractory Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma (DLBCL)</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="07-05-2006 10:47:29">
                    <nciDocumentNumber>CALGB-40503</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-40503</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Endocrine Therapy with or without Anti-VEGF Therapy: A Randomized, Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab (NSC 704865; IND 7921) for Women with Hormone Receptor-Positive Advanced Breast Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="07-13-2006 08:35:53">
                    <nciDocumentNumber>7863</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHII-82</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Phase II Study of Vorinostat or Placebo in Combination with Carboplatin and Paclitaxel for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="09-25-2006 10:59:09">
                    <nciDocumentNumber>8029</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ACRIN 6688</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Fluorine-18 3'-deoxy-3'-Fluorothymidine (F-18-FLT) in Invasive Breast Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="12-01-2006 08:36:44">
                    <nciDocumentNumber>7909</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of AZD6244 in Advanced or Metastatic Hepatocellular Carcinoma</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="12-06-2006 17:22:12">
                    <nciDocumentNumber>7860</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>07-C-0133</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of Topical Romidepsin (Depsipeptide) in Early Stage Cutaneous T-Cell Lymphoma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="01-05-2007 08:23:21">
                    <nciDocumentNumber>7952</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC068A</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Trial of Obatoclax Mesylate (GX15-070MS) in Combination with Bortezomib for the Treatment of Relapsed Multiple Myeloma</documentTitle>
                    <currentStatus>Temporarily Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="01-26-2007 14:41:06">
                    <nciDocumentNumber>RTOG-0534</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-0534</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA After Radical Prostatectomy</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="04-05-2007 14:39:33">
                    <nciDocumentNumber>CALGB-30607</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-30607</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib (NSC# 736511, IND # 74019) as Maintenance Therapy in Non-Progressing Patients Following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="06-18-2007 16:54:46">
                    <nciDocumentNumber>CALGB-10403</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-10403</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>An Intergroup Phase II Clinical Trial for Adolescents and Young Adults with Untreated Acute Lymphoblastic Leukemia (ALL)</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="07-27-2007 09:28:00">
                    <nciDocumentNumber>8064</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MCC-8064</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of Bortezomib and Vorinostat in Mantle Cell and Diffuse Large B-Cell Lymphomas</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-12-2012 10:36:33" createdDate="09-12-2007 09:00:39">
                    <nciDocumentNumber>ADVL0714</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ADVL0714</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of VEGF Trap (NSC # 724770, IND#  100137) in Children with Refractory Solid Tumors</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-12-2012 10:36:33" createdDate="07-24-2008 11:00:16">
                    <nciDocumentNumber>RTOG-0825</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG 0825</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Double-Blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="08-04-2008 11:36:42">
                    <nciDocumentNumber>8070</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab  in Patients with Refractory, Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="08-26-2008 10:21:30">
                    <nciDocumentNumber>8249</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>09-058</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II Trial of Temsirolimus and Perifosine for Recurrent or Progressive Malignant Gliomas</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="09-08-2008 12:41:09">
                    <nciDocumentNumber>8187</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>09-C-0101</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>An Open Label Phase I Study to Evaluate the Safety and Tolerability of a Vaccine ( GI-6207) Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express CEA Protein in Adults with Metastatic CEA-Expressing Carcinoma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="11-12-2008 10:35:17">
                    <nciDocumentNumber>8296</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>09-152</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 1/2 Study of SCH727965 in Patients with Malignant Melanoma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="11-24-2008 11:17:25">
                    <nciDocumentNumber>RTOG-0724</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG 0724/ GOG-0724</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="09-16-2009 10:45:34">
                    <nciDocumentNumber>8575</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-078</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of R04929097 in Combination with Gemcitabine in Patients with Advanced Solid Tumors</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="10-02-2009 09:21:00">
                    <nciDocumentNumber>8515</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CO09907</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 1 Study of RO4929097 (NSC749225) in Combination with Capecitabine in Refractory Solid Tumors</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="10-19-2009 11:37:31">
                    <nciDocumentNumber>8490</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>10-0273</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of the Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="10-20-2009 09:25:30">
                    <nciDocumentNumber>NCIC-MA.32</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCIC-MA.32</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="12-16-2009 13:27:02">
                    <nciDocumentNumber>8311</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>J1037</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Phase II Trial of Adjuvant Combined Epigenetic Therapy with 5-Azacitidine and Entinostat in Resected Stage I Non-small Cell Lung Cancer Versus Standard Care</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="05-18-2010 11:26:25">
                    <nciDocumentNumber>GOG-0241</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-0241</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab (NSC #704865, IND #7921) Compared with Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients with Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC)</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:45">
                    <nciDocumentNumber>NCCTG-90-60-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>90-60-51</localDocumentNumber>
                        <localDocumentNumber>90-60-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Comparison of Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) vs. Doxorubicin and Cisplatin (AC) in Women with Advanced Primary or Recurrent Metastatic Carcinoma of the Uterine Endometrium</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:46">
                    <nciDocumentNumber>RTOG-94-17</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-94-17</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Single-Arm, Open Label, Phase II Study of Intravenously Administered Tirapazamine Plus Radiation Therapy for High Grade Glioblastoma Multiforme</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:46">
                    <nciDocumentNumber>POG-9674</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9674</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Il-2 infusion in AML patients after autologous Bone Marrow Transplant: A Pediatric Oncology Group wide Phase I trial</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:46">
                    <nciDocumentNumber>T96-0035</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>96-C-0117</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of  ALL-TRANS-RETINOIC  ACID in combination INTERFERON-ALPHA-2A in children with recurrent  NEUROBLASTOMA or  WILMS' TUMOR</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:46">
                    <nciDocumentNumber>POG-7617</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-7617</localDocumentNumber>
                        <localDocumentNumber>SWOG-7617</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Combination chemotherapy with Vinblastine Sulfate and Bleomycin infusion in children with metastatic solid Tumors - Phase II protocol</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:50:46">
                    <nciDocumentNumber>POG-7695</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-7695</localDocumentNumber>
                        <localDocumentNumber>CCG-862</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>An evaluation of surgery, radiation therapy and chemotherapy in the treatment of previously untreated primary Malignanthepatoma in children (A Phase I -II, group-wide study)</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:47">
                    <nciDocumentNumber>T96-0010</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>91-140</localDocumentNumber>
                        <localDocumentNumber>91140</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III study comparing cisplatin, dacarbazine, carmustine and tamoxifen with dacarbazine alone in patients with advanced melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:47">
                    <nciDocumentNumber>P9457</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9457</localDocumentNumber>
                        <localDocumentNumber>POG-9457</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Intensive  therapy  with growth  factor support for Patients  with  EWING'S   TUMOR METASTATIC at  Diagnosis:  A  Pediatric  ONCOLOGY group Phase II trial</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:47">
                    <nciDocumentNumber>POG-9421</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9421</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III evaluation of standard vs. high dose ARA-C induction followed by the randomized use of Cylosporine A as an MDR reversal agent, compared to allogeneic BMT, in childhood AML</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:48">
                    <nciDocumentNumber>CCG-0956</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCG-0956</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of a continuous 21 day infusion of topotecan (nsc # 609699) in children with relapsed solid tumors.</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:48">
                    <nciDocumentNumber>NCCTG-93-72-02</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-93-72-02</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Preirradiation PCV Chemotherapy in Patients with Supratentorial Low-Grade Gliomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:48">
                    <nciDocumentNumber>POG-9574</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9574</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>INTERLEUKIN-4 in Pediatric patients with REFRACTORY ACUTE LEUKEMIA:  A Pediatric Oncology Group Phase I cooperative agreement study</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:48">
                    <nciDocumentNumber>POG-9573</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9573</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of Paclitaxel (Taxol) administered on a twice-weekly schedule to children with recurrent or refractory solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:48">
                    <nciDocumentNumber>POG-9553</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9553</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of Neoadjuvant Vincristine, Ifosfamide, Doxorubicin, and G-CSF in children with advanced stage Non-Rhabdomyosarcoma soft tissue Sarcomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:50:48">
                    <nciDocumentNumber>GOG-9602</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-9602</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of Paclitaxel Combined with Topotecan and Cisplatin and G-CSF in Patients with Newly Diagnosed Advanced Ovarian Epithelial Malignancies</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:49">
                    <nciDocumentNumber>C0590</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ECOG-C0590</localDocumentNumber>
                        <localDocumentNumber>EST-C-0590</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Double-blind Phase III trial of effects of low-dose 13-cis retinoic acid on prevention of second primaries in stages i-ii head and neck cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>E3695</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E3695</localDocumentNumber>
                        <localDocumentNumber>E3695</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III trial of Concurrent Biochemotherapy with Cisplatin, Vinblastine, Dacarbazine, IL-2 and Interferon Alpha-2b versus Cisplatin, Vinblastine, and Dacarbazine Alone in Patients with Metastatic Malignant Melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>INT-0131</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>BR.8</localDocumentNumber>
                        <localDocumentNumber>SWOG-9216</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A randomized Phase III study of code plus thoracic irradiation versus alternating cav and ep for extensive stage small cell lung cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 00:00:00">
                    <nciDocumentNumber>INT-0132</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E2993</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Randomized Trial of Autologous and Allogeneic Bone Marrow Transplantation Versus Intensive Conventional Chemotherapy in Acute Lymphoblastic Leukemia in First Remission</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>NCCTG-93-72-52</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-93-72-52</localDocumentNumber>
                        <localDocumentNumber>SWOG-9503</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Trial of BCNU and Cisplatin Versus BCNU Alone and Standard Radiation Therapy Versus Accelerated Radiation Therapy in Patients with Grade IV Glioma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>EST-3589</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-3589</localDocumentNumber>
                        <localDocumentNumber>RTOG-92-01</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Phase III study for small cell lung cancer:  prophylactic cranial irradiation versus observation in sclc patients achieving a complete response to induction therapy</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>NCCTG-86-72-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-86-72-51</localDocumentNumber>
                        <localDocumentNumber>EST-2389</localDocumentNumber>
                        <localDocumentNumber>RTOG-91-10</localDocumentNumber>
                        <localDocumentNumber>86-72-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Evaluation of Post Operative Radiation in Low Grade Intracranial Astrocytomas and Oligodendroglioma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>INT-0123</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-94-05</localDocumentNumber>
                        <localDocumentNumber>R9405</localDocumentNumber>
                        <localDocumentNumber>91-40-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Intergroup  Randomized comparison of combined  modality therapy for CARCINOMA  of the  ESOPHAGUS:  high dose vs. Conventional dose Radiation therapy.</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:50:52">
                    <nciDocumentNumber>INT-0079</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-2886</localDocumentNumber>
                        <localDocumentNumber>NCCTG-87-50-02</localDocumentNumber>
                        <localDocumentNumber>SWOG-8792</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III study of interferon alfa-nl (wellferon) as adjuvant treatment for resectable renal cell carcinoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:52">
                    <nciDocumentNumber>T95-0015</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UAB 9504</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Treatment of Chronic Myelogenous Leukemia with Bryostatin-1: A Phase I/II Pilot</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:52">
                    <nciDocumentNumber>POG-9720</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9720</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Idarubicin and Cladribine in Recurrent and Refractory Acute Myeloid Leukemia: A POG Phase II Study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:52">
                    <nciDocumentNumber>EST-4884</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-4884</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A randomized Phase III trial of intravesical prophylatic therapy for recurrent superficial papillary Bladder cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:50:52">
                    <nciDocumentNumber>EST-2382</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-2382</localDocumentNumber>
                        <localDocumentNumber>RTOG-84-06</localDocumentNumber>
                        <localDocumentNumber>SWOG-8493</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III simultaneous Cis-Platinum and Radiation therapy compared with standard Radiation therapy in the treatment of unresectable squamous or undifferentiated carcinoma of the Head and Neck</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:52">
                    <nciDocumentNumber>RTOG-89-01</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-89-01</localDocumentNumber>
                        <localDocumentNumber>EST-2591</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III study comparing combination chemotherapy and radiation therapy with preoperative chemotherapy and surgical resection in patients with Non-Small Cell Lung Cancer (NSCLC) with spread to Mediastinal Lymph Nodes (N2)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:52">
                    <nciDocumentNumber>CALGB-9130</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-9130</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III trial of vinblastine/cisplatin/radiation therapy with or without carboplatin (nsc# 241240) for inoperable stage iiia and stage iiib non-small cell lung cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:53">
                    <nciDocumentNumber>T95-0101</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCNSC 95-003</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II Evaluation of CI-980 for the treatment of RECURRENT or PROGRESSIVE MALIGNANT  GLIOMAS</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:53">
                    <nciDocumentNumber>E1496</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E1496</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Phase III Study in Low Grade Lymphoma Comparing Maintenance Anti-CD20 Antibody Versus Observation Following Induction Therapy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:53">
                    <nciDocumentNumber>C9732</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>C9732</localDocumentNumber>
                        <localDocumentNumber>C9732</localDocumentNumber>
                        <localDocumentNumber>C9732</localDocumentNumber>
                        <localDocumentNumber>C9732</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A randomized PHASE III study comparing ETOPOSIDE and CISPLATIN with ETOPOSIDE, CISPLATIN, and PACLITAXEL in patients with EXTENSIVE SMALL CELL LUNG CANCER</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:53">
                    <nciDocumentNumber>E5188</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-5188; INT-0101</localDocumentNumber>
                        <localDocumentNumber>CALGB-9192</localDocumentNumber>
                        <localDocumentNumber>SWOG-8851</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III comparison of combination CHEMOTHERAPY  (CAF) and CHEMOHORMONAL  Therapy (CAF + ZOLADEX  or CAF + ZOLADEX + TAMOXIFEN) in Premenopausal Women with Axillary Node-Positive Receptor-Positive BREAST  CANCER</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:55">
                    <nciDocumentNumber>NCCTG-91-72-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-91-72-51</localDocumentNumber>
                        <localDocumentNumber>91-72-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Mechlorethamine, Vincristine, and Procarbazine (MOP) in recurrent Glioma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:59">
                    <nciDocumentNumber>GOG-0076Z</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-76Z</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Limited Access Phase II Trial of Cisplatin and Navelbine (Vinorelbine) in Advanced and Recurrent Squamous Cell Carcinoma of the Cervix</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:00">
                    <nciDocumentNumber>T97-0023</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DM 97-022</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase II Trial of Taxol/VP-16/Estramustine vs. ketoconazole/Doxorubicin/Vinblastine/Estramustine in Androgen Independent Prostate Cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:00">
                    <nciDocumentNumber>C9734</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>C9734</localDocumentNumber>
                        <localDocumentNumber>C9734</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Study of Surgical Resection and Chemotherapy (Paclitaxel and Carboplatin) with or without Adjuvant Radiotherapy for Resected Stage IIIA Non-Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:00">
                    <nciDocumentNumber>RTOG-95-14</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>R9514</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of NEOADJUVANT  CHEMOTHERAPY  and  RADIATION  therapy in the management  of high-risk,  high-grade, soft tissue SARCOMAS  of the Extremities and Body Wall</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:01">
                    <nciDocumentNumber>CCG-09718</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>0</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Pediatric Phase I Study of Intravenous Dolastatin-10 (NSC 376128) in Patients with Refractory Solid Tumors</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:01">
                    <nciDocumentNumber>E2197</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E2197</localDocumentNumber>
                        <localDocumentNumber>E2197</localDocumentNumber>
                        <localDocumentNumber>E2197</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Study of Adriamycin/Taxotere vs. Adriamycin/Cytoxan for the Adjuvant Treatment of Node Positive or High Risk Node Negative Breast Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:02">
                    <nciDocumentNumber>T84-0495</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>IRB-29594</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of echinomycin in the treatment of advanced renal cell carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:02">
                    <nciDocumentNumber>POG-8018</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-8018</localDocumentNumber>
                        <localDocumentNumber>SWOG-8018</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Amsa Phase II evaluation of children with solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:02">
                    <nciDocumentNumber>POG-7623</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-7623</localDocumentNumber>
                        <localDocumentNumber>SWOG-7623</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Evaluation of systemic regimens in the treatment of Acute Leukemia of childhood - Phase III</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:03">
                    <nciDocumentNumber>T90-0072</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>90-C-178</localDocumentNumber>
                        <localDocumentNumber>CCG-0907</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of topotecan in pediatric patients with advanced neoplastic disease</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:03">
                    <nciDocumentNumber>T84-0302</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>834-05-222</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I testing of didemnin b</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:04">
                    <nciDocumentNumber>INT-0111</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-8952</localDocumentNumber>
                        <localDocumentNumber>EST-5489</localDocumentNumber>
                        <localDocumentNumber>HD.5</localDocumentNumber>
                        <localDocumentNumber>SWOG-8952</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Treatment of advanced hodgkin's disease-a randomized Phase III comparing abvd vs mopp/abv hybrid</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:04">
                    <nciDocumentNumber>T89-0063</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>89-C-148</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase 1b study of r24 monoclonal antibody given in conjunction with il-2</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:05">
                    <nciDocumentNumber>SWOG-8833</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-8833</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II investigation of chlorambucil and fludarabine monophosphate in relapsed or refractory chronic lymphocytic leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:05">
                    <nciDocumentNumber>T88-0011</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UMCC-8729</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of hexamethylene bisacetamide (hmba,nsc-95580) in patients with oral leukoplakia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:05">
                    <nciDocumentNumber>T87-0290</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>C094</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of acivicin (at-125) (nsc 163501) in patients with primary brain tumours</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:06">
                    <nciDocumentNumber>SWOG-8741</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-8741</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of recombinant tumor necrosis factor (rtnf) in patients with refractory carcinoma of the Breast</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:07">
                    <nciDocumentNumber>SEG-ST-78-222</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-ST-78-222</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A broad Phase II evaluation of maytansine in advanced solid tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:07">
                    <nciDocumentNumber>EST-4177</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-4177</localDocumentNumber>
                        <localDocumentNumber>N81-0978</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III hormonotherapy for metastatic Breast carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:07">
                    <nciDocumentNumber>EST-P-A286</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-P-A286</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II pilot study of Taxol (NSC 125973) in patients with advanced large Bowel cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:08">
                    <nciDocumentNumber>D79-048-0089</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CO-7813</localDocumentNumber>
                        <localDocumentNumber>EST-1179</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II evaluation in advanced Breast cancer of adriamycin dibromodulcitol, tamoxifen versus mitomycin-c, tamoxifen versus mitomycin-c, tasmoxifen, fluoxymesterone</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:08">
                    <nciDocumentNumber>T86-0066</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>LAK-COLORECTAL</localDocumentNumber>
                        <localDocumentNumber>EST-P-X287</localDocumentNumber>
                        <localDocumentNumber>IL2/LAK-#3</localDocumentNumber>
                        <localDocumentNumber>86-3</localDocumentNumber>
                        <localDocumentNumber>SWOG-8601</localDocumentNumber>
                        <localDocumentNumber>856-5011-104C</localDocumentNumber>
                        <localDocumentNumber>6150</localDocumentNumber>
                        <localDocumentNumber>CSU-392</localDocumentNumber>
                        <localDocumentNumber>804802-01-C</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of patients with metastatic or unresectable colorectal carcinoma with high dose il-2 and autologous lak cells</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:09">
                    <nciDocumentNumber>SEG-AML-83-236P</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-AML-83-236P</localDocumentNumber>
                        <localDocumentNumber>EST-4483</localDocumentNumber>
                        <localDocumentNumber>INT-0037</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of low dose ara-c in the treatment of myelodysplastic syndromes and aml</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:10">
                    <nciDocumentNumber>T85-0041</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CIC-85-4</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of menogarol in patients with adenocarcinoma of the pancreas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:10">
                    <nciDocumentNumber>INT-0065</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-8593</localDocumentNumber>
                        <localDocumentNumber>EST-2686</localDocumentNumber>
                        <localDocumentNumber>ME.6</localDocumentNumber>
                        <localDocumentNumber>NSABP-BP-63</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized trial of prophylactic isolation perfusion for stage i high risk malignant melanoma of the limbs, phase iii intergroup study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:10">
                    <nciDocumentNumber>RTOG-61-71</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-61-71</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Palliation of Brain Metastases: Phase I</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:11">
                    <nciDocumentNumber>GOG-86J</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-86J</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of Tumor Necrosis Factor (TNF) in patients with Advanced or Recurrent Endometrial Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:11">
                    <nciDocumentNumber>GOG-55</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-55</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Hormonal Contraception and Trophoblastic Sequelae after Hydatidiform Mole Phase III</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:11">
                    <nciDocumentNumber>T90-0216</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>91-C-77</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A pediatric Phase I evaluation of interleukin-3 given with the cytotoxic drug thiotepa</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:12">
                    <nciDocumentNumber>T92-0019</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>92-C-0214</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of iudr (nsc-39661) as a radiosensitizer in locally advanced cervix cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:12">
                    <nciDocumentNumber>T92-0063</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ICC-92U1</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of edatrexate in advanced renal cell carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:12">
                    <nciDocumentNumber>T92-0182</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DM 92-070</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of topotecan in patients with advanced, measurable pancreatic cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:12">
                    <nciDocumentNumber>CALGB-9362</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-9362</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of topotecan (nsc #609699) and Taxol</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:13">
                    <nciDocumentNumber>T84-0513</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>84-01-04</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of 6-thioguanine given by intravenous infusion daily for 7 days in patients with acute leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:14">
                    <nciDocumentNumber>POG-7422</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-7422</localDocumentNumber>
                        <localDocumentNumber>SWOG-7422</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Follow-up study on long-term remissions in Acute Leukemia of children - Phase III</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:14">
                    <nciDocumentNumber>W82-0559</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>81-339-NPD</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I homoharringtonine in patients with cancer and leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:17">
                    <nciDocumentNumber>N81-0903</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>81-C-13</localDocumentNumber>
                        <localDocumentNumber>NMOB-81-10</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>AZG straight Phase II previously treated small cell ca</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:17">
                    <nciDocumentNumber>CALGB-8984</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-8984</localDocumentNumber>
                        <localDocumentNumber>ECOG-1291</localDocumentNumber>
                        <localDocumentNumber>RTOG-9109</localDocumentNumber>
                        <localDocumentNumber>SWOG-9306</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II intergroup study of conservative treatment of adenocarcinoma of the distal rectum: local excision plus adjuvant radiation and concurrent 5-fu in selected patients</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:21">
                    <nciDocumentNumber>T90-0032</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>IL-4/RENAL</localDocumentNumber>
                        <localDocumentNumber>LU-2348</localDocumentNumber>
                        <localDocumentNumber>90-03-064</localDocumentNumber>
                        <localDocumentNumber>890-5011-209</localDocumentNumber>
                        <localDocumentNumber>90022-90-04-1</localDocumentNumber>
                        <localDocumentNumber>1918</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of recombinant il-4 in patients with metastatic renal cell carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:23">
                    <nciDocumentNumber>CCG-0895</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCG-0895</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I clinical and pharmacodynamic study of continuous infusion fludarabine followed by continuous infusion cytosine arabinoside in children with refractory acute lymphocytic leukemia and acute non-lymphocytic leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:24">
                    <nciDocumentNumber>NCOG-6G-82-1</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCOG-6G-82-1</localDocumentNumber>
                        <localDocumentNumber>NCOG-6G-82-1</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II study of radiotherapy plus BUDR and Procarbazine, CCNU, Vincristine for the treatment of primary malignant brain tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:25">
                    <nciDocumentNumber>NCOG-0R-81</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCOG-0R-81</localDocumentNumber>
                        <localDocumentNumber>RTOG-79-11</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II protocol of heavy charged particle radiotherapy for locally advanced and/or recurrent and/or metastatic cancers of multiple sites and types</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:25">
                    <nciDocumentNumber>T89-0107</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CWRCC-ICC-1389</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of local therapy of refractory grade iii and iv astrocytic brain tumors with autologous lymphokine activated killer cells and interleukin-2</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:26">
                    <nciDocumentNumber>T83-1156</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>83-275-NPD</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of menogaril in patients with advanced cancer and leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:26">
                    <nciDocumentNumber>T89-0058</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ICC-89H1</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of high dose azq combined with cyclophosphamide/tbi(total body irradiation) for refractory non-hodgkin's lymphomas in autologous bone marrow transplantation(abmt)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:26">
                    <nciDocumentNumber>NCCTG-87-41-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-87-41-51</localDocumentNumber>
                        <localDocumentNumber>CL-41-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of Etoposide (VP-16) plus Cis Platinum combinaton chemotherapy in advanced measurable gastric</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:26">
                    <nciDocumentNumber>NCCTG-86-30-52</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-86-30-52</localDocumentNumber>
                        <localDocumentNumber>86-30-52</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A retrospective study of the value of the tumor cell kinetic parameters DNA Ploidy and %s Phase I n patients with Breast Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:26">
                    <nciDocumentNumber>NCCTG-85-70-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-85-70-51</localDocumentNumber>
                        <localDocumentNumber>85-70-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of the combination of Recombinant Leukocyte a Human Interferon with 1,3-Bis(2-Chloro Ethyl)-1-Nitrosourea (BCNU) and the combination of BCNU with Cimetidine in patients with Advanced Malignant Melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:26">
                    <nciDocumentNumber>NCCTG-84-48-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-84-48-51</localDocumentNumber>
                        <localDocumentNumber>84-48-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of Pala, Thymidine and 5-Fluorouracil in advanced measurable Gastric Cancer and Anaplastic Colorectal Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:26">
                    <nciDocumentNumber>NCCTG-84-60-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-84-60-51</localDocumentNumber>
                        <localDocumentNumber>84-60-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Carboplatin by short infusion in women with Advanced Endometrial Cancer - a Phase II clinical trial</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:27">
                    <nciDocumentNumber>SWOG-8822</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-8822</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of continuous infusion recombinant interleukin-2 (ril-2) in patients with malignant lymphoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:27">
                    <nciDocumentNumber>T88-0236</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DM-88-130</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study to evaluate dfmo (eflornithine) for the treatment of recurrent malignant gliomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:27">
                    <nciDocumentNumber>T88-0228</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>OC-88-7</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I trial of cytoxan, total body irradiation and interleukin 2 activated bone marrow for transplantation therapy of refractory hematologic malignancies</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:28">
                    <nciDocumentNumber>T88-0200</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>89-C-07</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III study of icrf-187 (bisbiodoxopiperazine, adr-529), an adriamycin cardioprotector, in pediatric sarcoma patients</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:28">
                    <nciDocumentNumber>INT-0096</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-3588</localDocumentNumber>
                        <localDocumentNumber>RTOG-88-15</localDocumentNumber>
                        <localDocumentNumber>SWOG-8991</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III study of cisplatin plus etoposide combined with standard fractionation thoracic radiotherapy vs cisplatin plus etoposide combined with multiple daily fractionated thoracic radiotherapy for limited stage small cell lung cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:28">
                    <nciDocumentNumber>INT-0094</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-8795</localDocumentNumber>
                        <localDocumentNumber>EST-1888</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized prospective comparision of bacillus calmette-guerin and mitomycin-c therapy and prophylaxis in superficial transitional cell carcinoma of the bladder with dna flow cytometric analysis, Phase III</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:28">
                    <nciDocumentNumber>T88-0078</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UMCC-8802</localDocumentNumber>
                        <localDocumentNumber>T86-0302</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I and pharmacology study of intraperitoneal teroxirone (nsc 296934)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:29">
                    <nciDocumentNumber>T87-0266</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DM-87-044</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III study of adjuvant cyclophosphamide/etoposide/cisplatin (cep) plus chest and brain irradiation versus no adjuvant treatment after complete resection of stage ii-iii limited non-small cell lung cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:29">
                    <nciDocumentNumber>T87-0267</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DM-87-045</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III study of cyclophosphamide/etoposide/cisplatin (cep) plus chest and brain irradiation versus chest irradiation alone following partial resection of stage ii-iii limited non-small cell lung cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:29">
                    <nciDocumentNumber>T87-0130</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>87-05-14-01</localDocumentNumber>
                        <localDocumentNumber>UMCC-8717</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of hexamethylene bisacetamide (hmba, nsc 95580) in myelodysplastic syndromes (a) and acute myeloid leukemias (b)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:30">
                    <nciDocumentNumber>T87-0062</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DM-87-014</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of methyl-ccnu given in combination with 5-fluorouracil plus folinic acid in patients with metastatic colorectal carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:30">
                    <nciDocumentNumber>T87-0027</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>87-C-02</localDocumentNumber>
                        <localDocumentNumber>CCG-8603</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of the combination of 5 days intravenous 5-fu and 6 days of high dose oral leucovorin in pediatric patients</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:30">
                    <nciDocumentNumber>T86-0267</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>86-C-179</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of 2'-deoxycoformycin in patients with hairy cell leukemia or t-gamma lymphoproliferative disease refractory to or intolerant of low dose alpha interferon</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:30">
                    <nciDocumentNumber>T86-0165</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>LAK-BREAST</localDocumentNumber>
                        <localDocumentNumber>EST-P-X187</localDocumentNumber>
                        <localDocumentNumber>7/86-6A</localDocumentNumber>
                        <localDocumentNumber>SWOG-8618</localDocumentNumber>
                        <localDocumentNumber>856-5011-283</localDocumentNumber>
                        <localDocumentNumber>6217</localDocumentNumber>
                        <localDocumentNumber>CSU-403</localDocumentNumber>
                        <localDocumentNumber>804810-01</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Patients with Metastatic or Unresectable Breast Cell Carcinoma with High Dose IL-2 and Autologous LAK Cells</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:31">
                    <nciDocumentNumber>T83-1021</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>83-C-135</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of iododeoxyuridine given as a constant intravenous infusion</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:31">
                    <nciDocumentNumber>T83-1029</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>H-0382</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of spirogermanium in refractory multiple myeloma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:31">
                    <nciDocumentNumber>T83-0922</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>82-510</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of combination of cancer with pala and dipyrimadole</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:31">
                    <nciDocumentNumber>SWOG-8801</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-8801</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A study of the sequential combination of recombinant interferon gamma (rifn-gamma) and recombinant interleukin-2 (ril-2) in patients with disseminated malignant diseases: Phase I</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:33">
                    <nciDocumentNumber>SEG-78-THY-225</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-78-THY-225</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of Adriamycin plus Cis-Platinum in advanced Thyroid Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:35">
                    <nciDocumentNumber>D81-048-0515</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CO-8111</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Multimodality therapy of local-regionally advanced Breast cancer - a Phase I/II trial</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:37">
                    <nciDocumentNumber>T86-0065</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>LAK-MELANOMA</localDocumentNumber>
                        <localDocumentNumber>EST-P-X687</localDocumentNumber>
                        <localDocumentNumber>IL2/LAK-#2</localDocumentNumber>
                        <localDocumentNumber>86-2</localDocumentNumber>
                        <localDocumentNumber>SWOG-8603</localDocumentNumber>
                        <localDocumentNumber>856-5011-104B</localDocumentNumber>
                        <localDocumentNumber>6151</localDocumentNumber>
                        <localDocumentNumber>CSU-391</localDocumentNumber>
                        <localDocumentNumber>804802-01-B</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of patients with metastatic or unresectable melanoma with high dose il-2 and autologous lak cells</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:38">
                    <nciDocumentNumber>C80-0104</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>79-48-01</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Combined 5-fluorouracil, adriamycin and cisplatin therapy : a pilot study and Phase II trial in advanced gastric and pancreatic carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:39">
                    <nciDocumentNumber>T85-0200</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>845-5011-169</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of the oral administration of menogaril</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:43">
                    <nciDocumentNumber>CCG-904P</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCG-904P</localDocumentNumber>
                        <localDocumentNumber>BTRC-8026</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of 5-fu and ccnu before radiotherapy - hu- misonidazole for the treatment of primary brain stem tumors in children</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:45">
                    <nciDocumentNumber>T85-0142</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>85-C-209</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I and pharmacokinetic study of Dihydrolenperone (NSC 343513) in Lung Cancer patients</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:46">
                    <nciDocumentNumber>CALGB-8832</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-8832</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Etoposide (V[-16, NSC#141540), Carboplatin (CBDCA, NSC#241240), and Granulocyte-Macrophage-Colony-Stimulating Factor (GM-CSF) for extensive Small Cell Lung Cancer: Phase I -limited access</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:47">
                    <nciDocumentNumber>CALGB-8221</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-8221</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A pilot limited access comparative study of Post-Remission Intensive Cytosine Arabinoside in patients with Acute Non-Lymphocytic Leukemia in first remission, a Phase III study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:47">
                    <nciDocumentNumber>B83-0012</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CO-8398</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I evaluation of recombinant human Interferon Gamma Biological response modification and clinical tolerance following weekly intravenous administration</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:48">
                    <nciDocumentNumber>RTOG-83-19</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-83-19</localDocumentNumber>
                        <localDocumentNumber>NCOG-3L-83-1J</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III randomized prospective trial comparing Adriamycin and 5-FU and 131I Antiferritin IGG plus Adriamycin and 5-FU in the treatment of Malignant Hepatoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:48">
                    <nciDocumentNumber>RTOG-83-03</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-83-03</localDocumentNumber>
                        <localDocumentNumber>T83-1251</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I trial of the Hypoxic Cell Radiosensitizer, SR-2508</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:48">
                    <nciDocumentNumber>INT-0054</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-5885</localDocumentNumber>
                        <localDocumentNumber>RTOG-8529</localDocumentNumber>
                        <localDocumentNumber>POA-86185</localDocumentNumber>
                        <localDocumentNumber>SEG-INT-GU-318</localDocumentNumber>
                        <localDocumentNumber>SWOG-8596</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A randomized phase iii intergroup study of radiation therapy versus cisplatin plus etoposide plus bleomycin for advanced stage ii seminoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:49">
                    <nciDocumentNumber>INT-0048</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>8507-25</localDocumentNumber>
                        <localDocumentNumber>ICC-86M1</localDocumentNumber>
                        <localDocumentNumber>POA-71185</localDocumentNumber>
                        <localDocumentNumber>VU-SAR-4</localDocumentNumber>
                        <localDocumentNumber>UAB-273</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of cisplatin plus ifosfamide plus mesna plus vp-16 (vip) as salvage therapy in refractory small cell sarcomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:49">
                    <nciDocumentNumber>T89-0111</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GCSF-8815</localDocumentNumber>
                        <localDocumentNumber>T89-0110</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II trial of Recombinant Human Granulocyte Colony Stimulating Factor (R-MET HUG-CSF) as an adjunct to combination chemotherapy for advanced Breast cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:49">
                    <nciDocumentNumber>INT-0034</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-85-03</localDocumentNumber>
                        <localDocumentNumber>CALGB-8591</localDocumentNumber>
                        <localDocumentNumber>EST-1384</localDocumentNumber>
                        <localDocumentNumber>NCOG-7H-84-2J</localDocumentNumber>
                        <localDocumentNumber>SEG-INT-HN-301</localDocumentNumber>
                        <localDocumentNumber>SWOG-8590</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III study to determine the effect of combining chemotherapy with surgery and radiotherapy for resectable squamous cell carcinoma of the head and neck</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:49">
                    <nciDocumentNumber>INT-0018</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                        <localDocumentNumber>SEG-INT-81-306</localDocumentNumber>
                        <localDocumentNumber>SWOG-8093</localDocumentNumber>
                        <localDocumentNumber>GRP-81-001</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III - treatment of advanced malignant mesothelioma: a comparison of cia(cyclophosphamide, dtic, adriamycin) vs ca(cyclophosphamide, adriamycin)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:49">
                    <nciDocumentNumber>RTOG-89-06</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-89-06</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I pilot study to evaluate intraoperative radiation therapy and the Hypoxic Cell sensitizer SR-2508 in patients with locally advanced Malignancies</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:49">
                    <nciDocumentNumber>GOG-76K</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-76K</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of Menogaril in patients with Advanced Squamous Cell Carcinoma of the  Cervix</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:51">
                    <nciDocumentNumber>T90-0234</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>91-C-61</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of high dose Piroxantrone alone and in combination with Granulocyte Colony Stimulating Factor (G-CSF)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:51">
                    <nciDocumentNumber>T91-0031</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II trial of sequential active specific immunotherapy (Autologous Tumor Cell Vaccine) and recombinant Interleukin-2 (RO 23-6019) for metastatic Colorectal Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:51">
                    <nciDocumentNumber>RTOG-90-20</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-90-20</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of external beam radiation with Etanidazole (SR-2508) for the treatment of locally advanced Prostate Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:51">
                    <nciDocumentNumber>T91-0149</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>91-C-205</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of 5-Fluorouracil, Calcium Leucovorin, and Interferon Alpha-2A, (Fura/LV, IFN) in combination with surgery and consolidation chemotherapy in localized and locally Advanced Pancreatic Adenocarcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:52">
                    <nciDocumentNumber>T92-0060</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Leucovorin, Fluorouracil, and Iododeoxyuridine (LIF) combination chemotherapy for Advanced Pancreatic Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:52">
                    <nciDocumentNumber>T92-0028</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of All-Trans Retinoic Acid in the Myelodysplastic Syndromes</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:52">
                    <nciDocumentNumber>T92-0062</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Interleukin-6 (IL-6,SDZ ILS 969) administered by 120-hour continuous intravenous infusion</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:53">
                    <nciDocumentNumber>E2Y92</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-P-Y991</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of Interferon Alfa-2A and all Trans-Retinoic Acid in the treatment of Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:54">
                    <nciDocumentNumber>T93-0028</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>22193</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of 6-Thioguanine (NSC 752,IND 7258) in relapsed and refractory adult Acute Leukemia (AML, ALL) or untreated CGL in blast crisis (CGL-BC)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:54">
                    <nciDocumentNumber>T93-0058</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NU 93B1</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A randomized Phase III comparison of PIXY321 and GM-CSF for mobilization of hematopoietic progenitors in metastatic Breast Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:54">
                    <nciDocumentNumber>T93-0112</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>High dose ARA-C &amp; Mitoxantrone w/ PIXY 321 as remission induction therapy of relapsed or refractory Acute Myelogenous Leukemia(AML) or untreated, poor prognosis AML &amp; Chro. Myelogenous Leukemia in Myeloid blast crisis: A Phase II study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:54">
                    <nciDocumentNumber>T93-0046</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>94-C-0075</localDocumentNumber>
                        <localDocumentNumber>NMOB 93-04</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Imaging and Phase I Study of radiolabeled B3 Monoclonal antibody in adult patients with Metastatic Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:54">
                    <nciDocumentNumber>T93-0173</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DM 93-147</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II evaluation of Lovastatin for the treatment of recurrent and progressive malignant Gliomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:54">
                    <nciDocumentNumber>T94-0012</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>IND.82</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Phase II study of two schedules of Topotecan in previously treated patients with Ovarian Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:54">
                    <nciDocumentNumber>T94-0030</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>U0-9401</localDocumentNumber>
                        <localDocumentNumber>UMCC 9549</localDocumentNumber>
                        <localDocumentNumber>PC 94-07</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of Suramin in patients with metastatic Renal Cell Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:54">
                    <nciDocumentNumber>T94-0077</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of Sodium Phenylacetate in adults with high grade Gliomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:55">
                    <nciDocumentNumber>T95-0005</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UCDCC #104</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of Pyrazine Diazohydroxide (PZDH NSC #361456) in Androgen independent Prostate Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:55">
                    <nciDocumentNumber>T88-0061</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>867-5008-261</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of patients with primary malignant Gliomas treated with Intracranial recombinant IL-2 and autologous LAK cells</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:55">
                    <nciDocumentNumber>T91-0218</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UAC-1112</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of 131I-labeled Anti-Tag-72 Monoclonal Antibody, CC49, in patients with metastatic prostate cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:56">
                    <nciDocumentNumber>T92-0210</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UCI-92-04</localDocumentNumber>
                        <localDocumentNumber>UCI-92-04</localDocumentNumber>
                        <localDocumentNumber>UCI-92-04</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A multicenter Phase II study of all trans-retinoic acid and Interferon Alpha-2A in drug resistant multiple Myeloma and Waldenstrom's Macroglobulinemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:56">
                    <nciDocumentNumber>AMC-011</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>AMC-011</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial of COL-3 in Patients with HIV Related Kaposi's Sarcoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-12-1999 11:23:02">
                    <nciDocumentNumber>T98-0028</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DM 98-071</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Dolastatin 10 (NSC #376128)  Administered Intravenously Every 21 Days to Patients with Metastatic Pancreatic Adenocarcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-12-1999 17:06:11">
                    <nciDocumentNumber>T98-0034</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>99-C-0023</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Trial of Vaccination with Mutant Ras Peptide-Pulsed Dendritic Cells in the Treatment of HLA A2.1 Positive Patients with Colorectal Cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-29-1999 18:06:17">
                    <nciDocumentNumber>T97-0072</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>OC-97-1</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>PHASE I STUDY OF BRYOSTATIN-1 IN COMBINATION WITH CISPLATIN</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:17">
                    <nciDocumentNumber>E2598</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E2598</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Pilot Trial of Carboplatin, Paclitaxel, and Herceptin in HER2/Neu (+) Advanced NSCLC</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-29-1999 18:06:17">
                    <nciDocumentNumber>ADVL0018</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>A0981</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial of the HU14.18-IL2 (IND# BB-IND 9798, NSC# 721298) Fusion Protein in Children with Refractory Neuroblastoma and Other GD2 Positive Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:17">
                    <nciDocumentNumber>T98-0094</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>IDD#98-32</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II , Pharmacokinetic, and Biologic Correlative Study of G3139, NSC# 683428  (Phosphorothioate Antisense Oligonucleotide Directed  to Bcl-2) and Irinotecan in Patients with Metastatic Colorectal Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-29-1999 18:06:17">
                    <nciDocumentNumber>T97-0013</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A PHASE II trial of 9-Aminocamptothecin (NSC 603071) administered as a 120-hour continuous infusion in patients with previously untreated Gastric Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:18">
                    <nciDocumentNumber>T99-0004</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHASE I-24</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Oxaliplatin in Combination with Docetaxel (Taxotere) in Metastatic/Recurring Solid Tumors</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-29-1999 18:06:18">
                    <nciDocumentNumber>A09713</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCG-09713</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Continuous 21 Day Infusion of Topotecan (NSC #609699) in Children with Relapsed Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:18">
                    <nciDocumentNumber>T92-0171</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                        <localDocumentNumber>CCG-92-1</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I-II Trial of EDATREXATE in advanced Breast Cancer and other Malignancies</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-29-1999 00:00:00">
                    <nciDocumentNumber>T96-0039</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>8233</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A phase ii study of ci-958 (nsc #635371) in refractory or recurrent ovarian cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>T96-0080</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCNSC 96-213</localDocumentNumber>
                        <localDocumentNumber>NABTC</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Bryostatin in Patients with Recurrent High Grade Astrocytomas or Mixed Gliomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>T98-0024</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>97-50-02</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Dolastatin-10 in Patients with Advanced Renal Cell Carcinoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>T84-0347</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>97-C-0060</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase ii efficacy study of recombinant leukocyte a interferon in hairy cell leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:21">
                    <nciDocumentNumber>T92-0246</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>VCC LUN-65</localDocumentNumber>
                        <localDocumentNumber>SCC-9301</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Continuous Infusion Taxol In Combination With Thoracic Radiation Therapy In Untreated Locally Advanced Non-Small Cell Lung Cancer, A Phase I Study.</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:21">
                    <nciDocumentNumber>B93-0011</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UAC-1151</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study Of 131i-Labeled Anti-Tag-72 Monoclonal Antibody Combined With Total Body Irradiation After Treatment With High Dose Cyclosphophamide Followed By Autologous Stem Cell Rescue In Patients With Hormone Resistant Prostate Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:22">
                    <nciDocumentNumber>T94-0037</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>94-C-0172</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study Of Lmb-7,[B3(Fv)Pe38], A Recombinant Single-Chain Immunotoxin For Advanced Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:22">
                    <nciDocumentNumber>NABTT-9506</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>T94-0169</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II  Clinical  and  PHARMACOLOGIC   Study of  9-Amino-20(S)-CAMPTOTHECIN (9-AC) Administered   as A 72 hour Infusion In Adults  with Recurrent  or  Progressive Malignant GLIOMA</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:22">
                    <nciDocumentNumber>T94-0189</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of 9-Aminocamptothecin In Advanced Cutaneous T Cell Lymphoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:22">
                    <nciDocumentNumber>T94-0193</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>95-C-0090</localDocumentNumber>
                        <localDocumentNumber>95-C-0090</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I And Pharmacokinetic Trial Of Phenylacetate Given As A 28-Day Continuous Infusion In Pediatric Patients With Refractory Malignancy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:22">
                    <nciDocumentNumber>B95-0002</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase Ia/Ib Evaluation of 2b1 Bispecific Murine Monoclonal Antibody Therapy Combination with GM-CSF and IL-2 in Patients with C-Erbb-2 Expressing Refractory Metastatic Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:22">
                    <nciDocumentNumber>T95-0070</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>OC-96-3</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of the Biologic and Clinical Effects of 5-Aza-2'-Deoxycytidine (DAC) in Patients with Advanced Malignancies</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:22">
                    <nciDocumentNumber>T95-0008</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>95-2BA</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of IV L-PAM and BSO in Patients with Relapsed or Refractory Ovarian Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T96-0047</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>95-C-0119</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study Of SMS  201-995 PA LAR (NSC 685403) with/without  Tamoxifen in Patients with Osteosarcoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>NABTT-9601</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTT-9601</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Open Label Multicenter Dose Escalation Study of Gliadel in Patients with Recurrent Malignant Glioma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T97-0002</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CWRU 4Y96</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Clinical and Pharmacokinetic Study of Rebeccamycin Analogue NSC 655649 Given Daily for 5 Consecutive Days</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>E5296</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E5296</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Trial Comparing a 28 Day Schedule of Daily Oral 5-FU Plus Eniluracil to Protracted Intravenous Infusion in Previously Untreated Patients with Advanced Colorectal Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T97-0057</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>97-128</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of  Flavopiridol for Previously  Untreated Stage  IV Non-Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T97-0075</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A phase ii trial of bryostatin-1 (nsc 339555) administered as a 72-hour infusion every 2 weeks in patients with advanced sarcoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:24">
                    <nciDocumentNumber>NCCTG-98-24-52</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-98-24-52</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Phase II Study of Docetaxel and Gemcitabine for Stage IIIB/IV Non-Small Cell lung Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:24">
                    <nciDocumentNumber>RTOG-98-10</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-98-10</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>PHASE I trial of TIRAPAZAMINE, chemotherapy and thoracic radiation therapy for patients with locally advanced INOPERABLE NON-SMALL CELL LUNG CANCER</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:24">
                    <nciDocumentNumber>RTOG-DEV-1024</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-1024</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II trial of Marimastat and external Beam radiation in Glioblastoma Multiforme or Gliosarcoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:24">
                    <nciDocumentNumber>A5971</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>A5971</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Phase III Study for the Treatment of Newly Diagnosed Disseminated Lymphoblastic Lymphoma or Localized Lymphoblastic Lymphoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:24">
                    <nciDocumentNumber>E2298</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E2298</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Docetaxel and Carboplatin in patients with advanced Squamous Carcinoma of the Esophagus</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:24">
                    <nciDocumentNumber>E3598</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E3598</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Trial of Carboplatin, Paclitaxel and Thoracic Radiotherapy, with or without Thalidomide, in Patients with Stage III NSCLC</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:24">
                    <nciDocumentNumber>T99-0046</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ID99-303</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Multicenter, Open-Ended, Double-Blind, Placebo-Controlled, Phase III Study of AE-941 in Addition to Combined Modality Treatment (Chemotherapy/Radiotherapy) for Locally Advanced Unresectable Non-Small-Cell Lung Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="05-05-1999 09:39:22">
                    <nciDocumentNumber>RTOG-99-08</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-99-08</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of whole brain Irradiation followed by a radiosurgery boost with RSR13 for patients with one to three brain metastases</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="08-17-1999 11:00:04">
                    <nciDocumentNumber>T99-0103</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ID99-203</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Bryostatin-1 (NSC 339555) Plus Paclitaxel in Patients with Metastatic or Unresectable Locally Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="08-18-1999 14:57:54">
                    <nciDocumentNumber>19</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHII-25</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of Fenretinide (NSC 374551) in Recurrent Ovarian Cancer and Primary Peritoneal Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="08-20-1999 00:00:00">
                    <nciDocumentNumber>T99-0097</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>00-C-0137</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase II Study of Either Immunotherapy with a Regimen of Recombinant Pox Viruses that Express PSA/B7.1 Plus Adjuvant GM-CSF and IL-2 or Hormone Therapy with Nilutamide in Patients with Hormone Refractory Prostate Cancer and No Radiographic Evidence of Disease</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="08-24-1999 14:26:05">
                    <nciDocumentNumber>T99-0110</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NY 99-32</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I and Pharmacokinetic Study of the Farnesyl Transferase Inhibitor, R115777, in Combination with Continuous Infusion Topotecan</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="09-10-1999 09:55:21">
                    <nciDocumentNumber>S9923</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S9923</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of R115777 (NSC #702818) in Patients with Advanced Colorectal Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="09-14-1999 09:00:41">
                    <nciDocumentNumber>86</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ID99-213</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of 506U78 (NSC #686673) for Patients with Previously Treated Cutaneous T-Cell Lymphoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="10-27-1999 15:13:01">
                    <nciDocumentNumber>CALGB-119802</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-119802</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Fluoxetine in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC):  A Phase II Pilot Study to Improve Quality of Life During Chemotherapy</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-01-1999 13:35:18">
                    <nciDocumentNumber>57</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHII-26</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of CQS (NSC 339004) in Platinum-Refractory Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-28-1999 16:12:42">
                    <nciDocumentNumber>892</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCCWFU-98199</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A PHASE III, double-blind, randomized study of the effect of MEGESTROL ACETATE on weight and health related QUALITY OF LIFE in LUNG CANCER patients receiving THORACIC RADIATION THERAPY</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="01-05-2000 10:20:21">
                    <nciDocumentNumber>914</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCCWFU 59198</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A PHASE II study of twenty-four hour infusion GEMCITABINE for advanced COLORECTAL CANCER</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="01-27-2000 09:29:03">
                    <nciDocumentNumber>P9871</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>P9871</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Irinotecan in Patients Receiving Anticonvulsants, a POG/CCG Intergroup Study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="05-10-2000 13:25:55">
                    <nciDocumentNumber>751</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>01-C-0104L</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Concomitant Therapy with Proteasome Inhibitor PS-341 and Radiation in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck</documentTitle>
                    <currentStatus>Temporarily Closed to Accrual &amp;Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="06-05-2000 14:58:38">
                    <nciDocumentNumber>N9946</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>N9946</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), and Leucovorin (CF) in Patients with Metastatic Colorectal Carcinoma Previously Treated with Irinotecan (CPT-11)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="07-03-2000 12:45:16">
                    <nciDocumentNumber>2250</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>OSU 0045</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Study of Carboplatin/Paclitaxel/Suramin Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="08-21-2000 13:07:43">
                    <nciDocumentNumber>NABTT-2005</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTT-2005</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Trial of MGI 114 for Treatment of Patients with Recurrent Malignant Gliomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="09-20-2000 13:52:49">
                    <nciDocumentNumber>2795</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>01-049</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of PS-341 in Low Grade Lymphoproliferative Disorders</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="10-25-2000 11:01:16">
                    <nciDocumentNumber>RTOG-S-0120</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-S-0120</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase I/II Study of Preoperative Radiotherapy with/without  Sugen 5416 (NSC #696819; A TK Inhibitor Anti-Angiogenesis Compound) in the Management of Low to Intermediate Grade Soft Tissue Sarcoma of the Trunk or Extremity</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-01-2000 15:07:22">
                    <nciDocumentNumber>2251</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ID00-232</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Intraperitoneal Recombinant Human Interleukin-12 (rhIL-12) in Patients with Peritoneal Carcinomatosis (Residual Disease &lt;1 cm) Associated with Ovarian Epithelial Cancer or Primary Peritoneal Carcinoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="01-29-2001 15:05:46">
                    <nciDocumentNumber>E1A00</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E1A00</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III Trial of Thalidomide (NSC #66847) Plus Dexamethasone Versus Dexamethasone in Newly Diagnosed Multiple Myeloma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="02-28-2001 13:56:57">
                    <nciDocumentNumber>4390</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 1 Study of SU5416 with Androgen Ablation and Radiation in Patients with Intermediate- and Advanced- Stage Prostate Cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-16-2001 11:20:56">
                    <nciDocumentNumber>E4599</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E4599</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Phase II/III Trial of Paclitaxel Plus Carboplatin with or without Bevacizumab (NSC #704865) in Patients with Advanced Nonsquamous NSCLC</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-19-2001 08:27:59">
                    <nciDocumentNumber>ACOSOG-Z9000</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ACOSOG-Z9000</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Adjuvant STI571 (Gleevec TM) Therapy in Patients Following Completely Resected High-risk Primary GastroIntestinal Stromal Tumor (GIST)</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-24-2001 09:15:30">
                    <nciDocumentNumber>E2100</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E2100</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III Trial of Paclitaxel Versus Paclitaxel Plus Bevacizumab (rhuMAb VEGF) as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="05-29-2001 14:31:51">
                    <nciDocumentNumber>GOG-0197</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-0197</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Evaluation of SGN-00101 (HSP-E7) Fusion Protein in Women with Cervical Intraepithelial Neoplasia 3, CIN 3</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="06-11-2001 14:07:05">
                    <nciDocumentNumber>RTOG-0126</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-0126</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Randomized Study of High Dose 3D-CRT/IMRT Versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="07-16-2001 14:06:07">
                    <nciDocumentNumber>S0126</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0126</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of Chronic Oral  ZD1839 (Iressa) (NSC-715055) in Both Previously-Untreated and Previously-Treated Patients with Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-10-2001 12:10:26">
                    <nciDocumentNumber>5538</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-006</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II Study of UCN-01 in Combination with Fludarabine in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-23-2001 09:24:15">
                    <nciDocumentNumber>S0207</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0207</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Arsenic Trioxide in Male Patients with Refractory Germ Cell Malignancies</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="11-01-2001 11:17:44">
                    <nciDocumentNumber>5663</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-009</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of Imatinib Mesylate in Adenoid Cystic, Lymphoepithelioma-Like and Myoepithelial Salivary Gland Carcinomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-23-2002 11:06:06">
                    <nciDocumentNumber>5561</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>02-C-0303</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Pilot Study of Clinical Activity and Proteomic Pathway Profiling of the EGFR Inhibitor, ZD1839 (Iressa [R]; Gefitinib), in Patients with Epithelial Ovarian Cancer or Cervical Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="03-26-2002 14:04:46">
                    <nciDocumentNumber>NABTT-2115</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTT-2115</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of Combined Radiotherapy and Arsenic Trioxide for the Treatment of Newly Diagnosed Malignant Glioma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-28-2002 14:49:01">
                    <nciDocumentNumber>NCIC-152</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCIC-152</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of PS-341 (NSC 681239) in Patients with Untreated or Relapsed Waldenstrm's Macroglobulinemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="05-01-2002 14:30:55">
                    <nciDocumentNumber>NABTC-02-02</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTC-02-02</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Trial of R115777 with Radiation Therapy and Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="05-09-2002 10:05:02">
                    <nciDocumentNumber>PBTC-010</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PBTC-010</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Oxaliplatin in Children with Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors and Atypical Teratoid Rhabdoid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="06-12-2002 15:59:53">
                    <nciDocumentNumber>5641</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC0123</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of R115777, a Farnesyl Transferase Inhibitor, in Combination with Gemcitabine and Cisplatin in Advanced Non-Small Cell Lung Cancer (NSCLC)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="07-24-2002 17:02:54">
                    <nciDocumentNumber>5828</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHII-42</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of G3139 (Genasense) Anti-Bcl-2 Antisense Oligonucleotide Plus Alpha-Interferon in Metastatic Renal Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-16-2002 11:40:51">
                    <nciDocumentNumber>5835</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>02-66</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Study of Genasense (G3139) in Combination with Cisplatin and Fluorouracil in Patients with Advanced Esophageal, Gastro-Esophageal Junction and Gastric Cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-2002 14:06:20">
                    <nciDocumentNumber>6099</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHI-41</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of GTI-2040 in Combination with Oxaliplatin and Capecitabine in Patients with Advanced Metastatic Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-06-2003 07:42:04">
                    <nciDocumentNumber>6126</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ICC 3402</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial of PS-341 and Fludarabine for Relapsed and Refractory Indolent Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-14-2003 14:30:24">
                    <nciDocumentNumber>6150</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-018</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of PS-341 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter, and Renal Pelvis)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-21-2003 15:52:29">
                    <nciDocumentNumber>S0303</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0303</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Trial of Modified FOLFOX6 Versus CAPOX, with Bevacizumab (NSC-704865) or Placebo, as First-Line Therapy in Patients with Previously Untreated Advanced Colorectal Cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="05-19-2003 13:50:33">
                    <nciDocumentNumber>E6202</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E6202</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Bortezomib Plus Doxorubicin in Hepatocellular Carcinoma</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="06-03-2003 11:22:33">
                    <nciDocumentNumber>E2103</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E2103</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Trastuzumab Plus Weekly Ixabepilone (BMS-247550) and Carboplatin in Patients with HER2/Neu-Positive Metastatic Breast Cancer</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="06-10-2003 09:33:02">
                    <nciDocumentNumber>6171</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-021</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of CCI-779 in Metastatic Neuroendocrine Carcinomas</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="07-01-2003 09:20:08">
                    <nciDocumentNumber>6297</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>03-202</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of Trastuzumab in Combination with BMS-247550 in Women with Metastatic Breast Cancer</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="07-21-2003 13:22:45">
                    <nciDocumentNumber>WFU-01-012</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCCWFU-60A02</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Randomized Placebo Controlled, Double Blinded Trial to Evaluate the Effects of Fruit and Vegetable Extracts on Intermediate Biomarkers in Head and Neck Cancer Patients</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="08-06-2003 11:50:03">
                    <nciDocumentNumber>6257</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>OSU 0410</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Thrice Weekly Apolizumab in Patients with Chronic Lymphocytic Leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="08-13-2003 16:04:26">
                    <nciDocumentNumber>5991</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHII-43</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Combination Trial of PS-341 and 5-FU/LV in Gastric and/or GE Junction Adenocarcinoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-16-2003 19:00:59">
                    <nciDocumentNumber>5485</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 1 Study of Tirapazamine in Combination with Radiation and Weekly Cisplatin in Patients with Locally Advanced Cervical Cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-17-2003 11:09:37">
                    <nciDocumentNumber>6586</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PH1/095</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial of SJG-136 (a Minor Groove DNA Binding Drug) Given Intravenously Every 21 Days to Patients with Advanced Solid Tumours</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-09-2003 09:25:44">
                    <nciDocumentNumber>5926</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>04-C-0141</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Pilot Phase I Dose Escalation Study of the EGFR Tyrosine Kinase Inhibitor Gefitinib (Iressa) Combined with Paclitaxel (Taxol) and External Beam Radiation Therapy in Patients with Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-02-2003 12:08:04">
                    <nciDocumentNumber>6500</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PH2/049</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial to Assess the Activity of 17-allylamino, 17-demethoxygeldanamycin (17-AAG) in Patients with Metastatic (M1a , M1b &amp; M1c) Malignant Melanoma</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-08-2003 15:48:25">
                    <nciDocumentNumber>ADVL0411</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ADVL0411</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial of Temozolomide in Pediatric Patients with Refractory/Recurrent Leukemias</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="02-12-2004 09:37:59">
                    <nciDocumentNumber>6399</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>04-C-0238</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Von Hippel Lindau Disease and Renal Tumors</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="02-12-2004 16:27:24">
                    <nciDocumentNumber>6580</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>13200A</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase II Study of Bevacizumab (NSC# 704865) and Gemcitabine in Combination with Either Cetuximab (NSC# 714692) or OSI-774 (NSC# 718781) in Patients with Advanced Pancreatic Cancer</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-10-2004 14:28:05">
                    <nciDocumentNumber>6383</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC0313</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I and Pharmacological Trial of 17-Allylamino-17demethoxygeldanamycin (17-AAG) and Cytarabine in Refractory Leukemia and Myelodysplastic Syndrome</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-11-2004 08:50:58">
                    <nciDocumentNumber>6670</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-026</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Therapy with the Farnesyl Transferase Inhibitor R115777 (Zarnestra) Combined with Conventional Induction and Consolidation Chemotherapy for Previously Untreated Patients Over Age 55 with Acute Myeloid Leukemia (AML)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="06-16-2004 09:03:55">
                    <nciDocumentNumber>CALGB-90401</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-90401</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Double-Blinded Placebo Controlled Phase III Trial Comparing Doctaxel and Prednisone with and without Bevacizumab (IND #7921, NSC #704865) in Men with Hormone Refractory Prostate Cancer</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="06-21-2004 09:31:34">
                    <nciDocumentNumber>E5202</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E5202</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin Versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="07-13-2004 11:39:23">
                    <nciDocumentNumber>6696</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>OSU 0447</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Efficacy and Tolerability of GW572016 in Patients with Advanced Hepatocellular and Biliary Carcinomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="08-05-2004 09:28:33">
                    <nciDocumentNumber>CALGB-30306</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-30306</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Cisplatin, Irinotecan and Bevacizumab (NSC# 704865, IND# 7921) for Untreated Extensive Stage Small Cell Lung Cancer: A Phase II Study</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-22-2004 13:59:49">
                    <nciDocumentNumber>E1B03</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E1B03</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Pemetrexed Plus Gemcitabine or Carboplatin in Patients with Advanced Malignant Mesothelioma: A Randomized Phase II Trial</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="11-02-2004 13:09:10">
                    <nciDocumentNumber>6882</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC0483</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of Suberoylanilide Hydroxamic Acid (SAHA) in Acute Myeloid Leukemia (AML)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-02-2004 12:35:22">
                    <nciDocumentNumber>6637</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MCC 6637</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Trial of Vorinostat (SAHA) in Combination with Alvocidib (Flavopiridol) in Patients with Relapsed, Refractory, or (Selected) Poor Prognosis Acute Leukemia or Refractory Anemia with Excess Blasts-2</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-14-2004 08:13:58">
                    <nciDocumentNumber>7037</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CASE 5304</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of BAY 43-9006 in Patients with Advanced Anaplastic Carcinoma of the Thyroid</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-15-2004 12:11:53">
                    <nciDocumentNumber>6825</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>#04-10</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II, Pharmacokinetic and Biologic Correlative Study of Suberoylanilide Hydroxamic Acid (SAHA) in Patients with Advanced Renal Cell Carcinoma (RCC)</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-20-2004 11:32:24">
                    <nciDocumentNumber>6868</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-035</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 1 Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination with Capecitabine in Patients with Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-07-2005 08:16:07">
                    <nciDocumentNumber>C80405</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>C80405</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-18-2005 09:27:38">
                    <nciDocumentNumber>ADVL0414</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ADVL0414</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Temozolomide, Oral Irinotecan and Vincristine for Children with Refractory Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-18-2005 15:43:33">
                    <nciDocumentNumber>6835</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GCC 0514</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of SAHA in Combination with Bortezomib in Relapsed and Refractory Multiple Myeloma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-21-2005 08:40:15">
                    <nciDocumentNumber>7082</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC0511</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of the Raf Kinase/VEGFR Inhibitor BAY 43-9006 in Combination with the Proteasome Inhibitor PS-341 in Patients with Advanced Malignancies</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="05-05-2005 07:43:50">
                    <nciDocumentNumber>7060</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>05-081</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Multicenter Phase II Study of Sorafenib (BAY 43-9006) in Non-GIST Sarcomas</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="05-25-2005 14:21:15">
                    <nciDocumentNumber>S0438</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0438</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase II Trial of BAY 43-9006 (Sorafenib; NSC-724772) with Either CCI-779 (Temsirolimus; NSC-683864) or R115777 (Tipifarnib; NSC-702818) in Metastatic Melanoma</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-28-2005 11:30:56">
                    <nciDocumentNumber>S0351</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0351</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of CNTO 328, a Monoclonal Antibody Against Interleukin-6 (IL-6), in Patients with Advanced or Metastatic Renal Cell Cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-08-2005 13:19:39">
                    <nciDocumentNumber>7444</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-048</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Halichondrin B Analog E7389 in Combination with Gemcitabine in Patients with Refractory or Advanced Solid Tumors</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-24-2006 08:39:27">
                    <nciDocumentNumber>N0574</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>N0574</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Randomized Trial of the Role of Whole Brain Radiation Therapy in Addition to Radiosurgery in Patients with One to Three Cerebral Metastases</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-25-2006 07:41:10">
                    <nciDocumentNumber>7498</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-050</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of VEGF Trap in Patients with Previously Treated Metastatic Colorectal Cancer</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="02-01-2006 08:22:31">
                    <nciDocumentNumber>7389</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>2006-042</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase 2 Study of AZD2171 (NSC 732208) in Combination with Pemetrexed in Relapsed Non-Small Cell Lung Cancer (NOS: 10029514)</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="03-01-2006 09:30:08">
                    <nciDocumentNumber>7597</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>16077A</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of AZD0530 in Metastatic Melanoma</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="03-13-2006 14:29:42">
                    <nciDocumentNumber>7661</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC0553</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Safety and Efficacy Study with the VEGF Receptor Tyrosine Kinase Inhibitor GW786034 in Patients with Metastatic Urothelial Cancer</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-22-2006 15:07:15">
                    <nciDocumentNumber>7738</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Sunitinib Malate in Head and Neck Squamous Cell Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="04-07-2006 10:33:40">
                    <nciDocumentNumber>7832</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>07C0101</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 0 Trial of "111 Indium CHX-A" DTPA Trastuzumab Imaging in Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-10-2006 09:30:18">
                    <nciDocumentNumber>7757</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>2006-0329</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II and Pharmacokinetic Study of Docetaxel Plus VEGF Trap (AVE0005, NSC# 724770) in Patients with Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="06-20-2006 09:31:56">
                    <nciDocumentNumber>7689</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHI-57</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I and Pharmacodynamic Study of GTI-2040 (NSC 722929, IND 67368) in Acute Leukemias</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-12-2012 10:41:39" createdDate="07-05-2006 12:56:35">
                    <nciDocumentNumber>7868</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>06-12-487</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I-II Study of R115777 (Tipifarnib, Zarnestra) Plus Sequential Weekly Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients with Stage IIB-IIIC Breast Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="07-14-2006 13:38:56">
                    <nciDocumentNumber>CALGB-140503</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-140503</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (&lt;/= 2 cm) Peripheral Non-Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="09-06-2006 09:53:08">
                    <nciDocumentNumber>7754</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>07-014</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Imatinib Mesylate (STI571; NSC #716051; IND 61135) in Patients with Inoperable AJCC Stage III or IV Melanoma Harboring Somatic Alterations of c-KIT</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="09-18-2006 10:47:42">
                    <nciDocumentNumber>E1A05</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E1A05</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Phase III Trial of Consolidation Therapy with Bortezomib (Velcade) - Lenalidomide (Revlimid) - Dexamethasone (VRD) Versus Bortezomib (Velcade) - Dexamethasone (VD) for Patients with Multiple Myeloma Who Have Completed a Dexamethasone Based Induction Regimen</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="12-21-2006 14:07:44">
                    <nciDocumentNumber>7918</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>LOI 7918</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase 2 Study of AZD6244 in Iodine-131 Refractory Papillary Thyroid Carcinoma and Papillary Thyroid Carcinoma with Follicular Elements</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="12-26-2006 12:39:07">
                    <nciDocumentNumber>NSABP-B-43</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NSABP-B-43</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma in Situ Resected by Lumpectomy</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="02-21-2007 09:21:17">
                    <nciDocumentNumber>RTOG-0436</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG 0436</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients with Esophageal Cancer Who Are Treated Without Surgery</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="06-13-2007 15:16:43">
                    <nciDocumentNumber>CALGB-170601</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-170601</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Double Blind Trial of Oral Duloxetine for Treatment of Pain Associated with Chemotherapy-Induced Peripheral Neuropathy (CIPN)</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="06-19-2007 10:44:38">
                    <nciDocumentNumber>CALGB-40601</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-40601</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Phase III Trial of Paclitaxel Combined with Trastuzumab, Lapatinib, or Both as Neoadjuvant Treatment of HER2-Positive Primary Breast Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="07-10-2007 09:58:43">
                    <nciDocumentNumber>S0535</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0535</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients with Previously Untreated High-Risk Acute Promyelocytic Leukemia</documentTitle>
                    <currentStatus>Temporarily Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="08-02-2007 11:06:08">
                    <nciDocumentNumber>CALGB-30610</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB 30610/RTOG 0538</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="09-05-2007 11:28:55">
                    <nciDocumentNumber>8109</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>2007-0595</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of IMC-A12 (NSC# 742460) in Combination with Temsirolimus CCI-779 (NSC# 683864) in Patients with Advanced Cancers</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="10-05-2007 17:08:56">
                    <nciDocumentNumber>N0733</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>N0733</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 in Patients with HER2 Positive Breast Cancer Previously Treated with Trastuzumab and an Anthracycline and/or a Taxane</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="03-12-2008 11:38:45">
                    <nciDocumentNumber>8209</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ENT 0025</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of Sequential and Concurrent Chemoradiation for Patients with Advanced Nasopharyngeal Carcinoma (NPC)</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="03-28-2008 14:44:09">
                    <nciDocumentNumber>WFU-07-02-03</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>WFU-07-02-03</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Randomized, Double-Blind, Placebo Controlled Trial of North American Ginseng Extract (CVT-E002; COLD-fX) to Prevent Respiratory Infection and Reduce Antibiotic Use in Patients with Chronic Lymphocytic Leukemia.</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="04-08-2008 10:12:15">
                    <nciDocumentNumber>N0874</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>N0874</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients with Newly Diagnosed Glioblastoma</documentTitle>
                    <currentStatus>Temporarily Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="04-30-2008 14:18:31">
                    <nciDocumentNumber>S0800</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0800</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase II Trial of Weekly Nanoparticle Albumin Bound Paclitaxel (Nab-Paclitaxel) (NSC-736631) with or without Bevacizumab, Either Preceded by or Followed by Q 2 Week Doxorubicin (A) and Cyclophosphamide (C) Plus Pegfilgrastim (PEG-G) as Neoadjuvant Therapy for Inflammatory and Locally Advanced HER-2/Neu Negative Breast Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="05-05-2008 13:42:08">
                    <nciDocumentNumber>CALGB-90601</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-90601</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="05-09-2008 09:30:43">
                    <nciDocumentNumber>ADVL0812</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ADVL0812</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children with Relapsed/Refractory Solid Tumors</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="05-29-2008 09:08:50">
                    <nciDocumentNumber>8218</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC0875</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of Pazopanib (GW786034) in Pre-Treated and Untreated Metastatic Melanoma Patients</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="07-09-2008 07:55:37">
                    <nciDocumentNumber>PBTC-025</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PBTC-025</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Pharmacokinetic and Safety Study in Children with Recurrent or Refractory Medulloblastoma to Identify a Pharmacokinetic Based Dose for GDC-0449</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="09-09-2008 09:22:10">
                    <nciDocumentNumber>8231</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC0811</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Trial of the Combination of GDC-0449 and Erlotinib +/- Gemcitabine</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="09-12-2008 12:22:21">
                    <nciDocumentNumber>8327</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CASE 11808</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of Triapine (NSC #663249)  and Cisplatin in Combination with Pelvic Radiation for Treatment of Stage IB2-IV Cervical Cancer or Stage II-IV Vaginal Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="10-22-2008 13:37:47">
                    <nciDocumentNumber>8233</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC0845</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Temsirolimus and Bevacizumab in Patients with Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer</documentTitle>
                    <currentStatus>Temporarily Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="11-19-2008 07:57:46">
                    <nciDocumentNumber>RTOG-0920</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-0920</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="01-05-2009 11:23:46">
                    <nciDocumentNumber>ACOSOG-Z1071</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ACOSOG-Z1071</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study Evaluating the Role of Sentinel Lymph Node Surgery and Axillary Lymph Node Dissection Following Preoperative Chemotherapy in Women with Node Positive Breast Cancer (T0-4, N1-2, M0) at Initial Diagnosis</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="02-24-2009 10:50:38">
                    <nciDocumentNumber>CALGB-80701</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-80701</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Phase II Study of Everolimus Alone Versus Everolimus Plus Bevacizumab in Patients with Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="07-13-2009 08:02:57">
                    <nciDocumentNumber>ABTC-0903</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>0903</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase Ib Study of Cediranib in Combination with Cilengitide in Patients with Recurrent Glioblastoma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="07-22-2009 16:12:14">
                    <nciDocumentNumber>8477</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CO 09904</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Pharmacodynamic Trial of Sequential Sunitinib with Bevacizumab in Patients with Renal Cell Carcinoma and Other Advanced Solid Malignancies</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="08-26-2009 13:31:11">
                    <nciDocumentNumber>8598</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>10454</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of AZD6244 plus Erlotinib for Advanced Gemcitabine-Refractory Pancreatic Adenocarcinoma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="11-02-2009 16:05:43">
                    <nciDocumentNumber>8597</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PENDING</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Pilot and Phase II Study of Entinostat and Anastrozole in Postmenopausal Women with Operable Triple Negative Breast Cancer to Evaluate Biomarkers and Surrogates for Response</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="11-04-2009 12:05:38">
                    <nciDocumentNumber>GOG-9924</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-9924</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Pharmacokinetic Study of Intraperitoneal CTEP-Supplied Agent Bortezomib (PS-341, NSC 681239, IND# 58443) and Carboplatin (NSC# 241240) in Patients with Persistent or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="01-27-2010 15:49:27">
                    <nciDocumentNumber>E1808</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E1808</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="04-01-2010 14:10:14">
                    <nciDocumentNumber>8449</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial of Lenalidomide and Radiotherapy in Children with Diffuse Intrinsic Pontine Gliomas and High-Grade Gliomas</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-12-2012 10:41:39" createdDate="04-14-2010 14:16:37">
                    <nciDocumentNumber>8727</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>2010-0247</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase 2 Study of MK-2206 in Comparison with Everolimus in Refractory Renal Cell Carcinoma</documentTitle>
                    <currentStatus>Approved</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:45">
                    <nciDocumentNumber>NCCTG-90-46-52</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-90-46-52</localDocumentNumber>
                        <localDocumentNumber>SWOG-9401</localDocumentNumber>
                        <localDocumentNumber>90-46-52</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Controlled Phase III Evaluation of 5FU Combined with Levamisole and Leucovorin as Surgical Adjuvant Treatment Following Total Gross Resection of Metastatic Colorectal Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:45">
                    <nciDocumentNumber>POG-7615</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-7615</localDocumentNumber>
                        <localDocumentNumber>SWOG-7615</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>SWOG modified SLA2-l2 Therapy for Non-Hodgkin's Lymphoma, other than Burkitt's Tumor, in children - Phase II</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:46">
                    <nciDocumentNumber>E4494</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E4494</localDocumentNumber>
                        <localDocumentNumber>E4494</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Trial of CHOP Versus CHOP and Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Older Patients with Diffuse Mixed, Diffuse Large Cell and Immunoblastic Large Cell Histology Non-Hodgkin's Lymphoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:46">
                    <nciDocumentNumber>POG-7816</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-7816</localDocumentNumber>
                        <localDocumentNumber>SWOG-7816</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Combination therapy with Adriamycin and Cis-Diamminedichloroplatinum in children with metastatic Neuroblastoma (stage IV) resistant toVincristine and Cytoxan - Phase II</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:47">
                    <nciDocumentNumber>T95-0037</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>95-C-0030</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A pediatric Phase I trial and pharmacokinetic study of lgd1057 (9-cis-retinoic acid)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:47">
                    <nciDocumentNumber>T93-0109</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>93-C-0210</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial of D1694, an Inhibitor of Thymidylate Synthase, in Pediatric Patients with Advanced Neoplastic Disease</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:47">
                    <nciDocumentNumber>A0935A</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCG-0935</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Chimeric Human/Murine Anti-GD2 Monoclonal Antibody (CH14.18) with GM-CSF and Interleukin-2 (IL-2) in Children with Neuroblastoma and Other GD2 Positive Malignancies Immediately Post Autologous BMT or PBSC Rescue</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:50:47">
                    <nciDocumentNumber>POG-9406</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9406</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>ALINC 16: Protocol for Patients with newly diagnosed high risk Acute LYMPHOBLASTIC  LEUKEMIA -A PEDIATRIC ONCOLOGY  GROUP  PHASE  III Study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:47">
                    <nciDocumentNumber>E3194</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E3194</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase IB/II evaluation of the Bispecific Murine Monoclonal Antibody 2b1 in patients with Advanced Breast Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:48">
                    <nciDocumentNumber>POG-9464</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9464</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>CYCLOPHOSPHAMIDE   plus TOPETECAN in children with recurrent or Refractory SOLID TUMORS: a Pediatric ONCOLOGY  Group Phase II study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:48">
                    <nciDocumentNumber>POG-9572</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9572</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Bryostatin I in Children with Solid Tumors: A Pediatric Oncology Group Phase I Cooperative Agreement Study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:48">
                    <nciDocumentNumber>RTOG-96-15</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-96-15</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Multi-institutional Trial of Targeted Supradose Cisplatin Chemoradiation for Stage IV Squamous Cell Carcinoma of the Head and Neck</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:48">
                    <nciDocumentNumber>S9715</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S9715</localDocumentNumber>
                        <localDocumentNumber>S9715</localDocumentNumber>
                        <localDocumentNumber>S9715</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>S9715, Study of Patients with Advanced Nasopharyngeal Cancers Treated with Chemo-Radiotherapy, Phase II</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:48">
                    <nciDocumentNumber>INT-0141</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-9321</localDocumentNumber>
                        <localDocumentNumber>CALGB-9312</localDocumentNumber>
                        <localDocumentNumber>S9321</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Standard Dose Versus Myeloblative Therapy for Previously Untreated Symptomatic Multiple Myeloma: Phase III</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:48">
                    <nciDocumentNumber>INT-0128</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCG-9891</localDocumentNumber>
                        <localDocumentNumber>POG-9130</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Treatment of Newly Diagnosed Low-Grade Astrocytomas: A Phase III Study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>NCCTG-83-43-52</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-83-43-52</localDocumentNumber>
                        <localDocumentNumber>83-43-52</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of Bisantrene administered by continuous 72-hour infusion for advanced measurable Pancreatic Carcinoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>E8892</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E8892</localDocumentNumber>
                        <localDocumentNumber>E8892</localDocumentNumber>
                        <localDocumentNumber>E8892</localDocumentNumber>
                        <localDocumentNumber>E8892</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Trial of Orchiectomy/LHRH Analog + Flutamide + Suramin + Hydrocortisone vs. Orchiectomy/LHRH Analog + Flutamide in Patients with Metastatic Prostate Cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>C9581</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCIC CTG C0.14</localDocumentNumber>
                        <localDocumentNumber>C9581</localDocumentNumber>
                        <localDocumentNumber>C9581</localDocumentNumber>
                        <localDocumentNumber>C9581</localDocumentNumber>
                        <localDocumentNumber>C9581</localDocumentNumber>
                        <localDocumentNumber>C9581</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Randomized Study of Adjuvant Immunotherapy with Monoclonal Antibody 17-1A  Versus No Adjuvant Therapy Following Resection for Stage II (Modified Astler-Coller B2) Adenocarcinoma of the Colon</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>INT-0135</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-91-46-53</localDocumentNumber>
                        <localDocumentNumber>CO.9</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III evaluation of high-dose levamisole plus 5-fluorouracil and leucovorin as surgical adjuvant therapy for high-risk colon cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>SWOG-9300</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-9300</localDocumentNumber>
                        <localDocumentNumber>S9300</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase II Evaluation of All Trans-Retinoic Acid (ATRA) with Interferon-Alfa 2a (IFN-alfa2a) or All-Trans-Retinoic Acid with Hydroxyurea (HU) in Patients with Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>INT-0154</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9354</localDocumentNumber>
                        <localDocumentNumber>CCG-7942</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Evaluation of Intensified Vincristine, Doxorubicin, Cyclophosphamide, Ifosfamide, and Etoposide in the Treatment of Newly-Diagnosed Ewing's Sarcoma or Primitive Neuroectodermal Tumor of Bone or Soft Tissue</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>SWOG-9239</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-9239</localDocumentNumber>
                        <localDocumentNumber>S9239</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of sequential modification of immunosuppression, interferon alpha, and promace-cytabom for treatment of post-cardiac transplant lymphoproliferation</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>E3489</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-3489</localDocumentNumber>
                        <localDocumentNumber>CALGB-9120</localDocumentNumber>
                        <localDocumentNumber>SWOG-9034</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III study of three intensive post-remission therapies in adult acute non-lymphocytic Leukemia: comparison of autologous bone marrow transplantation, intensive chemotherapy and allogeneic bone marrow transplantation</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>INT-0100</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-8814</localDocumentNumber>
                        <localDocumentNumber>CALGB-9194</localDocumentNumber>
                        <localDocumentNumber>EST-4188</localDocumentNumber>
                        <localDocumentNumber>NCCTG-88-30-51</localDocumentNumber>
                        <localDocumentNumber>MA.9</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Comparison of Adjuvant Chemoendocrine Therapy with CAF and Concurrent or Delayed Tamoxifen to Tamoxifen Alone in Postmenopausal Patients with Involved Axillary Lymph Nodes and Positive Receptors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>INT-0086</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-8794</localDocumentNumber>
                        <localDocumentNumber>INT-0086</localDocumentNumber>
                        <localDocumentNumber>EST-9887</localDocumentNumber>
                        <localDocumentNumber>NCCTG-89-52-51</localDocumentNumber>
                        <localDocumentNumber>PR.2</localDocumentNumber>
                        <localDocumentNumber>RTOG-90-19</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Treatment of pathologic stage c carcinoma of the prostate with adjuvant radiotherapy:  Phase III</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:52">
                    <nciDocumentNumber>NCCTG-84-61-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-84-61-51</localDocumentNumber>
                        <localDocumentNumber>84-61-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase iii comparison of cyclophosphamide plus cbdca vs cyclophosphamide plus cddp in stage iii and iv ovarian carcinoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:52">
                    <nciDocumentNumber>INT-0113</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-89-11</localDocumentNumber>
                        <localDocumentNumber>CALGB-9091</localDocumentNumber>
                        <localDocumentNumber>ECOG-3290</localDocumentNumber>
                        <localDocumentNumber>NCCTG-90-40-51</localDocumentNumber>
                        <localDocumentNumber>SWOG-9013</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III intergroup trial: a prospective randomized comparison of combined modality therapy for squamous carcinoma of the esophagus:  chemotherapy plus surgery versus surgery alone for patients with local regional disease</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:53">
                    <nciDocumentNumber>E1380</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-1380</localDocumentNumber>
                        <localDocumentNumber>RTOG-81-07</localDocumentNumber>
                        <localDocumentNumber>SEG-INT-81-304</localDocumentNumber>
                        <localDocumentNumber>SWOG-8094</localDocumentNumber>
                        <localDocumentNumber>GRP-80-002</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Radiotherapy with and without Chemotherapy for malignant pleural Mesothelioma localized to one Hemithorax, Phase III intergroup Mesothelioma study I</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:54">
                    <nciDocumentNumber>CCG-9933</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCG-9933</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of high dose pre-irradiation chemotherapy (cyclophosphamide/vp-16/mesna or ifosfamide/vp-16/mesna or carboplatin/vp-16) in children with newly diagnosed high-grade astrocytoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:55">
                    <nciDocumentNumber>CCG-9942</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCG-9942</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Groupwide Trial of Pre-Irradiation Vincristine, Cisplatin, Cyclophosphamide and vp-16 Chemotherapy for Children 3 to 21 Years with Newly-Diagnosed Intracranial Ependymoma and Radiologic Evidence of Postoperative Residual Tumor</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:57">
                    <nciDocumentNumber>SWOG-8830</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-8830</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of continuous infusion recombinant interleukin-2 (ril-2) in patients with ovarian cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:59">
                    <nciDocumentNumber>GOG-0093</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-93</localDocumentNumber>
                        <localDocumentNumber>NCCTG-89-61-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Evaluation of Intraperitoneal Chronic Phosphate Suspension Therapy Following Negative Second-Look Laparotomy for Epithelial Ovarian Carcinoma, Stage III: Phase III</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:00">
                    <nciDocumentNumber>E2496</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E2496</localDocumentNumber>
                        <localDocumentNumber>E2496</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III Trial of ABVD Versus Stanford V +/- Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:01">
                    <nciDocumentNumber>JMA17</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MA.17</localDocumentNumber>
                        <localDocumentNumber>CALGB-49805</localDocumentNumber>
                        <localDocumentNumber>JMA.17</localDocumentNumber>
                        <localDocumentNumber>JMA.17</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Randomized Double Blind Study of Letrozole Versus Placebo in Women with Primary Breast Cancer Completing Five or More Years of Adjuvant  Tamoxifen (NCiC CTG MA.17)</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:01">
                    <nciDocumentNumber>NABTC-9801</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTC-9081</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II Trial of Irinotecan (CPT-11) in Patients with Recurrent Malignant Glioma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:01">
                    <nciDocumentNumber>RTOG-98-06</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-98-06</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Conventional Radiation Therapy Plus Thalidomide for Supratentorial Glioblastoma</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:01">
                    <nciDocumentNumber>POG-9631</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9631</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II feasibility study of oral Etoposide given concurrently with radiotherapy followed with dose intensive adjuvant chemotherapy for children with newly diagnosed high stage Medulloblastoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:01">
                    <nciDocumentNumber>T93-0057</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>BTRC 9332</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of Taxol chemotherapy for recurrent malignant glioma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:01">
                    <nciDocumentNumber>T97-0063</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Bryostatin-1 for the Treatment of Stage IV Breast Cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:01">
                    <nciDocumentNumber>AMC-008</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>AMC-008</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Pre-Phase II Trial of Interleukin-12 Following Response to Ifosfamide/Etoposide Chemotherapy for Refractory HIV-Associated Non-Hodgkin's Lymphoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:02">
                    <nciDocumentNumber>POG-8494</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-8494</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of Fludarabine Phosphate in Pediatric patients</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:02">
                    <nciDocumentNumber>W83-0538</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>83-C-37</localDocumentNumber>
                        <localDocumentNumber>71-15-09</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Pediatric Phase I study of 6-mercaptopurine administered by prolonged intravenous infusion</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:02">
                    <nciDocumentNumber>POA-99380</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POA-99380</localDocumentNumber>
                        <localDocumentNumber>BGSM-99380</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Vinca infusion:  a Phase II trial</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:03">
                    <nciDocumentNumber>INT-0114</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-9081</localDocumentNumber>
                        <localDocumentNumber>EST-4290</localDocumentNumber>
                        <localDocumentNumber>NCCTG-90-47-51</localDocumentNumber>
                        <localDocumentNumber>CO.6</localDocumentNumber>
                        <localDocumentNumber>RTOG-90-14</localDocumentNumber>
                        <localDocumentNumber>SWOG-9040</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Intergroup Rectal Adjuvant Protocol-A Phase III Study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:03">
                    <nciDocumentNumber>T90-0016</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>90-C-91</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of pentosan polysulfate in patients with advanced malignancies</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:03">
                    <nciDocumentNumber>T84-0268</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>84-03-02-03</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of trimetrexate</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:04">
                    <nciDocumentNumber>NCCTG-89-72-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-89-72-51</localDocumentNumber>
                        <localDocumentNumber>89-72-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of 5-Fluorouracil and Leucovorin in recurrent primary brain tumor</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:04">
                    <nciDocumentNumber>T83-1257</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>83-C-143</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase 1 trial of poly iclc in cancer patients</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:06">
                    <nciDocumentNumber>T86-0286</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>LAK-MEL-II</localDocumentNumber>
                        <localDocumentNumber>EST-P-X688</localDocumentNumber>
                        <localDocumentNumber>86-12-346</localDocumentNumber>
                        <localDocumentNumber>SWOG-8637</localDocumentNumber>
                        <localDocumentNumber>867-5011-113</localDocumentNumber>
                        <localDocumentNumber>6330</localDocumentNumber>
                        <localDocumentNumber>CSU-422</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of patients with metastatic or unresectable malignant melanoma with high dose il-2 and autologous lak cells</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:06">
                    <nciDocumentNumber>T86-0239</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CO-8699</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I trial of combination recombinant gamma interferon and recombinant tumor necrosis factor</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:06">
                    <nciDocumentNumber>T86-0210</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>OSP-86-229</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Evaluation of ifosfamide in advanced cervical cancer: Phase II</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:07">
                    <nciDocumentNumber>SEG-RAL-P51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-RAL-P51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II pilot study of indicine-n-oxide in refractory adult acute leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:07">
                    <nciDocumentNumber>SEG-LUN-80-271</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-LUN-80-271</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Amsa Phase II study in advanced small cell carcinoma of the lung</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:07">
                    <nciDocumentNumber>EST-3477</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-3477</localDocumentNumber>
                        <localDocumentNumber>N81-1004</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II master protocol for the evaluation of agents in patients with multiple Myeloma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:07">
                    <nciDocumentNumber>EST-2887</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-2887</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of Trimetrexate in advanced carcinoma of the Urothelium</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:07">
                    <nciDocumentNumber>EST-P-Y987</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-P-Y987</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I trial of recombinant Interleukin-2 and recombinant Interferon Gamma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:07">
                    <nciDocumentNumber>EST-P-A387</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-P-A387</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study for the evaluation of Spiromustine in metastatic Brain tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:08">
                    <nciDocumentNumber>D82-013-1082</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NU-82H3</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Methyl-g Phase II in refractory multiple myeloma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:09">
                    <nciDocumentNumber>T85-0257</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>OSU-8604</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I clinical and pharmacokinetic investigation of merbarone</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:10">
                    <nciDocumentNumber>CALGB-8421</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-8421</localDocumentNumber>
                        <localDocumentNumber>T84-1411</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>5-azacytidine to induce differentiation in myelodyplastic syndromes, a Phase I/II pilot study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:10">
                    <nciDocumentNumber>INT-0067</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-8516</localDocumentNumber>
                        <localDocumentNumber>EST-3487</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III comparison of chop versus m-bacod vs. pro-mace-cytabom vs. macop-b in patients with intermediate or high grade non-hodgkin's lymphoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:11">
                    <nciDocumentNumber>POG-8774</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-8774</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I trial ofMenogaril in children with Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:11">
                    <nciDocumentNumber>T91-0054</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>91-C-104</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I trial of amifostine (wr2721) and melphalan in pediatric patients with advanced neoplastic disease</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:11">
                    <nciDocumentNumber>POG-9173</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9173</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I trial of intravenous 6-Thioguanine (6-TG) in children with Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia, A PediatricOncology study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:12">
                    <nciDocumentNumber>NCCTG-92-77-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>92-77-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Taxotere in Advanced Soft Tissue Sarcomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:12">
                    <nciDocumentNumber>T93-0140</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I trial of tnp-470, a new inhibitor of angiogenesis</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:13">
                    <nciDocumentNumber>T84-0480</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>84-C-210</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of 6-mercaptopurine administered as an intravenous infusion for malignant brain tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:13">
                    <nciDocumentNumber>POG-7818</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-7818</localDocumentNumber>
                        <localDocumentNumber>SWOG-7818</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Evaluation of Rubidazone in children  with Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia in relapse - Phase III</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:14">
                    <nciDocumentNumber>W83-0079</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UMCC-8226</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of cbdca in patients with advanced gynecologic malignancies</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:14">
                    <nciDocumentNumber>POG-7637</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-7637</localDocumentNumber>
                        <localDocumentNumber>SWOG-7637</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Simal 1: Second induction and maintenance in Acute Leukemia: induction with Vincristine and Prednisone with or without L-Asparaginase, maintenance treatment with Prednisone,Vincristine, Adriamycin and 6-Thioguanine - Phase III</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:14">
                    <nciDocumentNumber>POG-7325</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-7325</localDocumentNumber>
                        <localDocumentNumber>SWOG-7325</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Adriamycin versusVincristine, Adriamycin and Prednisone in the induction of remission in children with Acute Leukemia, Phase III</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:14">
                    <nciDocumentNumber>T84-0384</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II trial of amsacrine with high dose cytarabine in the treatment of resistant leukemia or acute leukemia in relapse</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:15">
                    <nciDocumentNumber>W81-0773</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DT-81-40</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I evaluation of homoharringtonine in patients with leukemia and solid tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:15">
                    <nciDocumentNumber>W81-1021</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UMCC-8136</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I clinical and pharmacologic trial of platinum diammine (1,1-cyclobutane-dicarboxylate (2)-0;o') (cbdca nsc 241240)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:15">
                    <nciDocumentNumber>POA-59186</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POA-59186</localDocumentNumber>
                        <localDocumentNumber>T84-0456</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Sequential Methotrexate and 5-Flourouracil in the treatment of metastatic Colorectal Carcinoma: Phase III</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:15">
                    <nciDocumentNumber>GITSG-4C85</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GITSG-4C85</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of Recombinant Gamma Interferon in patients with measurable, Metastatic Carcinoid</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:15">
                    <nciDocumentNumber>W81-0257</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UMCC-8110</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Bisantrene straight Phase II refractory lymphomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:17">
                    <nciDocumentNumber>EST-9487</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-9487</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Ancillary laboratory study in conjunction with the Phase III clinical trials: EST-9486 - the treatment of multiple Myeloma utilizing VBMCP Chemotherapy with or without intensification or Alpha-2 Interferon</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:18">
                    <nciDocumentNumber>T90-0068</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>OC-90-4</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I trial of cytoxan and vp-16, plus total body irradiation or bcnu, and interleukin 2 activated bone marrow for transplantation therapy of refractory hematologic malignancies</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:19">
                    <nciDocumentNumber>N80-0056</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>79-C-120</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of AZQ in cancer patients</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:24">
                    <nciDocumentNumber>NCCTG-89-82-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-89-82-51</localDocumentNumber>
                        <localDocumentNumber>89-82-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II evaluation of Somatostatin Analogue (SMS 201-995, Sandostatin) in the therapy of measurable or evaluable hematologic malignancies</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:25">
                    <nciDocumentNumber>T83-1358</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>WOG-1582</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of 5-day vinblastine (velban) infusion in non-small cell carcinoma of the lung</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:25">
                    <nciDocumentNumber>T83-1302</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>834-05-041</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I and pharmacokinetic study of intraperitoneal 2-fluoro-ara-amp for peritoneal cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:26">
                    <nciDocumentNumber>T89-0099</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ONC-113</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of triciribine phosphate(tcn-p,tricyclic nucleoside 5'phosphate [nsc-280594]) in the treatment of advanced non small cell lung cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:26">
                    <nciDocumentNumber>T89-0066</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>89-C-43</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A pilot study to determine the feasibility of treating &lt;4 year old children with brain tumors with thiotepa in a Phase II window and as a component of a multimodality treatment regimen</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:26">
                    <nciDocumentNumber>NCCTG-85-81-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-85-81-51</localDocumentNumber>
                        <localDocumentNumber>85-81-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study for attenuated high dose ARA-C  in the treatment of Acute Nonlymphocytic Leukemia in patients older than 65</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:27">
                    <nciDocumentNumber>B89-0002</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RPC-2224</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase IA/IB clinical trial of R24 in combination with WR-2721 and Cisplatin in patients with malignant melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:27">
                    <nciDocumentNumber>T88-0269</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>89-C-44</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I trial of Anti-CD3 monoclonal antibodies in patients with advanced Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:27">
                    <nciDocumentNumber>T88-0210</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>88-C-183</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II evaluation of thiotepa in pediatric central nervous system tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:28">
                    <nciDocumentNumber>T88-0187</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>BGSM-89188</localDocumentNumber>
                        <localDocumentNumber>POA-89188</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II trial continuous 5-day intravenous fudr infusion for renal cell carcinoma: a clinical study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:28">
                    <nciDocumentNumber>CALGB-8881</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-8881</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I trial of recombinant granulocyte macrophage colony stimulating factor (gm-csf) plus cyclophosphamide in solid tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:28">
                    <nciDocumentNumber>POG-8871</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-8871</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of Recombinant Human Tumor Necrosis Factor (RTNF) in children with Refractory Tumors:  a Pediatric Oncology Group study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:29">
                    <nciDocumentNumber>T88-0001</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>8026</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of interleukin-2 (il-2) plus doxorubicin in solid tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:29">
                    <nciDocumentNumber>T87-0293</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>871102</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of combination iododeoxyuridine and bleomycin in patients with advanced cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:29">
                    <nciDocumentNumber>T87-0278</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>IL2-BOLUS/CI-LAK-REN</localDocumentNumber>
                        <localDocumentNumber>11/87-5B</localDocumentNumber>
                        <localDocumentNumber>878-5011-117</localDocumentNumber>
                        <localDocumentNumber>7146</localDocumentNumber>
                        <localDocumentNumber>CSU-434</localDocumentNumber>
                        <localDocumentNumber>H2381-02779-01</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Phase II study of patients with renal cell carcinoma treated with high dose il-2 by iv bolus or continuous infusion in combination with autologous lymphokine activated killer cells</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:29">
                    <nciDocumentNumber>T87-0203</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>87-C-129</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Anti-tumor and immunological correlates of individualized chronic interleukin- 2 administration: a Phase I b/ii study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:30">
                    <nciDocumentNumber>T87-0002</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>WCC-7086</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Pharmacokinetics and Phase I studies of continuous infusion intraarterial il-2 in patients with advanced primary or recurrent malignant melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:30">
                    <nciDocumentNumber>T86-0258</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>WCC-1186</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Pharmacokinetic and Phase I studies in patients with peritoneal carcinomatosis from colorectal cancer using ip il-2 via a tenckhoff catheter</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:30">
                    <nciDocumentNumber>T86-0226</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>6G-87-1</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III study of no therapy vs radiation therapy vs eflornithine (dfmo) plus methylbisguanylhydrazone (mgbg) for non-enhancing moderately and mildly anaplastic gliomas of the brain</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:30">
                    <nciDocumentNumber>T86-0168</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>LAK-NHL-UNFAV</localDocumentNumber>
                        <localDocumentNumber>EST-P-X488</localDocumentNumber>
                        <localDocumentNumber>7/86-6D</localDocumentNumber>
                        <localDocumentNumber>86-12</localDocumentNumber>
                        <localDocumentNumber>SWOG-8619</localDocumentNumber>
                        <localDocumentNumber>856-5011-285</localDocumentNumber>
                        <localDocumentNumber>804808-01A</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of patients with non-hodgkins lymphoma (unfavorable histology) with high dose il-2 and autologous lak cells</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:31">
                    <nciDocumentNumber>T83-1060</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>82-C-202</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II trial of plasma perfused over immobilized protein a in patients with Breast cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:33">
                    <nciDocumentNumber>SEG-LUN-76-308</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-LUN-76-308</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III randomized adjuvant immunotherapy with Levamisole and radiation therapy, vs. radiation therapy plus Placebo in limited extent medically inoperable or unresectable Non-Oat Cell Carcinoma of the Lung</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:33">
                    <nciDocumentNumber>SEG-LEU-206</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-LEU-206</localDocumentNumber>
                        <localDocumentNumber>EST-2488</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of Cyclosporine in the treatment of Myelodysplastic Syndrome</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:34">
                    <nciDocumentNumber>EST-1878</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-1878</localDocumentNumber>
                        <localDocumentNumber>N81-0990</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II evaluation of VM-26 in patients with metastatic Transitional Cell carcinoma of the urinary tract: an Eastern Cooperative Oncology Group study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:35">
                    <nciDocumentNumber>EST-P-C485</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-P-C485</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A multiple dose Phase II study of the treatment of chronic Lymphocytic leukemia with recombinant Interleukin-2</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:35">
                    <nciDocumentNumber>EST-P-B687</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-P-B687</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of Didemnin B (NSC 325319) in advanced malignant Melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:35">
                    <nciDocumentNumber>EST-P-B184</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-P-B184</localDocumentNumber>
                        <localDocumentNumber>T84-0244</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II evaluation of the cyclic administration of the combination Chemotherapy regimens CAF, D(DHAD)V and TSAVB in women with metastatic Breast cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:35">
                    <nciDocumentNumber>D82-043-0192</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DT-81-37</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I high-dose combination chemotherapy with autologous marrow pretreated with monoclonal antibodies--adult</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:35">
                    <nciDocumentNumber>D82-012-0899</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ICC-82N5</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Treatment of advanced head and neck cancer with htsca directed therapy or Phase II agents</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:36">
                    <nciDocumentNumber>D78-048-0062</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>77-480-013</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Dibromodulcitol Phase II single dose schedule in selected carcinomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:37">
                    <nciDocumentNumber>SEG-GU-303</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-GU-303</localDocumentNumber>
                        <localDocumentNumber>SWOG-8788</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III evaluation of high dose versus standard dose Cisplatin combined with Bleomycin and VP-16 for advanced Metastatic Testicular Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:39">
                    <nciDocumentNumber>T85-0236</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>BTRC-8525</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of spirohydantoin mustard for the treatment of recurrent adult and childhood malignant gliomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:40">
                    <nciDocumentNumber>C79-0178</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DT-79-42</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II evaluation of pala in metastatic colorectal cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:40">
                    <nciDocumentNumber>T85-0172</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>374-85-7</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of intravenous melphalan (l-phenylalanine mustard, nsc-8806) in the treatment of patients with anaplastic gliomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:42">
                    <nciDocumentNumber>SEG-AML-202P</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-AML-202P</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A limited access Phase II study of Daunorubicin plus high-dose Cytosine Arabinoside as induction and consolidation therapy for Acute Myelogenous Leukemia (for patients >= 51 years of age)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:44">
                    <nciDocumentNumber>SEG-AE-83-343</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-AE-83-343</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III randomized study of Nabilone and Dexamethasone compared with Chloropromazine and Dexamethasone as antiemetic therapy for patients with limited Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:47">
                    <nciDocumentNumber>CALGB-8525</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-8525</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III comparative study of post-remission intensive ARA-C in patients with Acute Non-Lymphocytic Leukemia in first remission</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:47">
                    <nciDocumentNumber>B85-0015</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CO-8693</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I evaluation of Autologous and Allogenic in vitro activated Cytotoxic cells combined with recombinant IL-2 given by 7 day continous infusion: A study of optimal biologic dose and clinical tolerance</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:47">
                    <nciDocumentNumber>B82-0990</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>72-82</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of Wellferon (purified natural Alpha Interferon) in Metastatic Malignant Melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:47">
                    <nciDocumentNumber>RTOG-84-13</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-84-13</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II dose-searching randomized study of fast neutrons for Tumors located in the Head and Neck</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:48">
                    <nciDocumentNumber>RTOG-84-05</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-84-05</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II dose escalating trial of accelerated fractionation in the pallative irradiation of Hepatic Metastases</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:48">
                    <nciDocumentNumber>RTOG-84-11</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-84-11</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III randomized study, RT and Hyperthermia vs RT alone in pts with Advanced Head and Neck, Breast, BR or soft tissue Tumors who have probability of significant survival or are potentially curable w/ RT</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:49">
                    <nciDocumentNumber>POG-8865</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-8865</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II: Recombinant Alpha-Interferon in relapsed T-Cell disease</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:49">
                    <nciDocumentNumber>POG-8759</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-8759</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>The effectiveness of Phase II agents in untreated Metastatic Osteosarcoma (MOS) or unresectable primary Osteosarcoma vs. previously treated recurrent Osteosarcoma: Phase II /III</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:49">
                    <nciDocumentNumber>GOG-76H</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-76H</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of Echinomycin (NSC#526417) in patients with Advanced Squamous Cell Carcinoma of the Cervix</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:50">
                    <nciDocumentNumber>GOG-42</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-42</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A treatment of Recurrent or Advanced Uterine Sarcoma - a randomized comparison of Adriamycin versus Adriamycin and Cyclophosphamide - Phase III</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:50">
                    <nciDocumentNumber>GOG-45</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-45</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Evaluation of Vinblastine, Bleomycin and Cis-Platinum in stage III, IV and Recurrent Malignant Germ Cell Tumors of the Ovary - Phase III</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:50">
                    <nciDocumentNumber>T90-0172</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PCI 92-36</localDocumentNumber>
                        <localDocumentNumber>DUGU 90-02</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of high dose intravenous Cyclophosphamide with GM-CSF in Hormone-Refractory Metastatic Prostate Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:51">
                    <nciDocumentNumber>EST-P-Z690</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-P-Z690</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A multicenter study of Phase I therapy of malignant Melanoma using Interleukin-2, A-Interferon and R24 Monoclonal Antibody</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:51">
                    <nciDocumentNumber>T91-0026</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>91-C-168</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I evaluation of intravenously administered 131I-Col-1 Monoclonal antibody in patients with Advanced Colorectal or Gastric Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:51">
                    <nciDocumentNumber>T91-0103</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase I trial of interleukin-1 alpha and carboplatin in patients with solid tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:51">
                    <nciDocumentNumber>T91-0105</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DM-91-042</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Carboplatin and Edatrexate (10-ETX) with Leucovorin rescue for patients with Recurrent Squamous Cell Carcinoma of the Head and Neck</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:52">
                    <nciDocumentNumber>T92-0026</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>92-04-128</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II clinical trial of recombinant Alfa-2A-Inteferon and All-Trans Retinoic Acid in patients with Advanced, recurrent or inoperable Carcinoma of the Cervix: A New York GOG Study.</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:52">
                    <nciDocumentNumber>T92-0033</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>HSC-91-120</localDocumentNumber>
                        <localDocumentNumber>HSC-91-120</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II trial of combined treatment with Recombinant Human Erythropoietin (Rhuepo) and Rhuil-3 (SDZ ILE 964) in patients with Myelodysplastic Syndromes.</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:53">
                    <nciDocumentNumber>T92-0075</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DM92-046</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Taxol (NSC# 125973) in patients with Non-Small Cell Lung Cancer who have failed platinum-containing chemotherapy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:53">
                    <nciDocumentNumber>T92-0083</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>92-C-0219</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of Hyperthermic isolated limb perfusion with Melphalan, Tumor Necrosis factor and Inteferon-Gamma as a limb salvage strategy in patients with locally unresectable Sarcoma or Melanoma of the extremity</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:53">
                    <nciDocumentNumber>GOG-9203</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-9203</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I trial of Taxol (NSC #125973) in combination with Etoposide in patients with Refractory Ovarian Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:53">
                    <nciDocumentNumber>T92-0214</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>93-02-040</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of Taxotere in Patients with Metastatic Melanoma Previously Untreated with Cytotoxic Chemotherapy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:53">
                    <nciDocumentNumber>T92-0237</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>93-C-0087</localDocumentNumber>
                        <localDocumentNumber>M1356XB</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Topotecan in combination with Doxorubicin</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:53">
                    <nciDocumentNumber>T92-0232</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>92-80</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I trial of Interleukin-1 Alpha and Carboplatin in patients with metastatic disease to the lung: Effects on tumor blood flow evaluated by Position Emission Tomography (PET)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:54">
                    <nciDocumentNumber>T93-0049</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of Interleukin-6(IL-6, SDZ ILS 969) administered by one-hour intravenous infusion in patients with Metastatic Melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:54">
                    <nciDocumentNumber>T92-0254</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Multi-center Phase I trial of Interleukin-1 Alpha and Dacarbazine in patients with solid tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:54">
                    <nciDocumentNumber>T93-0078</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>95-C-0005</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of Antineoplastons A10 and AS2-1 in patients with advanced recurrent Malignant Astrocytomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:54">
                    <nciDocumentNumber>T93-0154</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>93-144</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of Semi-Synthetic Taxol (Paclitaxel) in patients with advanced Carcinoma of the Breast</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:54">
                    <nciDocumentNumber>T93-0178</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>94-C-0084</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of Paclitaxel by 96-hour continuous infusion in patients with B-Cell chronic Lymphocytic Leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:55">
                    <nciDocumentNumber>T94-0145</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of Pyrazine Diazohydroxide (NSC 361456) administered daily for five days in patients with metastatic Renal Cell Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:55">
                    <nciDocumentNumber>T95-0009</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase II treatment of adults with primary malignant Glioma with Topotecan (NSC #609699)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:56">
                    <nciDocumentNumber>EST-8290</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-8290</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of Taxol (NSC 125973) in patients with Adenocarcinomas of the upper gastrointestinal tract</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:56">
                    <nciDocumentNumber>T97-0069</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ID 97-077</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Randomized Prospective Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer - Patients at High Risk for Recurrence</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:56">
                    <nciDocumentNumber>POG-9879</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9879</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Vincristine, Etoposide and Cyclosporine A in Concert with Standard Dose Radiation Therapy in Diffuse Intrinsic Brain Stem Glioma - A Phase I Study of Dose Escalation of Vincristine</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-12-1999 16:41:52">
                    <nciDocumentNumber>CALGB-19804</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-19804</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Newly Diagnosed Patients with  BCR/ABL  (+)  Chronic Myelogenous  Leukemia Treated  with Combined  Homoharringtonine  (NSC #141633)  and Low-Dose Cytarabine.</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-22-1999 10:48:15">
                    <nciDocumentNumber>T98-0033</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UPC-4697</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Trial of a Dendritic Cell Vaccine for Melanoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-29-1999 18:06:18">
                    <nciDocumentNumber>T98-0008</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial  of MGI-114 (NSC# 683863) Administered as a Five-Minute Infusion Daily for Five Days Every 4 Weeks in Patients with Previously Untreated Advanced Colorectal Cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:18">
                    <nciDocumentNumber>E1297</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E1297</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of Preoperative Radiation Therapy with Concurrent Protracted Continuous Infusion 5-FU and Dose Escalating Oxaliplatin Followed by Surgery, 5-FU, and Leucovorin for Locally Advanced (T3  and T4) Rectal Adenocarcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>CALGB-9351</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-9351</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study Of High Dose Chop in Previously Untreated Low intermediate, High intermediate, and High Risk Non-Hodgkin'S Lymphoma:  Iwf Grades E-H</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>T95-0050</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>95-81-01</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of Continuous Infusion Carboplatin and Topotecan in the Treatment of Relapsed Acute Leukemia and Blast Crisis Chronic Myelogenous Leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>T95-0081</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>OC-94-2 (PHI-05)</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/PHARMACODYNAMIC study of Sequence Dependency of IV HYDROXYUREA in combination with FLUOROURACIL</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>T95-0071</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>PHASE I study 5-FU, LEUKOVORIN and TOPOTECAN (NSC #609699) in patients with ADVANCED CANCER</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>T96-0020</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase II  Evaluation of  CI-980 in untreated extensive stage SMALL  CELL  LUNG  CANCER</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>T96-0059</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UPCI 96-035</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of Percutaneous Injections of Adeno-Virus p53 Construct (Adeno-p53) for Hepatocellular Carcinoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>T97-0068</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CO 9611</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial Of PERILLYL ALCOHOL (NSC 641066) Administered Daily In Patients With METASTATIC BREAST CANCER</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>T99-0027</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PH2/039</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of Bryostatin 1 in Ovarian Cancer administered by weekly 24 hour Intravenous Infusion</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>NCCTG-98-43-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-98-43-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I (Limited) / Phase II Study of Oxaliplatin(OXAL) and Gemcitabine (GEMZAR) in Patients with Metastatic Pancreatic Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-29-1999 18:06:20">
                    <nciDocumentNumber>T91-0238</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                        <localDocumentNumber>92-C-0105</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III Trial Of Hyperthermic Isolated Limb Perfusion With Melphalan And Tumor Necrosis Factor In Patients With Localized Advanced Extremity Melanoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:21">
                    <nciDocumentNumber>T93-0064</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UMCC-9310</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Cpt-11, 5-Fluorouracil and Leucovorin</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:21">
                    <nciDocumentNumber>B93-0013</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UAC-2153</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase ii study of interferon enhanced single dose 131i-cc49 monoclonal antibody therapy in patients with metastatic prostate cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:21">
                    <nciDocumentNumber>T93-0166</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial Of Bizelesin (NSC 615291) Using A Single Bolus Infusion Given Every Twenty-eight (28) Days in Patients with Advanced Cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:21">
                    <nciDocumentNumber>T93-0176</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase ii study of melphalan plus bso in patients with metastatic melanoma with cutaneous lesions that can be serially biopsied</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="03-29-1999 18:06:22">
                    <nciDocumentNumber>T94-0067</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>94-C-0169</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial of Continuous Infusion Flavopiridol in Patients with Refractory Neoplasms</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:22">
                    <nciDocumentNumber>T95-0063</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase ii clinical trial of 9 cis retinoic acid (9cra) in patients with advanced, locally advanced, recurrent or inoperable carcinoma of the cervix: a new york gog study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>NABTT-9606</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>T96-0085</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase Ib Study To Evaluate The Safety And Tolerance Of Repetitive Daily Intravenous Doses Of Rsr13 Administered To Patients Receiving Cranial Radiation Therapy For Glioblastoma Multiforme</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>NABTT-9605</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>T96-0086</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Clinical And Pharmacologic Evaluation Of Phenylbutyrate In Patients With Refractory Malignant Gliomas: Study Of Continuous Exposure Oral Phenylbutrate On A Three-Times Daily Schedule</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T96-0101</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>96-11-08-11</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II and Pharmacologic Study of Flavopiridol (NSC  649890) in Patients with Advanced Colorectal Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T97-0067</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CO 9685</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Perillyl Alcohol (NSC 641066) Administered Daily in Patients with Metastatic Androgen Independent Prostate Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T97-0109</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Dose Escalation and Pharmacokinetics Study of the Radiosensitizer, Gadolinium Texaphyrin (Gd-Tex, NSC 695238) with Concurrent Radiotherapy in Advanced Biliary Tree and Pancreatic Cancers</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:24">
                    <nciDocumentNumber>T98-0007</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of Dolastatin 10 in Indolent Lymphoma and Chronic Lymphocytic Leukemia</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:24">
                    <nciDocumentNumber>T98-0042</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>H-63-21</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of Phenylbutyrate Given as a Continuous Infusion in Pediatric Patients with Progressive or Recurrent CNS Malignancy</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:24">
                    <nciDocumentNumber>E4697</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E4697</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized, Placebo-Controlled Phase III Trial of Yeast Derived GM-CSF Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients with "No Evidence of Disease" After Complete Surgical Resection of  "Locally Advanced" and/or Stage IV Melanoma</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 00:00:00">
                    <nciDocumentNumber>C89803</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>C89803</localDocumentNumber>
                        <localDocumentNumber>C89803</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Intergroup Trial of Irinotecan (CPT-11) (NSC #616348) Plus Fluorouracil/Leucovorin (5-FU/LV) Versus Fluorouracil/Leucovorin Alone After Curative Resection for Patients with Stage III Colon Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:24">
                    <nciDocumentNumber>T98-0085</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>99-C-0051</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Multi-Institutional Randomized Study of Immunization with the gp100:209-217(210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients with Metastatic Melanoma</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:24">
                    <nciDocumentNumber>T99-0009</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Oxaliplatin  in Urothelial  Cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:24">
                    <nciDocumentNumber>T99-0010</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Oxaliplatin in Combination with Fluorouracil and Leucovorin in Carcinoma of the Esophagus and Gastric Cardia</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:24">
                    <nciDocumentNumber>S9900</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S9900</localDocumentNumber>
                        <localDocumentNumber>S9900</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Paclitaxel/Carboplatin in Clinical Stage IB (T2N0), II (T1-2N1, T3N0) and Selected IIIA (T3N1) Non-Small Cell Lung Cancer (NSCLC)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:24">
                    <nciDocumentNumber>T99-0039</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHII-21</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Bryostatin in Combination with Cisplatin in Patients with Recurrent or Persistent Epithelial Ovarian Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 00:00:00">
                    <nciDocumentNumber>GOG-0179</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-0179</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III Study of Cisplatin Versus Cisplatin Plus Topotecan Versus MVAC (Closed to Patient Entry 07/31/2001) in Stage IVB, Recurrent or Persistent Squamous Cell Carcinoma of the Cervix</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:24">
                    <nciDocumentNumber>RTOG-99-05</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-99-05</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Study of Adjuvant Postoperative Irradiation with or without Cisplatin/Paclitaxel Chemotherapy Following TAH/BSO for Patients with Endometrial Cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:24">
                    <nciDocumentNumber>T99-0016</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Oxaliplatin in Patients  with Advanced Carcinoma of the Head and Neck</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="05-25-1999 10:03:15">
                    <nciDocumentNumber>CALGB-39809</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-39809</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II randomized trial of Gemcitabine / Docetaxel and Gemcitabine / Irinotecan in stage IIIB / IV Non-Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="05-26-1999 08:53:30">
                    <nciDocumentNumber>D9802</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>D9802</localDocumentNumber>
                        <localDocumentNumber>D9802</localDocumentNumber>
                        <localDocumentNumber>D9802</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>D9802, A Phase II "Up-Front Window Study" of Irinotecan (CPT-11) Combined with Vincristine Followed by Multimodal, Multiagent, Therapy for Selected Children and Adolescents with Newly Diagnosed Stage 4/Clinical Group IV Rhabdomyosarcoma: An IRS-V/STS Study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="06-03-1999 14:21:19">
                    <nciDocumentNumber>T99-0065</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHI-28</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Dose Escalation Study of UCN-01 Plus Cisplatin in Advanced Malignant Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="06-30-1999 10:21:19">
                    <nciDocumentNumber>T99-0082</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Clinical Trial of Bryostatin-1 and Cisplatin in Patients with Recurrent and /or Advanced Inoperable Squamous Cell, Adeno or Adenosquamous Cell Carcinoma of the Cervix</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="06-30-1999 10:40:51">
                    <nciDocumentNumber>T99-0048</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHI-27 (USC 0C-00-03)</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of PS-341 in Combination with 5-FU/LV in Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="07-07-1999 13:20:16">
                    <nciDocumentNumber>E1599</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E1599</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase II Trial of Paclitaxel-Carboplatin or Gemcitabine-Cisplatin in ECOG Performance Status 2 Non-Small Cell Lung Cancer Patients</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="08-02-1999 16:28:37">
                    <nciDocumentNumber>NABTT-9905</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTT-9905</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II  study of Pre-Radiation CPT-11  (IRINOTECAN)  in patients with newly Diagnosed   GLIOBLASTOMA  MULTIFORME.</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="08-19-1999 10:55:59">
                    <nciDocumentNumber>20</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RRC 56-99</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of R115777 (NSC 702818) an Inhibitor of Farnesyl Protein Transferase, in Patients with Hormone Refractory Prostate Cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="08-20-1999 10:58:52">
                    <nciDocumentNumber>T99-0090</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>01-C-0222</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Randomized, Cross-Over, Double-Blinded, Placebo-Controlled Trial of the Farnesyltransferase Inhibitor R115777 in Pediatric Patients with Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="08-30-1999 14:53:43">
                    <nciDocumentNumber>T99-0053</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>00-C-0080</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Double Blind Randomized Crossover Phase III Study of Oral Thalidomide Versus Placebo in Patients with Stage D0 Androgen Dependent Prostate Cancer Following Limited Hormonal Ablation</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="09-15-1999 17:39:32">
                    <nciDocumentNumber>ANBL0321</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ADVL0024</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Fenretinide (NSC# 374551, IND# 40294) in Children with Recurrent/Resistant High Risk Neuroblastoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="09-22-1999 16:01:10">
                    <nciDocumentNumber>98</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Scientific Exploratory Study of Epothilone B Analog (BMS-247550; NSC 710428) in Patients with Solid Tumors and Gynecological  Malignancies</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="10-12-1999 13:47:27">
                    <nciDocumentNumber>NABTT-9911</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTT-9911</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Trial of EMD 121974 for the Treatment of Patients with Recurrent Anaplastic Gliomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="10-20-1999 10:54:34">
                    <nciDocumentNumber>P9973</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>P9973</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of STI571 in Ph+ Leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="10-21-1999 14:45:46">
                    <nciDocumentNumber>330</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>00-002</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of SU5416 (NSC # 696819) in Previously Treated Patients with Advanced, Metastatic and/or Locally Recurrent Soft Tissue Sarcomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="10-29-1999 10:38:31">
                    <nciDocumentNumber>430</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ID99-208</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of 506U78 (NSC #686673) for Patients with Relapsed or Refractory Indolent  B-Cell or Peripheral T-Cell Lymphoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-07-1999 14:01:21">
                    <nciDocumentNumber>P9963</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>P9963</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Rebeccamycin Analogue (NSC #655649) in Children with Solid Tumors: A COG Phase II Study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="01-13-2000 10:53:16">
                    <nciDocumentNumber>S0003</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0003</localDocumentNumber>
                        <localDocumentNumber>S0003</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Phase III Trial of Carboplatin and Paclitaxel Plus Tirapazamine Versus Carboplatin and Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-12-2012 10:41:39" createdDate="03-08-2000 10:26:18">
                    <nciDocumentNumber>1652</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ID99-406</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Oxaliplatin in Relapsed and Refractory Non-Hodgkin's Lymphoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-09-2000 15:02:06">
                    <nciDocumentNumber>1672</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>00-060</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of Flavopiridol and Paclitaxel in Patients with Paclitaxel-Refractory Esophageal Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-22-2000 10:39:46">
                    <nciDocumentNumber>550</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>00-C-0224</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Clinical Trial of BMS-247550 (NSC 710428), an Epothilone B Analog, in Patients with Refractory Neoplasms</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="04-10-2000 17:50:53">
                    <nciDocumentNumber>S0004</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0004</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Tirapazamine/Cisplatin/Etoposide and Concurrent Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="04-26-2000 12:15:05">
                    <nciDocumentNumber>1352</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UMGCC 0038</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Trial of Benzoylphenylurea (NSC# 639829) in Advanced Malignancy</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="04-27-2000 12:59:24">
                    <nciDocumentNumber>1312</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>01-C-0049</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of Depsipeptide in Patients with Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="05-03-2000 13:56:48">
                    <nciDocumentNumber>P9972</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>P9972</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of  ET-743 in Pediatric Refractory Solid Tumors A C.O.G. Study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="07-05-2000 10:41:22">
                    <nciDocumentNumber>1254</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>OSU 0101</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of Thrice Weekly Hu1D10 in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Acute Lymphoblastic Leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="07-18-2000 14:50:01">
                    <nciDocumentNumber>1930</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>01-C-0196</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial and Pharmacokinetic Study of R115777 in Pediatric Patients with Refractory Leukemias</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="09-06-2000 09:24:08">
                    <nciDocumentNumber>ADVL0016</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ADVL0016</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of ZD1839 (Iressa TM), an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Children with Refractory Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="09-13-2000 09:56:39">
                    <nciDocumentNumber>CALGB-159905</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-159905</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Correlative Studies of erbB -2/HER-2/NEU and P53 in CALGB Protocol 9344/INT Protocol 0148:  "Doxorubicin Dose Escalation, with or without Taxol, as Part of the CA Adjuvant Chemotherapy Regimen for Node Positive Breast Cancer:  A Phase III Intergroup Study</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="09-22-2000 11:07:19">
                    <nciDocumentNumber>NABTC-00-01</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTC-00-01</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>ZD1839 for Treatment of Recurrent or Progressive Malignant Astrocytoma or Glioblastoma and Recurrent or Progressive Meningioma: A Phase II Study with a Phase I Component for Patients Receiving EIAEDs</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="10-13-2000 09:07:16">
                    <nciDocumentNumber>NCIC-146</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCIC-146</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Second-Line SarCNU (NSC 364432) in Patients with Recurrent/Metastatic Colorectal Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="10-16-2000 13:00:38">
                    <nciDocumentNumber>S0023</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0023</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Trial of Cisplatin/Etoposide/Radiotherapy with Consolidation Docetaxel Followed by Maintenance Therapy with ZD1839 (NSC-715055) or Placebo in Patients with Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="11-07-2000 13:21:24">
                    <nciDocumentNumber>RTOG 0123</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-0123</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II RandomizedTrial with Captopril (CAPOTEN) in Patients Who Have Received Radiation Therapy =/- Chemotherapy for Stage II-IIIA Non-Small Cell Lung Cancer or Limited-Stage Small-Cell Lung Cancer</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="11-28-2000 15:00:28">
                    <nciDocumentNumber>E1899</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E1899</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Randomized Trial for Evaluating Second Line Hormonal Therapy (Ketoconazole/Hydrocortisone) Versus Docetaxel/Estramustine Combination Chemotherapy on Progression Free Survival in Asymptomatic Patients with a Rising PSA After Hormonal Therapy for Prostate Cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="11-30-2000 09:40:16">
                    <nciDocumentNumber>3358</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>00-1096</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of EMD 121974 in Patients with Advanced Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-14-2000 11:00:14">
                    <nciDocumentNumber>3670</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of Epothilone B Analog BMS- 247550 (NSC 710428D) in Patients with Advanced Colorectal Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-18-2000 14:54:53">
                    <nciDocumentNumber>2617</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>0155-01</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Prostatic Acid Phosphatase-Pulsed Dendritic Cells (Provenge) in Combination with Bevacizumab in Patients with Serologic Progression of Prostate Cancer After Definitive Local Therapy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="02-05-2001 15:15:50">
                    <nciDocumentNumber>5110</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>10992A</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Genasense, a Bcl-2 Antisense Oligonucleotide, Combined with Carboplatin and Etoposide in Patients with Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="02-20-2001 11:44:33">
                    <nciDocumentNumber>3792</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>01-142</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of ZD1839 (Iressa) in Combination with Irinotecan, Leucovorin, and 5-Fluorouracil in Previously Untreated, Stage IV Colorectal Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="02-27-2001 11:26:11">
                    <nciDocumentNumber>PBTC-006</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PBTC-006_PII</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Trial of STI571 in Children with Newly Diagnosed Poor Prognosis Brainstem Gliomas and Recurrent Intracranial Malignant Gliomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-05-2001 16:44:51">
                    <nciDocumentNumber>5353</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>OC-01-01</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of the Toxicities, Biologic and Clinical Effects of Daily 5-Aza-2'Deoxycytidine (DAC) for Four Weeks in Patients with Advanced Malignancies</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-07-2001 15:37:58">
                    <nciDocumentNumber>E1100</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E1100</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Trial of Herceptin and ZD1839 (Iressa, NSC #715055, IND #61187) in Patients with Metastatic Breast Cancer that Overexpresses HER2/neu (erbB-2)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-14-2001 10:13:28">
                    <nciDocumentNumber>4551</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>01-460</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of ZD1839 in Combination with Radiation and Chemotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-14-2001 13:54:49">
                    <nciDocumentNumber>GOG-0227B</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-0227B</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A PHASE II EVALUATION OF SU5416 (NSC 696819) IN PERSISTENT OR RECURRENT SQUAMOUS CELL CARCINOMA OF THE CERVIX</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="06-07-2001 15:14:28">
                    <nciDocumentNumber>NABTC-01-02</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTC-01-02</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of ZD1839 and Temozolomide for the Treatment of Gliomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="06-25-2001 09:45:08">
                    <nciDocumentNumber>5425</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>02-C-0031</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Trial and Pharmacokinetic Study of BMS-247550 (NSC 710428, Ixabepilone), an Epothilone B Analog, in Pediatric Patients with Refractory Solid Tumors and Leukemias</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="06-26-2001 15:12:11">
                    <nciDocumentNumber>5342</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MSKCC 02-046</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Multicenter Phase II Study of BMS 247550 (Epothilone B Analogue) in Indolent Lymphoproliferative Disorders</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="06-27-2001 10:29:23">
                    <nciDocumentNumber>ANHL01P1</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ANHL01P1</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Pilot Study to Determine the Toxicity of the Addition of Rituximab to the Induction and Consolidation Phases and the Addition of Rasburicase to the Reduction Phase in Children with Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated with LMB/FAB Therapy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="07-03-2001 16:49:03">
                    <nciDocumentNumber>2270</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>02-041</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Multi-Institutional, Open-Label, Phase II Study of Doxorubicin and Bevacizumab (Anti-VEGF Monoclonal Antibody, NSC 704865) for Patients with Advanced or Metastatic Soft-Tissue Sarcoma. CTEP Protocol #2270.</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="08-15-2001 15:45:06">
                    <nciDocumentNumber>5375</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of OSI-774 in Combination with Standard Fractionation Radiation Therapy in Patients with Oral Cavity or Oropharyngeal Cancer Stage II or III and in Combination with Standard Fractionation Radiation Therapy and Low Dose Daily Cisplatin in Patients with Oral Cavity or Oropharyngeal Cancer Stage III and IV</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-06-2001 09:51:55">
                    <nciDocumentNumber>ACOSOG-Z9001</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>Z9001</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Randomized Double-Blind Study of Adjuvant STI571 (Gleevec) Versus Placebo in Patients Following the Resection of Primary Gastrointestinal Stromal Tumor (GIST)</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-25-2001 09:34:19">
                    <nciDocumentNumber>5416</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>LUNG 2002-01</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of OSI 774 (IND Number 63383) in Combination with Celecoxib (Celebrex, Pharmacia) as Second-Line Therapy in Advanced Non-Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-31-2001 09:00:54">
                    <nciDocumentNumber>S0211</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0211</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of STI571 for the Treatment of Platinum and Taxane Refractory Stage III and IV Epithelial Ovarian Cancer and Primary Peritoneal Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="11-20-2001 16:02:35">
                    <nciDocumentNumber>5730</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHI-39</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Trial of E7389 (Halichondrin B Analog) (NSC# 707389) in Patients with Advanced Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="11-27-2001 10:51:23">
                    <nciDocumentNumber>5589</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHII-36</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Oxaliplatin in Hepatocellular Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-10-2001 14:56:30">
                    <nciDocumentNumber>CALGB-30102</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-30102</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Comparison of Catheter Based Therapy of Pleural Effusions in Cancer Patients (Optimal Pleural Effusion Control, OPEC)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-07-2002 11:38:02">
                    <nciDocumentNumber>CALGB-40101</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-40101</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Cyclophosphamide and  Doxorubicin (CA x 4 Cycles) Versus Paclitaxel (4 Cycles) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Lymph Nodes:  A Phase III Randomized Study</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-31-2002 10:53:31">
                    <nciDocumentNumber>E2499</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E2499</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Phase III Trial of Rituximab (NSC #687451) and Autologous Stem Cell Transplantation for B Cell Diffuse Large Cell Lymphoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-26-2002 10:07:44">
                    <nciDocumentNumber>NABTC-01-08</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTC-01-08</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of STI571 (NSC 716051) in Patients with Recurrent Meningioma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-15-2002 16:17:38">
                    <nciDocumentNumber>S0000A</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0000A</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Prevention of Alzheimer's Disease with Vitamin E and Selenium (PREADVISE) Phase III Ancillary to S0000 SELECT</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-19-2002 13:53:37">
                    <nciDocumentNumber>NCIC-MA.20</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCIC-MA.20</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Study of Regional Radiation Therapy in Early Breast Cancer</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="05-21-2002 15:10:44">
                    <nciDocumentNumber>GOG-9913</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-9913</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Pelvic Radiation Therapy with Concomitant Weekly Cisplatin and Topotecan Chemotherapy in Patients with Cervical Carcinoma without Extra-Pelvic Metastasis</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="08-13-2002 10:54:59">
                    <nciDocumentNumber>GOG-0146O</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-0146O</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Evaluation of Irofulven (IND# 55804, NSC# 683863) in the Treatment of Recurrent or Persistent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="08-13-2002 17:21:10">
                    <nciDocumentNumber>E2602</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E2602</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Low Dose Peginterferon Alfa-2b in Patients with Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor</documentTitle>
                    <currentStatus>Temporarily Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="08-29-2002 15:00:38">
                    <nciDocumentNumber>5734</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>5734</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-11-2002 10:14:01">
                    <nciDocumentNumber>E3201</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E3201</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Intergroup Randomized Phase III Study of Postoperative Irinotecan, 5-Fluorouracil and Leucovorin vs. Oxaliplatin, 5-Fluorouracil and Leucovorin vs. 5-Fluorouracil and Leucovorin for Patients with Stage II or III Rectal Cancer Receiving Either Preoperative Radiation and 5-Fluorouracil or Postoperative Radiation and 5-Fluorouracil</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-01-2002 08:33:20">
                    <nciDocumentNumber>5938</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UC#12198A / NU#C03N1</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Perifosine in Patients with Recurrent or Metastatic Head and Neck Cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-07-2002 15:30:36">
                    <nciDocumentNumber>5983</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-015</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of Perifosine as Second-Line Therapy for Advanced Pancreatic Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-25-2002 13:04:00">
                    <nciDocumentNumber>NABTT-2200</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTT-2200</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of R115777 for the Treatment of Adults with Newly Diagnosed Glioblastoma Multiforme</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="11-12-2002 11:25:26">
                    <nciDocumentNumber>5941</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>0103672</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of PS-341 Alone or in Combination with Irinotecan in Patients with Adenocarcinoma of the Gastroesophageal Junction (GEJ) or Stomach</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="11-18-2002 16:04:27">
                    <nciDocumentNumber>6032</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>02558</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Repetitive Dosing of Anti-CTLA-4 Antibody (Ipilimumab) in Combination with GM-CSF in Patients with Metastatic, Androgen-Independent Prostate Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="11-20-2002 16:15:00">
                    <nciDocumentNumber>5818</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of G3139 Antisense Oligonucleotide (Oblimersen) in Combination with CHOP and Rituximab in Untreated Advanced Stage Diffuse Large B Cell Lymphoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="02-14-2003 08:58:39">
                    <nciDocumentNumber>S0220</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0220</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Induction Chemoradiotherapy with Cisplatin/Etoposide Followed by Surgical Resection, Followed by Docetaxel, for Non-Small Cell Lung Cancer Involving the Superior Sulcus (Pancoast Tumors)</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-04-2003 09:05:39">
                    <nciDocumentNumber>PBTC-012</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PBTC-012</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of Cilengitide (EMD 121974) in Children with Refractory Brain Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="05-14-2003 10:14:42">
                    <nciDocumentNumber>S0230</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0230</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="05-29-2003 08:44:53">
                    <nciDocumentNumber>ADVL0215</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ADVL0215</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Decitabine (NSC# 127716, IND# 50733) in Combination with Doxorubicin and Cyclophosphamide in the Treatment of Relapsed or Refractory Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="06-17-2003 08:02:32">
                    <nciDocumentNumber>6359</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC0312</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II Study of Anti-CTLA-4 Monoclonal Antibody (MDX-010) in B-cell Non-Hodgkin's Lymphoma</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="07-22-2003 08:08:08">
                    <nciDocumentNumber>6413</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MCC-6413</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="08-04-2003 10:45:12">
                    <nciDocumentNumber>6485</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>2004-0305</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Rituximab-CHOP with Pegylated Liposomal Doxorubicin in Patients Older than 60 Years of Age with Untreated Aggressive B-Cell Non-Hodgkin's Lymphoma</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-26-2003 07:14:33">
                    <nciDocumentNumber>6345</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHII-49</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of Single Agent Depsipeptide(FK228) in the Treatment of Hepatocellular Carcinoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="11-19-2003 11:10:54">
                    <nciDocumentNumber>6480</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>04-056</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of 17-N-allylamino-17-demethoxy Geldanamycin (17-AAG, NSC #330507) Diluted in EPL Diluent (NSC #704057) in Metastatic Melanoma Patients</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="11-24-2003 16:50:44">
                    <nciDocumentNumber>6548</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UPCI  # 03-153</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of 17-Dimethylaminoethylamino-17-Demethoxygeldanamycin, (17-DMAG) (NSC 707545) in Patients with Advanced Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-02-2003 10:13:12">
                    <nciDocumentNumber>6494</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UPCI 03-152</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 1 Study of 17- Allylamino-17 Demethoxygeldanamycin (17-AAG) in Combination with Paclitaxel in Advanced Solid Malignancies</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-21-2004 10:13:43">
                    <nciDocumentNumber>6552</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>C-2803</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Clinical Trial of 17-Allyamino-17-Demethoxygeldanamycin (17-AAG) in Chemotherapy Refractory Metastatic Breast Cancer</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="02-23-2004 10:15:28">
                    <nciDocumentNumber>6588</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>IDD-03-32</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I, and Biologic Correlative Study of Erlotinib, in Combination with Cetuximab and Bevacizumab in Patients with Metastatic Renal Cell Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="02-24-2004 14:37:57">
                    <nciDocumentNumber>N02C4</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>N02C4</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Double-Blind, Placebo-Controlled Randomized Comparison of Creatine for Cancer-Associated Weight Loss</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-11-2004 08:01:51">
                    <nciDocumentNumber>6553</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>6258-04-9R0</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of BAY 43-9006 in Combination with Interferon Alpha-2b in Metastatic Renal Cell Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="04-14-2004 08:02:56">
                    <nciDocumentNumber>6697</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>HEAD AND NECK 04-3</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Trial of GW572016 in Patients with Metastatic and Recurrent Squamous Cell Carcinomas of the Head and Neck</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-21-2004 13:36:36">
                    <nciDocumentNumber>6718</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>13394A</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of GW572016 in Squamous Cell Carcinoma of the Head  and Neck (SCCHN)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-22-2004 10:08:40">
                    <nciDocumentNumber>6800</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHII-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase II Non-Comparative Study of SB-715992 Given Weekly or Every Three Weeks in Advanced or Metastatic Colorectal Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-27-2004 13:15:37">
                    <nciDocumentNumber>6777</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CASE 3904</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I and Pharmacodynamic Study of SB-715992 in Acute Leukemias</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="05-06-2004 09:20:14">
                    <nciDocumentNumber>6555</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>URO 470</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Trial of BAY 43-9006 in Combination with Bevacizumab in Patients with Advanced Renal Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="05-11-2004 11:11:14">
                    <nciDocumentNumber>S0418</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0418</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of SB-715992 (NSC-727990, IND-70273) in Taxane-Resistant Androgen-Independent Metastatic Prostate Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="06-30-2004 11:52:47">
                    <nciDocumentNumber>E2603</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E2603</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients with Unresectable Locally Advanced or Stage IV Melanoma</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="07-07-2004 09:28:38">
                    <nciDocumentNumber>6759</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>13576A</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Bevacizumab (NSC# 704865) and OSI-774 (NSC# 718781) in Recurrent Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="07-13-2004 14:19:06">
                    <nciDocumentNumber>6969</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DFCI 04-199</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of GW572016 for Brain Metastases in Patients with HER2-Positive Breast Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="08-04-2004 13:11:50">
                    <nciDocumentNumber>PBTC-017</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PBTC-017</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of Cloretazine (VNP40101M) in Children with Recurrent, Progressive or Refractory Primary Brain Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-15-2004 13:12:58">
                    <nciDocumentNumber>6986</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC0452</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Trial of CCI-779 and Bevacizumab in Stage IV Renal Cell Carcinoma</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-30-2004 09:56:34">
                    <nciDocumentNumber>7009</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>O5-017</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>An Open-Labeled Non-Randomized Phase I Study of 17-N-Allylamino-17-Demethoxy Geldanamycin (17AAG) Administered with Irinotecan (CPT-11) in Patients with Advanced Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-13-2004 14:54:39">
                    <nciDocumentNumber>6963</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHII-63</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Indolent Non-Hodgkin's Lymphoma</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-15-2004 10:34:29">
                    <nciDocumentNumber>6918</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHII-62</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Suberoylanilide Hydroxamic Acid (SAHA) (NSC 701852) as Salvage Therapy in Metastatic Breast Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="11-02-2004 08:20:46">
                    <nciDocumentNumber>NABTC-04-03</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTC04-03</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in Combination with Temozolomide in Patients with Malignant Gliomas</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="11-09-2004 10:41:32">
                    <nciDocumentNumber>6922</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHI 51 (UPC 04-170)</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA) (NSC 701852) in Combination with Paclitaxel/Carboplatin for Advanced and Refractory Solid Malignancies</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="11-15-2004 10:00:17">
                    <nciDocumentNumber>S0508</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0508</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Combination Thalidomide Plus Temozolomide in Patients with Metastatic Malignant Melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-07-2004 10:16:16">
                    <nciDocumentNumber>7111</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>14018A</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of AZD2171 in Patients with Advanced Renal Cell Carcinoma</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-15-2004 11:03:09">
                    <nciDocumentNumber>7137</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-038</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of AZD2171 in Previously Untreated Patients with Metastatic or Recurrent Malignant Melanoma</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-15-2004 11:16:53">
                    <nciDocumentNumber>S0423</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0423</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of Pemetrexed for Advanced Chondrosarcomas</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-26-2005 10:13:45">
                    <nciDocumentNumber>7225</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHI-52</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I and Pharmacokinetic Study of Oral 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, Triapine) in  the Treatment of Advanced Solid Tumors</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-27-2005 14:42:02">
                    <nciDocumentNumber>7103</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>14203B</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of AZD2171 (NSC #732208) in Patients with Malignant Mesothelioma</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="02-03-2005 14:26:00">
                    <nciDocumentNumber>7099</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>05-160</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-04-2005 16:12:38">
                    <nciDocumentNumber>6884</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>IRB #NA 00001107, SKCCC J0570</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination with the VEGF Inhibitor Bevacizumab in Patients with Metastatic Renal Cell Carcinoma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-07-2005 14:08:20">
                    <nciDocumentNumber>7237</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CTRG-HC06/21/05</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Study of PXD101 in Patients with Unresectable Hepatocellular Carcinoma with Pharmacokinetic and Pharmacodynamic Evaluation</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-07-2005 15:22:21">
                    <nciDocumentNumber>S0431</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0431</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Trastuzumab (NSC-688097) in Advanced High Grade Salivary Gland Carcinoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-22-2005 11:02:54">
                    <nciDocumentNumber>7258</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC0581</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of the Histone Deacetylase Inhibitor PXD101 for the Treatment of Myelodysplastic Syndrome</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-08-2005 12:24:42">
                    <nciDocumentNumber>S0410</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0410</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Tandem Autologous Stem Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin's Disease (A BMT Study), Phase II</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-29-2005 09:26:31">
                    <nciDocumentNumber>7311</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GCC 0507</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 1 Study of UCN-01 in Combination with Perifosine in Patients with Relapsed and Refractory Acute Leukemias and High Risk MDS</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="05-23-2005 13:59:31">
                    <nciDocumentNumber>S0514</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0514</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of BAY 43-9006 (NSC #724772) as Single Agent in Unresectable or Metastatic Gallbladder Carcinoma and Cholangiocarcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="06-22-2005 13:14:05">
                    <nciDocumentNumber>E2804</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E2804</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>The BeST Trial: A Randomized Phase II Study of VEGF, RAF Kinase, and mTOR Combination Targeted Therapy (CTT) with Bevacizumab, Sorafenib and Temsirolimus in Advanced Renal Cell Carcinoma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="06-23-2005 11:37:03">
                    <nciDocumentNumber>7396</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>06-C-0151</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of CDDO in Solid Tumors and Lymphomas</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="07-20-2005 08:29:04">
                    <nciDocumentNumber>6869</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-046</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 1 Study of Vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in Combination with Decitabine in Patients with Advanced Solid Tumors, Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia in Blast Crisis</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-04-2005 09:23:01">
                    <nciDocumentNumber>7401</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CASE 10805</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of MLN518 in Patients with Metastatic Clear Cell Renal Cell Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="11-15-2005 13:21:35">
                    <nciDocumentNumber>E5103</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E5103</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-03-2006 09:56:31">
                    <nciDocumentNumber>7674</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>14705A</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of CCI-779 (Temsirolimus) in Patients with Locally Advanced or Metastatic Breast Cancer</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-25-2006 14:32:04">
                    <nciDocumentNumber>CALGB-90203</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-90203</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-31-2006 09:01:49">
                    <nciDocumentNumber>7313</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>HO06401</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of Bevacizumab Combined with Lenalidomide and Dexamethasone (BEV/REV/DEX) in Relapsed or Refractory Multiple Myeloma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="03-21-2006 15:43:21">
                    <nciDocumentNumber>7702</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC058F</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Sunitinib (SU11248) in Multiple Myeloma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="03-29-2006 10:04:57">
                    <nciDocumentNumber>7745</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>06060</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-12-2012 10:41:39" createdDate="03-30-2006 09:46:58">
                    <nciDocumentNumber>7735</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>14696A</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers and Medullary Thyroid Cancers</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-05-2006 15:03:20">
                    <nciDocumentNumber>7759</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>J0658</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Study of Entinostat in Combination with 5-Azacytidine in Patients with Recurrent Advanced Non-Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="06-02-2006 17:06:42">
                    <nciDocumentNumber>RTOG-0517</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-0517</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases from Lung, Breast, and Prostate Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="06-12-2006 13:47:08">
                    <nciDocumentNumber>7859</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>07-C-0097</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Batracylin (NSC 320846) in Subjects with Solid Tumors and Lymphomas</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="07-13-2006 09:17:59">
                    <nciDocumentNumber>7831</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CASE 1706 - AMC 049</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Sunitinib (SU11248) in Patients with Kaposi's Sarcoma in East Africa</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-08-2006 09:46:04">
                    <nciDocumentNumber>7758</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>HIC# 0608001765</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of Dasatinib in Advanced Melanoma</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="09-27-2006 08:58:52">
                    <nciDocumentNumber>7889</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>J06133</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of a Pharmacologically Derived Hybrid Bolus-Infusion Schedule of Flavopiridol (NSC 649890, IND 46,211) Given in Timed Sequential Combination with Cytosine Arabinoside (ara-C) and Mitoxantrone for Adults with Relapsed and Refractory Acute Leukemias</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="01-03-2007 15:00:55">
                    <nciDocumentNumber>7932</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>07056</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of AZD6244 in Biliary Cancers</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-21-2007 11:19:46">
                    <nciDocumentNumber>HLMCC-0503</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>HLMCC-0503</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Randomized Double-Blinded Study of an Antiemetic Pump, using Benadryl, Activan, and Decadron (BAD), for Children Recieving Moderately or Highly Emetogenic Chemotherapy</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="03-28-2007 12:28:47">
                    <nciDocumentNumber>CALGB-10603</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-10603</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND # 101261) or Placebo in Newly Diagnosed Patients &lt; 60 Years of Age with FLT3 Mutated Acute Myeloid Leukemia (AML)</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="05-04-2007 10:33:45">
                    <nciDocumentNumber>8014</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of AT101, to Abrogate BCL-2 Mediated Resistance to Androgen Ablation Therapy in Patients with Newly Diagnosed Stage D2 Prostate Cancer</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="09-20-2007 09:31:06">
                    <nciDocumentNumber>ADVL0712</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ADVL0712</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, IND #100947, NSC #742460) in Children with Relapsed/Refractory Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="03-31-2008 13:30:51">
                    <nciDocumentNumber>8169</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC0778</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Suberoylanilide Hydroxamic Acid and Bortezomib in Advanced Soft Tissue Sarcomas</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="04-28-2008 10:55:48">
                    <nciDocumentNumber>S0805</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0805</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Combination of Hyper-CVAD and Dasatinib (NSC-732517) with or without Allogeneic Stem Cell Transplant in Patients with Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) (a BMT Study)</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="06-13-2008 11:22:46">
                    <nciDocumentNumber>8283</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>09-C-0111</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612, NSC 281612) in Advanced Malignancies</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="07-09-2008 13:16:15">
                    <nciDocumentNumber>8300</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>09-C-0138</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Broad Multi-Histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-Small Cell Lung, Head and Neck, Hepatocellular and Renal Cell Carcinomas and Pheochromocytoma and Thyroid Tumors</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="08-01-2008 14:04:33">
                    <nciDocumentNumber>8214</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>USMCI 8214/ACOSOG Z6091</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Pilot / Phase III Randomized Trial Comparing Standard Systemic Therapy to Cytoreduction + Hyperthermic Intraperitoneal Mitomycin C + Standard Systemic Therapy in Patients with Limited Peritoneal Dissemination of Colon Adenocarcinoma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="09-17-2008 10:43:31">
                    <nciDocumentNumber>8276</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>09-C-0089</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Targeted Phase I/II Trial of ZD6474 (Vandetanib; Zactima) Plus the Proteasome Inhibitor, Bortezomib (Velcade (R)), in Adults with Solid Tumors with a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="10-20-2008 09:46:15">
                    <nciDocumentNumber>S0816</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0816</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma Using Early Interim FDG-PET Imaging</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="11-13-2008 15:06:49">
                    <nciDocumentNumber>AMC-061</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>AMC-061</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 1/Pharmacokinetic Study of Sunitinib in Patients with Cancer Who Also Have HIV and are on HAART Therapy</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="12-22-2008 10:53:22">
                    <nciDocumentNumber>8297</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>2288.00</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 1/2 Study of Vorinostat (Zolinza) in Combination with Gemtuzumab Ozogamicin (Mylotarg) and Azacitidine (Vidaza) in Patients 50 Years of Age and Older with Relapsed/Refractory non-APL Acute Myeloid Leukemia (AML)</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="01-21-2009 15:09:40">
                    <nciDocumentNumber>GOG-0252</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-0252</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Clinical Trial of Bevacizumab with IV Versus IP Chemotherapy in Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma NCI-Supplied Agent(s): Bevacizumab (NSC #704865, IND #7921)</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="04-06-2009 14:11:24">
                    <nciDocumentNumber>8348</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DFCI IRB 09-293</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer.</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="04-15-2009 13:46:46">
                    <nciDocumentNumber>RTOG-0915</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG 0915</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase II Study Comparing 2 Stereotactic Body Radiation Therapy (SBRT) Schedules for Medically Inoperable Patients with Stage I Peripheral Non-Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="04-20-2009 10:38:51">
                    <nciDocumentNumber>ADVL0912</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ADVL0912</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 1/2 Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children with Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="04-27-2009 16:36:23">
                    <nciDocumentNumber>8418</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>09-068</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients with Metastatic Pancreatic Cancer (10052747)</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="05-11-2009 14:44:20">
                    <nciDocumentNumber>ADVL0916</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ADVL0916</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of  Vorinostat and Bortezomib in Children with Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="05-12-2009 15:24:23">
                    <nciDocumentNumber>E5508</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E5508</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="06-23-2009 14:58:39">
                    <nciDocumentNumber>GOG-0262</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-0262</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination with Carboplatin with or without Concurrent and Consolidation Bevacizumab (NSC #704865, IND #7921) in the Treatment of Primary Stage III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="06-30-2009 14:13:16">
                    <nciDocumentNumber>CALGB-80802</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-80802</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC)</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="07-02-2009 11:07:37">
                    <nciDocumentNumber>E1908</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E1908</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab, and Rituximab</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="07-22-2009 14:49:15">
                    <nciDocumentNumber>8147</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>09-117</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II Trial of Anti-IGF-IR Monoclonal Antibody IMC-A12 Plus mTOR Inhibitor Temsirolimus (CCI-779) in Metastatic Castration-Resistant Prostate Cancer (CRPC)</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="07-28-2009 10:02:37">
                    <nciDocumentNumber>8298</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>J09112</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of the Histone Deacetylase Inhibitor Entinostat (SNDX-275, NSC 706995, IND#61198) plus Clofarabine for Philadelphia Chromosome-Negative, Poor Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia in Newly Diagnosed Older Adults or in Adults with Relapsed and Refractory Disease</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="08-06-2009 10:17:42">
                    <nciDocumentNumber>8309</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>09-443-A</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II Investigation of Temsirolimus plus Lenalidomide in Relapsed Non-Hodgkin Lymphomas</documentTitle>
                    <currentStatus>Temporarily Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="08-11-2009 09:32:13">
                    <nciDocumentNumber>8474</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>2009-165</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of Suberoylanilide Hydroxamic Acid (SAHA) in Subjects with Locally Advanced, Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC) (IND 71976)</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="08-18-2009 14:38:50">
                    <nciDocumentNumber>8485</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>OSU # 09150</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of Decitabine, Vorinostat, and Cytarabine in Acute Myeloid Leukemia</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="08-25-2009 09:28:36">
                    <nciDocumentNumber>8561</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-076</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of RO4929097 (IND 109291) in Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Carcinoma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="09-08-2009 12:04:39">
                    <nciDocumentNumber>8539</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>8539</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Dose Escalation Trial of RO4929097 Administered in Combination with Exemestane in Pre- and Postmenopausal Patients with ER + Metastatic Breast Cancer / A Randomized Phase II Trial Comparing Exemestane in Combination with RO4929097 Compared with Exemestane Alone as Second or Third Line Hormonal Treatment of ER + Metastatic Breast Cancer in Pre- and Post-Menopausal Patients</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="10-14-2009 10:12:43">
                    <nciDocumentNumber>8406</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>10-049 A</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination with RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="11-04-2009 08:33:38">
                    <nciDocumentNumber>8446</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>10-436-B</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Discontinuation Phase 2 Study of AZD0530 as a Metastasis Inhibitor in Castrate Resistant Prostate Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="11-09-2009 10:40:57">
                    <nciDocumentNumber>8489</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>VICC GYN 1003</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Evaluation of SJG-136 in Women with Cisplatin-Refractory or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="11-09-2009 13:17:27">
                    <nciDocumentNumber>8323</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CASE 9209</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of AZD2171 (Cediranib) with Modified FOLFOX6 in Patients with Advanced Biliary Cancers</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="11-17-2009 14:22:53">
                    <nciDocumentNumber>8503</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PJC-004</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 1, Pharmacokinetic and Pharmacodynamic Study of the Combination of RO4929097 and Cediranib in Patients with Advanced Solid Tumors</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="12-08-2009 10:19:38">
                    <nciDocumentNumber>S0933</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0933</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="12-30-2009 15:02:52">
                    <nciDocumentNumber>8537</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MCC 16221</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Open-Label Study of RO4929097 in Metastatic Colorectal Cancer</documentTitle>
                    <currentStatus>Temporarily Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="01-05-2010 11:04:17">
                    <nciDocumentNumber>E3A06</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E3A06</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="05-20-2010 14:23:06">
                    <nciDocumentNumber>N2008-02</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>N2008-02</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of Vorinostat in Combination with 13-Cis-Retinoic Acid in Patients with Refractory/Recurrent Neuroblastoma.</documentTitle>
                    <currentStatus>Approved</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:45">
                    <nciDocumentNumber>POG-9466</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9466</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of Pyrazoloacridine in children with refractory solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:45">
                    <nciDocumentNumber>SWOG-9510</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-9510</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Evaluation of  Topotecan  in  Hormone Refractory  Prostate Cancer, Phase II</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:46">
                    <nciDocumentNumber>SWOG-9350</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-9350</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Limited institution pilot trial of alpha interferon with combination chemotherapy in disseminated malignant melanoma: Phase II</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:46">
                    <nciDocumentNumber>S9701</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S9701</localDocumentNumber>
                        <localDocumentNumber>S9701</localDocumentNumber>
                        <localDocumentNumber>S9701</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Randomized Trial of 12 Months vs. 3 months of  Paclitaxel in Patients with Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer Who Attain a Clinically Defined Complete Response (CR) Following Platinum/Paclitaxel-Based Chemotherapy</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:46">
                    <nciDocumentNumber>T96-0009</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DM 96-135</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of 5-day continuous intravenous infusion of 9-amino camptothecin (9-ac, nsc 603071) weekly for three weeks in patients with metastatic adenocarcinoma of the colon or rectum</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:46">
                    <nciDocumentNumber>POG-7607</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-7607</localDocumentNumber>
                        <localDocumentNumber>SWOG-7607</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Ad-Con-Fu: combination chemotherapy with Adriamycin, Cyclophosphamide, Oncovin and 5-Fluorouracil in children with metastatic solid Tumors - Phase II</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:47">
                    <nciDocumentNumber>T92-0114</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DM 92-035</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Post-radiation therapy Phase III randomized study of DFMO-PCV  versus PCV chemotherapy for the treatment of malignant gliomas</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:47">
                    <nciDocumentNumber>SWOG-8993</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-8993</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of High Dose Melphalan with Hemopoietic Stem Cell Support and GM-CSF in Refractory Multiple Myeloma (MM)</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:48">
                    <nciDocumentNumber>CALGB-9565</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-9565</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of gemcitabine in patients with organ dysfunction</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:48">
                    <nciDocumentNumber>POG-9431</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9431</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>PHASE II upfront window followed by radiation therapy and chemotherapy in high grade Gliomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:48">
                    <nciDocumentNumber>INT-0146</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-93-46-53</localDocumentNumber>
                        <localDocumentNumber>CALGB-9396</localDocumentNumber>
                        <localDocumentNumber>E7293</localDocumentNumber>
                        <localDocumentNumber>CO.12</localDocumentNumber>
                        <localDocumentNumber>CI64</localDocumentNumber>
                        <localDocumentNumber>RTOG-94-15</localDocumentNumber>
                        <localDocumentNumber>SWOG-9411</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Colectomy Versus Open Colectomy for Colon Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:49">
                    <nciDocumentNumber>EST-5283</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-5283</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III protocol for the evaluation of combined modalities in the treatment of colonic carcinoma, dukes' c , dukes' b2, dukes' b3, surgical resection alone vs. postoperative immunotherapy (autologous irradiated tumor cells plus bcg)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:49">
                    <nciDocumentNumber>NCCTG-85-72-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-85-72-51</localDocumentNumber>
                        <localDocumentNumber>85-72-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III comparative evaluation of PCNU and BCNU combined with radiation therapy for primary brain tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>SWOG-8735</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-8735</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of recombinant human interferon-alfa and recombinant human interferon-gamma in previously untreated patients with chronic myelogenous leukemia</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>S9619</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S9619</localDocumentNumber>
                        <localDocumentNumber>S9619</localDocumentNumber>
                        <localDocumentNumber>S9619</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of Intraperitoneal Cisplatin and Intravenous and Intraperitoneal Paclitaxel in Women with Optimally-Debulked Stage III Epithelial Ovarian Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>C9741</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>C9741</localDocumentNumber>
                        <localDocumentNumber>C9741</localDocumentNumber>
                        <localDocumentNumber>C9741</localDocumentNumber>
                        <localDocumentNumber>C9741</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A randomized Phase III trial of sequential chemotherapy using doxorubicin, paclitaxel, and cyclophosphamide or concurrent doxorubicin and cyclophosphamide followed by paclitaxel at 14 or 21 day intervals in women with node positive.......</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>RTOG-91-11</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-91-11</localDocumentNumber>
                        <localDocumentNumber>R9111</localDocumentNumber>
                        <localDocumentNumber>SWOG-9201</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III trial to preserve the Larynx:  induction chemotherapy and Radiation Therapy versus concomitant chemotherapy and Radiation Therapy versus Radiation Therapy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>E3893</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E3893</localDocumentNumber>
                        <localDocumentNumber>SWOG-9403</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of 13-cis-retinoic acid plus interferon alpha-2a in advanced stage penile carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>EST-3887</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-3887</localDocumentNumber>
                        <localDocumentNumber>CALGB-8991</localDocumentNumber>
                        <localDocumentNumber>SWOG-8997</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Chemotherapy of disseminated advanced stage Testicular cancer with Cisplatin plus Etoposide with either Bleomycin or Ifosfamide</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>INT-0080</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-8710</localDocumentNumber>
                        <localDocumentNumber>CALGB-8891</localDocumentNumber>
                        <localDocumentNumber>EST-1887</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III trial of cystectomy alone versus neoadjuvant m-vac + cystectomy in patients with locally advanced bladder cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:52">
                    <nciDocumentNumber>RTOG-88-08</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-88-08</localDocumentNumber>
                        <localDocumentNumber>EST-4588</localDocumentNumber>
                        <localDocumentNumber>SWOG-8992</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III study of Radiation Therapy alone or in combination with Chemotherapy for patients with Non-Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:50:52">
                    <nciDocumentNumber>GOG-81C</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-81C</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III trial of high vs intermediate dose Medroxyprogesterone Acetate (MPA) in patients with Advanced or Recurrent Endometrial Carcinoma negative for Estrogen and Progesterone Receptors</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:52">
                    <nciDocumentNumber>GOG-81E</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-81E</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III trial of high vs inermediate dose Medroxyprogesterone Acetate (MPA) in patients with Advanced or Recurrent Endometrial Carcinoma with unknown Estrogen and Progesterone Receptors</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:53">
                    <nciDocumentNumber>CALGB-9254</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-9254</localDocumentNumber>
                        <localDocumentNumber>C9254</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Anti-b4-blocked ricin (nsc #639185) adjuvant therapy post-autologous bone marrow transplant:  a Phase III study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 00:00:00">
                    <nciDocumentNumber>INT-0151</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EB193</localDocumentNumber>
                        <localDocumentNumber>CALGB 9443</localDocumentNumber>
                        <localDocumentNumber>NCCTG-95-30-52</localDocumentNumber>
                        <localDocumentNumber>SWOG-9514</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Double-Blind, Placebo-Controlled, Prospective Randomized Comparison of Adjuvant Therapy with Tamoxifen vs. Tamoxifen and Fenretinide in Postmenopausal Women with Involved Axillary Lymph Nodes and Positive Receptors.</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:53">
                    <nciDocumentNumber>PBT01</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PBT01</localDocumentNumber>
                        <localDocumentNumber>T90-0180</localDocumentNumber>
                        <localDocumentNumber>T90-0180</localDocumentNumber>
                        <localDocumentNumber>PBT01</localDocumentNumber>
                        <localDocumentNumber>T90-0180</localDocumentNumber>
                        <localDocumentNumber>T90-0180</localDocumentNumber>
                        <localDocumentNumber>PBT-1</localDocumentNumber>
                        <localDocumentNumber>T90-0180</localDocumentNumber>
                        <localDocumentNumber>T90-0180</localDocumentNumber>
                        <localDocumentNumber>T90-0180</localDocumentNumber>
                        <localDocumentNumber>SWOG-9412</localDocumentNumber>
                        <localDocumentNumber>T90-0180</localDocumentNumber>
                        <localDocumentNumber>T90-0180</localDocumentNumber>
                        <localDocumentNumber>PBT01</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III randomized comparison of maintenance chemotherapy w/CTX ,MTX,and 5-FU vs. high dose chemotherapy w/ CTX,Thiotepa,and CBDCA and ABMT support for women w/ metastatic Breast CA responding to conventional induction chemotherapy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:57">
                    <nciDocumentNumber>GOG-9704</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-9704</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of LIPOSOMAL DOXORUBICIN (DOXIL) and prolonged ETOPOSIDE as second line therapy in recurrent or persistent OVARIAN, TUBAL and PERITONEAL CARCINOMA</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:59">
                    <nciDocumentNumber>GOG-0076Y</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-76Y</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A limited access Phase II trial of Pyrazoloacridine (PZA) (NSC #366140) in patients with Advanced, Persistent or Recurrent Squamous Cell Carcinoma of the Cervix</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:59">
                    <nciDocumentNumber>T97-0113</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DM97-308</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of MGI-114 (NSC# 683863) Administered Intravenously for Five Days Every 28 Days to Patients with Metastatic Colorectal Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:00">
                    <nciDocumentNumber>CALGB-9840</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-9840</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Study of Paclitaxel Via Weekly 1 Hour Infusion Versus Standard 3 Hour Infusion Every 3 Weeks with Herceptin (Trastuzumab) (NSC #688097) in the Treatment of Patients with/without HER-2/Neu-Overexpressing Metastatic Breast Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:01">
                    <nciDocumentNumber>CALGB-19801</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-19801</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of 506U78 in Patients with Refractory or Relapsed T-Lineage Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:01">
                    <nciDocumentNumber>POG-9362</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9362</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Alpha Interferon in HIV-Related Malignancies</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:01">
                    <nciDocumentNumber>T98-0010</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Dolastatin-10 (NSC 376128) Administered as an IV Bolus Every 3 Weeks in Patients with Hepatobiliary Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:01">
                    <nciDocumentNumber>GOG-0076BB</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-76-BB</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Limited Access Phase II Trial of Cisplatin and Irinotecan in Advanced, Persistent and Recurrent Squamous Cell Carcinoma of the Cervix</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:02">
                    <nciDocumentNumber>T84-0444</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>84-C-159</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of 6-mercaptopurine administered as an intravenous infusion for relapsed acute lymphoblastic leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:02">
                    <nciDocumentNumber>W83-0248</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CIC-82-154</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II trial of homoharringtonine in patients with refractory acute leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:02">
                    <nciDocumentNumber>POG-7317</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-7317</localDocumentNumber>
                        <localDocumentNumber>SWOG-7317</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Adjuvant chemotherapy in Osteogenic Sarcoma: Compadri II study, Phase II</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:02">
                    <nciDocumentNumber>T84-0351</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>834-05-193</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I testing of tiazofurin on a weekly schedule</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:03">
                    <nciDocumentNumber>T90-0014</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>90-C-129</localDocumentNumber>
                        <localDocumentNumber>90-C-129</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I trial of tetraplatin</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:03">
                    <nciDocumentNumber>T84-0262</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>83-C-214</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A pilot Phase I trial of Immune Interferon (IML gamma) in patients with Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:04">
                    <nciDocumentNumber>NCOG-7O-81</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCOG-7O-81</localDocumentNumber>
                        <localDocumentNumber>RTOG-79-08</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I - II study of heavy charged particle radiotherapy of localized Ocular Melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:04">
                    <nciDocumentNumber>T83-1285</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>OSU-8405</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Evaluation of 2'deoxycoformycin (dcf) in hairy cell leukemia - a Phase II study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:04">
                    <nciDocumentNumber>T83-1191</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ICC-5</localDocumentNumber>
                        <localDocumentNumber>IRB-2-83-6A</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II single agent chemotherapy cbdca for non-small cell lung cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:04">
                    <nciDocumentNumber>T89-0084</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase II evaluation of suramin in patients with advanced stage d2 carcinoma of the prostate</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:04">
                    <nciDocumentNumber>NCCTG-87-46-52</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-87-46-52</localDocumentNumber>
                        <localDocumentNumber>87-46-52</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>An evaluation of a Somatostatin analogue in the therapy of Advanced Colorectal Cancer, a Phase III study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:04">
                    <nciDocumentNumber>NCCTG-82-81-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-82-81-51</localDocumentNumber>
                        <localDocumentNumber>82-81-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of VP-16,213 in the treatment of accelerated phase or blast crisis of CGL</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:05">
                    <nciDocumentNumber>NCCTG-88-48-01</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-88-48-01</localDocumentNumber>
                        <localDocumentNumber>88-48-01</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of 5-Fu and Leucovorin in patients with metastatic gastric or pancreatic carcinomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:05">
                    <nciDocumentNumber>POG-8870</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-8870</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I trial of  Ifosfamide/VP-16-213/Mesna in children with resistant/recurrent Acute Leukemias- A Pediatric Oncology Group study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:05">
                    <nciDocumentNumber>T88-0067</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ICC-88N2</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of new agents in the treatment of patients with advanced squamous cell carcinoma of the head and neck</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:06">
                    <nciDocumentNumber>T86-0170</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>IL-2-MELANOMA</localDocumentNumber>
                        <localDocumentNumber>EST-P-X686</localDocumentNumber>
                        <localDocumentNumber>7/89-61</localDocumentNumber>
                        <localDocumentNumber>889-5011-437</localDocumentNumber>
                        <localDocumentNumber>6218</localDocumentNumber>
                        <localDocumentNumber>CSU-413</localDocumentNumber>
                        <localDocumentNumber>804804-01</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of patients with metastatic or unresectable malignant melanoma with high dose il-2</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:06">
                    <nciDocumentNumber>SWOG-8722</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-8722</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase ii: evaluation of amonafide in adenocarcinoma of the prostate</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:07">
                    <nciDocumentNumber>SEG-MM-P37</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-MM-P37</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II study of hemi-body irradiation in multiple myeloma relapsing after or resistant to chemotherapy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:08">
                    <nciDocumentNumber>D82-002-0725</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>7H-82-1</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of vp-16 in head and neck cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:09">
                    <nciDocumentNumber>C79-0200</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CIC-78-118</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Pala Phase II broad study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:09">
                    <nciDocumentNumber>SEG-AML-81-312R</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-AML-81-312R</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized prospective Phase III trial in acute non-lymphocytic leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:09">
                    <nciDocumentNumber>T85-0121</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>85-C-79</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I trial of various routes of administration of recombinant interleukin-2 in patients with cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:10">
                    <nciDocumentNumber>RTOG-79-22</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-79-22</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I protocol for the initial clinical study of single dose WR-2721</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:10">
                    <nciDocumentNumber>INT-0055</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-85-14</localDocumentNumber>
                        <localDocumentNumber>EST-1886</localDocumentNumber>
                        <localDocumentNumber>SWOG-8597</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Phase III intergroup study of supradiaphragmatic irradiation in stage ii-a seminoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:11">
                    <nciDocumentNumber>T84-0543</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ICC-85I2</localDocumentNumber>
                        <localDocumentNumber>T85-0226</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II evaluation of new agents in patients with advanced colon carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:11">
                    <nciDocumentNumber>POG-8591</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-8591</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II trial ofTrimetrexate in children with solid Tumors and Acute Leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:11">
                    <nciDocumentNumber>CALGB-9033</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-9033</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Oral versus intravenous etoposide in combination with intravenous cisplatin in extensive small cell lung cancer:  Phase III</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:11">
                    <nciDocumentNumber>T90-0194</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>91-C-37</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of interferon-alpha in metastatic Breast cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:11">
                    <nciDocumentNumber>T90-0249</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>90-31-01</localDocumentNumber>
                        <localDocumentNumber>NCCTG-90-31-91</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of piroxantrone in women with advanced Breast cancer failing non-anthracycline chemotherapy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:11">
                    <nciDocumentNumber>T91-0032</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II trial of sequential active specific immunotherapy (autologous tumor cell vaccine) and recombinant interleukin-2 (ro 23-6019) for metastatic renal cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:11">
                    <nciDocumentNumber>T91-0067</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>91-027</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of pala, 5-fu and recombinant ifn-alpha in advanced head and neck carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:11">
                    <nciDocumentNumber>T91-0121</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>91-C-177</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of ici d1694 in adult patients with solid tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:12">
                    <nciDocumentNumber>T93-0021</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>93-C-0126</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of Taxol by 14 day continuous intravenous infusion in advanced metastatic cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:12">
                    <nciDocumentNumber>T93-0044</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>93-C-0165</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I and pharmacologic study of paclitaxel (Taxol) plus 5-fluorouracil with leucovorin and granulocyte colony-stimulating factor</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:12">
                    <nciDocumentNumber>T95-0002</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>95-065</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of thalidomide in patients with recurrent high grade astrocytomas or mixed gliomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:12">
                    <nciDocumentNumber>T84-0524</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>84-C-220</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I trial of purified recombinant interleukin-2 in patients with metastatic cancer who have failed conventional therapy administered intraperitoneally, intramuscularly or as a frequent intravenous bolus</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:13">
                    <nciDocumentNumber>POG-8561</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-8561</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of 6-Mercaptopurine administered as an intravenous infusion for malignant solid Tumors and Acute Leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:13">
                    <nciDocumentNumber>T84-0486</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>84-C-199</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of intraperitonael aclacinomycin with pharmacokinetics in patients with refractory ovarian cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:14">
                    <nciDocumentNumber>T90-0109</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>90-C-211</localDocumentNumber>
                        <localDocumentNumber>CHP-524</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of high-dose cyclophosphamide with gm-csf in malignant brain tumors in children</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:14">
                    <nciDocumentNumber>W82-0925</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>JH82-19</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of n-methylformamide in patients with advanced cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:14">
                    <nciDocumentNumber>T84-0421</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DM-85-16</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of tiazofurin in recurrent squamous cell carcinoma of the head and neck</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:16">
                    <nciDocumentNumber>W81-0333</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DT-80-62</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of spirogermanium hydrochloride</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:20">
                    <nciDocumentNumber>CCG-0894</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCG-0894</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II groupwide study of the combination of ifosfamide, carboplatin,and etoposide (vp-16-213) (ice) followed by a randomization between two dose levels (r-methug-csf) in children with recurrent solid tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:21">
                    <nciDocumentNumber>NCCTG-89-49-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-89-49-51</localDocumentNumber>
                        <localDocumentNumber>89-49-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III trial of Hydrazine Sulfate in advanced 5FU-Resistant Colorectal Cancer with a randomized comparison of quality of life measurement tools</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:22">
                    <nciDocumentNumber>EST-1890</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-1890</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of Taxol in metastatic Prostate cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:22">
                    <nciDocumentNumber>POG-9074</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9074</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I trial of Xomazyme-H65 in children with T-Cell Acute Lymphoblastic Leukemia/Lymphoma:  A Pediatric Oncology Group study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:23">
                    <nciDocumentNumber>EST-P-Z189</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-P-Z189</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of dose escalation of Cyclophosphamide, Adriamycin, and 5-Fluorouracil (CAF) with Granulocyte-Macrophage colony stimulating factor (GM-CSF) in metastatic Breast cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:23">
                    <nciDocumentNumber>T84-0192</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>83-105</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I trial of high dose dibromodulcitol with and without bone marrow support</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:24">
                    <nciDocumentNumber>NCOG-5O-84-1</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCOG-5O-84-1</localDocumentNumber>
                        <localDocumentNumber>T87-0007</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of Intra-Peritoneal Carboplatin chemotherapy in Advanced Carcinoma of the ovary and other Peritoneal cancers</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:25">
                    <nciDocumentNumber>T83-1361</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CO-8133</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of vinblastine and verapamil by concurrent intravenous infusion</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:25">
                    <nciDocumentNumber>T83-1189</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ICC-3</localDocumentNumber>
                        <localDocumentNumber>IRB-2-83-7D</localDocumentNumber>
                        <localDocumentNumber>T83-1024</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II single agent chemotherapy with cbdca for metastatic bladder carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:26">
                    <nciDocumentNumber>T83-1157</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>8401</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of homoharringtonine in patients with previously treated acute non-lymphocytic leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:26">
                    <nciDocumentNumber>NCCTG-86-61-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-86-61-51</localDocumentNumber>
                        <localDocumentNumber>86-61-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of subsequent treatments for patients with microscopic or minimal residual Ovarian Carcinoma following platinum-based chemotherapy and second-look surgery whole abdominal irradiation vs. continuous infusion etoposide + cisplatin</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:26">
                    <nciDocumentNumber>NCCTG-85-52-52</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-85-52-52</localDocumentNumber>
                        <localDocumentNumber>85-52-52</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II randomized trial of Megestrol Acetate (Megace) or Dexamethasone (DXM) in the treatment of hormonally refractory Advanced Carcinoma of the Prostate</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:27">
                    <nciDocumentNumber>T89-0028</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>0C-90-3</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of cisplatin and carboplatin with wr-2721 pretreatment in solid tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:27">
                    <nciDocumentNumber>INT-0099</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-8892</localDocumentNumber>
                        <localDocumentNumber>EST-2388</localDocumentNumber>
                        <localDocumentNumber>RTOG-88-17</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A study of radiotherapy with or without concurrent cisplatin in patients with nasopharyngeal cancer: Phase III</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:27">
                    <nciDocumentNumber>NCCTG-88-46-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-88-46-51</localDocumentNumber>
                        <localDocumentNumber>88-46-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III a prospectively randomized trial of high dose Leucovorin + weekly 5Fu (GITSG Regimen) versus low dose Leucovorin + intensive course 5Fu (NCCTG Regimen) for the treatment of Advanced Colorectal Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:28">
                    <nciDocumentNumber>SWOG-8832</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-8832</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of continuous infusion recombinant interleukin-2 (ril-2) in patients with pancreatic cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:28">
                    <nciDocumentNumber>CALGB-8851</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-8851</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of amonafide (nsc# 308847) in non-hodgkin's lymphoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:28">
                    <nciDocumentNumber>T88-0110</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>WFCC-62288</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of interleukin-2 in previously treated small cell lung cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:29">
                    <nciDocumentNumber>T87-0149</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>870602</localDocumentNumber>
                        <localDocumentNumber>5019</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II and pharmacodynamic study of amonafide (nsc 308847) in unresectable or metastatic pancreatic cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:29">
                    <nciDocumentNumber>T87-0125</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>87-C-72</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I evaluation of recombinant human granulocyte-macrophage colony stimulating factor</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:30">
                    <nciDocumentNumber>T87-0065</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>87-C-83</localDocumentNumber>
                        <localDocumentNumber>UMCC-8709</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I and biochemical pharmacology study of uridine and 5-fluorouracil</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:30">
                    <nciDocumentNumber>T87-0077</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>87-022</localDocumentNumber>
                        <localDocumentNumber>RTOG-86-03</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of sr 2508 radiosensitizer combined with radiotherapy for treatment of locally extensive prostate adenocarcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:30">
                    <nciDocumentNumber>T86-0208</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UNC-8603</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of alpha interferon and pentostatin in hematologic malignancies</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:31">
                    <nciDocumentNumber>T83-1073</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase III study comparing azq with bcnu in the treatment of patients with primary anaplastic brain tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:31">
                    <nciDocumentNumber>T83-0872</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UMCC-8029</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II trial of azq in patients with recurrent primary or metastatic brain tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:33">
                    <nciDocumentNumber>SEG-NHL-82-296</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-NHL-82-296</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II investigation of human Lymphoblastoid Interferon in Refractory Non-Hodgkin's Lymphomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:33">
                    <nciDocumentNumber>SEG-MM-76-311</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-MM-76-311</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III study of induction therapy with BCNU, Cyclophosphamide and Prednisone (BCP) in previously untreated Myeloma patients, randomizing responders to maintenance therapy or to no further therapy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:33">
                    <nciDocumentNumber>SEG-LUN-P05</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-LUN-P05</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I and Phase II pilot study in Metastatic Non-Oat Cell Carcinoma of Lung with combination of Hexamethylmelamine (HMM) and Dichlorodiammino-Platinum (DDP)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:34">
                    <nciDocumentNumber>EST-1280</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-1280</localDocumentNumber>
                        <localDocumentNumber>N81-0988</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II - III trial of Neocarzinostatin versus M-amsa or Adriamycin in Hepatocellular carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:35">
                    <nciDocumentNumber>D82-047-0140</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CTEPIS-0033</localDocumentNumber>
                        <localDocumentNumber>D81-047-0140</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III pilot for the treatment of non-small cell lung cancer with bleomycin, vp-16 and cis-platinum (bep)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:37">
                    <nciDocumentNumber>T86-0063</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UMCC-8608</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of interleukin-2 for melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:37">
                    <nciDocumentNumber>T86-0027</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DM 86-38</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of high-dose melphalan-total body irradiation and bone marrow transplatation in refractory multiple myeloma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:38">
                    <nciDocumentNumber>T85-0225</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>85-C-154</localDocumentNumber>
                        <localDocumentNumber>CCG-8605</localDocumentNumber>
                        <localDocumentNumber>CHP-473</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of the combination of ifosfamide mesna &amp; vp16 in children and young adults with recurrent or refractory sarcomas and primitive neuroectodermal tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:41">
                    <nciDocumentNumber>SEG-BLPR-P04</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-BLPR-P04</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of BCNUand Cyclophosphamide followed by Adriamycin in patients with Prostatic Adenocarcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:41">
                    <nciDocumentNumber>SEG-BRE-P08</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-BRE-P08</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I feasibility study of chemotherapy for metastatic Breast cancer using cytoreduction with cytoxan, adriamycin and 5-fu followed by a cycle-active regimen of cytosine arabinoside, hd mtx with leucovorin rescue and vcr</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:42">
                    <nciDocumentNumber>SEG-AML-77-318</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-AML-77-318</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III study of Daunorubicin and Arabinosyl Cytosine as induction therapy of Acute Myelogenous Luekemia randomizing responders to consolidation therapy...with subsequent randomization to maintenance therapy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:44">
                    <nciDocumentNumber>CCG-191</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCG-191</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III total sanctuary vs. conventional cns treatment for newly diagnosed acute lymphoblastic leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:47">
                    <nciDocumentNumber>T85-0117</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>85-C-73</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I and limited Phase II evaluation of the effect of Indomethacin on therapy with recombinant interferon alpha for metastatic malignant melanoma without hepatic involvement</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:47">
                    <nciDocumentNumber>RTOG-84-12</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-84-12</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II dose-searching randomized study of fast neutrons for Tumors located in the Thorax</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:48">
                    <nciDocumentNumber>INT-0051</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-8501</localDocumentNumber>
                        <localDocumentNumber>EST-3885</localDocumentNumber>
                        <localDocumentNumber>GOG-104</localDocumentNumber>
                        <localDocumentNumber>NCOG-5O-85-2J</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Intraperitoneal cis-platinum/intravenous cyclophosphamide vs. intravenous cis-platinum/ intravenous cyclophosphamide in patients with non-measurable disease stage iii ovarian ca: Phase III</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:49">
                    <nciDocumentNumber>BTCG-83-01</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>BTCG-83-01</localDocumentNumber>
                        <localDocumentNumber>CIC-83-118</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III study of surgery, radiotherapy, intravenous BCNU vs. S,RIB &amp; Intra-5-FU</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:49">
                    <nciDocumentNumber>INT-0027</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>INT-AML-2</localDocumentNumber>
                        <localDocumentNumber>CALGB-8101</localDocumentNumber>
                        <localDocumentNumber>EST-P-C481</localDocumentNumber>
                        <localDocumentNumber>SEG-INT-81-211P</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of reinduction therapy with ara-c and adriamycin(10+3) in acute myeloblastic leukemia in relapse and a randomized trial of ara-c and a msa for 10+3 treatment failures of proven refractories to anthracyclines</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:49">
                    <nciDocumentNumber>POG-8832</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-8832</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Pre-Irradiation combination Chemotherapy with Cisplatin and ARA-C for children with incompletely-resected supratentorial Malignant Tumors: Phase II</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:49">
                    <nciDocumentNumber>POG-8739</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-8739</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Evaluation of Alpha Interferon in the treatment of recurrent Brain Tumors in children - a Phase II study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:49">
                    <nciDocumentNumber>POG-8763</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-8763</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Evaluation of response and toxicity of Ifosfamide and VP-16-213 in children with resistant Malignant Tumors: A Phase II study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:49">
                    <nciDocumentNumber>POG-8776</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-8776</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of Interleukin-2 (IL-2) in the treatment of children with refractory Solid Tumors: a POG single-institution study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:49">
                    <nciDocumentNumber>GOG-85</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-85</localDocumentNumber>
                        <localDocumentNumber>SWOG-8695</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A randomized comparison of Hydroxyurea vs. 5-FU infusion and Bolus Cisplatin as an adjunct to radiation therapy in patients with stages II-B, III, IV-A Carcinoma of the Cervix and Negative Para-Aortic Nodes: (Phase III ).</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:49">
                    <nciDocumentNumber>GOG-86B</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-86B</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II trial of Hexamethylmelamine (NSC# 13875) in patients with Advanced or Recurrent Endometrial Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:50">
                    <nciDocumentNumber>POG-8602</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-8602</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>0valuation of treatment regimens in Acute Lymphoid Leukemia of childhood (ALINC #14): A Pediatric Oncology Group Phase III study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:50">
                    <nciDocumentNumber>T90-0154</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase II pilot study of concomitant Cisplatin/dtic/Tamoxifen chemotherapy and high dose Interleukin-2 in patients with metastatic Melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:50">
                    <nciDocumentNumber>EST-6890</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-6890</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of Interferon-gamma and Interferon-gamma plus Interferon-alpha in the treatment of advanced Renal Cell Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:50">
                    <nciDocumentNumber>NCCTG-90-20-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-90-20-51</localDocumentNumber>
                        <localDocumentNumber>90-20-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of 10-Edam in previously treated patients and untreated patients with extensive stage Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:51">
                    <nciDocumentNumber>T90-0237</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CO-9096</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of iododeoxyuridine and leucovorin as radiosensitizers in advanced gi malignancies</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:51">
                    <nciDocumentNumber>T91-0001</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>91026</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Pala in combination with 5-Fluorouracil in recurrent or Metastatic Breast Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:52">
                    <nciDocumentNumber>T91-0245</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>91-C-226</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A rising dose-level, multiple-dose intravesical administration safety and tolerability Phase I Study of l-691,912 (TP-40) in patients with Superficial Bladder Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:53">
                    <nciDocumentNumber>T92-0148</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A pediatric Phase II Study of all-trans-retinoic acid and Interferon-Alpha2 a combination therapy in advanced Acute Non Lymphocytic Leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:54">
                    <nciDocumentNumber>T93-0007</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>JHOC 93-23</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of the addition of escalating doses of Taxol (NSC 125973) to concurrent Thoracic Radiotherapy for patients with inoperable Stage III-A or Stage IIIB Non- Small cell lung cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:54">
                    <nciDocumentNumber>T94-0029</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                        <localDocumentNumber>94-C-0123</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of RTGF-Beta2 administered as mouthwash to patients with chemotherapy-induced Stomatitis</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:55">
                    <nciDocumentNumber>T94-0158</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DM94-112</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of Intravenous 72 hour continuous infusion 9-Amino Camptothecin (9-AC) in patients with Metastatic Adenocarcinoma of the colon or rectum</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:55">
                    <nciDocumentNumber>T94-0172</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II clinical trial of Suramin for the treatment of patients with metastatic Breast Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:55">
                    <nciDocumentNumber>T95-0069</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>10M-95-4</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I trial of a vaccine combining a Mart-1 Peptide emulsified with incomplete Freund's adjuvant for patients with resected Stages IIB, III and IV Melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:55">
                    <nciDocumentNumber>SWOG-8371</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-8371</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Chip and CBDCA in advanced (M1) and recurrent Squamous Cell Cancer of the head and neck</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:55">
                    <nciDocumentNumber>T85-0168</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>OSU-8520</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I clinical and Pharmacokinetic investigation of Flavone acetic acid (NSC 347512)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:56">
                    <nciDocumentNumber>GOG-0175</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-175</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III Trial of IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q21 days x 3 Courses Plus Low Dose Paclitaxel 40 mg/m2/wk Versus IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q21 days x 3 Courses Plus Observation in Patients with Early Stage Ovarian Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:56">
                    <nciDocumentNumber>E6597</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E6597</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Pilot Trial of Adenovirus p53 in Bronchioloalveolar Cell Lung Carcinoma (BAC) Administered by Bronchoalveolar Lavage</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:56">
                    <nciDocumentNumber>T97-0094</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>9281</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Suramin Once Monthly x 3 Months for Hormone Refractory Peostate Cancer (NSC #34936)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-12-1999 17:12:07">
                    <nciDocumentNumber>T98-0046</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>9710-07</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A PHASE II trial of  PERILLYL ALCOHOL in patients with RESECTABLE PANCREATIC CANCER</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-18-1999 08:48:53">
                    <nciDocumentNumber>CALGB-39804</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-39804</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>PHASE III randomized prospective trial of open versus minimally invasive, video-assisted resection of PULMONARY METASTASES</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:17">
                    <nciDocumentNumber>T97-0091</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>97-27</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I, Pharmacologic and Biologic Study of COL-3 (NSC 683551) Administered on a 28-day Oral Dosing Schedule in Patients with Advanced Solid Tumors</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-29-1999 18:06:18">
                    <nciDocumentNumber>NABTT-9704</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTT-9704</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of Penicillamine and reduction of Copper for Angiosuppressive   therapy of adults with newly diagnosed Glioblastoma.</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 00:00:00">
                    <nciDocumentNumber>E4298</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E4298</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Chemoembolization in Hepatocellular Carcinoma or Neuroendocrine Hepatic Metastases: A Phase II Multi-Center Trial</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-29-1999 18:06:18">
                    <nciDocumentNumber>CALGB-39808</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-39808</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>TOPOTECAN/PACLITAXEL INDUCTION followed by consolidation CHEMORADIOTHERAPY for limited STAGE SMALL CELL LUNG CANCER: A PHASE II STUDY</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>T94-0050</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PCI 94-09</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial Of Topotecan And Paclitaxel With G-CSF (Filgrastim) Support In Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>T97-0001</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase ii trial of pyrazoloacridine (pza) in metastatic gastric carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>T97-0062</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CWRU 3Y97</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial of Combination Bryostatin 1 (NSC 339555) and Vincristine in B-Cell Malignancies</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>T97-0076</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A phase ii trial of bryostatin-1(nsc 339555) administered as a 72-hour infusion every 2 weeks in patients with advanced head and neck cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>A09712</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCG-09712</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Motexafin Gadolinium (Xcytrin, NSC 695238) and Involved Field Radiation Therapy for Intrinsic Pontine Glioma of Childhood</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>T98-0078</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>98-056</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II and Pharmacokinetic Study of CPT-11and Trastuzumab (rhuMAB HER-2, Herceptin) in Advanced Colo-Rectal Cancer with P185 HER-2 Overexpression</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 00:00:00">
                    <nciDocumentNumber>T98-0086</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>99-C-0071</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:21">
                    <nciDocumentNumber>T93-0009</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>93-117</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>All-Trans Retinoic Acid and Bryostatin 1 in Combination: A Phase I Study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:22">
                    <nciDocumentNumber>T94-0043</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Gallium Nitrate (NSC #15200) in Non-Hodgkins Lymphoma in Patients with Acquired Immunodeficiency Syndrome</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:22">
                    <nciDocumentNumber>T94-0175</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>2O-94-1</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Feasibility Trial of 9-Aminocamptothecin (NSC 603071) Plus G-CSF in Extensive Stage Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:22">
                    <nciDocumentNumber>T95-0053</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>95-0395</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study to Evaluate the Clinical Benefit of Docetaxel (Taxotere) in Patients with Hormone Refractory Prostate Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T96-0062</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CO 9694</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial Of Perillyl Alcohol (Nsc 641066) Administered On A Two Weeks On, Two Weeks Off Schedule</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T96-0071</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RAD-9305</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A phase ii prospective trial of accelerated concomitant boost radiotherapy in transitional cell carcinoma of the bladder</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T96-0095</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>8551</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A  Phase II Trial of  Flavopiridol (NSC 649890) Administered as a 72-Hour Continuous Infusion Every 2 Weeks in Patients with Previously Treated Multiple  Myeloma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T97-0021</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CWRU 1A96</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of O6-Benzylguanine (NSC 637037) and BCNU in Patients with Multiple Myeloma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T97-0058</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of Bryostatin-1 (NSC 339555) and Cisplatin in Advanced Malignancies</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T97-0099</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>IND 6170</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A randomized phase ii trial of a vaccine combining tyrosinase/gp100 peptides emulsified with montanide isa 51 with and without interleukin-12 for patients with resected stages iii and iv melanoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:24">
                    <nciDocumentNumber>T98-0069</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>IDD 98-34</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I and Pharmacokinetic Study of Sequences of NSC 655649 (Rebeccamycin Analogue) and Cisplatin without and with Granulocyte Colony-Stimulating  Factor Support Every 21 Days</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:24">
                    <nciDocumentNumber>RTOG-98-04</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-98-04</localDocumentNumber>
                        <localDocumentNumber>CALGB-49801</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Trial of Observation +/- Tamoxifen vs. RT +/- Tamoxifen for Good Risk Duct Carcinoma IN-SITU (DCIS) of the Female Breast</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:24">
                    <nciDocumentNumber>T99-0003</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-23</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Oxaliplatin in Combination with Gemcitabine</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="04-28-1999 15:49:18">
                    <nciDocumentNumber>T99-0050</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHI - 26</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of Oxaliplatin in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="08-03-1999 09:51:28">
                    <nciDocumentNumber>T99-0068</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHI-22</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Dose Escalation Study of Tirapazamine (NSC 130181) in Combination with Carboplatin + Paclitaxel in Advanced Malignant Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="08-03-1999 14:43:44">
                    <nciDocumentNumber>T99-0088</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>12935B</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of O6-Benzylguanine (NSC 637037) and BCNU (Carmustine) in Patients with Advanced Soft Tissue Sarcoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="08-17-1999 11:27:50">
                    <nciDocumentNumber>E2998</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E2998</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Study of FLT3 Ligand (FLT3L) Therapy in Acute Myeloid Leukemia (AML) Patients in Remission</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="08-18-1999 13:32:39">
                    <nciDocumentNumber>T99-0092</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I, Dose De-Escalation to Minimal Effective Pharmacologic Dose Trial of Sodium Phenylbutyrate  (PB, NSC 657802)  in Combination with 5-Azacytidine (5-AZA, NSC 102816) in Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="08-24-1999 12:09:04">
                    <nciDocumentNumber>T99-0077</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCRC-99-29</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Arsenic Trioxide in Advanced Hormone-Refractory Prostate Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="08-26-1999 11:30:35">
                    <nciDocumentNumber>44</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of SU5416 (NSC #696819) in Patients with Malignant Mesothelioma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="08-26-1999 16:25:25">
                    <nciDocumentNumber>49</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of SU-5416 (NSC# 696819) in Patients with Hormone Refractory Prostate Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="09-02-1999 10:48:19">
                    <nciDocumentNumber>62</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>IDD#99-26</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I, Pharmacokinetic, and Biologic Correlative Study of R115777 (NSC 702818) and Herceptin in Patients with Advanced Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="09-29-1999 14:43:35">
                    <nciDocumentNumber>S9922</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S9922</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Trial of Dexamethasone, Cyclophosphamide, Etoposide, Cisplatin (DCEP) and G-CSF with or without Thalidomide (NSC # 66847) as Salvage Therapy for Patients with Refractory Multiple Myeloma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="10-07-1999 07:35:00">
                    <nciDocumentNumber>N9831</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>N9831</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel with or without Trastuzumab as Adjuvant Treatment for Women with HER-2 Over-Expressing or Amplified Node Positive or High-Risk Node Negative Breast Cancer</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="10-07-1999 13:20:48">
                    <nciDocumentNumber>198</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UMCC-9955</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Evaluation of Trastuzumab (Herceptin), Paclitaxel, Carboplatin, and Gemcitabine in the Treatment of Advanced Urothelial Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="10-13-1999 11:38:58">
                    <nciDocumentNumber>ADVL0011</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>A0993</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Temozolomide and CCNU in Pediatric Patients with Newly Diagnosed Incompletely Resected Non-Brainstem High-Grade Gliomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="10-18-1999 13:59:00">
                    <nciDocumentNumber>250</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>99-94</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of Bryostatin-1 and Paclitaxel in Patients with Advanced Esophageal Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="11-12-1999 16:12:18">
                    <nciDocumentNumber>571</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHI-31</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Tirapazamine (NSC 130181), Paclitaxel, and Carboplatin with Concurrent Radiation Followed by Paclitaxel/Carboplatin Consolidation for Stage III Non-Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-13-1999 13:08:13">
                    <nciDocumentNumber>CALGB-39901</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-39901</localDocumentNumber>
                        <localDocumentNumber>CALGB-39901</localDocumentNumber>
                        <localDocumentNumber>CALGB-39901</localDocumentNumber>
                        <localDocumentNumber>CALGB-39901</localDocumentNumber>
                        <localDocumentNumber>CALGB-39901</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive Stage Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-21-2000 11:00:34">
                    <nciDocumentNumber>GOG-9908</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-9908</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Toxicity Trial of Doxorubicin-Cisplatin Followed by Whole Abdominal Irradiation for Advanced Endometrial Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-21-2000 13:37:15">
                    <nciDocumentNumber>639</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Phase II Study of Thalidomide Versus Thalidomide Plus Fludarabine for Patients with Chronic Lymphocytic Leukemia Previously Treated with Fludarabine</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="04-06-2000 16:02:44">
                    <nciDocumentNumber>27</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>OSU 0051</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Depsipeptide in Selected Hematologic Malignancies (NSC 630176)</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="06-06-2000 13:16:21">
                    <nciDocumentNumber>GOG-9909</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-9909</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A PHASE I TRIAL OF COMBINATION CARBOPLATIN AND LIPOSOMAL DOXORUBICIN (DOXIL) IN RECURRENT OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="06-27-2000 11:38:42">
                    <nciDocumentNumber>GOG-0187</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-0187</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Paclitaxel for Ovarian Stromal Tumors as  Second-Line Therapy</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="09-12-2000 15:59:10">
                    <nciDocumentNumber>CALGB-49808</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-49808</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A 2 X 2 X 2 Factorial Randomized Phase III Trial of Multimodality Therapy Comparing 4 Cycles of Doxorubicin and Cyclophosphamide with or without Dexrazoxane (AC +/- Z) Followed by 12 Weeks of Weekly Paclitaxel with or without Trastuzumab (T +/- H) Followed by Local Therapy Followed by 40 Weeks of Weekly Trastuzumab or None in Women with Her-2+ Stage IIIA, IIIB or Regional Stage IV Breast Cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="09-28-2000 10:25:43">
                    <nciDocumentNumber>1757</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>1757</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Multi-institutional, Open-label, Two-group, Phase II Study of PS-341 (LDP-341, NSC #681239) in Patients with Advanced or Metastatic Sarcoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="09-28-2000 12:43:31">
                    <nciDocumentNumber>2794</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UCLA IRB # 01-01-071-02D</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Dose-Finding Study to Determine the Safety, Tolerability, and Anti-Leukemic Effects of STI571 in Combination with Interferon-alpha in Patients with Chronic Myelogenous Leukemia in Chronic Phase</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="10-19-2000 12:49:24">
                    <nciDocumentNumber>CALGB-90006</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-90006</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Estramustine, Docetaxel, and Bevacizumab (IND # 7921, NSC 704865) in Men with Hormone Refractory Prostate Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-14-2000 08:39:57">
                    <nciDocumentNumber>S0109</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0109</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Flavopiridol (NSC-649890) 1 Hour Bolus Days 1-3 Q 21 Days in Patients with Advanced Renal Cell Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-27-2000 10:56:31">
                    <nciDocumentNumber>3753</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>IDD 01-01</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Clinical, Biological and Pharmacological Study of ZD1839 in Patients with Advanced Colorectal Carcinoma Refractory to 5-Fluorouracil (5-FU) and Irinotecan Chemotherapy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="01-19-2001 10:54:23">
                    <nciDocumentNumber>4710</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Bryostatin 1 (NSC 339555) and High-Dose 1-B-D-Arabinofuranosylcytosine (HiDAC) in Patients with Refractory Leukemia (Not Limited to First Relapse)</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="02-14-2001 10:29:54">
                    <nciDocumentNumber>CALGB-99811</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-99811</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Neo-Adjuvant Paclitaxel, Estramustine and Carboplatin (TEC) Plus Androgen Ablation Prior to Radiation Therapy in Patients with Poor Prognosis Localized Prostate Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="02-14-2001 17:08:25">
                    <nciDocumentNumber>S0011</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0011</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of Surgery with Perioperative INGN 201 (Ad5CMV-p53) Gene Therapy Followed by Chemoradiotherapy for Advanced, Resectable Squamous Cell Carcinoma of the Oral Cavity, Oropharynx, Hypopharynx, and Larynx</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-21-2001 12:52:49">
                    <nciDocumentNumber>GOG-0229B</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-0229-B</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Evaluation of Thalidomide (NSC #66847, IND 48832) in the Treatment of Recurrent or Persistent Endometrial Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-02-2001 16:15:47">
                    <nciDocumentNumber>RTOG-P-0014</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-P-0014</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Randomized Study of Patients with High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade with 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade with Delayed Chemotherapy</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-04-2001 12:22:04">
                    <nciDocumentNumber>2715</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>01-239; OSU 0218</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase 2 Study of Bevacizumab in Combination with Docetaxel in Patients with Advanced Breast Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="05-29-2001 15:41:11">
                    <nciDocumentNumber>PBTC-007</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PBTC-007</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Trial of ZD1839 (Iressa TM ) and Radiation in Pediatric Patients Newly Diagnosed with Brain Stem Tumors or Incompletely Resected Supratentorial Malignant Gliomas with Phase II Limited to Brain Stem Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="06-12-2001 10:21:45">
                    <nciDocumentNumber>5624</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>01-09-224</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Sequential Paclitaxel and Bryostatin-1 for Patients with Advanced Pancreatic Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="07-03-2001 17:21:55">
                    <nciDocumentNumber>4630</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>OSU-0164</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of G3139 ( NSC # 683428) in Combination with Cytarabine and Daunorubicin in Previously Untreated Patients with Acute Myeloid Leukemia (AML)>= 60 Years of Age</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="08-07-2001 11:03:33">
                    <nciDocumentNumber>5536</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHII-33</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of UCN-01 in Metastatic Melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="08-07-2001 17:24:24">
                    <nciDocumentNumber>CALGB-60101</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-60101</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of OSI-774 (NSC 718781) for Solid Tumors in Patients with Hepatic or Renal Dysfunction</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="08-09-2001 14:36:52">
                    <nciDocumentNumber>5550</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>11367</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase II Study of Interleukin-2 in Combination with Three Different Doses of Bryostatin in Patients with Renal Cell Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="08-13-2001 12:39:05">
                    <nciDocumentNumber>5582</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SCC 01-02</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of UCN-01 in Combination with Irinotecan in Resistant Solid Tumor Malignancies (Part I) and in Triple Negative (ER-Negative, PgR-Negative, HER-2 Not-Amplified) Recurrent Breast Cancers (Part II)</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="08-15-2001 15:03:45">
                    <nciDocumentNumber>5410</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>IDD 01-27</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II, Pharmacokinetic and Biologic Correlative Study of OSI-774, an EGFR Tyrosine Kinase Inhibitor, in Patients with Advanced Renal Cell Carcinoma</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-10-2001 10:38:02">
                    <nciDocumentNumber>5518</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-005</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of UCN-01 in Combination with Topotecan in Patients with Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="11-29-2001 14:11:27">
                    <nciDocumentNumber>GOG-0170E</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-0170E</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Evaluation of Gleevec (Imatinib Mesylate) (IND #61135, NSC #716051) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal  Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-06-2001 09:17:35">
                    <nciDocumentNumber>5612</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-007</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of  R115777 (Zarnestra) in Superficial Transitional Cell Carcinoma of Bladder</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-11-2001 15:47:20">
                    <nciDocumentNumber>5689</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>J0252</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of the Farnesyltransferase Inhibitor Zarnestra (Tipifarnib, R115777, NSC #702818, IND #58,359) in Complete Remission Following Induction and/or Consolidation Chemotherapy in Adults with Poor-Risk Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplasia (MDS)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-04-2002 08:34:09">
                    <nciDocumentNumber>5867</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>01-177</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Herceptin/Flavopiridol in HER-2 Positive Metastatic Breast Cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-12-2002 13:34:44">
                    <nciDocumentNumber>5599</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC0131</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase Ib/II Neoadjuvant Trial of the Farnesyltransferase Inhibitor, R115777 with Docetaxel and Capecitabine for Patients with Stage IIIA or IIIB Breast Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-17-2002 15:18:46">
                    <nciDocumentNumber>NABTT-2111</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTT-2111</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Trial of BMS-247550 for Treatment of Patients with Recurrent High-Grade Gliomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="02-07-2002 14:08:26">
                    <nciDocumentNumber>5903</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>04-C-0168</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Pediatric Phase I Trial Multi-Institutional Trial of LMB-2 for Refractory CD25-Positive Leukemias and Lymphomas</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="02-13-2002 14:42:05">
                    <nciDocumentNumber>5824</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>21-0421</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Multi-Center Phase 2 Study of Genasense in Combination with Thalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-07-2002 15:28:16">
                    <nciDocumentNumber>5762</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>03-C-0040</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Multicenter Phase I-II Study of Tumor Vaccine Following Chemotherapy in Patients with Metastatic Breast Cancer Untreated with Chemo/Radiation in the Previous 18 Months:  Vaccine-Induced Bias of T-Cell Repertoire Reconstitution After T-Cell Re-Infusion</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-14-2002 13:14:35">
                    <nciDocumentNumber>RTOG-0214</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-0214</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Comparison of Prophylactic Cranial Irradiation Versus Observation in Patients with Locally Advanced Non-Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-09-2002 11:40:29">
                    <nciDocumentNumber>5894</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UPCC #06202</localDocumentNumber>
                        <localDocumentNumber>UPCC#06202</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Iressa (NSC 715055, IND 61187) in Combination with 5-FU/LV/CPT-11 in Patients with Advanced or Recurrent Colorectal Cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-17-2002 09:53:59">
                    <nciDocumentNumber>CALGB-10107</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB 10107</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of G3139 (Genasense, NSC # 683428, IND # 58842) + Imatinib Mesylate (Gleevec, STI571) in Patients with Imatinib-Resistant Chronic Myeloid Leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="07-09-2002 12:57:30">
                    <nciDocumentNumber>ADVL0212</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ADVL0212</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Depsipeptide (NSC# 630176, IND# 51810) in Pediatric Patients with Refractory Solid Tumors and Leukemias</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-18-2002 15:14:41">
                    <nciDocumentNumber>5978</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHII-44</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Perifosine (IND 58,156; NSC# 639966) in Biochemically Recurrent, Hormone Sensitive Prostate Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-07-2002 11:43:52">
                    <nciDocumentNumber>5982</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-014</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of Perifosine in Metastatic or Advanced Breast Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="11-20-2002 13:27:36">
                    <nciDocumentNumber>6013</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of Flavopiridol in Combination with Imatinib Mesylate (STI571, Gleevec) in Bcr/Abl + Hematological Malignancies</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-15-2003 12:35:53">
                    <nciDocumentNumber>5966</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase I CRC Study of Depsipeptide and Rituximab in Patients with Previously Treated B-cell Chronic Lymphocytic Leukemia</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="02-27-2003 11:30:44">
                    <nciDocumentNumber>6168</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHII-47</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Fenretinide (4-HPR) in Biochemically Recurrent, Hormone Naive Prostate Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-14-2003 15:40:46">
                    <nciDocumentNumber>S0222</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0222</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Tirapazamine (NSC-130181)/Cisplatin/Etoposide and Concurrent Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-20-2003 09:53:26">
                    <nciDocumentNumber>CALGB-90106</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-90106</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III Study of Paclitaxel, Ifosfamide and Cisplatin versus Vinblastine, Ifosfamide and Cisplatin as Second-Line Therapy for Patients with Relapsed/Resistant Germ Cell Tumors</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-12-2012 10:41:39" createdDate="03-24-2003 15:26:37">
                    <nciDocumentNumber>6122</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>2003-0761</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase IIA Study to Determine the Safety and Efficacy of a NCI-Supplied Agent:  G3139 (NSC 683428, IND 58842) and Imatinib Mesylate in Patients with Refractory or Relapsed Gastrointestinal Stromal Tumors</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="05-13-2003 10:40:29">
                    <nciDocumentNumber>S0330</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0330</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="05-29-2003 07:22:20">
                    <nciDocumentNumber>ADVL0311</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ADVL0311</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Pemetrexed (LY231514, Alimta) (NSC# 698037, IND # 67,952) in Children and Adolescents with Recurrent Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="06-26-2003 07:37:31">
                    <nciDocumentNumber>6254</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>0803-945</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Triapine in Combination with Gemcitabine in Adenocarcinoma of the Biliary Ducts and Gall Bladder</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="07-01-2003 09:36:38">
                    <nciDocumentNumber>6243</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>12975A</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Study of G3139 (Genasense) in Combination with RICE Chemotherapy in Relapsed Non-Hodgkin's Lymphoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="07-23-2003 07:53:37">
                    <nciDocumentNumber>ADVL0314</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ADVL0314</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Bevacizumab in Refractory Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="08-06-2003 11:55:26">
                    <nciDocumentNumber>E1103</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E1103</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Capecitabine in Combination with the Farnesyltransferase Inhibitor, R115777 (Tipifarnib, Zarnestra) in Patients with Metastatic Breast Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-10-2003 08:48:57">
                    <nciDocumentNumber>ADVL0317</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ADVL0317</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of PS-341 (Velcade, Bortezomib) in Pediatric Patients with Refractory/Recurrent Leukemias</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-10-2003 13:49:28">
                    <nciDocumentNumber>6444</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>03-135</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase II Study of Bevacizumab in Combination with Cetuximab Plus Irinotecan, or in Combination with Cetuximab Alone, in Irinotecan-Refractory Colorectal Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-16-2003 11:04:42">
                    <nciDocumentNumber>S0336</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0336</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of Depsipeptide (NSC-630176) in Colorectal Cancer Patients Who Have Received Either One or Two Prior Chemotherapy Regimens for Metastatic or Locally Advanced, Unresectable Disease</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-06-2003 15:29:37">
                    <nciDocumentNumber>6102</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-024</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of GTI-2040 in Combination with Docetaxel and Prednisone in Hormone-Refractory Prostate Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-27-2003 09:26:19">
                    <nciDocumentNumber>ADVL0222</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ADVL0222</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Campath-1H in Children with Acute Lymphoblastic Leukemia in Second or Greater Relapse or Twice Induction Failure</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="11-06-2003 12:32:26">
                    <nciDocumentNumber>6321</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCCWFU 83403</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Single Agent Depsipeptide (FK228) in Recurrent, Platinum Sensitive Adenocarcinoma of the Ovary or Peritoneum</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-20-2004 08:24:04">
                    <nciDocumentNumber>S0345</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0345</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Imatinib (NSC-716051) in Patients with Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-28-2004 08:57:03">
                    <nciDocumentNumber>6939</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>2004-0154</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of XK469R (NSC 698215) in Patients with Refractory Hematologic Malignancies</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-12-2012 10:41:39" createdDate="01-28-2004 12:35:25">
                    <nciDocumentNumber>6132</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>2004-0059</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-28-2004 14:48:14">
                    <nciDocumentNumber>CALGB-100104</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-100104</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Randomized, Double-Blind Study of Maintenance Therapy with CC-5013 (NSC # 703813, IND # 70116) or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-08-2004 12:54:48">
                    <nciDocumentNumber>6735</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>2004-045</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Evaluation of EMD 121974 (NSC 707544, Cilengitide) in Patients with Non-Metastatic Androgen Independent Prostate Cancer</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="03-10-2004 09:50:05">
                    <nciDocumentNumber>6567</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>13169B</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of BAY 43-9006/Gemcitabine for Advanced Pancreatic Cancer</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-15-2004 09:21:01">
                    <nciDocumentNumber>NSABP-C-08</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NSABP-C-08</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil (5-FU), Leucovorin, and Oxaliplatin (mFOLFOX6) Every Two Weeks with Bevacizumab to the Same Regimen without Bevacizumab for the Treatment of Patients with Resected Stages II and III Carcinoma of the Colon</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-22-2004 11:21:52">
                    <nciDocumentNumber>S0412</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0412</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of the RAF-Kinase Inhibitor BAY 43-9006 (NSC-724772, IND-69,896) in Combination with Interferon-Alpha 2B in Patients with Advanced Renal Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-19-2004 08:50:08">
                    <nciDocumentNumber>6121</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC0214</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial of 17-Allylaminogeldanamycin (17-AAG) and PS341 in Advanced Malignancies</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-26-2004 07:55:58">
                    <nciDocumentNumber>PBTC-016</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PBTC-016</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Molecular Biology and Phase II Study of Lapatinib (GW572016) in Pediatric Patients with Recurrent or Refractory Medulloblastoma, Malignant Glioma or Ependymoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="05-21-2004 13:18:22">
                    <nciDocumentNumber>E1Z03</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E1Z03</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Quality of Life Companion Study for JMA27 (NCIC-MA.27): A Randomized Phase III Trial of Exemestane Versus Anastrozole in Postmenopausal Women with Receptor Positive Primary Breast Cancer</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="06-04-2004 13:27:22">
                    <nciDocumentNumber>7000</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>OSU 0491</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Flavopiridol Administered as a 30 Minute Loading Dose Followed by a 4-Hour Continuous Infusion in Patients with Previously Treated B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising from CLL</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="06-14-2004 12:53:23">
                    <nciDocumentNumber>ADVL04P2</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ADVL04P2</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Feasibility Pilot and Phase 2 Study of Chemoimmunotherapy with Epratuzumab (IND #12034) for Children with Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="07-15-2004 16:04:57">
                    <nciDocumentNumber>NSABP-B-39</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NSABP-B-39/RTOG-0413</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer</documentTitle>
                    <currentStatus>Temporarily Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="07-21-2004 08:49:50">
                    <nciDocumentNumber>7003</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHII-57</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Bortezomib (PS-341) for Patients with Advanced Bronchiolo-Alveolar Carcinoma (BAC) or Adenocarcinoma with BAC Features</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="07-23-2004 15:10:33">
                    <nciDocumentNumber>S0346</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0346</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Trastuzumab (NSC-688097) in Treatment of Locally Advanced or Metastatic Synovial Sarcoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-02-2004 15:02:17">
                    <nciDocumentNumber>6823</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>5402</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of Tipifarnib in Large Granular Lymphocyte (LGL) Leukemia</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-09-2004 07:41:11">
                    <nciDocumentNumber>6981</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>0501007709</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Trial of BAY 43-9006 Plus Gemcitabine and Capecitabine in the Treatment of Patients with Advanced Renal Cell Carcinoma</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-24-2004 09:16:47">
                    <nciDocumentNumber>RTOG-0411</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-0411</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Bevacizumab with Concurrent Capecitabine and Radiation Followed by Maintenance Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-27-2004 16:39:30">
                    <nciDocumentNumber>NSABP-C-09</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NSABP C-09</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Clinical Trial Comparing Oxaliplatin, Capecitabine and Hepatic Arterial Infusion of Floxuridine to Oxaliplatin and Capecitabine in Patients with Resected or Ablated Liver Metastases from Colorectal Cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="11-05-2004 13:09:00">
                    <nciDocumentNumber>CALGB-40302</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-40302</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Endocrine Therapy with or without Inhibition of EGF and HER2 Growth Factor Receptors: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant with or without Lapatinib (GW572016) for Postmenopausal Women with Hormone Receptor Positive Advanced Breast Cancer</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="11-22-2004 10:41:28">
                    <nciDocumentNumber>ADVL0419</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ADVL0419</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 1 Study of Valproic Acid in Children with Recurrent/Progressive Solid Tumors Including CNS Tumors</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-09-2004 09:13:35">
                    <nciDocumentNumber>7147</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DFCI IRB 05-311</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of AZD2171 in Hepatocellular Carcinoma</documentTitle>
                    <currentStatus>Temporarily Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-11-2005 13:59:58">
                    <nciDocumentNumber>6837</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CTRG NP03/19/04</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial of 5Azacitidine and Suberoylanilide Hydroxamic Acid in Patients with Metastatic or Locally Recurrent Nasopharyngeal Carcinoma and Nasal NK-T Cell Lymphoma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-03-2005 10:35:18">
                    <nciDocumentNumber>S0421</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0421</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Study of Docetaxel and Atrasentan versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-07-2005 16:12:51">
                    <nciDocumentNumber>NCIC-MY.10</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>JMY10</localDocumentNumber>
                        <localDocumentNumber>JMY10</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III Study of Thalidomide and Prednisone as Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-21-2005 16:05:52">
                    <nciDocumentNumber>7336</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CASE 1805</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of Intravenous Triapine (IND #68338) in Combination with Pelvic Radiation Therapy with or without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-18-2005 10:31:24">
                    <nciDocumentNumber>RTOG-0522</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-0522</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin Versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab (C225) Followed by Surgery for Selected Patients] for Stage III and IV Head and Neck Carcinomas</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="05-06-2005 09:53:28">
                    <nciDocumentNumber>RTOG-0521</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-0521</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT vs AS and 3DCRT/IMRT Followed by Chemotherapy with Docetaxel and Prednisone for Localized, High-Risk Prostate Cancer</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="05-09-2005 12:42:28">
                    <nciDocumentNumber>NABTC-05-02</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTC05-02</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination with OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients with Recurrent Glioblastoma Multiforme or Gliosarcoma</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="07-06-2005 08:36:54">
                    <nciDocumentNumber>PBTC-015</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PBTC-015</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of O6-Benzylguanine and Temozolomide in Pediatric Patients with Recurrent or Progressive High-Grade Gliomas and Recurrent or Progressive Brainstem Tumors</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="07-26-2005 10:08:53">
                    <nciDocumentNumber>6896</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>0511008257</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Combination with Isotretinoin (13-cis Retinoic Acid, 13-CRA) in the Treatment of Patients with Advanced Renal Cell Carcinoma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="08-02-2005 15:41:28">
                    <nciDocumentNumber>6829</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GCC 0447</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Vorinostat (Suberoylanilide Hydroxamic Acid, or SAHA) in Combination with Cytosine Arabinoside (ara-C) and Etoposide for Patients with Relapsed and/or Refractory Acute Leukemias, Myelodysplasias and Myeloproliferative Disorders</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="08-09-2005 15:33:19">
                    <nciDocumentNumber>7351</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC0542</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-26-2005 08:09:54">
                    <nciDocumentNumber>7208</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC044I</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Bevacizumab Plus Erlotinib in Patients with Advanced Hepatocellular Cancer (HCC)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-19-2005 10:11:36">
                    <nciDocumentNumber>ANHL06P1</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ANHL06P1</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Pilot Study of Ifosfamide, Carboplatin and Etoposide Therapy (ICE) and SGN-30 (NSC #731636, IND # 100057) in Children with CD30+ Recurrent Anaplastic Large Cell Lymphoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-22-2005 12:33:03">
                    <nciDocumentNumber>7690</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHII-78</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Prophylactic Radiation Therapy for the Prevention of Hemoptysis in Advanced Non Small Cell Lung Cancer in Combination with Bevacizumab, Paclitaxel, and Carboplatin in Patients at High Risk for Bevacizumab-Associated Hemoptysis</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="01-18-2006 09:54:10">
                    <nciDocumentNumber>7602</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC0547</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of AZD0530 in Previously Treated Metastatic Pancreas Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="01-27-2006 08:15:20">
                    <nciDocumentNumber>7555</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-053</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of AZD0530 in Patients with Advanced, Recurrent Non-Small Cell Lung Cancer Who Have Previously Received Platinum-Based Combination Chemotherapy</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="01-30-2006 07:22:50">
                    <nciDocumentNumber>7518</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHII-73</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of VEGF Trap (NSC 724770) in Patients with MDS</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="02-15-2006 13:01:54">
                    <nciDocumentNumber>E1105</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E1105</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>E1105: A Randomized Phase III Double-Blind Placebo-Controlled Trial of First-Line Chemotherapy and Trastuzumab with or without Bevacizumab for Patients with HER-2/NEU Over-Expressing Metastatic Breast Cancer</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="04-13-2006 09:40:03">
                    <nciDocumentNumber>7713</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-062</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of Sunitinib Malate in Recurrent or Metastatic Endometrial Carcinoma</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="06-21-2006 14:27:40">
                    <nciDocumentNumber>7731</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CASE 3206</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Sunitinib Malate and Standard Infusion Gemcitabine in Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="06-26-2006 12:44:00">
                    <nciDocumentNumber>7678</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>07-C-0106</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase 2.5 Study of 153Sm-EDTMP (Quadramet) with or without a PSA/TRICOM Vaccine in Men with Androgen-Insensitive Metastatic Prostate Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="08-17-2006 09:01:00">
                    <nciDocumentNumber>N063D</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>N063D</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>ALTTO: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study:  A Randomised, Multi-Centre, Open-Label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="09-20-2006 07:33:47">
                    <nciDocumentNumber>7881</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>07-070</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Trial of Pertuzumab in Combination with Cetuximab in Cetuximab-Refractory Metastatic Colorectal Cancer</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-17-2006 08:48:38">
                    <nciDocumentNumber>S0635</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0635</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (rhuMAb VEGF; NSC-704865) in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma with BAC Features (AdenoBAC)</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="01-16-2007 14:46:22">
                    <nciDocumentNumber>E3F05</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E3F05</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="01-17-2007 08:43:06">
                    <nciDocumentNumber>7943</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHI-58</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of GX15-070 (NSC #729280) and Bortezomib in Aggressive Relapsed/Recurrent Non-Hodgkin's Lymphoma</documentTitle>
                    <currentStatus>Temporarily Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="01-30-2007 10:49:07">
                    <nciDocumentNumber>8057</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UPCI 07-013</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I and Pharmacokinetic Study of Vorinostat for Solid Tumors and Lymphomas in Patients with Varying Degrees of Hepatic Dysfunction</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="03-05-2007 16:21:17">
                    <nciDocumentNumber>8045</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MCC 15267</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 1 Study of 1-Methyl-D-Tryptophan in Patients with Advanced Malignancies</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="03-20-2007 13:03:49">
                    <nciDocumentNumber>NABTT-0702</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTT 0702</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of R-(-)-gossypol (Ascenta's AT-101) in Recurrent Glioblastoma Multiforme</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="03-29-2007 10:47:31">
                    <nciDocumentNumber>RTOG-0623</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-0623</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Combined Modality Therapy with Growth Factor Support for Patients with Limited Stage Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="06-15-2007 09:04:15">
                    <nciDocumentNumber>NCCTG-N06C6</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>N06C6</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Randomized Trial of Cryoablation Vs. Radiation for the Palliation of Painful Bone Metastases</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="09-12-2007 10:20:51">
                    <nciDocumentNumber>8131</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>16227A</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 1/2 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="10-29-2007 10:54:06">
                    <nciDocumentNumber>N0723</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>N0723</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Biomarker Validation Study of Second-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="11-07-2007 15:48:26">
                    <nciDocumentNumber>S0717</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0717</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I and a Randomized Phase II Study of Maximal Angiogenic Blockade in Advanced Renal Carcinoma: Bevacizumab (NSC-704865) with or without MEDI-522 (NSC-719850)</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="12-18-2007 11:10:05">
                    <nciDocumentNumber>N0577</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>N0577</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="04-30-2008 13:02:14">
                    <nciDocumentNumber>GOG-0249</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-0249</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed By Paclitaxel/Carboplatin Chemotherapy in Patients with High Risk, Early Stage Endometrial Carcinoma</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-12-2012 10:41:39" createdDate="05-06-2008 08:49:01">
                    <nciDocumentNumber>8199</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>16402A</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Multi-Institutional Phase II Study of IMC-A12, a Recombinant Human IgG1/Gamma Monoclonal Antibody Directed at the Type I Insulin-Like Growth Factor Receptor (IGF-1R), in Adrenocortical Carcinoma: A Randomized Trial Comparing the Activity of IMC-A12 with Mitotane Versus Mitotane Alone</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-12-2012 10:41:39" createdDate="05-28-2008 10:02:57">
                    <nciDocumentNumber>8121</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>09-097</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of Temsirolimus (CCI-779, NSC 683864) and IGF-1 Receptor Antibody Cixutumumab (IMC-A12, NSC 742460) in Patients with Metastatic Sarcomas</documentTitle>
                    <currentStatus>Temporarily Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="07-17-2008 14:02:18">
                    <nciDocumentNumber>AALL07P1</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>AALL07P1</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Pilot Trial of Bortezomib (PS-341, Velcade, IND #58,443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="09-23-2008 11:18:59">
                    <nciDocumentNumber>8288</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC0888</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of Cdk Inhibitor SCH 727965 in Multiple Myeloma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="10-02-2008 16:20:47">
                    <nciDocumentNumber>CALGB-70604</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-70604</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-12-2012 10:36:33" createdDate="11-05-2008 10:04:55">
                    <nciDocumentNumber>ADVL0815</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ADVL0815</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Pazopanib as a Single Agent for Children with Relapsed or Refractory Solid Tumors, Including CNS</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="01-26-2009 16:03:12">
                    <nciDocumentNumber>8329</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC0861</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Trial of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients with Solid Tumors (Phase I) and Relapsed or Refractory Ovarian Cancer or Primary Peritoneal Cancer (Phase II) After Prior Platinum Containing First-Line Chemotherapy</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="03-13-2009 09:33:42">
                    <nciDocumentNumber>RTOG-0815</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG 0815</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="05-04-2009 08:45:48">
                    <nciDocumentNumber>8341</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC084B</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Azacitadine and Entinostat in Patients with Metastatic Colorectal Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="05-05-2009 13:30:09">
                    <nciDocumentNumber>8592</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>10-C-0032</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial of SS1 (dsFv) PE38 with Paclitaxel, Carboplatin, and Bevacizumab in Subjects with Unresectable Non-Small Cell Lung Adenocarcinoma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-12-2012 10:41:39" createdDate="05-07-2009 14:30:10">
                    <nciDocumentNumber>8376</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NYU 09-0356</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients with Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="08-19-2009 10:12:20">
                    <nciDocumentNumber>8556</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>09-177</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase 1 Trial of RO4929097 in Combination with Standard Radiotherapy and Temozolomide for Newly Diagnosed Malignant Glioma: A Pharmacokinetic and Pharmacodynamic Study</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="08-24-2009 11:04:01">
                    <nciDocumentNumber>8501</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PJC-003</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Various Administration Schedules of RO4929097 with Multi-parameter Assessment (Biomarkers, Pharmacokinetics, Pharmacodynamics) in Patients with Advanced Solid Cancers</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="09-10-2009 10:26:49">
                    <nciDocumentNumber>8456</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GCC 0940</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 1 Study of the PARP Inhibitor ABT-888 in Combination with Temozolomide in Acute Leukemias</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="09-15-2009 10:59:04">
                    <nciDocumentNumber>8576</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>081001</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase II Study of Peripheral Androgen Blockade with Bicalutamide Followed by Placebo or Treatment with the Gamma Secretase Inhibitor RO4929097 in Men with Rising PSA after Definitive Local Therapy for Adenocarcinoma of the Prostate</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="09-16-2009 10:28:16">
                    <nciDocumentNumber>8563</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-077</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of RO4929097 (IND 109291) in Patients with Advanced Renal Cell Carcinoma (RCC, NOS 10038415) that has Progressed After VEGF/VEGFR Directed Therapy</documentTitle>
                    <currentStatus>Temporarily Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="09-16-2009 15:09:48">
                    <nciDocumentNumber>8602</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>8602</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 1/2 Study of PXD101(Belinostat) in Combination with Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic Malignancies</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="10-05-2009 13:25:22">
                    <nciDocumentNumber>8408</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of GDC-0449 in Patients with Advanced Chondrosarcomas</documentTitle>
                    <currentStatus>Approved</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="10-29-2009 11:36:46">
                    <nciDocumentNumber>S0931</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0931</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="11-03-2009 15:27:29">
                    <nciDocumentNumber>PBTC-029</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PBTC-029</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase 1 and Pharmacokinetic Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="11-04-2009 10:33:41">
                    <nciDocumentNumber>8457</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination with Bortezomib in Women with ER Positive Metastatic Breast Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="11-24-2009 09:37:12">
                    <nciDocumentNumber>8272</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>I 165409</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Sorafenib in Combination with the Histone Deacetylase Inhibitor, Entinostat in Patients with Advanced Cancers</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="02-22-2010 07:58:02">
                    <nciDocumentNumber>8792</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>10-C-0146</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of IMC-A12 in Patients with Mesothelioma Who Have Been Previously Treated with Chemotherapy</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="04-05-2010 13:53:54">
                    <nciDocumentNumber>8609</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>OSU 10080</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 1 Dose-Escalation Study of ABT-888 (veliparib) in Combination with Carboplatin in HER2 Negative Metastatic Breast Cancer</documentTitle>
                    <currentStatus>Approved</currentStatus>
                </document>
                <document updatedDate="04-12-2012 10:41:39" createdDate="04-13-2010 14:32:36">
                    <nciDocumentNumber>8731</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>2010-0243</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of the AKT Kinase Inhibitor MK-2206 in Patients with Relapsed Refractory Acute Myelogenous Leukemia</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="05-05-2010 08:31:27">
                    <nciDocumentNumber>RTOG-1010</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-1010</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma</documentTitle>
                    <currentStatus>Approved</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="05-05-2010 10:46:54">
                    <nciDocumentNumber>8500</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PJC-005</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Safety and Efficacy of RO4929097 in Combination with Temsirolimus: A Pharmacokinetic and Pharmacodynamic Phase I Study in Patients with Advanced Solid Tumours with an Expansion of Cohort with Patients with Recurrent/Metastatic Endometrial and Renal Cell Cancers</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="06-07-2010 09:16:06">
                    <nciDocumentNumber>PBTC-032</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PBTC-032</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children with Recurrent or Refractory Medulloblastoma</documentTitle>
                    <currentStatus>Approved</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:45">
                    <nciDocumentNumber>CCG-0942</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCG-0942</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of topotecan and cisplatin in the treatment of solid tumors in children</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:46">
                    <nciDocumentNumber>POG-8823-24</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-8823/24</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II: Recombinant A-Interferon in childhood Chronic Myelogenous Leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:46">
                    <nciDocumentNumber>POG-9343</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9343</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Interleukin-6 in children receiving autologous Bone Marrow Transplantation for advanced Neuroblastoma: A Pediatric Oncology Group Phase I trial</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:46">
                    <nciDocumentNumber>E3592</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E3592</localDocumentNumber>
                        <localDocumentNumber>SWOG-9311</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Cisplatin plus etoposide versus daily oral etoposide in elderly patients with extensive-stage small cell lung cancer: a Phase III trial of the eastern cooperative oncology group</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:46">
                    <nciDocumentNumber>T95-0001</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>95-01</localDocumentNumber>
                        <localDocumentNumber>E9501</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of 9-20-S-AMINO-CAMPTOTHECIN   (9-AC)  as second line therapy in advanced OVARIAN CARCINOMA: a New York  GYNEOCOLOGIC  ONCOLOGY Group Study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:47">
                    <nciDocumentNumber>SWOG-9312</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-9312</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II evaluation of cisplatin + 5-fu + radiation therapy in patients with locally advanced/inoperable bladder cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:48">
                    <nciDocumentNumber>NCCTG-93-73-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-93-73-51</localDocumentNumber>
                        <localDocumentNumber>N9371</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of Chemotherapy Plus Radiotherapy for Management of Primary Central Nervous System Non-Hodgkin's Lymphoma (PCNSL)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:48">
                    <nciDocumentNumber>CCG-B972</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCG-B972</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Immune status and activation in children participating in ccg-2961 "a Phase III trial in children with untreated acute myelogenous leukemia (aml) or myelodysplastic syndrome"</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>P9673</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>P9673</localDocumentNumber>
                        <localDocumentNumber>P9673</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Compound 506U78 in Patients with Refractory T-Cell Malignancies-POG/CCG Intergroup Study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>INT-0153</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-9415</localDocumentNumber>
                        <localDocumentNumber>CALGB-9498</localDocumentNumber>
                        <localDocumentNumber>S9415</localDocumentNumber>
                        <localDocumentNumber>S9415</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III randomized trial of 5-fu/leucovorin/levamisole versus 5-fu continuous infusion/levamisole as adjuvant therapy for high risk resectable colon cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>RTOG-94-04</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-94-04</localDocumentNumber>
                        <localDocumentNumber>NCCTG-94-72-51</localDocumentNumber>
                        <localDocumentNumber>SWOG-9340</localDocumentNumber>
                        <localDocumentNumber>T91-0056</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III randomized study of radiotherapy with or without BUDR plus Procarbazine, CCNU, and Vincristine (PCV) for the treatment of Anaplastic Astrocytomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>E1694</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E1694</localDocumentNumber>
                        <localDocumentNumber>E1694</localDocumentNumber>
                        <localDocumentNumber>E1694</localDocumentNumber>
                        <localDocumentNumber>E1694</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III study of adjuvant Ganglioside vaccination GM2-KLH/QS-21 therapy vs. high-dose Interferon Alfa-2B (Introna) for high-risk melanoma (T4.>4MM primary or regional lymph node metastasis)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>INT-0083</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-8790</localDocumentNumber>
                        <localDocumentNumber>EST-8887</localDocumentNumber>
                        <localDocumentNumber>GOG-133</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A randomized trial of adjuvant intraperitoneal recombinant interferon alpha-2 in stage iii ovarian carcinoma in patients who have no evidence of disease after surgery and chemotherapy: Phase III</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:51">
                    <nciDocumentNumber>INT-0159</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-9480</localDocumentNumber>
                        <localDocumentNumber>C9480</localDocumentNumber>
                        <localDocumentNumber>SWOG-9452</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Study of Three Different Doses of Suramin (NSC #34936) Administered with a Fixed Dosing Schedule in Patients with Advanced Prostate Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:52">
                    <nciDocumentNumber>INT-0098</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCG-8881</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>An intergroup protocol for the treatment of childhood hepatoblastoma and hepatocellular carcinoma a Phase III groupwide study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:50:52">
                    <nciDocumentNumber>NCCTG-90-62-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-90-62-51</localDocumentNumber>
                        <localDocumentNumber>90-62-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Comparison of MVAC vs. MVAC + Rhgmcsf Bone Marrow Protection in Women with Advanced Carcinoma of the Uterine Cervix or Vagina</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:52">
                    <nciDocumentNumber>EST-P-Z991</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-P-Z991</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phaseiclinical trial of the combination of 5-Fluorouracil (5FU), recombinant Alpha-2A-interferon (RIFN-Alpha), and Granulocyte colony-stimulating factor (G-CSF) in patients with advanced cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:53">
                    <nciDocumentNumber>E3197</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E3197</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Phase II study of human C-raf kinase antisense oligonucleotide Isis 5132 (CGP 69846A) or human Pkc-alpha antisense oligonucleotide Isis 3521 (CGP 64128A) in women with previously treated metastatic Breast cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:53">
                    <nciDocumentNumber>T94-0110</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PR.3</localDocumentNumber>
                        <localDocumentNumber>ECOG JPR3</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Intergroup (NCIC CTG, CUOG, SWOG, MRC-UK) Phase III Randomized Trial Comparing Total Androgen Blockade Versus Total Androgen Blockade Plus Pelvic Irradiation in Clinical Adenocarcinoma of the Prostate</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:53">
                    <nciDocumentNumber>E1292</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E1292</localDocumentNumber>
                        <localDocumentNumber>CALGB-9395</localDocumentNumber>
                        <localDocumentNumber>NSABP-CI63</localDocumentNumber>
                        <localDocumentNumber>SWOG-9250</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Intergroup Prospectively Randomized Trial of Perioperative 5-FU After Curative Resection, Followed by 5-FU/Leucovorin for Patients with Colon Cancer</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:53">
                    <nciDocumentNumber>E3193</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E3193</localDocumentNumber>
                        <localDocumentNumber>CALGB-9494</localDocumentNumber>
                        <localDocumentNumber>NCCTG-93-32-52</localDocumentNumber>
                        <localDocumentNumber>SWOG-9347</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III comparison of Tamoxifen versus Tamoxifen with Ovarian Ablation in premenopausal women with axillary node-negative receptor-positive Breast cancer &lt; or = to 3 cm.</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:56">
                    <nciDocumentNumber>CCG-2941</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCG-2941</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II pilot study in children with untreated acute myelogenous leukemia (aml) or myelodysplastic syndrome (mds)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:57">
                    <nciDocumentNumber>GOG-9803</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-9803</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Whole Pelvic Radiation Therapy with Concomitant Paclitaxel and Cisplatin Chemotherapy in Patients with Cervical Carcinoma (Stages I-IV) Limited to the Pelvis</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:00">
                    <nciDocumentNumber>T98-0002</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of Post Transplant rhIL-12 Following High Dose Cyclophosphamide, Thiotepa, and Carboplatin in the Treatment of Metastatic Breast Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:00">
                    <nciDocumentNumber>CALGB-9863</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-9863</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of irinotecan (cpt-11) in patients with abnormal liver or renal function or with prior pelvic radiation therapy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:00">
                    <nciDocumentNumber>RTOG-96-01</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG 96-01</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Trial of Radiation Therapy with or without Casodex in Patients with PSA Elevation Following Radical Prostactomy for pT3NO Carcinoma of the Prostate</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:01">
                    <nciDocumentNumber>T97-0030</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHII-08</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of  9-Aminocamptothecin-CD in Androgen Independent (D3) Adenocarcinoma of the Prostate (CAP)</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:02">
                    <nciDocumentNumber>W83-0661</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CTEPIS-0152</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I pediatric trial of cbdca</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:02">
                    <nciDocumentNumber>W83-0328</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>OSU-8302</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I - pharmacokinetic study of 2'fluoro-ara- amp</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:02">
                    <nciDocumentNumber>GITSG-4H85</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GITSG-4H85</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of Alpha-2-Interferon in Hepatocellular Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:03">
                    <nciDocumentNumber>EST-P-B390</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ECOG-P-B390</localDocumentNumber>
                        <localDocumentNumber>T90-0098</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of amonafide in head and neck cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:03">
                    <nciDocumentNumber>T90-0082</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>90-C-174</localDocumentNumber>
                        <localDocumentNumber>CCG-0906</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A pediatric Phase I evaluation of all-trans retinoic acid</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:03">
                    <nciDocumentNumber>T90-0077</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>90-126</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I trial of prolonged infusions of suramin in patients with advanced cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:03">
                    <nciDocumentNumber>W79-0298</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>79-C-136</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of dihydroxy anthracenedione in pediatric patients</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:04">
                    <nciDocumentNumber>T83-1469</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CO-8193</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of whole body hyperthermia using heat apparatus for the treatment of human neoplasia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:04">
                    <nciDocumentNumber>T83-1474</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>82-C-117</localDocumentNumber>
                        <localDocumentNumber>MOB-001</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Bisantrene Phase II in refractory childhood cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:04">
                    <nciDocumentNumber>NCOG-5O-83-1</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCOG-5O-83-1</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of Megestrol acetate in the palliative treatment of women with advanced Ovarian Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:04">
                    <nciDocumentNumber>T83-1275</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DM-83-64</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II study of 2-fluoro-ara-amp in hematologic malignancies</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:04">
                    <nciDocumentNumber>NCCTG-88-72-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-88-72-51</localDocumentNumber>
                        <localDocumentNumber>88-72-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of Ifosfamide with Mesna in recurrent primary brain tumor</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:05">
                    <nciDocumentNumber>T89-0021</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>89-C-71</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II evaluation of suramin in advanced, stage d2 carcinoma of the prostate</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:05">
                    <nciDocumentNumber>T83-1125</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>82-10-487</localDocumentNumber>
                        <localDocumentNumber>CCG-321P3</localDocumentNumber>
                        <localDocumentNumber>82-10-487</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II intensive multimodal therapy and bone marrow transplantation for newly diagnosed stage iv neuroblastoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:05">
                    <nciDocumentNumber>T88-0080</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>88-C-121</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I trial of hepsulfam (nsc-329680) administered as a single dose every 21 days</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:05">
                    <nciDocumentNumber>T88-0030</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>88-C-18</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of flavone-8-acetic acid in combination with interleukin-2</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:05">
                    <nciDocumentNumber>T87-0200</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>87-C-127</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I and pharmacokinetic study of arabinosyl-5-azacytidine (fazarabine, nsc 281272) (ara-ac) in pediatric malignancies</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:05">
                    <nciDocumentNumber>T87-0152</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ICC-87U2</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of new agents in the treatment of patients with advanced hormone-resistant cancer of the prostate</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:06">
                    <nciDocumentNumber>T83-1068</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CO-8393</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of acivicin and dipyridamole administered by concurrent intravenous infusion</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:07">
                    <nciDocumentNumber>EST-4888</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-4888</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of Melphalan and 6-Thioguanine in advanced renal cell carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:08">
                    <nciDocumentNumber>T85-0265</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UMCC-8525</localDocumentNumber>
                        <localDocumentNumber>CIC-86-100</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of trimetrexate in endocrine resistant metastatic prostatic carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:09">
                    <nciDocumentNumber>C76-0101</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DT-75-56</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of gallium nitrate</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:09">
                    <nciDocumentNumber>SEG-BRE-P20</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-BRE-P20</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II study of hexamethylmelamine (nsc# 13875) plus dibromodulcitol (nsc# 104800) in refractory Breast cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:09">
                    <nciDocumentNumber>CCG-097</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCG-097</localDocumentNumber>
                        <localDocumentNumber>84-C-244</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of fludarabine phosphate in pediatric patients</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:10">
                    <nciDocumentNumber>B85-0005</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CO-8593</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I evaluation of repetitive dosing of IFN-Y in cancer patients</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:10">
                    <nciDocumentNumber>B85-0017</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CO-8595</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I trial of adoptive Chemoimmunotherapy with Cyclophosphamide and Allogeneic Lymphokine activated killer(LAK) cells</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:10">
                    <nciDocumentNumber>RTOG-83-20</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-83-20</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of conventional radiation therapy followed by sequential half body irradiation in unfavorable prognosis Carcinoma of the Prostate</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:11">
                    <nciDocumentNumber>T91-0078</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                        <localDocumentNumber>UNM-0291-C</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I trial of subcutaneous il-1 alpha</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:11">
                    <nciDocumentNumber>T91-0224</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ICC-91M1</localDocumentNumber>
                        <localDocumentNumber>ICC-91M1</localDocumentNumber>
                        <localDocumentNumber>ICC-91M1</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II investigation of all-trans retinoic acid in the treatment of aids-related kaposi's sarcoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:11">
                    <nciDocumentNumber>T91-0237</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>92-C-68A</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I and Pharmacokinetic Study of Pyrazoloacridine in Pediatric Patients with Advanced Malignancy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:11">
                    <nciDocumentNumber>T91-0252</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of topotecan in advanced prostate cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:11">
                    <nciDocumentNumber>T91-0264</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>92-006</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of topotecan in advanced carcinoma of the pancreas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:12">
                    <nciDocumentNumber>T92-0065</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of interleukin-2(il-2) therapy in acute myeloid leukemia (aml) patients in remission</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:12">
                    <nciDocumentNumber>T92-0079</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>6580</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A multicenter Phase II trial of 10-edam (10-ethyl-10 deaza-aminoterin) in patients with progressive malignant glioma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:12">
                    <nciDocumentNumber>GOG-9204</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-9204</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of Taxol and Topotecan without and with G-CSF in patients with Advanced Ovarian Epithelial Malignancies</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:12">
                    <nciDocumentNumber>SWOG-9207</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-9207</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of edatrexate plus carboplatin in metastatic non-small cell lung cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:12">
                    <nciDocumentNumber>T94-0144</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of aminocamptothecin (9-ac) in patients with non-small cell lung cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:13">
                    <nciDocumentNumber>77-C-67</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>77-C-67</localDocumentNumber>
                        <localDocumentNumber>MOB-76-17</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of icrf-159 and the treatment of advanced gastric cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:13">
                    <nciDocumentNumber>T84-0519</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>84-C-217</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of mercaptopurine administered as an intravenous infusion for refractory lymphoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:13">
                    <nciDocumentNumber>113-256C</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>2001</localDocumentNumber>
                        <localDocumentNumber>87-27</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Icrf-159 Phase II tx of adv bronchogenic ca and adv adenocarcinoma of colon</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:13">
                    <nciDocumentNumber>POG-7712</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-7712</localDocumentNumber>
                        <localDocumentNumber>SWOG-7712</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Comparison of treatment regimens for the first CNS relapse in children with Acute Lymphocytic Leukemia - CNS Leukemia study 6 - Phase III</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:14">
                    <nciDocumentNumber>GITSG-9382</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GITSG-9382</localDocumentNumber>
                        <localDocumentNumber>MAOP-5783</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III trial in Non-Measurable Pancreatic Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:14">
                    <nciDocumentNumber>T90-0110</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>90-C-210</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of recombinant human interleukin-2 (il-2) plus tumor-infiltrating lymphocytes (til) with low-dose, recombinant human interferon-gamma (ifn-gamma) for the treatment of advanced neuroblastoma in children</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:14">
                    <nciDocumentNumber>W83-0323</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>83-C-38</localDocumentNumber>
                        <localDocumentNumber>CCG-094</localDocumentNumber>
                        <localDocumentNumber>R-83-35</localDocumentNumber>
                        <localDocumentNumber>83-02-015</localDocumentNumber>
                        <localDocumentNumber>123-84</localDocumentNumber>
                        <localDocumentNumber>CHP-451</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of tiazofurin in pediatric patient</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:15">
                    <nciDocumentNumber>W81-0308</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>WMCC-8031</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Bisantrene straight Phase II cl 216, 942 advanced renal cell carcinoma using a single dose schedule</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:15">
                    <nciDocumentNumber>W81-0309</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UMCC-8040</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Bisantrene straight Phase II in previously treated small cell carcinoma of the lung</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:17">
                    <nciDocumentNumber>N81-0115</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>81-C-21</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II study of M-AMSA administered as a continuous infusion</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:19">
                    <nciDocumentNumber>W81-0190</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Bisantrene Phase II in small cell carcinoma of the lung</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:21">
                    <nciDocumentNumber>CCG-0901</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCG-0901</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I /ib trial of mouse monoclonal anti-gd-2 antibody 14.g2a plus il-2 in children with refractory neuroblastoma or melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:21">
                    <nciDocumentNumber>T90-0030</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>IL-4/MELANOMA</localDocumentNumber>
                        <localDocumentNumber>LU-2347</localDocumentNumber>
                        <localDocumentNumber>90-03-063</localDocumentNumber>
                        <localDocumentNumber>890-5011-208</localDocumentNumber>
                        <localDocumentNumber>90023-90-03-1</localDocumentNumber>
                        <localDocumentNumber>1919</localDocumentNumber>
                        <localDocumentNumber>H6042-05366-01</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of recombinant il-4 in patients with metastatic malignant melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:22">
                    <nciDocumentNumber>GOG-76S</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-76S</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of Taxol NSC #125973) in patients with Advanced Cervical Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:22">
                    <nciDocumentNumber>NSABP-B-07A</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NSABP-B-07A</localDocumentNumber>
                        <localDocumentNumber>EST-1175</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III, a clinical trial to compare combination chemotherapy in the management of patients with surgically "curable"Breast Cancer who have one or more positive axillary nodes</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:23">
                    <nciDocumentNumber>T84-0211</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>4118</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of 4'deoxydoxorubicin for advanced measurable adenocarcinoma of the pancreas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:24">
                    <nciDocumentNumber>NCOG-8L-82-4</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCOG-8L-82-4</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III trial of Adjuvant Interferon following CVP chemotherapy in the management of adults with favorable Non-Hodkin's Lymphomas (DLWD, NLPD, NM,  in rappaport system)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:24">
                    <nciDocumentNumber>T89-0137</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>89-C-156</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of cis-platinum in combination with interferon-alfa and interleukin-2 in patients with malignant melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:24">
                    <nciDocumentNumber>T83-1459</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>82-C-60</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I trial of 13-cis retinoic acid as an immunomodulatory compound in cancer patients</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:24">
                    <nciDocumentNumber>NCOG-4B-83-1</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCOG-4B-83-1</localDocumentNumber>
                        <localDocumentNumber>NCOG-4B-83-1</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of Cisplatin, Methotrexate, and Vinblastine (CMV) chemotherapy followed by surgery in Advanced Transitional Cell Carcinoma of the Urothelium</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:25">
                    <nciDocumentNumber>T83-1289</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>83-C-198</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I and pharmacokinetic study of spirohydantoin mustard (nsc 172112) in adults</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:25">
                    <nciDocumentNumber>T83-1281</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>83-C-186</localDocumentNumber>
                        <localDocumentNumber>NCI-NMOB-83-5</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of cbdca in non-small cell and small cell lung cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:25">
                    <nciDocumentNumber>T89-0115</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>89-C-168</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I b trial of levamisole alone and in combination with recombinant interferon gamma in patients with advanced malignancies and as adjuvant therapy for patients with malignant melanoma or renal cell carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:25">
                    <nciDocumentNumber>T83-1253</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>83-C-67</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I trial of plurified human interleukin 2 (il-2) in patients with metastatic cancer who have failed conventional therapy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:25">
                    <nciDocumentNumber>T83-1187</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ICC-1</localDocumentNumber>
                        <localDocumentNumber>N83-0518</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II single agent chemotherapy with cbdca for metastatic Breast carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:26">
                    <nciDocumentNumber>NCOG-0C-82-1</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCOG-0C-82-1</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I trial of single agent NMHE for inoperable extensive cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:26">
                    <nciDocumentNumber>T89-0060</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>89-C-106</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I trial of concurrent recombinant interleukin-2 and recombinant interferon-alpha administered subcutaneously</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:26">
                    <nciDocumentNumber>T89-0047</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>89-C-24</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I pharmacokinetic study of fluconazole(uk-49858) in pediatric cancer patients</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:26">
                    <nciDocumentNumber>NCCTG-82-46-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-82-46-51</localDocumentNumber>
                        <localDocumentNumber>CO2</localDocumentNumber>
                        <localDocumentNumber>SWOG-8491</localDocumentNumber>
                        <localDocumentNumber>82-46-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Controlled Phase III evaluation of prolonged intra-arterial FUDR for selected patients with hepatic metastases from Colorectal Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:27">
                    <nciDocumentNumber>T89-0014</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of intravenous melphalan and the sensitizer sr2508(etanidazole) in the treatment of multiple myeloma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:27">
                    <nciDocumentNumber>T89-0008</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>88-C-0219</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of 2,3-dideoxyinosine (ddi) in children with symptomatic human immunodeficiency virus (hiv) infection</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:28">
                    <nciDocumentNumber>T88-0169</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CIC-88-98</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I dose seeking trial of fludarabine phosphate (famp) and chlorambucil in patients with chronic lymphocytic leukemia (cll)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:28">
                    <nciDocumentNumber>SWOG-8802</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-8802</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Evaluation of echinomycin in renal cell carcinoma, Phase II</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:28">
                    <nciDocumentNumber>T88-0082</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UMCC-8801</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of iv 6-thioguanine in patients with recurrent squamous cell carcinomas of the head and neck</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:29">
                    <nciDocumentNumber>T88-0054</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>88H0088</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I investigation of the combination of deoxycoformycin and fludarabine monophosphate in chronic lymphocytic leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:29">
                    <nciDocumentNumber>T87-0240</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>LAK-HD/NHL</localDocumentNumber>
                        <localDocumentNumber>9/87-5C</localDocumentNumber>
                        <localDocumentNumber>87-10-290</localDocumentNumber>
                        <localDocumentNumber>878-5011-065</localDocumentNumber>
                        <localDocumentNumber>CSU-449</localDocumentNumber>
                        <localDocumentNumber>H2381-01619-02A</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of patients with refractory hodgkin's disease and non hodgkin's lymphoma treated with il-2 and autologous lak cells</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:29">
                    <nciDocumentNumber>T87-0221</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>H-684-87</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of human lymphoblastoid interferon with whole body hyperthermia in renal cell carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:29">
                    <nciDocumentNumber>T87-0239</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RIGS - 100</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II clinical study: the intraoperative detection of colorectal cancer by radiolabeled b72.3 monoclonal antibody</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:29">
                    <nciDocumentNumber>T87-0145</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>87-C-79</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II study of intraperitoneal immunotoxin therapy of refractory ovarian cancer using ricin a chain conjugated to antibody 260f9</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:30">
                    <nciDocumentNumber>T87-0051</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>87-C-12</localDocumentNumber>
                        <localDocumentNumber>GOG-95</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized clinical trial for the treatment of woman with selected stage ic and ii(a,b,c) and selected stage iai + ibi and iaii + ibii ovarian cancer (Phase III )</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:31">
                    <nciDocumentNumber>T83-0930</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>83-22</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of spiromustine in patients with advanced cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:31">
                    <nciDocumentNumber>T83-0900</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CIC-83-11</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of cbdca in patients with epidermoid carcinoma of the esophagus</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:33">
                    <nciDocumentNumber>SEG-RAL-P18</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-RAL-P18</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of Pyrazofurin and 5-Azacytidine in Refractory Acute Leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:33">
                    <nciDocumentNumber>SEG-MM-P24</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-MM-P24</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of Platinum, Diamminedichloro CIS, BCNU, Cyclophosphamide and Prednisone in Refractory Multiple Myeloma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:33">
                    <nciDocumentNumber>SEG-LUN-P22</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-LUN-P22</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II pilot study in Large Cell Anaplastic Carcinoma of the Lung:  Cytoxan, Adriamycin, Cis-Platinum</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:33">
                    <nciDocumentNumber>EST-6483</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-6483</localDocumentNumber>
                        <localDocumentNumber>CALGB-8694</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III randomized comparison of M-bacod and chop combination Chemotherapy in advanced stage diffuse large cell(histiocytic) and diffuse mixed Non-Hodgkin's Lymphoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:34">
                    <nciDocumentNumber>EST-4883</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-4883</localDocumentNumber>
                        <localDocumentNumber>SEG-INT-GU-202</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Intergroup randomized Phase II evaluation of Carboplatin and chip in patients with advanced Transitional Cell carcinoma of the Urethelium</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:34">
                    <nciDocumentNumber>EST-4887</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-4887</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III trial of Bleomycin, Etoposide, and Cisplatin versus Etoposide and Cisplatin without Bleomycin in minimal extent (good prognosis) disseminated germ cell tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:34">
                    <nciDocumentNumber>EST-2279</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-2279</localDocumentNumber>
                        <localDocumentNumber>N81-0989</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II - III master protocol for treatment of advanced Pancreatic adenocarcinoma : Pala versus Streptozotocin + Adr +Meccnu (SAM)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:34">
                    <nciDocumentNumber>EST-2375</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-2375</localDocumentNumber>
                        <localDocumentNumber>N81-1002</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III comparative study of Adriamycin versus Adriamycin plus Cis-diammine-dichloroplatinum in patients with Thyroidcarcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:35">
                    <nciDocumentNumber>EST-P-B887</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-P-B887</localDocumentNumber>
                        <localDocumentNumber>T87-0298</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of high-dose Carboplatin/Etoposide and autologous bone marrow rescue for refractory Germ Cell neoplasms</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:36">
                    <nciDocumentNumber>D80-036-0352</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>06-80-BMT</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I pilot study : intensive melphalan chemotherapy and autologous bone marrow transplantation for the treatment of refractory malignancies</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:37">
                    <nciDocumentNumber>C82-1314</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DT-81-06A</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Chemotherapy of advanced lung cancer with aclacinomycin-a administered as a 24-hour continuous intravenous infusion Phase II</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:37">
                    <nciDocumentNumber>T86-0008</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CORN-8611</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of fludarabine phosphate in patients with chronic lymphocytic leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:37">
                    <nciDocumentNumber>C80-0627</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UMCT-1580</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Icrf-187 Phase II in patients with head and neck cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:40">
                    <nciDocumentNumber>T85-0167</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>85-61-01</localDocumentNumber>
                        <localDocumentNumber>NCCTG-85-61-01</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of menogaril (nsc 269148) in women with advanced ovarian cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:41">
                    <nciDocumentNumber>SEG-BRE-P09</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-BRE-P09</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II non-randomized study of a combination of Mitomycin-C, Cisplatin and Hexamethylmelamine in Metastatic Carcinoma of the Breast</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:42">
                    <nciDocumentNumber>SEG-AML-81-227P</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-AML-81-227P</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Protocol for Warner-Lambert/Park-Davis trial. Phase II study of M-AMSA Gluconate in patients with Acute Leukemia in relapse or Refractory Acute Leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:43">
                    <nciDocumentNumber>CCG-8603</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCG-8603</localDocumentNumber>
                        <localDocumentNumber>T87-0027</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of the combination of 5 days intravenous 5-flourouracil (nsc-19893) and 6 days of high dose oral leucovorin (nsc-3590) in pediatric patients</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:45">
                    <nciDocumentNumber>T85-0132</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>19-85(1)</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A multi-center open label Phase I trial of Suramin in patients with the Acquired Immune Deficiency Syndrome (AIDS)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:46">
                    <nciDocumentNumber>CALGB-8691</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-8691</localDocumentNumber>
                        <localDocumentNumber>EST-7486</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Cyclophosphamide vs. Cyclophosphamide plus Alpha 2 Interferon in the treatment of Follicular, Low Grade Lymphomas: Phase III</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:47">
                    <nciDocumentNumber>CALGB-8552</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-8552</localDocumentNumber>
                        <localDocumentNumber>T84-0293</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of Ifosfamide and MESNA in Non-Hodgkin's Lymphoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:47">
                    <nciDocumentNumber>RTOG-85-30</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-85-30</localDocumentNumber>
                        <localDocumentNumber>SWOG-8895</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III study of the role of Cricopharyngeal Myotomy in the treatment of Dysphagia following major Head and Neck surgery</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:47">
                    <nciDocumentNumber>B87-0002</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CO-8796</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I trial of continuous infusion combination Interferon-Beta-Ser and Interferon-Gamma in patients with advanced malignancy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:47">
                    <nciDocumentNumber>RTOG-85-01</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-85-01</localDocumentNumber>
                        <localDocumentNumber>NCCTG-88-40-51</localDocumentNumber>
                        <localDocumentNumber>SWOG-8598</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III prospective trial for localized Cancer of the Esophagus:  comparing radiation as a single modality to the combination of radiation therapy and chemotherapy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:48">
                    <nciDocumentNumber>RTOG-82-01</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-82-01</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I treatment of Glioblastoma Multiforme with hyperfractionation</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:48">
                    <nciDocumentNumber>RTOG-81-04</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-81-04</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A randomized Phase II study of efficacy of radiation and Hyperthermia (43 C) compared with radiation alone in the treatment of some Measurable Human Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:48">
                    <nciDocumentNumber>INT-0060</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-8520</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Cis-diamminedichloroplatinum (ii), methotrexate and bleomycin in the treatment of advanced epidermoid carcinoma of the penis: Phase II</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:49">
                    <nciDocumentNumber>POG-8671</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-8671</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I trial of Recombinant IL-2 in children with Solid Tumors: A  PediatricOncology Group single-institution study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:50">
                    <nciDocumentNumber>T85-0010</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>BTRC-8022</localDocumentNumber>
                        <localDocumentNumber>D80-004-178</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of dibromodulcitol for recurrent medulloblastoma and ependymoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:51">
                    <nciDocumentNumber>NCCTG-90-61-53</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-90-61-53</localDocumentNumber>
                        <localDocumentNumber>90-61-53</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of Leuprolide Acetate and Chemotherapy in patients with advanced Ovarian Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:51">
                    <nciDocumentNumber>T90-0242</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase I trial of Fludarabine Phosphate plus Alpha-Interferon in patients with Refractory Low-Grade Non-Hodgkin's Lymphoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:51">
                    <nciDocumentNumber>T91-0090</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>91-C-156</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of Interleukin-1Alpha with Ifosfamide, CBDCA and Etoposide with Autologous Bone Marrow Transplant in Metastatic Carcinoma and Lymphoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:51">
                    <nciDocumentNumber>T91-0101</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase I trial of Interleukin-1 Alpha and Methotrexate in patients with solid tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:52">
                    <nciDocumentNumber>T91-0175</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UPCC-1591</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II evaluation of All-Trans-Retinoic Acid in metastatic Non- Small Cell Lung Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:52">
                    <nciDocumentNumber>CCG-0917</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCG-0917</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of Anti-B4-Blocked Ricin in children with Recurrent/Refractory B-Lineage Leukemia or Lymphoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:52">
                    <nciDocumentNumber>T92-0036</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>912-5011-209</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II evaluation of MGBG (NSC# 32946) in Non- Hodgkin's Lymphoma in patients with Acquired Immunodeficiency Syndrome</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:53">
                    <nciDocumentNumber>CALGB-9264</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-9264</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of Taxol for patients with Primary or Metastatic Liver Tumors and/or Abnormal Liver Function</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:53">
                    <nciDocumentNumber>T92-0119</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DM 92-038</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Taxol and Granulocyte-colony stimulating factor in patients with advanced squamous cell carcinoma or Adenocarcinoma of the Esophagus</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:53">
                    <nciDocumentNumber>T92-0218</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DM92-095</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of combination chemotherapy with Edatrexate, Ifosfamide, and Cisplatin (EIP) plus Leucovorin and Mesna rescue for patients with Stage IIIB or IV Non-Small cell lung cancer (NSCLC)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:53">
                    <nciDocumentNumber>RTOG-93-02</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-93-02</localDocumentNumber>
                        <localDocumentNumber>R9302</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A prospective randomized Phase III clinical trial evaluating the use of post-operative adjuvant radiotherapy in the treatment of patients with Cutaneous Melanoma of the Head and Neck</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:54">
                    <nciDocumentNumber>T93-0038</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Interleukin-6(IL-6, SDZ ILS 969) administered by 120-hour continuous intravenous infusion in patients with Renal Cell Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:54">
                    <nciDocumentNumber>T93-0013</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>COG BR-15</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of Taxol and Cisplatin in patients with metastatic Breast Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:54">
                    <nciDocumentNumber>B93-0007</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A multi-part Phase I clinical trial of high dose Interleukin-2 in combination with the TNF Receptor IGG Chimera(TNFR:FC)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:54">
                    <nciDocumentNumber>T94-0042</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>93-076</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II evaluation of 131-I-CC49 monoclonal antibody following intravenous administration in patients with hormone-refractory prostate cancer pretreated with Gamma-Interferon</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:54">
                    <nciDocumentNumber>T93-0188</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase I trial of IL-1 and Methotrexate in patients with solid tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:54">
                    <nciDocumentNumber>CALGB-9331</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-9331</localDocumentNumber>
                        <localDocumentNumber>SWOG-9433</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II feasibility study of high dose Cyclophosphamide, Cisplatin, Carmustine (CB[) therapy as consolidation for patients with Limited Small Cell Lung Cancer (SCLC) in or near complete response to chemoradiotherapy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:55">
                    <nciDocumentNumber>T94-0124</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>IDD 94-17</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I trial of Rhizoxin (NSC 332598) administered as a 72 hour continuous intravenous infusion every 21 days</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:55">
                    <nciDocumentNumber>T94-0147</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of Aminocamptothecin (9-AC) in patients with malignant Gliomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:55">
                    <nciDocumentNumber>INT-0156</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E1C93</localDocumentNumber>
                        <localDocumentNumber>CALGB-9590</localDocumentNumber>
                        <localDocumentNumber>EORTC-08961</localDocumentNumber>
                        <localDocumentNumber>SWOG-9449</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of vip (etoposide, ifosfamide and cisplatin) in treatment of invasive thymoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:55">
                    <nciDocumentNumber>T95-0074</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of Trimethylcolchinic acid Methyl Ether D-Tartrate (TMCA) in patients with hormone refractory prostate cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:55">
                    <nciDocumentNumber>T96-0008</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of CI-980 in advanced Non-small cell Lung Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:55">
                    <nciDocumentNumber>T96-0041</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Trial of Pre-Surgery O6-Benzylguanine in the Treatment of Patients with Newly Diagnosed or Recurrent Cerebral Anaplastic Gliomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:56">
                    <nciDocumentNumber>RTOG-98-11</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>R9811</localDocumentNumber>
                        <localDocumentNumber>R9811</localDocumentNumber>
                        <localDocumentNumber>R9811</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Randomized Study of 5-Fluorouracil, Mitomycin-C, and Radiotherapy Versus 5-Fluorouracil, Cisplatin and Radiotherapy in Carcinoma of the Anal Canal</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:56">
                    <nciDocumentNumber>E1697</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCIC-CTG ME.10</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Randomized Study of Four Weeks High Dose IFN-alpha2b in Stage T2b N0, T3a-bN0, T4a-b N0, and T1-4, N1a, 2a (Microscopic) Melanoma</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:56">
                    <nciDocumentNumber>T97-0029</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CWRU 6496</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Trial of O6 Benzylguanine and BCNU in Cutaneous T-cell Lymphoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:56">
                    <nciDocumentNumber>T97-0097</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Evaluation of Bryostatin-1 (NSC#339555) in Patients with advanced Non-Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:56">
                    <nciDocumentNumber>T97-0106</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>VCC THO 9817</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of 6-Hydroxymethylacylfulvene (MGI-114, NSC #683863) in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-12-1999 16:41:17">
                    <nciDocumentNumber>CALGB-19803</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-19803</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A RANDOMIZED PHASE II trial  of  Oral TOPETECAN  given  twice a day for 5 days or once a day for 10  days to Patients with  MYELODYSPLASTIC  SYNDROMES (MDS)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-12-1999 16:46:21">
                    <nciDocumentNumber>GOG-0176</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-176</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A PHASE II trial of pulse ACTINOMYCIN-D as salvage therapy for failed low risk GESTATIONAL TROPHOBLASTIC NEOPLASIA</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-12-1999 17:05:52">
                    <nciDocumentNumber>S9809</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S9809</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>The Effect of Fluoroquinolones on the Disease-Free Interval in Patients with Stage TA Transitional Cell Carcinoma of the Bladder, Phase III</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:17">
                    <nciDocumentNumber>T98-0083</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>99-097</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Recombinant Humanized Monoclonal Antibody Against HER-2 for the Treatment of Recurrent Osteosarcoma DCT-Supplied Investigational Agent: rhuMAb (Trastuzumab, Herceptin) (NSC #688097)</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-29-1999 18:06:17">
                    <nciDocumentNumber>T93-0106</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CARTOP</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A PHASE I EVALUATION OF COMBINATION CHEMOTHERAPY WITH TOPTECAN (NSC 609699) AND CARBOPLATIN IN PEDIATRIC MALIGNANCIES</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:18">
                    <nciDocumentNumber>E5397</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E5397</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized, Double Blind, Placebo Controlled Phase III Evaluation of Cisplatin + Placebo Versus Cisplatin + C225 a Mouse/Human Monoclonal Antibody to the Epidermal Growth Factor Receptor, in Patients with Metastatic and/or Recurrent Squamous Cell Cancer of the Head and Neck</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:18">
                    <nciDocumentNumber>T99-0019</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UICC-LW-02</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Trial of Humanized 1D10 Monoclonal Antibody (Hu1D10) in Patients with Relapsed Non-Hodgkin's Lymphoma (NHL)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-29-1999 18:06:18">
                    <nciDocumentNumber>T93-0097</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CHW 93/59</localDocumentNumber>
                        <localDocumentNumber>ARRC 223-93</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Gallium Nitrate For The Treatment Of Malignant Tumors:A Phase I Study</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>AMC-002</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>T96-0042</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial Of 9-Cis Retinoic Acid (Alrt1057) in AIDS-KS</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>T96-0051</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study Of Cordycepin (NSC 63984) Plus 2'-Deoxycoformycin (NSC 218321) In Patients With Refractory TdT-Positive Leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>T98-0082</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>99-046</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial of Sarcosinamide Nitrosourea (SarCNU) in Patients with Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>T99-0040</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHII-22 (USC 3S-00-1)</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Combination Trial of Bryostatin-1 and Cisplatin in the Treatment of Metastatic Gastric Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="03-29-1999 18:06:20">
                    <nciDocumentNumber>T90-0037</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase ii study of high-dose 24 hour continous infusion of 5-fu and leucovorin and low-dose pala for patients with colorectal cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:21">
                    <nciDocumentNumber>T92-0248</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>VCC HN-16</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Radiation Therapy With Concomitant Continuous Infusion Taxol For Previously Unirradiated Locally Advanced Head &amp; Neck Squamous Cell Cancer, A Phase I Study</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:22">
                    <nciDocumentNumber>T94-0054</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>94-C-0209</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase ii study of chemotherapy of non-hodgkin's lymphoma arising in the cns or eye</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:22">
                    <nciDocumentNumber>T94-0125</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCNSC 96-314</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A phase ii trial of recombinant human interferon beta in the treatment of patients with recurrent gliomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:22">
                    <nciDocumentNumber>NABTT-9404</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>T94-0168</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II/I Clinical And Pharmacologic Study Of PRE-IRRADIATION 9-AMINO-20(S)-CAMPTOTHECIN (9-AC) Administered  As A 72 Hour  INFUSION  In Adults  With Newly  Diagnosed  GLIOBLASTOMA MULTIFORME</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:22">
                    <nciDocumentNumber>T94-0181</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UMCC 9421</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of the Orally Administered Butyrate Prodrug, Tributyrin, in Patients with Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:22">
                    <nciDocumentNumber>T95-0027</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>HIC 8147</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of TOPOTECAN  (NSC# 609699) and  CYCLOPHOSPHAMIDE,  with G-CSF (FILGRASTIM) in high-risk  SMALL  CELL  LUNG  CANCER</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T96-0045</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>VCC THO 9814 \ 99-C-0142</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of Individualized Mutant p53 Peptide-Pulsed Cultured Autologous Dendritic Cells in the Adjuvant Treatment of Patients with Locally Advanced Non-Small Cell Lung Cancer After Standard Therapy</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T96-0076</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>AMC-004</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial To Determine The Safety, Tolerance And ANTI-TUMOR effects of PROTEASE Inhibitor Based ANTIRETROVIRALl Therapy Combined With INTEFERON ALPHA-2B In Patients With HIV-Related KAPOSI'S SARCOMA</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>NABTC-9702</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>T96-0103</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial of Pre-Surgical O6-Benzylguanine in the Treatment of Patients with Malignant Gliomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T96-0122</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A phase ii trial of pyrazoloacridine (nsc 366140) administered as a 3-hour infusion every 3 weeks in patients with hepatobiliary cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T97-0015</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A phase ii trial of 9-aminocamptothecin (nsc 603071) administered as a 120-hour continuous infusion in patients with previously treated gastric cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T97-0025</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>97-C-0136</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial of 5-Fluorouracil Given with 776C85 (GW776) and Low-Dose Leucovorin in Adult Patients with Solid Tumors</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T97-0037</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>9711 GCC</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Bryostatin (NSC 339555, IND #42780) in Acquired Immunodeficiency Syndrome (AIDS)-Related Lymphomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>NABTT-9706</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTT-9706</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II evaluation of isis 3521 (cgp64128a) administered as a 21 day continuous intravenous infusion in patients with progressive or recurrent high grade astrocytomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T97-0116</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MCC/CCHR 9801-2C</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of Bryostatin 1 (NSC 339555) and Fludarabine in Patients with Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin's Lymphoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T98-0004</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DFHCC 98-262</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Randomized Trial of Recombinant Fowlpox and Recombinant Vaccinia Virus Expressing PSA in Patients with Adenocarcinoma of the Prostate</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:24">
                    <nciDocumentNumber>NABTT-9804</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTT-9804</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II Study of Pyrazoloacridine (PZA) in Adults with Newly Diagnosed Glioblastoma Mulitforme</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:24">
                    <nciDocumentNumber>T99-0012</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>99-C-0129</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of Decitabine Mediated Induction of Tumor Antigen and Tumor Suppressor Gene Expression in Patients with Cancers Involving the Lung, Esophagus, or Pleura</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:24">
                    <nciDocumentNumber>NABTT-9901</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTT-9901</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II  Study of Oral PROCARBAZINE  in the  treatment of Recurrent High  Grade  ASTROCYTOMAS</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:24">
                    <nciDocumentNumber>T99-0030</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>9802  GCC</localDocumentNumber>
                        <localDocumentNumber>980300</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study to Determine Biological Endpoints of Up to 21 Day Dosing of the Farnesyltransferase Inhibitor R115777 (IND #52,302) for Refractory and Relapsed  Adult Leukemias</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="05-04-1999 15:57:21">
                    <nciDocumentNumber>S9903</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S9903</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Pilot Study of Stereotactic Radiosurgery for Limited Malignant Melanoma Brain Metastases</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="05-24-1999 16:43:50">
                    <nciDocumentNumber>T99-0060</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Oxaliplatin in Adult Patients with Impaired Renal Function</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="06-03-1999 13:30:00">
                    <nciDocumentNumber>RTOG-99-09</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-99-09</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Postoperative Adjuvant Immunotherapy and Radiation in Patients with Completely Resected Stage II and Stage IIIA Non-Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="08-04-1999 15:43:41">
                    <nciDocumentNumber>T99-0087</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ID99-201</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Surrogate Endpoint Trial of Human Recombinant Endastatin in Patients with Advanced Solid Tumor Amendable to Biopsy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="08-05-1999 09:51:43">
                    <nciDocumentNumber>GOG-9903</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-9903</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial Using Multiple Cycles of High Dose Sequential Carboplatin, Paclitaxel and Topetecan with Peripheral Blood Stem Cell (PBSC) Support as Initial Chemotherapy in Patients with Optimally Debulked Stage III Ovarian and Primary Peritoneal Carcinoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="08-18-1999 10:50:52">
                    <nciDocumentNumber>T99-0098</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CWRU 3Y99</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial of Fenretinide in Combination with Paclitaxel and Cisplatin</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="08-31-1999 13:56:56">
                    <nciDocumentNumber>T99-0066</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>00-C-0128</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Daily Bolus Flavopiridol for Five Consecutive Days in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="09-16-1999 10:21:04">
                    <nciDocumentNumber>89</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CWRU 1298</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of O6 Benzylguanine and BCNU in Patients with Colon and Rectal Carcinoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="09-16-1999 10:27:13">
                    <nciDocumentNumber>91</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CWRU 1599</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase II Trial of Two Different Schedules of Administration of Rebeccamycin Analog in Patients with Advanced Non-Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="10-07-1999 12:33:58">
                    <nciDocumentNumber>195</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>9945</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of Anti-HER-2 Monoclonal Antibody Trastuzumab (Herceptin) in Combination with Low Dose Interleukin-2 (Proleukin) in Metastatic Breast Cancer Patients who have Previously Failed Trastuzumab</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="10-07-1999 12:56:54">
                    <nciDocumentNumber>197</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>99-283</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase 2 Study of Rebeccamycin Analog in Advanced Breast Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="10-26-1999 18:23:51">
                    <nciDocumentNumber>370</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CWRU 5Y99</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of Oxaliplatin (NSC# 266046), Irinotecan, and Capecitabine in Patients with Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="11-09-1999 10:37:05">
                    <nciDocumentNumber>38</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II Study of Tipifarnib [Zarnestra TM], Farnesyl Transferase Inhibitor R115777 (NSC 702818) in Patients with Myeloproliferative Disorders</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="01-10-2000 08:58:53">
                    <nciDocumentNumber>470</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>10M-99-3</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial of a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides emulsified with Montanide ISA 51 with ProGP for Patients with Resected Stages III and IV Melanoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="08-23-2000 16:20:33">
                    <nciDocumentNumber>CALGB-99903</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-99903</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Arsenic Trioxide (NSC #706363, IND #57974) in Urothelial Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="09-21-2000 11:22:56">
                    <nciDocumentNumber>3170</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>J0254</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Study of Flavopiridol (NSC 649890, IND 46,211) in Timed Sequential Combination with Cytosine Arabinoside (ara-C) and Mitoxantrone for Adults with Poor-Risk Acute Leukemias</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-12-2012 10:39:05" createdDate="10-19-2000 10:16:14">
                    <nciDocumentNumber>1857</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>0158</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of PS-341 in Combination with Paclitaxel in Metastatic Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="11-01-2000 14:14:21">
                    <nciDocumentNumber>2669</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>2001C0185; 0132</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Bevacizumab and Interferon-alpha-2b in Metastatic Malignant Melanoma</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="11-14-2000 11:58:07">
                    <nciDocumentNumber>2490</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UMGCC 0076</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of the Recombinant Human Monoclonal Anti-Vascular Endothelial Growth Factor Antibody (rhuMAB VEGF) Bevacizumab (NSC# 704865, IND# 7,921) Administered in Timed Sequential Combination with Cytosine Arabinoside (ara-C) and Mitoxantrone for Adults with Refractory and Relapsed Acute Myelogenous Leukemias (AMLs)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-13-2000 13:31:54">
                    <nciDocumentNumber>3656</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UC#11045A</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of the Epothilone B Analog BMS-247550 (NSC 710428D) in Patients with Hepatobiliary Cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-04-2001 09:50:36">
                    <nciDocumentNumber>GOG-0191</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-0191</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Trial to Evaluate the Efficacy of Maintaining Hemoglobin Levels Above 120 G/L with Erythropoietin Versus Above 100 G/L without Erythropoietin in Anemic Patients Receiving Concurrent Radiation and Cisplatin for Cervical Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="01-17-2001 09:42:27">
                    <nciDocumentNumber>3293</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC007A</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of PS-341 in the Treatment of Metastatic Malignant Melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="01-22-2001 09:48:27">
                    <nciDocumentNumber>2716</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>01-013</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Bevacizumab in Combination with Vinorelbine in Stage IV Breast Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="01-30-2001 15:08:21">
                    <nciDocumentNumber>1754</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UMGCC 0116</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Farnesyl Transferase Inhibitor R115777 (Zarnestra) (R115777 ( Zarnestra), Tipifarnib, R115777, NSC #702818) in Elderly Patients with Previously Untreated Poor-Risk Acute Myeloid Leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="02-13-2001 11:49:40">
                    <nciDocumentNumber>GOG-0076CC</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-0076CC</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Limited Access Phase II Trial of Capecitabine (NSC #712807) in the Treatment of Advanced, Persistent or Recurrent Squamous Cell Carcinoma of the Cervix.</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="05-11-2001 15:02:38">
                    <nciDocumentNumber>S0026</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0026</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Evaluation of Interferon Alpha-2b (NSC-377523) and Thalidomide (NSC-66847) in Patients with Disseminated Malignant Melanoma, Phase II</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="05-22-2001 17:33:59">
                    <nciDocumentNumber>E6200</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E6200</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase II Trial of Two Dose Levels of ZD1839 (Iressa) (NSC 715055, IND 61187) in Patients with Recurrent Colorectal Adenocarcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="05-23-2001 09:56:39">
                    <nciDocumentNumber>1831</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>10401</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Open-Label Study of Recombinant Human Interleukin-12 (NSC 672423) in Mycosis Fungoides (MF) Patients with Cross-Over to Phase I Evaluation of Escalating Doses of Interleukin-2 (NSC 373364) Administered with Interleukin-12</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="06-08-2001 12:02:17">
                    <nciDocumentNumber>RTOG-0132</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG S-0132</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Neoadjuvant/Adjuvant STI-571 (Gleevec NSC #716051) for Primary and Recurrent Operable Malignant GIST Expressing the KIT Receptor Tyrosine Kinase (CD117) (ACRIN 6665)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="07-19-2001 15:55:12">
                    <nciDocumentNumber>NCIC-148</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCIC-148</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of OSI-774 (NSC 718781) in Patients with Locally Advanced and/or Metastatic Carcinoma of the Endometrium</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="08-23-2001 09:37:39">
                    <nciDocumentNumber>ADVL0013</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ADVL0013</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of  90Yttrium-Ibritumomab Tiuxetan (90Y Zevalin, Yttrium (90)-Anti-CD20, NSC #710085) Preceded by Rituximab in Children with Recurrent/Refractory CD20 Positive Lymphoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-29-2001 13:03:30">
                    <nciDocumentNumber>GOG-0127R</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-0127-R</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Evaluation of Liposomal Doxorubicin (DOXIL) (NSC #712227) in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-27-2001 12:01:17">
                    <nciDocumentNumber>5576</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC0184</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of R115777 in Myelofibrosis with Myeloid Metaplasia (MMM)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-10-2002 11:16:24">
                    <nciDocumentNumber>GOG-0087K</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-0087-K</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Evaluation of DMAP Plus GM-CSF in the Treatment of Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-28-2002 12:01:19">
                    <nciDocumentNumber>5839</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>5839</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Arsenic Trioxide in Patients with Adenocarcinoma of the Pancreas Refractory to Gemcitabine</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-09-2002 09:10:25">
                    <nciDocumentNumber>N014C</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>N014C</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase II Trial of PS-341 and Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-09-2002 14:03:31">
                    <nciDocumentNumber>NABTT-2105</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTT 2105</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Brachytherapy Dose Escalation Using the GliaSite RTS[TM] in Newly Diagnosed Glioblastoma Multiforme in Conjunction with External Beam Radiation Therapy</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-24-2002 09:40:20">
                    <nciDocumentNumber>N0124</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>N0124</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of STI571 in Patients with Relapsed Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="05-01-2002 18:50:40">
                    <nciDocumentNumber>NABTC-01-06</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTC01-06</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Poly ICLC in Patients with Recurrent Anaplastic Glioma</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="06-18-2002 09:21:57">
                    <nciDocumentNumber>5840</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>0902-492</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Oxaliplatin in Combination with Paclitaxel in Patients with Locally Recurrent or Metastatic Cervical Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="07-03-2002 12:38:24">
                    <nciDocumentNumber>NCIC-MA.27</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCIC-MA.27 (COMPANION)</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III Trial of Exemestane Versus Anastrozole in Postmenopausal Women with Receptor Positive Primary Breast Cancer</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="07-24-2002 15:59:46">
                    <nciDocumentNumber>5736</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NYU 02-12</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I and Pharmacokinetic Study of Oxaliplatin (Eloxatin) in Combination with Bortezomib (PS-341, Velcade) in Patients with Advanced Malignancy</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="08-09-2002 07:18:51">
                    <nciDocumentNumber>5932</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>C-2599</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of the Combination of 17-AAG and Imatinib Mesylate (Gleevec) in Patients with Blastic Phase, Accelerated Phase of Chronic Myeloid Leukemia (CML) or Patients with Chronic Phase CML Who Have not Achieved a Cytogenetic Response with Imatinib Mesylate</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-17-2002 12:14:07">
                    <nciDocumentNumber>5965</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>12209B</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of Depsipeptide in Patients with Relapsed or Refractory AML</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-08-2002 12:09:57">
                    <nciDocumentNumber>6041</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CTRG G15/02</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of Irofulven as First Line Therapy in Recurrent or Metastatic Gastric Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-21-2002 14:26:57">
                    <nciDocumentNumber>5996</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>0403-765</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of Depsipeptide in Relapsed/Refractory Multiple Myeloma</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-28-2002 13:26:00">
                    <nciDocumentNumber>RTOG-0232</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-0232</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone for Selected Patients with Intermediate Risk Prostatic Carcinoma</documentTitle>
                    <currentStatus>Temporarily Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-30-2002 15:08:39">
                    <nciDocumentNumber>6046</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UCSF #02555</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase II Study of BMS 247550 or Mitoxantrone and Prednisone in Patients with Taxane Resistant Hormone Refractory Prostate Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-28-2003 10:29:55">
                    <nciDocumentNumber>CALGB-90206</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-90206</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III Trial of Interferon Alfa-2B or Interferon Alfa-2B Plus Bevacizumab in Patients with Advanced Renal Carcinoma</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-14-2003 07:43:41">
                    <nciDocumentNumber>GOG-0211</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-0211</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Pilot Investigation of the Relationship of Short Term Depo-Provera (Medroxyprogesterone Acetate) (NSC #27408) Exposure to the Morphologic, Biochemical, and Molecular Changes in Primary Endometrioid Adenocarcinoma of the Uterine Corpus</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="05-08-2003 11:47:17">
                    <nciDocumentNumber>S0313</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0313</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Evaluation of CHOP Plus Involved Field Radiotherapy Followed by Yttrium-90 Ibritumomab Tiuxetan for Stages I, IE, and Non-Bulky Stages II and IIE, CD20 Positive, High-Risk Localized, Aggressive Histologies of Non-Hodgkin's Lymphoma, Phase II</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-12-2012 10:41:39" createdDate="06-10-2003 12:09:11">
                    <nciDocumentNumber>5954</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>2003-0308</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Decitabine in Patients with Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Radioiodine</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="07-29-2003 15:05:00">
                    <nciDocumentNumber>6323</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>04-069</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Multicenter Phase I Trial of 17-N-allylamino-17-demethoxy Geldanamycin (17-AAG, NSC #330507) in Patients with Recurrent/Refractory Pediatric Solid Tumors (Ewing's Sarcoma, Desmoplastic Small Round Cell Tumor, Osteosarcoma, Neuroblastoma, and Rhabdomyosarcoma) and Leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-15-2003 15:23:40">
                    <nciDocumentNumber>ADVL0316</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ADVL0316</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of 17-AAG in Relapsed/Refractory Pediatric Patients with Solid Tumors or Leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="11-19-2003 08:30:50">
                    <nciDocumentNumber>6449</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CASE1203</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-12-2012 10:41:39" createdDate="12-10-2003 08:42:50">
                    <nciDocumentNumber>6372</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UMCC 2004.030</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Evaluation of EMD 121974 (NSC 707544, Cilengitide) in Asymptomatic Patients with Metastatic Androgen Independent Prostate Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-22-2004 08:07:14">
                    <nciDocumentNumber>6547</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PH1/102</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Cancer Research UK Phase 1 Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of 17-Dimethylaminoethyl-Amino-17-Demethoxygeldanamycin (17-DMAG) Given as a Once Weekly Infusion in Patients with Advanced Solid Tumours</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="02-24-2004 14:30:39">
                    <nciDocumentNumber>6608</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>OSU 0441</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of BAY 43-9006 in Patients with Metastatic Thyroid Carcinoma</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-05-2004 10:58:57">
                    <nciDocumentNumber>6454</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>06-C-0076</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Multi-Institutional, Phase II Clinical Trial of 17-(Allylamino)-17-demethoxygeldanamycin (17-AAG, NSC 330507 and EPL Diluent,NSC 704057) in Adult Patients with Systemic Mastocytosis</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-05-2004 11:15:37">
                    <nciDocumentNumber>CALGB-80303</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-80303</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III Trial of Gemcitabine Plus Bevacizumab (NSC# 704865 IND #7921) Versus Gemcitabine Plus Placebo in Patients with Advanced Pancreatic Cancer</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-28-2004 08:30:01">
                    <nciDocumentNumber>S0413</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0413</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of GW572016 (NSC-727989) as First Line Therapy in Patients with Advanced or Metastatic Gastric Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="04-28-2004 09:35:18">
                    <nciDocumentNumber>GOG-0213</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-0213</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab (NSC #704865, IND #7921) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC#704865, IND#7921)</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="06-07-2004 11:48:27">
                    <nciDocumentNumber>6724</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>C-2876</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of GW572016 and Tamoxifen in Patients with Metastatic Breast Cancer Resistant to Single-Agent Tamoxifen</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="07-21-2004 10:33:56">
                    <nciDocumentNumber>S0344</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0344</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Surgical Trial of Intralesional Resection of Low-Grade Intracompartmental Chondrosarcoma of Bone</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="07-27-2004 11:06:57">
                    <nciDocumentNumber>6317</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NYU 03-67</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Oxaliplatin Combined with Continuous Infusion Topotecan as Chemotherapy for Patients with Previously Treated Ovarian Cancer</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="08-03-2004 13:02:03">
                    <nciDocumentNumber>PBTC-018</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PBTC-018</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial of CC-5013 (Lenalidomide) in Pediatric Patients with Recurrent or Refractory Primary CNS Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="08-17-2004 10:00:53">
                    <nciDocumentNumber>6569</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>13572A</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of BAY 43-9006 in Advanced/Recurrent Uterine Carcinoma/Carcinosarcoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="09-13-2004 10:05:27">
                    <nciDocumentNumber>RTOG-0412-SWOG-S0332</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-0412</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Randomized Trial of Preoperative Chemotherapy Versus Preoperative Concurrent Chemotherapy and Thoracic Radiotherapy Followed by Surgical Resection and Consolidation Chemotherapy in Favorable Prognosis Patients with Stage IIIA (N2) Non-Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="12-08-2004 15:14:44">
                    <nciDocumentNumber>7135</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC048H</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of AZD2171 in the Treatment of Patients with Acute Leukemia and Myelodysplastic Syndrome</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-09-2004 13:33:13">
                    <nciDocumentNumber>7133</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC047F</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of AZD2171 in Adult Patients with Neurofibromatosis Type 1 and Extensive Plexiform and Paraspinal Neurofibromas</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-15-2004 13:23:48">
                    <nciDocumentNumber>7105</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>05-254</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of AZD2171 in Recurrent Glioblastoma</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-21-2004 09:26:34">
                    <nciDocumentNumber>6858</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>05-109</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination with Alvocidib (Flavopiridol) in Advanced Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-04-2005 14:12:01">
                    <nciDocumentNumber>E1104</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E1104</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination with Trastuzumab (Herceptin) in Patients with Advanced Metastatic and/or Local Chest Wall Recurrent Her-2 Amplified Breast Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-13-2005 10:36:30">
                    <nciDocumentNumber>7325</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CASE 1205</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Dose-Dense and Dose-Intense Alternating Irinotecan/Capecitabine and Oxaliplatin/Capecitabine: Phase I in Solid Tumors and Phase II with Bevacizumab as First-Line Therapy of Advanced Colorectal Cancer</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-23-2005 14:27:46">
                    <nciDocumentNumber>7267</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-041</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of PXD101 in Platinum Resistant Epithelial Ovarian Tumors and Micropapillary/Borderline (LMP) Ovarian Tumors</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-25-2005 09:33:06">
                    <nciDocumentNumber>7251</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHI-53</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 1 Trial of PXD101 in Combination with 13-cis-Retinoic Acid in Advanced Solid Tumor Malignancies</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-27-2005 10:18:54">
                    <nciDocumentNumber>CALGB-80403</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-80403/E1206</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Phase II Study of ECF-C, IC-C, or FOLFOX-C in Metastatic Esophageal and GE Junction Cancer</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="06-06-2005 09:32:39">
                    <nciDocumentNumber>E2204</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E2204</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>An Intergroup Randomized Phase II Study of Bevacizumab (NSC 704865) or Cetuximab (NSC 714692) in Combination with Gemcitabine and in Combination with Chemoradiation (Capecitabine and Radiation) in Patients with Completely-Resected Pancreatic Carcinoma</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="09-28-2005 15:58:09">
                    <nciDocumentNumber>ACOSOG-Z1041</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>Z1041</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III Trial Comparing a Neoadjuvant Regimen of FEC-75 Followed by Paclitaxel Plus Trastuzumab with a Neoadjuvant Regimen of Paclitaxel Plus Trastuzumab Followed by FEC-75 Plus Trastuzumab in Patients with HER-2 Positive Operable Breast Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="11-22-2005 12:24:45">
                    <nciDocumentNumber>7435</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHII-75</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Study of E7389 Halichondrin B Analog (NSC # 707389; IND # 64395) in Metastatic Urothelial Tract Cancer and Renal Insufficiency</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="01-17-2006 10:57:01">
                    <nciDocumentNumber>7584</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>06-074</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of AZD0530 for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="02-03-2006 11:01:05">
                    <nciDocumentNumber>PBTC-021</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PBTC-021</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy  in Children with Newly Diagnosed Brainstem Gliomas and High Grade Gliomas</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-12-2012 10:41:39" createdDate="02-06-2006 12:23:08">
                    <nciDocumentNumber>7451</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>2007-015</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized, Phase II Trial of AZD2171, Docetaxel, and Prednisone Compared to Docetaxel and Prednisone in Patients with Metastatic, Hormone Refractory Prostate Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="02-08-2006 09:51:49">
                    <nciDocumentNumber>7704</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>J0638</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of Triapine (IND #68338, NSC #663249, 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbone) Plus Fludarabine (NSC #312887, Fludarabine Monophosphate) in Adults with Aggressive Myeloproliferative Disorders (MPDs) Including Chronic Myelomonocytic Leukemia (CMML) and Chronic Myelogenous Leukemia in Accelerated Phase (CML-AP) or Blast Crisis (CML-BC)</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="02-08-2006 10:34:25">
                    <nciDocumentNumber>ADVL0517</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ADVL0517</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Ispinesib (SB-715992) in Pediatric Patients with Relapsed or Refractory Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="02-21-2006 15:17:07">
                    <nciDocumentNumber>7609</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>OSU 06054 / IRB 2006C0050</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Sorafenib (BAY 43-9006) in Patients with Metastatic Medullary Thyroid Carcinoma</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="03-13-2006 14:42:31">
                    <nciDocumentNumber>S0518</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0518</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-20-2006 15:14:32">
                    <nciDocumentNumber>ADVL0515</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ADVL0515</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Vinblastine in Combination with Carboplatin for Children with Newly Diagnosed and Recurrent Low-Grade Gliomas</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="10-10-2006 12:48:23">
                    <nciDocumentNumber>7813</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>07070</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of Dasatinib in Patients with Transplant and Non-Transplant Related Unresectable or Metastatic Cutaneous Squamous Cell Carcinoma and RAI Stage 0-1 Chronic Lymphocytic Leukemia</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-12-2012 10:41:39" createdDate="10-31-2006 09:02:35">
                    <nciDocumentNumber>7756</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>2006-0851</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study Trastuzumab (NSC 688097) in Her2/neu Positive Cancer of the Gallbladder or Biliary Tract</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="12-26-2006 10:25:50">
                    <nciDocumentNumber>7925</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>15455B</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of AZD6244 in Relapsed or Refractory AML</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="02-28-2007 10:00:07">
                    <nciDocumentNumber>7968</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>J0783</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 1 Study of ABT-888 in Combination with Topotecan Plus Carboplatin for Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasias and Myeloproliferative Disorders</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="03-05-2007 14:43:28">
                    <nciDocumentNumber>8027</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC0721</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of AT-101 in Recurrent Extensive Stage Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-12-2012 10:36:33" createdDate="07-17-2007 15:52:35">
                    <nciDocumentNumber>7856</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>08-C-0180</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Trial of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, Nexavar) in Children and Young Adults with Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="09-25-2007 09:30:45">
                    <nciDocumentNumber>8129</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC0736</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II Trial of IMC-A12 in Combination with Temsirolimus in Patients with Metastatic Breast Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="10-16-2007 16:52:31">
                    <nciDocumentNumber>ACOSOG-Z6051</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ACOSOG-Z6051</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="12-03-2007 08:59:37">
                    <nciDocumentNumber>NABTC-07-01</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTC07-01</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Trial of Aflibercept (VEGF Trap) with Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients with Malignant Glioma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="02-19-2008 16:26:47">
                    <nciDocumentNumber>7870</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>I 145208</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II Study of High Dose Interleukin 2, Aldesleukin, in Combination with the Histone Deacetylase Inhibitor Entinostat in Patients with Metastatic Renal Cell Carcinoma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="05-07-2008 11:37:12">
                    <nciDocumentNumber>8273</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>10-C-0056</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults with Relapsed Solid Tumors and Lymphomas</documentTitle>
                    <currentStatus>Temporarily Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="05-09-2008 12:48:46">
                    <nciDocumentNumber>8060</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Multicenter Random Assignment Phase II Study of Irinotecan and Alvocidib (Flavopiridol) Versus Irinotecan Alone for Patients with p53 Wild Type Gastric Adenocarcinoma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="06-30-2008 14:10:05">
                    <nciDocumentNumber>S0809</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0809</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed by Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="08-07-2008 16:13:58">
                    <nciDocumentNumber>8271</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>16691B</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and for Non-Adenoid Cystic Malignant Salivary Tumors</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="09-23-2008 12:29:00">
                    <nciDocumentNumber>8258</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>09-034</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Non-Randomized Phase 2 Study of Alvocidib (Flavopiridol) Plus Oxaliplatin with or without 5-FU and Leucovorin for Relapsed or Refractory Germ-Cell Tumors</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="11-25-2008 07:39:44">
                    <nciDocumentNumber>ADVL0911</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ADVL0911</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 1 Dose Escalation Study of Seneca Valley Virus (NTX-010), a Replication-Competent Picornavirus, in Relapsed/Refractory Pediatric Patients with Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors with Neuroendocrine Features</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="12-01-2008 15:52:12">
                    <nciDocumentNumber>8351</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>09-C-0214</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine with Tetrahydrouridine (FdCyd + THU)</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="03-02-2009 13:13:44">
                    <nciDocumentNumber>PBTC-025B</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PBTC-025B</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults with Recurrent or Refractory Medulloblastoma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="03-24-2009 13:51:59">
                    <nciDocumentNumber>PBTC-027</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PBTC-027</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of ABT-888, an Oral Inhibitor of Poly (ADP-ribose) Polymerase and Temozolomide in Children with Recurrent/Refractory CNS Tumors</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="04-24-2009 15:15:25">
                    <nciDocumentNumber>RTOG-0848</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG 0848</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="06-29-2009 13:57:46">
                    <nciDocumentNumber>8420</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>WSU 2009-099</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of the Hedgehog Smoothened Antagonist GDC-0449 (NSC # 747691) Plus Pan-Notch Inhibitor RO4929097 (NSC # 749225) Administered in Patients with Advanced Breast Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="08-25-2009 10:21:39">
                    <nciDocumentNumber>8476</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PJC-002</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Randomized Study of Cediranib (AZD2171) Alone Compared with the Combination of Cediranib (AZD2171) plus BMS-354825 (dasatinib, Sprycel) in Docetaxel Resistant, Castration Resistant Prostate Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="09-17-2009 08:50:33">
                    <nciDocumentNumber>ADVL0919</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ADVL0919</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 1 Study of RO4929097, an Oral Small Molecule Inhibitor of Gamma-Secretase, in Children with Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="12-04-2009 15:21:30">
                    <nciDocumentNumber>8317</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>10-182-B</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="12-14-2009 14:12:28">
                    <nciDocumentNumber>CALGB-80702</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-SWOG C80702</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="01-19-2010 11:04:27">
                    <nciDocumentNumber>8412</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHII-95</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized, Phase II Trial of AZD6244 Alone and AZD6244 Plus Temsirolimus for Soft-Tissue Sarcomas</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="01-26-2010 08:45:08">
                    <nciDocumentNumber>E3108</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E3108</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Prospective Trial Correlating Progression Free Survival with CYP2D6 Activity in Patients with Metastatic Breast Cancer Treated with Single Agent Tamoxifen</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="05-20-2010 15:39:43">
                    <nciDocumentNumber>CALGB-90802</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-90802</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Phase III Trial Comparing Everolimus Plus Placebo Versus Everolimus plus Bevacizumab for Advanced Renal Cell Carcinoma Progressing After Treatment with Tyrosine Kinase Inhibitors</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="06-11-2010 11:13:38">
                    <nciDocumentNumber>8828</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>11-C-0029</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of the Hsp90 Inhibitor, AT13387, in Adults with Refractory Solid Tumors</documentTitle>
                    <currentStatus>Approved</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:45">
                    <nciDocumentNumber>NCCTG-90-24-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>90-24-51</localDocumentNumber>
                        <localDocumentNumber>90-24-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III trial in Stage IIIA and IIIB Non-small cell lung cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:45">
                    <nciDocumentNumber>CALGB-9013</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-9013</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Subcutaneous Interferon-Alpha-2b and Low Dose Cytarabine (lodac) in Previously Untreated Chronic Phase Chronic Myelogenous Leukemia: A Phase II Study of Philadelphia Chromosome-Positive Patients</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:45">
                    <nciDocumentNumber>CCG-0943</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCG-0943</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of ci 958 in pediatric and adolescent patients with relapsed solid tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:46">
                    <nciDocumentNumber>POG-9347</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9347</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Combined use of Human-Mouse Chimeric Anti-GD2 Monoclonal Antibody and GM-CSF in the treatment of recurrent Neuroblastoma:  A POG Phase II study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:46">
                    <nciDocumentNumber>POG-9372</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9372</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I trial of 9-Aminocamptothecin in children with refractory solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:46">
                    <nciDocumentNumber>T95-0034</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTC-9404</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I trial and pharmacokinetic study of the sequential administration of carmustine (bcnu) and temozolomide in patients with cns or systemic tumors refractory to standard therapy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:47">
                    <nciDocumentNumber>POG-9472</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9472</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I trial of CI-980 in children with relapsed Acute Leukemia</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:47">
                    <nciDocumentNumber>CCG-0952</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCG-0952</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of topotecan (nsc #609699) and involved field radiation therapy for intrinsic pontine glioma of childhood</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:48">
                    <nciDocumentNumber>POG-9461</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9461</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Deferoxamine for the Treatment of Children with Refractory Lymphoblastic Leukemia and Lymphoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:48">
                    <nciDocumentNumber>CCG-0954</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCG-0954</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Pediatric Phase I Study of Gemcitabine (NSC# 613327) in Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:48">
                    <nciDocumentNumber>CCG-0957</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCG-0957</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of B43-PaP Immunotoxin in combination with standard 4 drug induction for patients with CD19 + all in relapse</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:48">
                    <nciDocumentNumber>E5995</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E5995</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of 2-chlorodeoxyadenosine (2-cda) in relapsed and refractory acute myeloid leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:48">
                    <nciDocumentNumber>POG-9432</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9432</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of pre-irradiation Topotecan in newly diagnosed children with Intracranial Ependymoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:49">
                    <nciDocumentNumber>EST-9486</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-9486</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>The treatment of MULTIPLE MYELOMA utilizing VBMCP chemotherapy with or without intensification or ALPHA-2 INTERFERON: a Phase III study for previously untreated MULTIPLE MYELOMA</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>E1A95</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E1A95</localDocumentNumber>
                        <localDocumentNumber>C1A95</localDocumentNumber>
                        <localDocumentNumber>O1A95</localDocumentNumber>
                        <localDocumentNumber>J1A95</localDocumentNumber>
                        <localDocumentNumber>S1A95</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Study of PSC-833 in Combination with Vincristine, Doxorubicin and Dexamethasone (psc-833/vad) Versus Vad Alone in Patients with Relapsing or Refractory Multiple Myeloma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>EORTC-62933</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EORTC-62933</localDocumentNumber>
                        <localDocumentNumber>EORTC-62933</localDocumentNumber>
                        <localDocumentNumber>EORTC-62933</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Metastasectomy and chemotherapy for lung metastases from soft tissue sarcoma. a randomized Phase III study</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>A09701</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>A09701</localDocumentNumber>
                        <localDocumentNumber>A09701</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Temodal (SCH 52365; Temozolomide, IND #52797) in Children and Adolescents with Recurrent Central Nervous System (CNS) Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>JCO10</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>JCO10</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III study of immediate versus delayed chemotherapy for asymptomatica advanced colorectal cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 00:00:00">
                    <nciDocumentNumber>E9622</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E9622</localDocumentNumber>
                        <localDocumentNumber>NYU 96-22</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II pilot study of prolonged topotecan infusion with cisplatin as first-line treatment of ovarian cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>INT-0139</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-9309</localDocumentNumber>
                        <localDocumentNumber>CALGB-9592</localDocumentNumber>
                        <localDocumentNumber>R9309</localDocumentNumber>
                        <localDocumentNumber>R9309</localDocumentNumber>
                        <localDocumentNumber>NCIC CTG BR.13</localDocumentNumber>
                        <localDocumentNumber>93-17</localDocumentNumber>
                        <localDocumentNumber>SWOG-9336</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III comparison between concurrent chemotherapy plus radiotherapy, and concurrent chemotherapy plus radiotherapy followed by surgical resection for stage iiia (n2) non-small cell lung cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>CALGB-9633</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-9633</localDocumentNumber>
                        <localDocumentNumber>C9633</localDocumentNumber>
                        <localDocumentNumber>C9633</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Study of Adjuvant Chemotherapy After Resection for Patients with T2N0 Stage I Non-Small Cell Carcinoma of the Lung</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>INT-0162</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-9346</localDocumentNumber>
                        <localDocumentNumber>S9346</localDocumentNumber>
                        <localDocumentNumber>S9346</localDocumentNumber>
                        <localDocumentNumber>30985</localDocumentNumber>
                        <localDocumentNumber>JPR.8</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Intermittent Androgen Deprivation in Patients with Stage D2 Prostate Cancer, Phase III</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>T98-0018</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DM 98-062</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Dolastatin 10 (NSC# 376128) Administered Intravenously Every 21 Days to Patients with Metastatic Colorectal Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:52">
                    <nciDocumentNumber>NCCTG-83-46-52</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-83-46-52</localDocumentNumber>
                        <localDocumentNumber>83-46-52</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Controlled Phase III study of combination chemotherapy in the treatment of advanced colorectal Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:52">
                    <nciDocumentNumber>GOG-81D</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-81D</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III trial of high vs intermediate dose Medroxyprogesterone Acetate (MPA) in patients with Advanced or Recurrent Endometrial Carcinoma positive for either Estrogen or Progesterone Receptors but not both</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:53">
                    <nciDocumentNumber>RTOG-97-04</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>R9704</localDocumentNumber>
                        <localDocumentNumber>R9704</localDocumentNumber>
                        <localDocumentNumber>R9704</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Study of Pre and Post Chemoradiation 5-FU vs. Pre and Post Chemoradiation Gemcitabine for Postoperative Adjuvant Treatment of Resected Pancreatic Adenocarcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:53">
                    <nciDocumentNumber>T97-0017</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>IND.108</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of topotecan and etoposide in patients with intermediate grade non-hodgkin's lymphoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:50:53">
                    <nciDocumentNumber>T96-0089</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>IND.104</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A randomized Phase II study of two schedules of bryostatin 1 (nsc 339555) in patients with advanced malignant melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:53">
                    <nciDocumentNumber>E2290</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-2290</localDocumentNumber>
                        <localDocumentNumber>CALGB-9092</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III protocol for the evaluation of 5-Fluorouracil versus 5-Fluorouracil+Pala or 5-Fluorouracil+Oral Leucovorin or 5-Fluorouracil+intravenous Leucovorin or 5-Fluorouracil+RIFN-Alpha-2A in patients with advanced Colorectal cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:53">
                    <nciDocumentNumber>E3886</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-3886</localDocumentNumber>
                        <localDocumentNumber>SWOG-8793</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Phase III Evaluation of Hormonal Therapy Versus Observation in Patients with Stage D1 Adenocarcinoma of the Prostate Following Pelvic Lymphadenectomy and Radical Prostatectomy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:57">
                    <nciDocumentNumber>GOG-9703</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-9703</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Paclitaxel, Carboplatin, and Increasing Doses of Doxil in Untreated Ovarian, Peritoneal, and Tubal Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:57">
                    <nciDocumentNumber>E4397</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E4397</localDocumentNumber>
                        <localDocumentNumber>E4397</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Preradiation Multiagent Chemotherapy for Adults with "Poor Risk" Medulloblastoma, PNET, and Disseminated Ependymoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:59">
                    <nciDocumentNumber>GOG-0076X</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-76X</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A limited access PHASE II trial of CISPLATIN and PACLITAXEL in advanced and recurrent SQUAMOUS CELL CARCINOMA of the CERVIX</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:59">
                    <nciDocumentNumber>GOG-0095</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-95</localDocumentNumber>
                        <localDocumentNumber>T87-0051</localDocumentNumber>
                        <localDocumentNumber>SWOG-9047</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized clinical trial for the treatment of women with selected stage IC and II (A, B, C) and selected stage IA &amp; IB Ovarian Cancer: Phase III</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:00">
                    <nciDocumentNumber>T97-0101</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DM 97-200</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II CCOPP  Trial of High Dose Methotrexate/Ara-C and HCVAD for Newly Diagnosed Nodular and Diffuse Mantle Cell Lymphoma and Their Blastic Variants</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:00">
                    <nciDocumentNumber>T97-0050</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DM 97-073</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Recombinant Human Interleukin-12 (rhIL-12) for the Treatment of Relapsed Lymphoma and Hodgkin's Disease</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:01">
                    <nciDocumentNumber>T98-0027</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase II Trial of a Mutated gp100 Melanoma Peptide (G209-217(210M) with High Dose Interleukin-2 (IL-2) in HLA-A2.1 + Patients with Metastatic Melanoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:01">
                    <nciDocumentNumber>N9741</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCIC-CTG:  CO.13</localDocumentNumber>
                        <localDocumentNumber>N9741</localDocumentNumber>
                        <localDocumentNumber>N9741</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III Trial of Combinations of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), and Irinotecan (CPT-11) as Initial Treatment of Patients with Advanced Adenocarcinoma of the Colon and Rectum</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:02">
                    <nciDocumentNumber>T84-0427</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>84-C-136</localDocumentNumber>
                        <localDocumentNumber>8502</localDocumentNumber>
                        <localDocumentNumber>T84-0278</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I and pharmacokinetic study of trimetrexate glucuronate (tmtx), nsc-352122</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:02">
                    <nciDocumentNumber>W81-0907</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CO-8199</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of cbdca (nsc-241240)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:03">
                    <nciDocumentNumber>T84-0339</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UMCC-8406</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II trial of CBDCA for refractory Leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:03">
                    <nciDocumentNumber>T89-0188</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>2301</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I trial of intravenous melphalan and ethacrynic acid in patients with advanced cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:04">
                    <nciDocumentNumber>POG-9071</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9071</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I trial of Fazarabine in children with Acute Leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:04">
                    <nciDocumentNumber>T89-0139</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>90-C-9</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II evaluation of suramin and hydrocortisone in advanced cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:05">
                    <nciDocumentNumber>CALGB-8855</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-8855</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Hydroxyurea plus fludarabine phosphate (nsc #312887) for relapsed or refractory non-hodgkin's lymphoma: a Phase II limited access study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:05">
                    <nciDocumentNumber>SWOG-8808</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-8808</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of recombinant tumor necrosis factor (rtnf) in patients with chronic myeloid leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:05">
                    <nciDocumentNumber>T87-0007</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>50-87-1</localDocumentNumber>
                        <localDocumentNumber>NCOG-5O-84-1</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of intraperitoneal carboplatin chemotherapy in advanced carcinoma of the ovary</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:06">
                    <nciDocumentNumber>T86-0227</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>86-09-15-04</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of oxantrazole (nsc 349174) in patients with advanced cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:07">
                    <nciDocumentNumber>SEG-MSAR-76-206</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-MSAR-76-206</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of piperazinedione in refractory sarcomas and malignant melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:08">
                    <nciDocumentNumber>D81-014-0062</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>3254</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of amsa for refractory acute leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:08">
                    <nciDocumentNumber>D80-004-0178</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>BTRC-8022</localDocumentNumber>
                        <localDocumentNumber>T85-0010</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II chemotherapy with dibromodulcitol for recurrent medulloblastoma &amp; ependymoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:08">
                    <nciDocumentNumber>C82-0751</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II study of intravenous misonidazole for intra operative radiation therapy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:08">
                    <nciDocumentNumber>C82-1122</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>208734</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I and pharmacokinetic study of intraperitoneal aclacinomycin-a</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:10">
                    <nciDocumentNumber>B85-0013</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CO-8696</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I trial of Interleukin-2 (RIL-2)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:10">
                    <nciDocumentNumber>B82-0988</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>82-C-131</localDocumentNumber>
                        <localDocumentNumber>B82-0998</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I trial of Leukocyte Interferon in pts. with wide spread Chronic Viral Papillomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:10">
                    <nciDocumentNumber>RTOG-80-02</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-80-02</localDocumentNumber>
                        <localDocumentNumber>T84-0394</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I protocol for the initial clinical study of WR-2721</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:11">
                    <nciDocumentNumber>GOG-76P</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-76P</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of Didemnin B (NSC #325319) in patients with Advanced Squamous Cell Carcinoma of the Cervix</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:11">
                    <nciDocumentNumber>T85-0003</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>IRB-2967-5</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of echinomycin in the treatment of non-hodgkin's lymphomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:11">
                    <nciDocumentNumber>T90-0206</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DM-90-086</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of 10-edam in the treatment of metastatic Breast cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:11">
                    <nciDocumentNumber>T91-0213</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>92-C-0079</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of an il-3/gm-csf fusion protein (pixy321) and carboplatin (cbdca) in patients with advanced cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:11">
                    <nciDocumentNumber>T92-0038</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>BRMP #9206</localDocumentNumber>
                        <localDocumentNumber>92-C-142</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of thymopentin in mycosis fungoides/sezary syndrome</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:12">
                    <nciDocumentNumber>T92-0146</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>92-C-0269</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II evaluation of topotecan in pediatric central nervous system tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:12">
                    <nciDocumentNumber>T92-0249</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase I trial of continuous infusion Taxol with radiotherapy for the treatment of carcinoma of the cervix</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:13">
                    <nciDocumentNumber>106-21</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DS-1406</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of retinyl acetate in mild &amp; moderate dysplasia of the cervix</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:14">
                    <nciDocumentNumber>W82-0989</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>82-44-01</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Maytansine Phase II treatment of advanced islet cell cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:14">
                    <nciDocumentNumber>POG-7627</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-7627</localDocumentNumber>
                        <localDocumentNumber>SWOG-7627</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>The use of Daunomycin for the treatment of Acute Promyelocytic Leukemia - Phase III</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:14">
                    <nciDocumentNumber>T84-0429</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>OC-86-2</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I clinical trial loading course oral tmca in advanced malignancies</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:20">
                    <nciDocumentNumber>T90-0050</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of etanidazole (sr2508) and radiotherapy in malignant glioma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:22">
                    <nciDocumentNumber>T90-0017</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>90-C-128</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I evaluation of killer cells activated in vitro with anti-cd3 administered in combination with systemic il-2 or il-2 plus cyclophosphamide</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:22">
                    <nciDocumentNumber>CALGB-9031</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-9031</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Dihydro-5-azacytidine (nsc #264880) and cisplatin for malignant mesothelioma:  a limited access Phase II study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:22">
                    <nciDocumentNumber>T89-0218</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RPC-3209</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of til expanded in vitro with rhuil-4 and ril-2 and autologous tumor restimulation in patients with renal cell carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:23">
                    <nciDocumentNumber>T84-0244</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CO-8313</localDocumentNumber>
                        <localDocumentNumber>EST-P-B184</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II evaluation of cyclic administration of the combination chemotherapy regimens caf, d(dhad)v and t'savb in women with metastatic Breast cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:23">
                    <nciDocumentNumber>T84-0197</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>A-532-84</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of acodazole hcl</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:23">
                    <nciDocumentNumber>T84-0188</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>84-C-57</localDocumentNumber>
                        <localDocumentNumber>BRMP-8407</localDocumentNumber>
                        <localDocumentNumber>NCI-NMOB-83-18</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II treatment of relapsed t cell lymphomas with recombinant leukocyte a interferon (ro 22-8181; ifl-ra)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:24">
                    <nciDocumentNumber>NCOG-6G-82-2</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCOG-6G-82-2</localDocumentNumber>
                        <localDocumentNumber>NCOG-6G-82-2</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of external brain Irradiation and Hydroxyurea with an interstitial "boost" followed by Procarbazine, CCNU and Vincristine for the treatment of primary malignant brain tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:25">
                    <nciDocumentNumber>NCOG-3S-91</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCOG-3S-91</localDocumentNumber>
                        <localDocumentNumber>RTOG-81-14</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II study evaluating the toxicity and effectiveness of charged particle radiotherapy for patients with unresectable localized Gastric Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:25">
                    <nciDocumentNumber>T83-1273</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>82-C-61</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I trial of recombinant leukocyte a interferon (iflra) by intralesional injection</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:25">
                    <nciDocumentNumber>T89-0121</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                        <localDocumentNumber>8/89-6K</localDocumentNumber>
                        <localDocumentNumber>89-08-187</localDocumentNumber>
                        <localDocumentNumber>889-5011-439</localDocumentNumber>
                        <localDocumentNumber>89113</localDocumentNumber>
                        <localDocumentNumber>H6042-04704-01</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of high dose il-2 by iv bolus in combination with interferon-alpha-2b</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:25">
                    <nciDocumentNumber>NCOG-2N-84-1J</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCOG-2N-84-1J</localDocumentNumber>
                        <localDocumentNumber>NCOG-2N-84-1J</localDocumentNumber>
                        <localDocumentNumber>RTOG-85-20</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III randomized trial of heavy charged particle radiotherapy vs. conventional photon irradiation of unresectable Non-Oat Cell Carcinoma of the lung</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:25">
                    <nciDocumentNumber>T83-1190</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ICC-4</localDocumentNumber>
                        <localDocumentNumber>IRB-2-83-7B</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II single agent chemotherapy with cbdca for advanced squamous cell head and neck cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:26">
                    <nciDocumentNumber>NCOG-P-5O-85-1</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCOG-P-5O-85-1</localDocumentNumber>
                        <localDocumentNumber>T85-0105</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I and Phase II trial of intraperitoneal chemotherapy with Chip (Iproplatin, JM9) in patients with Intraabdominal Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:26">
                    <nciDocumentNumber>POG-8970</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-8970</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I trial of Fazarabine in children with refactory Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:26">
                    <nciDocumentNumber>NCCTG-86-47-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-86-47-51</localDocumentNumber>
                        <localDocumentNumber>CALGB-8894</localDocumentNumber>
                        <localDocumentNumber>EST-1288</localDocumentNumber>
                        <localDocumentNumber>RTOG-88-11</localDocumentNumber>
                        <localDocumentNumber>SWOG-8896</localDocumentNumber>
                        <localDocumentNumber>86-47-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Protocol for Surgical Adjuvant Therapy of Rectal Carcinoma:  A Controlled Evaluation of Protracted Infusion 5 Fluorouracil as a Radiation Enhancer and 5-Fu Plus Methyl-CCNU Chemotherapy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:26">
                    <nciDocumentNumber>NCCTG-83-32-02</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-83-32-02</localDocumentNumber>
                        <localDocumentNumber>83-32-02</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II evaluation of Trilostane plus Hydrocortisone in women with Advanced Breast Cancer prior to hormonal therapy exposure</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:27">
                    <nciDocumentNumber>T88-0261</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>BGSM-99189</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Vincristine with high-dose vp-16:a Phase I study in advanced refractory malignancy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:27">
                    <nciDocumentNumber>T88-0242</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>88-035</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I trial of l-buthionine sulfoximine(bso; nsc-326231) together with melphalan(lpam; nsc-8806)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:27">
                    <nciDocumentNumber>EST-4589</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-4589</localDocumentNumber>
                        <localDocumentNumber>SEG-LUN-82-260</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of PAC(Cis-Platinum, Adriamycin, and Cyclophosphamide) plus Radiotherapy in treatment of limited unresectable invasive Thymoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:28">
                    <nciDocumentNumber>T88-0194</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UMCT-8816</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I trial of wr-2721 administered with high dose cisplatin</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:28">
                    <nciDocumentNumber>SWOG-8823</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-8823</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of continuous infusion recombinant interleukin-2 (ril-2) in patients with colorectal carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:28">
                    <nciDocumentNumber>NCCTG-88-60-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-88-60-51</localDocumentNumber>
                        <localDocumentNumber>88-60-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II clinical trial of Methotrexate, Vinblastine, Doxorubicin, and Cisplatin combination chemotherapy in women with Advanced Endometrial Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:28">
                    <nciDocumentNumber>T88-0173</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>88-C-113</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of doxorubicin, etoposide and quinidine in patients with colorectal cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:28">
                    <nciDocumentNumber>EST-P-Z388</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-P-Z388</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase 1B trial of the effect of peritumoral and intranodal injections of Interleukin-2 in patients with advanced Squamous Cell carcinoma of the Head and Neck</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:29">
                    <nciDocumentNumber>T88-0027</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UMCC-8728</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of tumor necrosis factor in patients with recurrent squamous cell carcinomas of the head and neck</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:29">
                    <nciDocumentNumber>T87-0183</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>88-12-30-4</localDocumentNumber>
                        <localDocumentNumber>DS-87-35</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Efficacy of pentostatin in chronic phase of chronic myelocytic leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:29">
                    <nciDocumentNumber>T87-0148</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ICC-88-H1</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of interleukin-2 in in treatment of cutaneous t cell lymphomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:30">
                    <nciDocumentNumber>T87-0015</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase I clinical study of intra-arterial radiosensitization of malignant gliomas with bromodeoxyuridine and 5-fluorouracil</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:30">
                    <nciDocumentNumber>T87-0018</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CIC-86-46</localDocumentNumber>
                        <localDocumentNumber>UMCC-8720</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of carboplatin and vinblastine in patients with epidermoid carcinoma of the esophagus</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:30">
                    <nciDocumentNumber>T86-0287</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>LAK-RENAL-II</localDocumentNumber>
                        <localDocumentNumber>EST-P-X486</localDocumentNumber>
                        <localDocumentNumber>86-12-347</localDocumentNumber>
                        <localDocumentNumber>SWOG-8638</localDocumentNumber>
                        <localDocumentNumber>867-5011-114</localDocumentNumber>
                        <localDocumentNumber>6329</localDocumentNumber>
                        <localDocumentNumber>CSU-421</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of patients with renal cell carcinoma with high dose il-2 and autologous lak cells</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:30">
                    <nciDocumentNumber>T86-0288</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>LAK-NHL-II</localDocumentNumber>
                        <localDocumentNumber>EST-P-X489</localDocumentNumber>
                        <localDocumentNumber>86-12-348</localDocumentNumber>
                        <localDocumentNumber>SWOG-8639</localDocumentNumber>
                        <localDocumentNumber>867-5011-115</localDocumentNumber>
                        <localDocumentNumber>7052</localDocumentNumber>
                        <localDocumentNumber>CSU-423</localDocumentNumber>
                        <localDocumentNumber>804807-01B</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of patients with refractory hodgkin's disease and non-hodgkin's lymphoma with high dose il-2 and autologous lak-cells</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:30">
                    <nciDocumentNumber>T86-0265</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>86-C-174</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I evaluation of azidothymidine (azt) in children with aids related conditions (arc) or acquired immune deficiency syndrome (aids)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:30">
                    <nciDocumentNumber>T86-0249</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>86-C-161</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of muramyl tripeptide derivative (mtp-pe cgp 19835a acemuramide) intravenously (encapsulated in liposomes)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:30">
                    <nciDocumentNumber>T86-0167</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>LAK-NHL-FAV</localDocumentNumber>
                        <localDocumentNumber>EST-P-X487</localDocumentNumber>
                        <localDocumentNumber>7/86-6C</localDocumentNumber>
                        <localDocumentNumber>86-11</localDocumentNumber>
                        <localDocumentNumber>SWOG-8620</localDocumentNumber>
                        <localDocumentNumber>856-5011-284</localDocumentNumber>
                        <localDocumentNumber>CSU-401</localDocumentNumber>
                        <localDocumentNumber>804807-01A</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of patients with non-hodgkins lymphoma (favorable histology) with high dose il-2 and autologous lak cells</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:31">
                    <nciDocumentNumber>T83-0983</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>78-C-118</localDocumentNumber>
                        <localDocumentNumber>BCRC-7808</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III alternating mopp (nm/vcr/pcb/pred) and scab (szc/ccnu/adr/bleo) vs mopp alone for advanced stage iii/iv hodgkin's disease</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:31">
                    <nciDocumentNumber>T83-0989</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>07</localDocumentNumber>
                        <localDocumentNumber>8403</localDocumentNumber>
                        <localDocumentNumber>4758</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of triazinate in advanced head &amp; neck cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:33">
                    <nciDocumentNumber>SEG-78-PR-342</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-78-PR-342</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III randomized comparison of des therapy followed by Cyclophosphamide at the time of progression vs. Des plus Cyclophosphamide as initial therapy for stage IV Prostatic Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:33">
                    <nciDocumentNumber>SEG-LUN-78-326R</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-LUN-78-326R</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III randomized study in advanced Lung Cancer (Squamous, Large Cell and Adenocarcinoma)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:34">
                    <nciDocumentNumber>EST-3888</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-3888</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II protocol for the evaluation of Amonafide, Caracemide, and Homoharringtonine in advanced Renal Cell carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:35">
                    <nciDocumentNumber>D82-012-0886</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ICC-81U3</localDocumentNumber>
                        <localDocumentNumber>V83-0144</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of bisantrene straight in advanced, hormone-resistant prostatic carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:36">
                    <nciDocumentNumber>D79-048-0184</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CO-7814</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III randomized evaluation of cyclic therapy in metastatic Breast cancer utilizing dibromodulcitol, vincristine, adriamycin, tamoxifen, fluoxymesteron and cyclophosphamide, methotrexate, 5-fluorouracil and prednisone</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:36">
                    <nciDocumentNumber>SEG-GU-83-321</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-GU-83-321</localDocumentNumber>
                        <localDocumentNumber>SWOG-8595</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III study comparing Intravesical BCG vs. Intravesical Thiotepa in the treatment of multiple or recurrent Non-Invasive Bladder Carcinomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:37">
                    <nciDocumentNumber>T86-0041</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>BTRC-8622</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of infusional melphalan for the treatment of recurrent adult &amp; childhood malignant gliomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:38">
                    <nciDocumentNumber>SEG-GI-78-238</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-GI-78-238</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II study of Adriamycin and ICRF-159 in the treatment of Adenocarcinoma of the gastrointestinal tract</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:42">
                    <nciDocumentNumber>SEG-BRE-203</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-BRE-203</localDocumentNumber>
                        <localDocumentNumber>SWOG-8636</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of Echinomycin in Metastatic Carcinoma of the Breast utilizing two concurrent groups, stratified according to previous Anthracycline exposure</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:42">
                    <nciDocumentNumber>SEG-BL-79-351</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-BL-79-351</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III randomized study of combination chemotherapy with Cyclophosphamide, Adriamycin and Cisplatin vs single agent Cisplatin in Metastatic Bladder Cancer with subsequent randomization of non-progressors to maintenance therapy or no TX</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:44">
                    <nciDocumentNumber>RTOG-86-12</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-86-12</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of Iododeoxyuridine (IUDR) and radiotherapy in the treatment of primary malignant Brain Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:47">
                    <nciDocumentNumber>CALGB-8531</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-8531</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>5-FU and Cisplatin vs. 5-FU, Cisplatin, and Vinblastine in Advanced Non-Small Cell Lung Cancer:  randomized Phase II</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:47">
                    <nciDocumentNumber>T85-0105</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>5141</localDocumentNumber>
                        <localDocumentNumber>NCOG-P-5O-85-1</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I and Phase II trial of intraperitoneal chemotherapy with chip (Iproplatin, JM9) in patients with Intraabdominal Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:47">
                    <nciDocumentNumber>PROG-85-26</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PROG-85-26</localDocumentNumber>
                        <localDocumentNumber>RTOG-85-26</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II randomized study of charged particle radiation in the treatment of Chordomas or low grade Chondrosarcomas of the base of Skull or Cervical Spine</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:47">
                    <nciDocumentNumber>B85-0010</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CO-8692</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I trial of combination recombinant human Interferon Gamma and recombinant human Interferon Beta - Determination of optimal biologic dose and biologic response modification</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:47">
                    <nciDocumentNumber>B83-0017</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>82-582</localDocumentNumber>
                        <localDocumentNumber>B85-0007</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of mouse Monoclonal Anti-T suppressor cell antibody</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:48">
                    <nciDocumentNumber>RTOG-82-02</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-82-02</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II dose searching study of fast neutron irradiation in Advanced Head and Neck Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:48">
                    <nciDocumentNumber>RTOG-80-11</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-80-11</localDocumentNumber>
                        <localDocumentNumber>N81-0219</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I protocol for the Pharmacokinetics of Desmethylmisonidazole (DMM)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:49">
                    <nciDocumentNumber>B82-0956</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>202-82-4</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A randomized Phase II protocol to investigate the therapeutic and toxic effects of human Lymphoblastoid Interferon given at two different doses to patients with incurable Colorectal Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:50">
                    <nciDocumentNumber>T90-0111</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>90-C-214</localDocumentNumber>
                        <localDocumentNumber>WRAMC-9001</localDocumentNumber>
                        <localDocumentNumber>MB-259</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of interferon alfa-2a (recombinant roche) in combination with 5-fluorouracil plus calcium leucovorin in metastatic or recurrent colorectal carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:50">
                    <nciDocumentNumber>T90-0132</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>91-C-0009</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study to evaluate the safety and toxicity of the combination of zidovudine and 2',3'-dideoxyinosine in children with hiv infection</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:50">
                    <nciDocumentNumber>T90-0169</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of weekly Pala, Alpha Interferon, and 5-Fluorouracil by 24 hour continuous infusion in Advanced Renal Cell Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:50">
                    <nciDocumentNumber>T90-0177</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>91-C-21</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Fludarabine Monophosphate and Interferon Alfa in Mycosis Fungoides/Sezary Syndrome</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:51">
                    <nciDocumentNumber>INT-0122</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-P-E289</localDocumentNumber>
                        <localDocumentNumber>RTOG-90-12</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A prospective Phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and radiation for squamous cell carcinoma of the esophagus</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:51">
                    <nciDocumentNumber>T91-0056</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>6G-90-3</localDocumentNumber>
                        <localDocumentNumber>6G-90-3</localDocumentNumber>
                        <localDocumentNumber>RTOG-94-04</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III randomized study of radiotherapy with or without BUDR or IUDR, plus Procarbazine, CCNU, and Vincristine (PCV) for the treatment of Anaplastic Astrocytomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:51">
                    <nciDocumentNumber>EST-P-Y990</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-P-Y990</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I trial of Alpha-Interferon and Cyclophosphamide, Adriamycin and 5-Fluorouracil in the treatment of Advanced Breast cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:52">
                    <nciDocumentNumber>SWOG-9122</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-9122</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Evaluation of 5-Fluorouracil by intermittent infusion in combination with Alpha-Interferon for patients with advanced Renal Cell Carcinoma: Phase II</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:52">
                    <nciDocumentNumber>T91-0246</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>91-C-234</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Pilot and Phase II Study of low dose rate chest radiotherapy for treatment of Intrathoracic Relapse of small cell lung cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:53">
                    <nciDocumentNumber>CCG-0924</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCG-0924</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of GM-CSF/Il-3 Fusion Protein (Pixy321) following Ifosfamide, Carboplatin, and Etoposide (IEC) in children with Recurrent Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:53">
                    <nciDocumentNumber>T92-0125</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>HSPC 93-04-179</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of Taxol and G-CSF in Non-Hodgkins Lymphoma and Hodgkin's Disease</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:53">
                    <nciDocumentNumber>T92-0172</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RPC-3209</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of TIL expanded in vitro with RHIL-4 and RIL-2 and autologous tumor restimulation in patients with Renal Cell Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:53">
                    <nciDocumentNumber>T92-0185</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>93-C-0105</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of isolated Hepatic perfusion with Tumor Necrosis factor and Interferon-Gamma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:53">
                    <nciDocumentNumber>E1293</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E20692</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of Taxotere in Patients with Adenocarcinoma of the Upper Gastrointestinal Tract Previously Untreated with Cytotoxic Chemotherapy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:53">
                    <nciDocumentNumber>T93-0011</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DM 93-013</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of 5-Fluorouracil, Folinic acid, and Dipyridamole in patients with advanced Adenocarcinoma of the Colorectum</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:54">
                    <nciDocumentNumber>T94-0069</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PCI 94-87</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of Suramin in relapsed or metastatic head and neck cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:54">
                    <nciDocumentNumber>T94-0024</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase I trial of Paclitaxel + Gallium Nitrate + Filgrastim (G-CSF) in patients with selected refractory malignancies</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:55">
                    <nciDocumentNumber>T94-0086</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MSKCC 9476</localDocumentNumber>
                        <localDocumentNumber>E3894</localDocumentNumber>
                        <localDocumentNumber>SWOG-9442</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Multi-Institutional Phase III Trial of BEP and High Dose Chemotherapy versus BEP Alone in Previously Untreated Patients with Poor and Intermediate Risk Germ Cell Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:55">
                    <nciDocumentNumber>T94-0116</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I trial of vaccine combining a Mage-3 peptide with helper Peptide Padre-965.10 emulsified with incomplete Freund's adjuvant for patients with resected Stages IIB, III and IV Melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:55">
                    <nciDocumentNumber>T94-0122</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of Paclitaxel and Dexverapamil in patients with metastatic Breast Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:55">
                    <nciDocumentNumber>T95-0028</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UMCC-9508</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of Aminocamptothecin (9-AC/DMA) in the treatment of hormone refractory Prostate Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:55">
                    <nciDocumentNumber>SWOG-8716</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-8716</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II: Evaluation of Amonafide in Renal Cell Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:55">
                    <nciDocumentNumber>BTCG-87-30</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>BTCG-87-30</localDocumentNumber>
                        <localDocumentNumber>RTOG-88-16</localDocumentNumber>
                        <localDocumentNumber>SWOG-8891</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Low-grade Glioma Phase III : Surgery and immediate radiotherapy vs. surgery and delayed radiotherapy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:55">
                    <nciDocumentNumber>POG-8711</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-8711</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Simal #5: Bone Marrow Transplant protocol: Phase III</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:56">
                    <nciDocumentNumber>P9772</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9772</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Trial of MGI 114 in Children with Solid Tumors:  A Pediatric Oncology Group Phase I Cooperative Agreement Study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:56">
                    <nciDocumentNumber>E1D96</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E1D96</localDocumentNumber>
                        <localDocumentNumber>AMC-009</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Study of Paclitaxel Versus Liposomal Doxorubicin for the Treatment of Advanced AIDS-Associated Kaposi's Sarcoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:56">
                    <nciDocumentNumber>T94-0080</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Trial of BCNU Plus 06-Benzylguanine in the Treatment of Patients with Recurrent, Persistent or Progressive Cerebral Anaplastic Gliomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:56">
                    <nciDocumentNumber>T98-0016</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>98-70</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Dolastatin-10 (NSC #376128) in Patients with Advanced Non-Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:17">
                    <nciDocumentNumber>T98-0026</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>98-019</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of Dolastatin-10 in Patients with Previously Untreated Recurrent/Metastatic Sarcoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-29-1999 18:06:17">
                    <nciDocumentNumber>NCCTG-98-92-55</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>98-92-55</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Double-blind, Placebo-controlled randomized comparison of Megestrol Acetate Megace) versus an N-3 Fatty Acid (EPA) enriched nutritional supplement versus both for the treatment of Cancer Cachexia and Anorexia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:18">
                    <nciDocumentNumber>C19807</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>C19807</localDocumentNumber>
                        <localDocumentNumber>C19807</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A PHASE III study of INTERFERON-REFRACTORY patients with BCR/ABL (+) CHRONIC MYELOGENOUS LEUKEMIA  (CML) treated with HOMOHARRINGTONINE (NSC # 141633) vs. HYDROXYUREA</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:18">
                    <nciDocumentNumber>C9710</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>C9710</localDocumentNumber>
                        <localDocumentNumber>C9710</localDocumentNumber>
                        <localDocumentNumber>C9710</localDocumentNumber>
                        <localDocumentNumber>C9710</localDocumentNumber>
                        <localDocumentNumber>C9710</localDocumentNumber>
                        <localDocumentNumber>C9710</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Randomized Study of Concurrent Tretinoin and Chemotherapy with or without Arsenic Trioxide (AS2O3) (NSC # 706363) as Initial Consolidation Therapy Followed by Maintenance Therapy with Intermittent Tretinoin Versus Intermittent Tretinoin Plus Mercaptopurine and Methotrexate for Patients with Untreated Acute Promyelocytic Leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:18">
                    <nciDocumentNumber>T90-0213</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>BUMC-3333</localDocumentNumber>
                        <localDocumentNumber>BCH 1993-115</localDocumentNumber>
                        <localDocumentNumber>95-MED-173</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>PHASE II study of patients with CML IN BLAST CRISIS treated with TIAXOFURIN (nsc 286193)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:18">
                    <nciDocumentNumber>T92-0238</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>93-C-0085</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study Of Intrathecal Topotecan</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>T97-0034</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ID97-027</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of Intraperitoneal Recombinant Human Interleukin-12 (rhIL-12) in Patients with Peritoneal Carcinomatosis, Associated with Mullerian and Gastrointestinal Carcinomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>T97-0038</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CO 9781</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of  Flavopiridol in Patients with Metastatic Androgen Independent Prostate Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>T97-0070</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A phase ii study of bryostatin-1 (nsc #339555) in relapsed/refractory b-cell chronic lymphocytic leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-29-1999 18:06:20">
                    <nciDocumentNumber>T91-0055</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Treatment of  MYELODYPLASTIC  SYNDROME  With Human  Recombinant ERYTHROPOIETIN  Plus Human  Recombinant GRANULOCYTE  Colony  Stimulating Factor:  Phase II MULTICENTER  Trial</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:22">
                    <nciDocumentNumber>T94-0064</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RC-1785</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of SURAMIN In Non-Small Cell Lung Cancer: Induction of differentiation and Apoptosis</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:22">
                    <nciDocumentNumber>T94-0162</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>95-C0055</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin with G-CSF for Patients with Newly Diagnosed Advanced Stage Ovarian Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:22">
                    <nciDocumentNumber>T94-0202</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Evaluation of Thalidomide in Patients with Metastatic Breast Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:22">
                    <nciDocumentNumber>T95-0066</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>96-C-0013</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Irinotecan (CPT-11) Administered as a Prolonged Infusion in Adult Patients with Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:22">
                    <nciDocumentNumber>T95-0093</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>96-C-0120</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Trial in Patients with Metastatic Melanoma of Immunization with a Recombinant Vaccinia Virus Encoding the gp100 Melanoma Antigen</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T96-0028</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PH1-08</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of Taxotere in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T96-0093</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>8552</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Flavopiridol (NSC 649890) Administered as a 72-Hour Continuous Infusion Every 2 Weeks in Patients with Metastatic Renal Cell Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T96-0111</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>97-50</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>An Open-Label, Non-Randomized Phase II Study of the Protein Kinase C Inhibitor Flavopiridol Administered in Patients with Advanced Gastric Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T96-0112</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>96-278</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase II Trial of  All-Trans Retinoic Acid and One of Two Schedules of Bryostatin 1 in Patients  with Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T97-0016</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>C-1388</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Clinical Evaluation of Bryostatin 1 in Combination with 2-CDA in Patients with Relapsed CLL</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T97-0039</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Flavopiridol in the Treatment of Relapsed or Refractory Mantle Cell Lymphoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>NABTT-9701</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>T97-0052</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I, Open-Label, Dose-Escalation, Trial of Intratumoral Injection with an E1B-Attenuated Adenovirus, ONYX-015, into Recurrent  Malignant Gliomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T98-0001</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DM98-187</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of Dolastatin-10 in Acute Leukemias, Myelodysplastic Syndromes and Chronic Myeloid Leukemia in Blast Phase</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:24">
                    <nciDocumentNumber>NABTT-9803</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTT-9803</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Gliadel and Continuous Infusion of Intravenous O6-Benzylguanine Trial in Patients with Recurrent Malignant Glioma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:24">
                    <nciDocumentNumber>NABTC-9803</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTC 9803</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Evaluation of Temodal (SCH52365) and 13-CIS-Retinoic Acid (Isotretinoin; CRA) for the Treatment of Recurrent and Progressive Malignant Gliomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:24">
                    <nciDocumentNumber>NCCTG-98-78-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-98-78-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of C2B8 in patients with Asymptomatic CD20+ B-Cell Follicular Small Cleaved Low-Grade Non-Hodgkin'S Lymphoma or Relapsed CD20+ Hodgkin'S Disease</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="04-07-1999 14:05:01">
                    <nciDocumentNumber>T98-0081</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>99-9</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase II Trial to Determine the Immune Response to a Mutated gp100 Melanoma Peptide (209-2M) Vaccine in HLA-A2 Positive Patients with a >1mm Melanoma on Initial Biopsy</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="05-25-1999 10:49:19">
                    <nciDocumentNumber>GOG-0127P</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-127P</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Evaluation of Oxalilplatin in Persistent or Recurrent Squamous Cell Carcinoma of the Cervix</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="05-26-1999 13:22:46">
                    <nciDocumentNumber>S9918</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S9918</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of  Daunomycin and Ara-C Given by Continuous IV Infusion with PSC-833 for Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) in Patients of Age 56 or Older.</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="06-03-1999 13:48:02">
                    <nciDocumentNumber>CALGB-69803</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-69803</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Compound 506U78  (NSC # 686673) in Patients with Hematologic Malignancies and Renal or Hepatic Impairment</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="06-17-1999 09:33:42">
                    <nciDocumentNumber>NCCTG-98-20-52</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-98-20-52</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of Oral Topotecan and Paclitaxel  with G-CSF (Filgrastim) Support in Patients with Previously Untreated Extensive-Stage Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="06-17-1999 13:31:22">
                    <nciDocumentNumber>T99-0072</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MAYO 98-24-01</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of the Farnesyl Transferase Inhibitor R115777 in Patients with Advanced Non-Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="06-18-1999 13:24:04">
                    <nciDocumentNumber>GOG-9807</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-9807</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Sequential Prolonged Oral Topetecan (IND# 58,131) and Prolonged Oral Etoposide as Second Line Therapy in Ovarian, Peritoneal or Tubal Carcinoma.</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="08-04-1999 14:05:33">
                    <nciDocumentNumber>T99-0100</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DM99-165</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of UCN-01 (NSC 638850) and Cytarabine (Ara-C) in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndromes</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="08-18-1999 12:51:07">
                    <nciDocumentNumber>T99-0093</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NU-99HS</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Multicenter Phase II Trial of Arsenic Trioxide in Relapsed and Refractory Hodgkin's Disease</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="08-24-1999 15:23:20">
                    <nciDocumentNumber>T99-0070</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Multicenter Phase II Trial of MGI-114 in Patients with Stage IV Malignant Melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="08-26-1999 15:19:53">
                    <nciDocumentNumber>48</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>10395</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of SU5416 (NSC # 696819) in Patients with Metastatic Melanoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="08-26-1999 17:28:23">
                    <nciDocumentNumber>50</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GCC 9948</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Weekly Paclitaxel and Bryostatin-1 in Hormone Refractory Prostate Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="08-30-1999 08:56:32">
                    <nciDocumentNumber>T99-0061</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DS-99-08</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Oxaliplatin in Combination with Continuous Infusion 5-Fluorouracil and Radiation in Esophageal Cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="08-30-1999 14:33:34">
                    <nciDocumentNumber>T99-0049</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase IA/IB Trial of Modulation of the Biological Response to Interleukin-2 (IL-2) with Bryostatin 1 (BRYO; NSC 339555)</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="09-02-1999 11:25:14">
                    <nciDocumentNumber>65</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>BIDMC #99-1332</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Trial of Twice Weekly IV IL-12 Plus Low-Dose Subcutaneous IL-2 in Patients with Advanced Malignancies</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="09-30-1999 09:14:24">
                    <nciDocumentNumber>AOST0121</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>P9852</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Groupwide Phase II Study of Trastuzumab (Herceptin) in Metastatic Osteosarcoma Patients with Tumors that Overexpress HER-2</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="10-07-1999 14:06:06">
                    <nciDocumentNumber>P9962</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>P9962</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Intrathecal Topotecan (NSC #609699) in Patients with Refractory Meningeal Malignancies: A COG Group-Wide Study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="10-21-1999 10:39:00">
                    <nciDocumentNumber>314</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NYGOG 99-001</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Thalidomide (NSC #66847) in Patients with Sarcomas of Gynecologic Origin</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="10-21-1999 14:57:16">
                    <nciDocumentNumber>POG-9905</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9905</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>ALinC 17: Protocol for Patients with Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia (ALL): A Phase III Study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="11-16-1999 11:22:21">
                    <nciDocumentNumber>PBTC-002</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PBTC-002</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A PHASE I Study of SU5416 in Pediatric Patients with Recurrent or Progressive Poor Prognosis BRAIN TUMORS</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-13-1999 10:04:06">
                    <nciDocumentNumber>GOG-9906</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-9906</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Feasibility Trial of Carboplatin and Topotecan Followed by Carboplatin and Paclitaxel (Sequential Doublets) in Patients with Previously Untreated Epithelial Ovarian Carcinoma and Primary Peritoneal Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-29-1999 14:06:08">
                    <nciDocumentNumber>894</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>00-C-0154</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase II Study of a PSA-Based Vaccine in Patients with Localized Prostate Cancer Receiving Standard Radiotherapy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="01-03-2000 12:58:15">
                    <nciDocumentNumber>910</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of Fenretinide in Renal Cell Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="02-08-2000 13:21:04">
                    <nciDocumentNumber>1230</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Arsenic Trioxide (NSC #706363) for Induction Therapy of Adult Patients with Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia and Previously Untreated or Relapsed or Refractory Blast Crisis of Chronic Myeloid Leukemia</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-21-2000 10:07:33">
                    <nciDocumentNumber>GOG-9907</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-9907</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Trial of the Treatment of Advanced Endometrial Cancer with Concurrent Weekly Paclitaxel and Cisplatin and Whole Abdominal Radiation Therapy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-2000 08:28:21">
                    <nciDocumentNumber>690</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NYU 00-16</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Dose-Finding Study of Oxaliplatin (NSC #266046) Combined with Continuous-Infusion Topotecan Hydrochloride as Chemotherapy for Patients with Previously Treated Ovarian Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="04-06-2000 13:05:29">
                    <nciDocumentNumber>2030</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Evaluation of FTI (R115777) in Treatment of Advanced Multiple Myeloma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="05-15-2000 09:12:44">
                    <nciDocumentNumber>GOG-0126L</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-0126L</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Evaluation of Gemcitabine and Cisplatin in Recurrent, Platinum Resistant and Refractory Ovarian and Peritoneal Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="07-05-2000 16:44:45">
                    <nciDocumentNumber>1721</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>1721</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of ZD 1839 in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="11-02-2000 12:29:51">
                    <nciDocumentNumber>N0032</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>N0032</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of Faslodex  in Women with Metastatic Breast Cancer and Failure on Aromatase Inhibitor Therapy</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="11-29-2000 10:19:16">
                    <nciDocumentNumber>2655</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>01H0114/0120</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of Neoadjuvant rhuMAb VEGF (Bevacizumab) in Combination with Paclitaxel and Carboplatin in Surgically Resectable Non-Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="11-29-2000 10:54:12">
                    <nciDocumentNumber>AMC-027</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>AMC-027</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A  Phase II Trial of COL-3 in Patients with HIV Related Kaposi's Sarcoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-19-2000 08:36:37">
                    <nciDocumentNumber>3291</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of PS-341 in Patients with Renal Cell Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-27-2000 10:59:58">
                    <nciDocumentNumber>3634</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>01-064</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 1 and Randomized Phase 2 Trial of Epothilone B Analogue BMS 247550 (NSC# 710428) Administered Every 21 Days  with or without Oral Estramustine Phosphate in Patients with Androgen Independent Prostate Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="01-25-2001 09:36:07">
                    <nciDocumentNumber>S0106</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0106</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg) During Induction Therapy Versus Standard Induction with Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy with Gemtuzumab Ozogamicin (Mylotarg) or No Additional Therapy for Patients Under Age 61 with Previously Untreated De Novo Acute Myeloid Leukemia (AML)</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="02-01-2001 12:27:24">
                    <nciDocumentNumber>3857</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/Randomized Phase II Trial of Oxaliplatin (NSC# 266046) with or without ZD1839 (NSC# 715055) in Patients with Advanced Colorectal Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="02-15-2001 10:52:41">
                    <nciDocumentNumber>AMC-029</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>AMC-029</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial of Combination Bryostatin-1 and Vincristine in HIV-Related B-cell Neoplasms</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="02-21-2001 12:15:23">
                    <nciDocumentNumber>5332</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>57100</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of Induction Gemcitabine/Cpt-11 Followed by Twice-Weekly Infusion Gemcitabine and Concurrent External Beam Radiation for the Treatment of Locally Advanced  Pancreatic Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-14-2001 08:40:31">
                    <nciDocumentNumber>1611</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>11156B</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Multi-Center Study of Open-Label, Pre-Cystectomy Intravesical PV701 in Patients with Bladder Cancer (IMT Codes 24731-24734).</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="04-12-2001 14:16:20">
                    <nciDocumentNumber>3632</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>12602</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Epothilone B Analogue BMS-247550 in Relapse and /or Refractory Stage III or IV Ovarian Epithelial Cancer, Following Front-Line Treatment with Platinum Plus Taxane-Based Chemotherapy</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="07-24-2001 12:16:32">
                    <nciDocumentNumber>5380</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-002</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Study of OSI-774 in Combination with Cisplatin in Patients with Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="08-02-2001 12:01:21">
                    <nciDocumentNumber>5615</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHII-32</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Phase II Trial of BMS-275291 (NSC 713763, IND 62573) in Hormone Refractory Prostate Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="08-07-2001 16:03:51">
                    <nciDocumentNumber>5429</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC0152</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of OSI-774 in Patients with Hepatocellular or Biliary Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-20-2001 14:45:53">
                    <nciDocumentNumber>CALGB-10001</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB 10001/SWOG C10001</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Sequential Chemotherapy, Imatinib Mesylate (Gleevec, STI571) (NSC # 716051, IND #61135), and Transplantation for Adults with Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by the CALGB and SWOG</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="11-13-2001 10:28:01">
                    <nciDocumentNumber>AMC-035</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>AMC-035</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Trial of SGN-00101 in the Treatment of High-Grade Anal Intraepithelial Neoplasia (AIN) in HIV-Positive Individuals</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="11-20-2001 15:51:49">
                    <nciDocumentNumber>5591</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-004</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of 5-Aza-2'-Deoxycytidine (Decitabine) as a Biologic Modifier of Retinoid Responsive Genes in Patients with High-Risk Myelodysplastic Syndromes and Acute Myelogenous Leukemia (De-novo, Relapsed or Secondary)</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="11-20-2001 15:54:32">
                    <nciDocumentNumber>5598</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>02-05-125</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I-II Study of R115777 (Zarnestra) Plus Doxorubicin and Cyclophosphamide in Patients with Locally Advanced Breast Cancer and Metastatic Breast Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-16-2002 15:37:19">
                    <nciDocumentNumber>5758</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC018B</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Flavopiridol in Patients with Relapsed and Refractory Multiple Myeloma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-22-2002 14:26:00">
                    <nciDocumentNumber>E1301</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E1301</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Randomized Study of Adjuvant Biologic Therapy in Patients with Stages III/IV Head and Neck Squamous Cell Carcinoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-07-2002 10:22:36">
                    <nciDocumentNumber>S0204</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0204</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Thalidomide/Dexamethasone Induction Followed by Tandem Melphalan Transplant and Prednisone/Thalidomide Maintenance in Newly Diagnosed Multiple Myeloma Patients, (A BMT Study)</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-25-2002 09:33:49">
                    <nciDocumentNumber>PBTC-009</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PBTC-009</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Trial of Gliadel and O6 - Benzylguanine in Pediatric Patients with Recurrent Malignant Gliomas</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="05-10-2002 15:22:46">
                    <nciDocumentNumber>S0205</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0205</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine as First-Line Therapy of Patients with Advanced Pancreas Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="06-06-2002 09:33:07">
                    <nciDocumentNumber>IBCSG-25-02</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>IBCSG-25-02</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="07-02-2002 15:29:03">
                    <nciDocumentNumber>5886</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NYU 02-30</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of OSI-774 in Combination with Carboplatin and Paclitaxel in Patients with Ovarian, Cancer of the Fallopian Tube or Primary Peritoneal Carcinoma</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-03-2002 09:39:53">
                    <nciDocumentNumber>S0227</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0227</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Randomized Trial of Cisplatin/Paclitaxel Versus Cisplatin/Gemcitabine in Recurrent, Persistent or Metastatic Carcinoma of the Cervix</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-18-2002 14:10:29">
                    <nciDocumentNumber>6012</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>2004-0204</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of ZD1839 and Radiation in Patients with Squamous Cell Carcinoma of the Skin</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="11-14-2002 15:23:13">
                    <nciDocumentNumber>IBCSG-26-02</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>IBCSG-26-02</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Trial Evaluating the Role of Chemotherapy as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer who Receive Endocrine Therapy</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-30-2002 11:02:20">
                    <nciDocumentNumber>GOG-0209</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-0209</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF Versus Carboplatin/Paclitaxel in Patients with Stage III &amp; IV or Recurrent Endometrial Cancer</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-10-2003 16:27:06">
                    <nciDocumentNumber>S0226</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0226</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women with Metastatic Breast Cancer</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-13-2003 16:43:56">
                    <nciDocumentNumber>E1A02</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E1A02</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Pilot Study of Rituximab + CHOP in Patients with Newly Diagnosed Waldenstrom's Macroglobulinemia</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-22-2003 11:38:12">
                    <nciDocumentNumber>AMC-037</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>AMC-037</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Study: Zevalin Radioimmunotherapy for Patients with Post Transplant Lymphoproliferative Disease Following Solid Organ Transplantation</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="02-04-2003 08:37:40">
                    <nciDocumentNumber>6015</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UMGCC #0307</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Single Agent Depsipeptide (NSC 630176) Followed by a Phase I Study of Rituximab/Fludarabine Combination with an Escalating Dose of Depsipeptide in Relapsed or Refractory Low Grade B Cell Lymphomas</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="02-06-2003 09:32:48">
                    <nciDocumentNumber>5972</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC0276</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Perifosine in Soft Tissue Sarcoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-04-2003 13:52:38">
                    <nciDocumentNumber>6113</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC0279</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of ZD1839 (Iressa) in Metastatic Neuroendocrine Tumors</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-16-2003 14:15:32">
                    <nciDocumentNumber>S0327</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0327</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of PS-341 (NSC-681239) in Patients with Platinum-Treated Extensive Stage Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-18-2003 08:25:50">
                    <nciDocumentNumber>6402</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-019</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of UCN-01 in Combination with Topotecan in Patients with Advanced Ovarian Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-25-2003 11:04:02">
                    <nciDocumentNumber>6139</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC0255</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of PS-341 in Patients with Hepatocellular Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="06-19-2003 13:29:34">
                    <nciDocumentNumber>6255</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>J0357</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial of Sequential Administration of Triapine (3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, NSC #663249) Followed by Fludarabine (NSC #312887) in Adults with Relapsed and Refractory Leukemias and Myelodysplasias</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="07-15-2003 12:02:19">
                    <nciDocumentNumber>6256</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>LUN012</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Triapine and Gemcitabine as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer in Patients Who Had Prior Gemcitabine with Evaluation of the Effect of Triapine  on Gemcitabine Pharmacokinetics and Cellular Uptake in Peripheral Mononuclear Cells</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="07-29-2003 14:56:52">
                    <nciDocumentNumber>6271</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-023</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Triapine in Combination with Gemcitabine in Recurrent/Unresectable/Metastatic Pancreatic Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="08-18-2003 10:31:44">
                    <nciDocumentNumber>S0310</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0310</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of CG8123, an Autologous Cancer Vaccine (GVAX), in Patients with Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC)</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="08-18-2003 13:12:05">
                    <nciDocumentNumber>6307</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC0362</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Gemcitabine in Combination with 17-Allylaminogeldanamycin (17-AAG) in Advanced Epithelial Ovarian and Primary Peritoneal Carcinoma</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-03-2003 13:10:53">
                    <nciDocumentNumber>6347</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Depsipeptide in Patients with Relapsed or Refractory Ovarian Carcinoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-16-2003 12:35:33">
                    <nciDocumentNumber>S0400</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0400</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Depsipeptide (NSC-630176) in Patients with Advanced Transitional Cell Carcinoma of the Urinary Tract Who Have Progressed After Receiving One Prior Chemotherapy Regimen for Advanced Disease</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-21-2003 11:31:01">
                    <nciDocumentNumber>6335</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>04-02-025S</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Single Agent Depsipeptide (FK228; NSC 630176; IND 51,810) in Patients with Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-22-2003 11:59:43">
                    <nciDocumentNumber>6446</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>10M-03-6</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>An Extended Dosing, Two-phase Study of MDX-010 as Monotherapy or in Combination with Tyrosinase/gp100/MART-1 Peptides Emulsified with Montanide ISA 51 in the Treatment of Subjects with Resected Stage III or Stage IV Melanoma</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="11-18-2003 07:56:16">
                    <nciDocumentNumber>6458</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHI-45</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Trial of Arsenic Trioxide in Combination with Pamidronate Disodium</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-11-2003 09:21:56">
                    <nciDocumentNumber>ACOSOG-Z1031</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ACOSOG-Z1031</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg daily), Letrozole (2.5 mg), or Anastrozole (1 mg) in Postmenopausal Women with Clinical Stage II and III Estrogen Receptor Positive Breast Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-30-2003 07:19:31">
                    <nciDocumentNumber>6384</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>2003-1007</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of EMD 121974 as Maintenance Therapy for Patients with Acute Myeloid Leukemia in Complete Remission</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-08-2004 11:51:32">
                    <nciDocumentNumber>6618</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>10M-03-8</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase II Continuation Booster Trial After a Vaccine Combining Tyrosinase/gp100/MART-1 Peptides Emulsified with Montanide ISA 51 or ISA 51 VG with or Without GM-CSF for Patients with Resected Stages IIB/C, III and IV Melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-22-2004 11:43:36">
                    <nciDocumentNumber>6369</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>2003-0895</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Single Agent Depsipeptide (FK228) in Breast Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="02-23-2004 12:26:25">
                    <nciDocumentNumber>S0341</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0341</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of OSI-774 (NSC-718781) in Patients with Advanced Non-Small Cell Lung Cancer and a Performance Status of 2</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="02-23-2004 14:11:40">
                    <nciDocumentNumber>E4503</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E4503</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study to Evaluate the Tumor Biochemical Effects of the EGFR Tyrosine Kinase Inhibitor OSI-774 (Erlotinib) Administered Prior to Surgical Resection in Patients with Early Stage Non-Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="04-06-2004 16:12:18">
                    <nciDocumentNumber>6803</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-031</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of SB-715992 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="05-04-2004 11:35:00">
                    <nciDocumentNumber>6581</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHI-47</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Trial of R115777 (NSC 702818) in Relapsed, Refractory or High Risk Myeloid Leukemia</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="05-06-2004 15:17:14">
                    <nciDocumentNumber>S0347</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0347</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Study of Weekly Vinorelbine (Navelbine) Alone or in Combination with Trastuzumab (Herceptin) (NSC-688097) for Patients with HER-2-Positive Metastatic Breast Cancer Whose Tumors Have Progressed After Taxane + Trastuzumab Combination Therapy - Phase III</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="05-25-2004 11:39:23">
                    <nciDocumentNumber>6651</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC0453</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin (17-AAG) in Patients with Hormone-Refractory Metastatic Prostate Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="05-27-2004 09:58:36">
                    <nciDocumentNumber>6490</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>1004-528 (COESUS #0409007464)</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients with Colorectal Cancer</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="06-07-2004 10:28:49">
                    <nciDocumentNumber>6617</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NYU 04-38</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of BAY 43-9006 (NCS 724772) in Unresectable Stage III and IV Melanoma (IND 69,869)</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="06-14-2004 17:05:31">
                    <nciDocumentNumber>CALGB-50303</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-50303/CTSU 50303</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Randomized Study of R-CHOP v. Dose-Adjusted Epoch-R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="06-21-2004 12:41:38">
                    <nciDocumentNumber>6654</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>05-C-0049</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of BAY 43-9006 (Sorafenib) with Evaluation of RAS Signal Pathway in Patients with Relapsed Non-Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-01-2004 14:27:09">
                    <nciDocumentNumber>NABTC-04-02</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTC04-02</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>NABTC04-02: Phase I/II Study of OSI-774 (Erlotinib) and CCI-779 (Temsirolimus) in Patients with Recurrent Malignant Glioma</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-15-2004 10:31:32">
                    <nciDocumentNumber>6879</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHII-61</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Recurrent or Metastatic Transitional Cell Carcinoma of the Urothelium</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-22-2004 10:08:47">
                    <nciDocumentNumber>GOG-0219</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-0219</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III, Randomized Trial of Weekly Cisplatin and Radiation Versus Cisplatin and Tirapazamine (IND# 46525) and Radiation in Stage IB2, IIA, IIB, IIIB and IVA Cervical Carcinoma Limited to the Pelvis</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-25-2004 15:19:33">
                    <nciDocumentNumber>6860</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CO 04510</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Patients with Relapsed Non-small Cell Lung Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-25-2004 16:33:27">
                    <nciDocumentNumber>6916</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-040</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Vorinostat in Patients with Advanced Melanoma</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="11-24-2004 09:22:00">
                    <nciDocumentNumber>7046</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC044H</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Bay 43-9006 in Progressive Metastatic Neuroendocrine Tumors</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-03-2004 12:31:50">
                    <nciDocumentNumber>S0502</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0502</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Randomized Study of Imatinib, with or without Bevacizumab (NSC-704865), in Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-28-2004 14:56:40">
                    <nciDocumentNumber>6862</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UMCC 2005.127</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Evaluation of Suberoylanilide Hydroxamic Acid (NSC 701852) in Patients with Advanced Prostate Cancer that has Progressed on One Prior Chemotherapy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-21-2005 12:16:51">
                    <nciDocumentNumber>S0515</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0515</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab Plus Bevacizumab for Advanced Stage Diffuse Large B-Cell NHL</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-26-2005 12:38:36">
                    <nciDocumentNumber>7229</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>0504007857</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Study of BMS 247550 (Ixabepilone) and Pegylated Liposomal Doxorubicin (Doxil) in Patients with Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer Who Have Been Previously Treated with a Platinum and a Taxane and Phase I Study of Patients with Metastatic Breast Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="02-24-2005 10:17:46">
                    <nciDocumentNumber>GOG-0218</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-0218</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC #704865, IND #7921) Followed by Placebo, Versus Caroboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women with Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-12-2012 10:41:39" createdDate="03-30-2005 10:49:25">
                    <nciDocumentNumber>7149</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>2005-0215</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase 1/2 Study of the Combination of BAY 43-9006 (Sorafenib) and CCI-779 (Temsirolimus) in Patients with Metastatic Melanoma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-05-2005 14:21:06">
                    <nciDocumentNumber>7146</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>IDD#05-12</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I, Pharmacokinetic and Pharmacodynamic Study of BAY 43-9006 (Sorafenib) in Combination with CCI-779 (Temsirolimus) in Advanced Solid Malignancies</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-20-2005 15:34:25">
                    <nciDocumentNumber>E4903</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E4903</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Lenalidomide (CC-5013) in Combination with Prednisone for the Treatment of Myelofibrosis with Myeloid Metaplasia</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-27-2005 12:31:39">
                    <nciDocumentNumber>CALGB-80302</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-80302</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Preoperative Irinotecan, Cisplatin and Radiation in Esophageal Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="06-14-2005 11:31:56">
                    <nciDocumentNumber>RTOG-0433</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG 0433/NCIC CTG SC.20</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III International Randomized Trial of Single Versus Multiple Fractions for Re-Irradiation of Painful Bone Metastases</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="08-03-2005 15:18:58">
                    <nciDocumentNumber>6898</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 1/2 Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Azacitidine in Patients with the Myelodysplastic Syndrome (MDS)</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-12-2012 10:41:39" createdDate="09-27-2005 09:08:46">
                    <nciDocumentNumber>7372</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>2005-0627</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of SGN-30 in Combination with CHOP in Anaplastic Large Cell Lymphoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-27-2005 09:34:59">
                    <nciDocumentNumber>7537</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CASE 5Y05</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Bevacizumab in Combination with SU11248</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="11-01-2005 15:07:22">
                    <nciDocumentNumber>7427</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHI-55</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 1 Study of Halichondrin B Analog (E7389) in Combination with Cisplatin in Advanced Solid Tumors</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="11-17-2005 11:51:13">
                    <nciDocumentNumber>NABTT-0504</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTT 0504</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Feasibility Assessment and a Phase I/II Trial of MLN518 for Treatment of Patients with Recurrent Glioblastoma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="12-01-2005 13:58:29">
                    <nciDocumentNumber>E2905</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E2905</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia</documentTitle>
                    <currentStatus>Temporarily Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-07-2005 14:06:02">
                    <nciDocumentNumber>7448</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-049</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of the Halichondrin B Analog E7389 as Second Line Therapy for Patients with Locally Advanced Unresectable or Metastatic Pancreatic Cancer</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-13-2005 10:31:09">
                    <nciDocumentNumber>7533</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHII-76</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of VEGF Trap (NSC 724770) in Patients with Recurrent or Metastatic Transitional Carcinoma of the Urothelium</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="01-26-2006 10:11:02">
                    <nciDocumentNumber>7557</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-054</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of AZD0530 in Recurrent or Metastatic Soft Tissue Sarcoma</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="06-05-2006 10:58:25">
                    <nciDocumentNumber>S0600</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0600</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC-714692) or Bevacizumab (NSC-704865) as Second-Line Therapy for Patients with Metastatic Colorectal Cancer who have Progressed on Bevacizumab with Either FOLFOX, OPTIMOX or XELOX</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="08-29-2006 15:58:36">
                    <nciDocumentNumber>7786</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>15431A</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Dasatinib (NSC 732517) in Previously-Treated Patients with Metastatic Colorectal Cancer</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="12-15-2006 14:27:39">
                    <nciDocumentNumber>7937</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>07-082</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II Study of Obatoclax Mesylate (GX15-070MS), a bcl-2 Antagonist, Plus Topotecan in Relapsed Small Cell Lung Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="12-18-2006 14:48:38">
                    <nciDocumentNumber>RTOG-0617</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-0617</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III Comparison of Standard-Dose (60 Gy) Versus High-Dose (74 Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel +/- Cetuximab (IND #103444) in Patients with Stage IIIA/IIIB Non-Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="02-01-2007 10:58:30">
                    <nciDocumentNumber>7967</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UPCI # 07-015</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 1 Study of ABT-888 in Combination with Carboplatin and Paclitaxel in Advanced Solid Malignancies</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="02-07-2007 16:11:24">
                    <nciDocumentNumber>7977</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>2007-014</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) Plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients with Advanced Solid Tumors</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="02-21-2007 08:19:34">
                    <nciDocumentNumber>7893</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCR 7205</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of Bortezomib and Cetuximab without or with Cisplatin in Combination with Radiation Therapy for Advanced Head and Neck Cancer</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="03-13-2007 08:36:11">
                    <nciDocumentNumber>8035</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC0771</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of the Orally Administered Negative Enantiomer of Gossypol (AT-101) in Patients with Advanced Adrenocortical Carcinoma (ACC)</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="05-11-2007 08:49:17">
                    <nciDocumentNumber>E1906</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E1906</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Randomized Trial of Carboplatin and Topotecan; Flavopiridol, Mitoxantrone and Cytosine Arabinoside; and Sirolimus, Mitoxantrone, Etoposide and Cytosine Arabinoside for the Treatment of Adults with Primary Refractory or Initial Relapse of Acute Myelogenous Leukemia (AML)</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="06-25-2007 15:13:16">
                    <nciDocumentNumber>S0711</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0711</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Pharmacokinetic Study of Dasatinib (BMS-354825) (NSC-732517; IND-73969) in Patients with Advanced Malignancies and Varying Levels of Liver Dysfunction</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="06-27-2007 10:55:02">
                    <nciDocumentNumber>7353</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of CCI-779 in Combination with Dexamethasone in Multiple Myeloma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="12-20-2007 17:26:17">
                    <nciDocumentNumber>CALGB-40502</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-40502</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound NAB-Paclitaxel or Ixabepilone Combined with Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="12-21-2007 09:12:05">
                    <nciDocumentNumber>S0000D</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0000D</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Study of the Effect of Vitamin E and/or Selenium on Adenomatous Colorectal Polyps (ACP) in Participants Enrolled in SELECT, Phase II Ancillary to S0000-SELECT</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="02-13-2008 16:24:52">
                    <nciDocumentNumber>8236</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>IUCRO-0214</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of AZD0530 for Patients with Relapsed/Refractory Thymic Malignancies (Thymoma and Thymic Carcinoma)</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="07-22-2008 09:59:36">
                    <nciDocumentNumber>8248</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NA_00034732</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase 2 Study of Bevacizumab in Children and Adults with Neurofibromatosis Type 2 and Symptomatic Vestibular Schwannoma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="08-26-2008 12:11:32">
                    <nciDocumentNumber>8282</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UPCI # 08-121</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 1 Study of Chronically-Dosed, Single-Agent ABT-888 in Patients with Either BRCA 1/2 -Mutated Cancer; Platinum-Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; or Basal-Like Breast Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="09-17-2008 10:15:04">
                    <nciDocumentNumber>ADVL0813</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ADVL0813</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of IMC-A12 (Anti-Insulin-Like Growth Factor-I Receptor Monoclonal Antibody) in Combination with CCI-779 (Temsirolimus) in Pediatric Patients with Recurrent or Refractory Solid Tumors</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="10-22-2008 16:07:11">
                    <nciDocumentNumber>8281</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DFCI 09-005</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Clinical Trial of the MEK 1/2 Inhibitor AZD6244 in Cancers with BRAF Mutations Identified by Prospective Genotypic Analysis</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="11-10-2008 08:33:16">
                    <nciDocumentNumber>ADVL0816</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ADVL0816</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Obatoclax (Pan Anti-Apoptotic BCL-2 Family Small Molecule Inhibitor), in Combination with Vincristine/Doxorubicin/Dexrazoxane, in Children with Relapsed/Refractory Solid Tumors or Leukemia</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="12-15-2008 10:57:43">
                    <nciDocumentNumber>CALGB-50604</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-50604</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of Response-Adapted Chemotherapy Based on Positron Emission Tomography for Non-Bulky Stage I and II Hodgkin Lymphoma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="03-10-2009 12:04:47">
                    <nciDocumentNumber>8463</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>09-C-0192</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Cediranib (AZD2171) in Patients with Alveolar Soft Part Sarcoma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="04-22-2009 12:09:45">
                    <nciDocumentNumber>8167</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Pilot Phase II Study of Temsirolimus in Patients with Recurrent Mixed Mesodermal and Mullerian Tumors (Carcinosarcoma) of the Uterus</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="06-19-2009 07:51:55">
                    <nciDocumentNumber>E4A08</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E4A08</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with Systemic Light-Chain (AL) Amyloidosis Ineligible for Autologous Stem-Cell Transplantation</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="07-28-2009 15:18:18">
                    <nciDocumentNumber>GOG-9923</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-9923</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Carboplatin/Paclitaxel/CTEP-Supplied Agent Bevacizumab (NSC #704865, IND #7921) and CTEP-Supplied Agent ABT-888 (NSC #737664 IND#77840) in Newly Diagnosed Patients with Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="08-24-2009 15:25:10">
                    <nciDocumentNumber>8631</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCI-8631</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of AZD6244 in Multiple Myeloma</documentTitle>
                    <currentStatus>Temporarily Closed to Accrual &amp;Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="09-30-2009 09:10:51">
                    <nciDocumentNumber>8511</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>VICC GI 09106</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of Cetuximab with RO4929097 in Metastatic Colorectal Cancer and Phase II Study of Cetuximab with RO4929097 vs Cetuximab with Placebo in Metastatic Colorectal Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="11-06-2009 15:07:14">
                    <nciDocumentNumber>8593</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 1 Study of AZD6244 in Combination with Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the Rectum</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="01-06-2010 16:39:34">
                    <nciDocumentNumber>8265</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>J1023</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 1/2 Study of SNDX-275 in Combination with Imatinib for Relapsed/Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="02-22-2010 09:41:31">
                    <nciDocumentNumber>8703</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHII-102</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Randomized Study of Vorinostat or Placebo in Combination with Carboplatin and Paclitaxel for Patients with Advanced Non-small Cell Lung Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="03-16-2010 16:49:56">
                    <nciDocumentNumber>8784</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MCC16264</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 1 Study of 1-Methyl-D-tryptophan (NSC-721782; IND # 78060) in Combination with Docetaxel in Metastatic Solid Tumors</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="08-03-2010 13:24:28">
                    <nciDocumentNumber>ADVL1014</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ADVL1014</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 1 Dose Escalation Study of Reolysin, a Replication Competent Reovirus, in Pediatric Patients with Relapsed or Refractory Solid Tumors</documentTitle>
                    <currentStatus>Approved</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:45">
                    <nciDocumentNumber>GOG-9201</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-9201</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I trial of Ifosfamide and Taxol in refractory Pelvic Malignancies</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:45">
                    <nciDocumentNumber>NCCTG-89-30-52</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-89-30-52</localDocumentNumber>
                        <localDocumentNumber>89-30-52</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Trial of Adjuvant Therapy with Tamoxifen Alone or Combined with Fluoxymesterone in Postmenopausal Women with Resected Estrogen Receptor Positive Breast Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:45">
                    <nciDocumentNumber>POG-9470</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9470</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I trial of CI-980 in children with solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:45">
                    <nciDocumentNumber>CCG-7943</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCG-7943</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II window of topotecan (nsc #609699) in children with newly diagnosed metastatic osteosarcoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:45">
                    <nciDocumentNumber>CCG-0962</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCG-0962</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Docetaxel (Taxotere) (NSC# 628503) in Children with Recurrent Solid Tumors: A Groupwide Phase II Study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:45">
                    <nciDocumentNumber>POG-7516</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-7516</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Cyclocytidine Phase I/II in Pediatric and solid Tumors</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:46">
                    <nciDocumentNumber>CCG-0931</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCG-0931</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of il-6 plus g-csf (5 ug/kg/d) following ifosfamide, carboplatin, and etoposide (i.c.e.) in children with recurrent solid tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:46">
                    <nciDocumentNumber>T93-0076</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ID 93-013</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study to evaluate the efficacy and toxicity of Taxol (paclitaxel) administered intravenously as a single infusion every 21 days to women with advanced or recurrent squamous cell cancer of the cervix</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:46">
                    <nciDocumentNumber>T95-0079</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DM95-033</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Topotecan (SKF 104864, Hycamptamine) and Cytarabine (ARA-C) Combination in Myelodysplastic Syndrome (MDS)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:50:47">
                    <nciDocumentNumber>E4293</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E4293</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of topotecan 21-day infusion in advanced colorectal cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:47">
                    <nciDocumentNumber>POG-9370</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9370</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial of TIAZOFURIN and 6-THIOGUANINE in Children with Acute Leukemia</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:47">
                    <nciDocumentNumber>POG-9315</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9315</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III study of large Cell Lymphomas in children and adolescents; comparison of APO vs APO + IDMTX/HDARA-C and continuous vs bolus infusion of Doxorubicn</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:47">
                    <nciDocumentNumber>POG-9379</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9379</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of the Thymidylate synthase inhibitor ZD1694 administered as a short intravenous infusion in Pediatric patients with Acute Leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:50:47">
                    <nciDocumentNumber>RTOG-94-08</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-94-08</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Trial of the Study of Endocrine Therapy Used as a Cytoreductive and Cytostatic Agent Prior to Radiation Therapy in Good Prognosis Locally Confined Adenocarcinoma of the Prostate</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:48">
                    <nciDocumentNumber>POG-9412</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9412</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Treatment of Isolated CNS Relapse of Acute Lymphoblastic Leukemia - A Pediatric Oncology Group-Wide Phase II Study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:48">
                    <nciDocumentNumber>CCG-0955</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCG-0955</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A PHASE I study of GEMCITABINE (NSC# 613327) in children with relapsed or refractory LEUKEMIA and NON-HODGKIN'S LYMPHOMA</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:48">
                    <nciDocumentNumber>POG-9575</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9575</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Topotecan For Children With Refractory Leukemia:  A Pediatric Oncology Group Phase I Cooperative Agreement Study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:48">
                    <nciDocumentNumber>S9617</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S9617</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of PSC833 as Chemotherapy-Resistance Modifier in Patients Over Age 55 with Previously Untreated Acute Myeloid Leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:48">
                    <nciDocumentNumber>POG-9486</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9486</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of pre-irradiation chemotherapy for Pediatric patients with Nasopharyngeal Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:48">
                    <nciDocumentNumber>A9961</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>A9961</localDocumentNumber>
                        <localDocumentNumber>A9961</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Prospective Randomized Study of Craniospinal Radiotherapy Followed by One of Two Adjuvant Chemotherapy Regimens (CCNU, CDDP, VCR or CPM, CDDP,VCR) in Children with Newly-Diagnosed Average-Risk Medulloblastoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:48">
                    <nciDocumentNumber>E1395</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E1395</localDocumentNumber>
                        <localDocumentNumber>E1395</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III Evaluation of Paclitaxel + Cisplatin Versus Cisplatin + 5-FU in Advanced Head and Neck Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:48">
                    <nciDocumentNumber>CCG-0902</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCG-0902</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Fazarabine in Children with Recurrent Solid Tumor Malignancies</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:48">
                    <nciDocumentNumber>POG-7831</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-7831</localDocumentNumber>
                        <localDocumentNumber>SWOG-7831</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Neocarzinostatin Phase II in children with ALL and ANLL  in relapse</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:48">
                    <nciDocumentNumber>E1193</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E1-02-92</localDocumentNumber>
                        <localDocumentNumber>NCCTG-92-32-52</localDocumentNumber>
                        <localDocumentNumber>SWOG-9332</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Trial of Adriamycin Versus Taxol Versus Taxol plus Adriamycin Plus G-CSF in Metastatic Breast Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:48">
                    <nciDocumentNumber>INT-0143</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-93-10</localDocumentNumber>
                        <localDocumentNumber>SWOG-9310</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>An intergroup Phase II combined modality treatment of primary central nervous system lymphoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:49">
                    <nciDocumentNumber>EST-5275</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-5275</localDocumentNumber>
                        <localDocumentNumber>N81-0984</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II studies of streptozotocin combined with 5-fu versus adriamycin in the treatment of islet cell carcinoma and carcinoid tumor</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>INT-0130</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-91-46-52</localDocumentNumber>
                        <localDocumentNumber>E8293</localDocumentNumber>
                        <localDocumentNumber>CO.8</localDocumentNumber>
                        <localDocumentNumber>RTOG-92-03</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Study of Radiation Therapy, Levamisole and 5-Fluorouracil vs 5-Fluorouracil and Levamisole in Selected Patients with Completely Resected Colon Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>INT-0102</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-8897</localDocumentNumber>
                        <localDocumentNumber>CALGB-8897</localDocumentNumber>
                        <localDocumentNumber>EST-2188</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Comparison of Adjuvant Chemotherapy with or without Endocrine Therapy in High-Risk, Node Negative Breast Cancer Patients, and a Natural History Follow-Up Study in Low-Risk, Node Negative Patients</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:52">
                    <nciDocumentNumber>NCCTG-83-70-52</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-83-70-52</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized, Phase III Surgical Adjuvant Clinical Trial of Recombinant Leukocyte A Interferon (RO22-8191; IFL-rA) in Selected Patients with Malignant Melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:53">
                    <nciDocumentNumber>E7296</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E7296</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of Neoadjuvant Paclitaxel - Cisplatin Chemotherapy, Surgery and Adjuvant Radiation Therapy and 5-FU/Leucovorin for Gastric Cancer</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:54">
                    <nciDocumentNumber>GOG-9801</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-9801</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Feasibility Trial of Carboplatin, Paclitaxel, and Gemcitabine in Patients with Previously Untreated Epithelial Ovarian Carcinoma and Primary Peritoneal Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:58">
                    <nciDocumentNumber>GOG-0150</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-150</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Randomized Study of Whole Abdominal Radiotherapy (WAR) Versus Combination Ifosfamide-Mesna with Cisplatin in Optimally Debulked Stage I, II, III or IV Carcinosarcoma (CS) of the Uterus</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:00">
                    <nciDocumentNumber>T98-0011</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>98-C-0074</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of intravenous cereport(rmp-7) and carboplatin in childhood brain tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:01">
                    <nciDocumentNumber>T97-0078</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DM 97-050</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III randomized evaluation of 13-cis-retinoic acid (cra) plus procarbazine versus procarbazine alone in the treatment of patients with recurrent primary malignant gliomas</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:02">
                    <nciDocumentNumber>T84-0470</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>84-C-193</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of trimetrexate in pediatric patients</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:02">
                    <nciDocumentNumber>W83-0066</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>OSU-8210</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II evaluation of aclacinomycin in lung cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:03">
                    <nciDocumentNumber>T90-0085</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>90-C-220</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I evaluation of intratumoral interleukin-1 alpha</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:03">
                    <nciDocumentNumber>NCCTG-89-72-52</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-89-72-52</localDocumentNumber>
                        <localDocumentNumber>89-72-52</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of Amonafide in recurrent Glioma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:04">
                    <nciDocumentNumber>T84-0149</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>82-C-95</localDocumentNumber>
                        <localDocumentNumber>BRMP-8207</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A preliminary Phase I trial of immune interferon in cancer patients</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:04">
                    <nciDocumentNumber>T83-1198</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>83-08-29-01</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of menogaril in patients with advanced cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:04">
                    <nciDocumentNumber>NCCTG-86-72-52</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-86-72-52</localDocumentNumber>
                        <localDocumentNumber>E6489</localDocumentNumber>
                        <localDocumentNumber>86-72-52</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of chemotherapy plus radiotherapy for management of primary central nervous system Non-Hodgkin's Lymphoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:04">
                    <nciDocumentNumber>NCCTG-84-72-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-84-72-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II evaluation of Fludarabine Phosphate in primary brain tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:04">
                    <nciDocumentNumber>EST-8489</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-8489</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III study comparing VAD Chemotherapy with VAD plus recombinant Alpha2 interferon in refractory or relapsed multiple Myeloma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:05">
                    <nciDocumentNumber>NCCTG-88-64-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-88-64-51</localDocumentNumber>
                        <localDocumentNumber>88-64-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Clinical Trial of Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Women with Advanced Carcinoma of the Uterine Cervix or Vagina</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:05">
                    <nciDocumentNumber>SWOG-8825</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-8825</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I trial of intravenous bolus melphalan with gm-csf</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:05">
                    <nciDocumentNumber>T87-0163</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>87-C-92</localDocumentNumber>
                        <localDocumentNumber>CCG-0881</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of interleukin-2 in pediatric patients with refractory hematologic malignancies and solid tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:06">
                    <nciDocumentNumber>SWOG-8728</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-8728</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase ii: evaluation of didemnin b in metastatic adenocarcinoma of the kidney</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:06">
                    <nciDocumentNumber>SWOG-7827</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-7827</localDocumentNumber>
                        <localDocumentNumber>EST-4186</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Combined modality therapy for Breast carcinoma, Phase III</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:08">
                    <nciDocumentNumber>D82-012-0898</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ICC-81U2</localDocumentNumber>
                        <localDocumentNumber>V83-0145</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of new agents in adv bladder cancer with methyl-g</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:08">
                    <nciDocumentNumber>D80-002-0159</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>01734</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Bcg-mer Phase II in melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:08">
                    <nciDocumentNumber>D79-017-0183</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>JHOC-7927</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Melphalan Phase II high dose intravenous study in refract and relapse pts</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:08">
                    <nciDocumentNumber>C83-0537</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CIC-82-163A</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Methyl-g, Phase II study in pts with advanced germ cell malignancies</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:09">
                    <nciDocumentNumber>SEG-GI-77-221</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-GI-77-221</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Anguidine Phase II study in a cyclic daily schedule in adenocarcinoma of gastrointestinal tract</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:09">
                    <nciDocumentNumber>SEG-BL-80-P52</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-BL-80-P52</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of cis-platinum as topical therapy in non-invasive bladder cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:10">
                    <nciDocumentNumber>T85-0098</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>85-C-66</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II study of suramin, alpha-interferon, and il-2 combination therapy for early stage aids</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:10">
                    <nciDocumentNumber>CALGB-8331</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-8331</localDocumentNumber>
                        <localDocumentNumber>T84-0371</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II treatment of refractory small cell lung cancer with cis platinum &amp; vp-16</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:10">
                    <nciDocumentNumber>RTOG-84-16</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-84-16</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II dose-searching randomized study of fast neutrons for Tumors located in the upper Abdomen</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:11">
                    <nciDocumentNumber>EST-P-A390</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-P-A390</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II pilot study of Taxol (nsc 125973) and filgrastim (g-csf)in patients with advanced head and neck cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:11">
                    <nciDocumentNumber>T91-0084</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DM-91-028</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of piroxantrone in patients with advanced gastric cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:11">
                    <nciDocumentNumber>T91-0196</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>IND.67</localDocumentNumber>
                        <localDocumentNumber>IND.67</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of fostriecin given as an intravenous bolus daily for 5 consecutive days</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:12">
                    <nciDocumentNumber>B92-0001</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CO 9293</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase IB trial of GM-CSF and IL-2</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:12">
                    <nciDocumentNumber>T92-0181</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>93-C-0065</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Pediatric Phase II study of topotecan</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:12">
                    <nciDocumentNumber>T95-0083</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>8014</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of aminocamptothecin (9-ac/dma) in patients with advanced squamous cell carcinoma of the head and neck</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:13">
                    <nciDocumentNumber>T84-0483</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>84-C-175</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of tricyclic nucleoside 5'-phosphate (tcn-p) in patients with refractory ovarian cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:13">
                    <nciDocumentNumber>POG-8362</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-8362</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I evaluation of maximum tolerable dosage of DHAD in combination with Cytosine Arabinoside in children with Acute Leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:13">
                    <nciDocumentNumber>W83-0447</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>83-C-31</localDocumentNumber>
                        <localDocumentNumber>MOB-CPB-174</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I and pharmacokinetic study of tiazofurin (tcar, nsc 286193) in adults</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:13">
                    <nciDocumentNumber>POG-7837</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-7837</localDocumentNumber>
                        <localDocumentNumber>SWOG-7837</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Evaluation of systemic therapy for children with Lymphoblastic Lymphoma including T-Cell disease - Phase III</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:14">
                    <nciDocumentNumber>GITSG-6384</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GITSG-6384</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A randomized Phase III study of Advanced Measurable Colorectal Carcinoma - clinical evaluation of biochemical and pharmacological modulation of 5-Fluorouracil</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:15">
                    <nciDocumentNumber>T84-0352</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>84-10-195</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II study of deoxydoxorubicin in patients with previously treated acute leukemia with pharmacokinetic analysis</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:19">
                    <nciDocumentNumber>N78-0173</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>78-C-140</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of Isophosphamide in refractory pediatric malignancies</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:21">
                    <nciDocumentNumber>T90-0033</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DS-89-37</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Gm-csf in combination with escalating doses of etoposide, doxorubicin and cisplatin (eap) - a Phase I study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:24">
                    <nciDocumentNumber>T89-0160</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>IL-2/ALPHA/RENAL</localDocumentNumber>
                        <localDocumentNumber>10/89-6</localDocumentNumber>
                        <localDocumentNumber>89-10-240</localDocumentNumber>
                        <localDocumentNumber>889-5011-117</localDocumentNumber>
                        <localDocumentNumber>89153-89-11-1</localDocumentNumber>
                        <localDocumentNumber>1779</localDocumentNumber>
                        <localDocumentNumber>H6042-05093-01A</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A randomized Phase II study of high dose il-2 by iv bolus versus high dose il-2 in combination with interferon-alpha 2b in patients with metastatic or unresectable renal cell carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:24">
                    <nciDocumentNumber>NCOG-7O-85-1</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCOG-7O-85-1</localDocumentNumber>
                        <localDocumentNumber>NCOG-7O-85-1</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A randomized Phase III study of heavy charged particle radiotherapy versus Iodine (125I) plaque radiotherapy in the treatment of localized uveal Melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:24">
                    <nciDocumentNumber>NCOG-4P-85-1J</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCOG-4P-85-1J</localDocumentNumber>
                        <localDocumentNumber>NCOG-4P-85-1J</localDocumentNumber>
                        <localDocumentNumber>RTOG-85-21</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III controlled randomized trial comparing definitive supervoltage external beam irradiation alone w/combined supervoltage x-ray therapy and heavy charged particle therapy for patients w/localized stage T2B,T3,T4 Prostatic Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:25">
                    <nciDocumentNumber>NCOG-2N-80-1J</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCOG-2N-80-1J</localDocumentNumber>
                        <localDocumentNumber>RTOG-79-17</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III study to compare Misonidazole combined with irradiation of radiation therapy alone in the treatment of locally advanced (Stage III) Non-Oat Cell Lung Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:25">
                    <nciDocumentNumber>T83-1251</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>83-C-56</localDocumentNumber>
                        <localDocumentNumber>RTOG-83-03</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I trial of the hypoxic cell radiosensitizer , sr-2508</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:25">
                    <nciDocumentNumber>T83-1188</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ICC-2</localDocumentNumber>
                        <localDocumentNumber>IRB-12-82-6A</localDocumentNumber>
                        <localDocumentNumber>N83-0519</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II single agent chemotherapy with cbdca for metastatic ovarian carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:26">
                    <nciDocumentNumber>T89-0081</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>89-C-132</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of RHGMCSF given in combination with 5-fluorouracil plus Calcium Leucovorin in metastatic Gastrointestinal Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:26">
                    <nciDocumentNumber>NCCTG-87-81-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-87-81-51</localDocumentNumber>
                        <localDocumentNumber>87-81-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of VP-16/ARA-C combination in the treatment of unfavourable Myelodysplastic Syndromes</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:26">
                    <nciDocumentNumber>NCCTG-86-72-54</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-86-72-54</localDocumentNumber>
                        <localDocumentNumber>86-72-54</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of infusional Cis Platinum and Etoposide in Recurrent Primary Brain Tumor</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:26">
                    <nciDocumentNumber>NCCTG-87-24-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-87-24-51</localDocumentNumber>
                        <localDocumentNumber>87-24-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III study in the treatment of extensive Non-Small Cell Lung Cancer: A controlled evaluation of a new approach to combined Etoposide and Cis Platinum Therapy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:26">
                    <nciDocumentNumber>NCCTG-87-32-52</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-87-32-52</localDocumentNumber>
                        <localDocumentNumber>87-32-52</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized clinical trial in women with Metastatic Breast Cancer: Integration of Phase II testing of new agents into a Phase III trial examining Estrogenic recruitment as a means of increasing the efficacy of combination chemotherapy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:26">
                    <nciDocumentNumber>NCCTG-84-80-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-84-80-51</localDocumentNumber>
                        <localDocumentNumber>84-80-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Myeloma resistant to a Melphalan (or Cyclophosphamide) and Prednisone containing regimen: Phase II trial of Hydroxyurea Primed VBAP [Vincristine,BCNU(Carmustine), Adriamycin, (Doxorubicin) &amp; Pred. ]</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:26">
                    <nciDocumentNumber>NCCTG-85-32-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-85-32-51</localDocumentNumber>
                        <localDocumentNumber>85-32-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A double-blind clinical Phase III trial of Tamoxifen plus placebo versus Tamoxifen plus Prednisolone in women with Advanced Breast Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:27">
                    <nciDocumentNumber>T83-1112</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CO-8396</localDocumentNumber>
                        <localDocumentNumber>83-01-05</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I toxicity evaluation of recombinant leukocyte a interferon(ro 22-8181)in combination with cyclophosphamide,vincristine,prednosone and adriamycin (i-copa)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:28">
                    <nciDocumentNumber>T88-0176</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                        <localDocumentNumber>9/88-5G</localDocumentNumber>
                        <localDocumentNumber>889-5011-053</localDocumentNumber>
                        <localDocumentNumber>8115</localDocumentNumber>
                        <localDocumentNumber>CSU-463</localDocumentNumber>
                        <localDocumentNumber>H2381-03693-01</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of patients with colorectal carcinoma expressing high levels of hla-dr surface antigens treated with high dose il-2 by iv bolus in combination with autologous lymphokine activated killer cells</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:28">
                    <nciDocumentNumber>T88-0083</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UCHSC-87190</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Gallium nitrate continuous infusion therapy for advanced bladder carcinoma Phase II trial</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:29">
                    <nciDocumentNumber>T88-0040</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ICC-88I1</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of new agents in treatment of advanced adenocarcinoma of stomach</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:29">
                    <nciDocumentNumber>T87-0269</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UH8788</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of 6-thioguanine in previously untreated patients with advanced head and neck cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:29">
                    <nciDocumentNumber>T87-0162</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CIC-87-70</localDocumentNumber>
                        <localDocumentNumber>UMCC-8770</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of carboplatin and vinblastine in previously untreated patients with adenocarcinoma of the upper gastrointestinal tract</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:29">
                    <nciDocumentNumber>T87-0167</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CI-IL2/MEL</localDocumentNumber>
                        <localDocumentNumber>7/87-6C</localDocumentNumber>
                        <localDocumentNumber>87-08-194</localDocumentNumber>
                        <localDocumentNumber>867-5011-328</localDocumentNumber>
                        <localDocumentNumber>7090</localDocumentNumber>
                        <localDocumentNumber>804814-01</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II study of high dose continuous infusion il-2 and autologous lak cells in patients with metastatic or unresectable malignant melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:29">
                    <nciDocumentNumber>T87-0133</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>87-C-66</localDocumentNumber>
                        <localDocumentNumber>MB-215</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I evaluation of the toxicity and immunomodulating effects of recombinant tumor necrosis factor given in combination with recombinant human interferon gamma in patients with solid tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:31">
                    <nciDocumentNumber>T83-0971</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>82-C-175</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of vp-16,213 in the treatment of  patients with multiple myeloma after failure on primary chemotherapy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:31">
                    <nciDocumentNumber>SWOG-8743</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-8743</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of recombinant tumor necrosis factor in patients with metastatic colorectal adenocarcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:33">
                    <nciDocumentNumber>SEG-MEL-77-314</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-MEL-77-314</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III study of surgical adjuvant immunotherapy comparing Corynebacterium Parvum vs. BCG in selected melanoma patients with stage I disease (scalp and genitals only) or stage II disease (limited to 4 or less metastatic nodes)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:33">
                    <nciDocumentNumber>SEG-LUN-81-343R</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-LUN-81-343R</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III randomized study of simultaneously administered radiotherapy to the chest and combination chemotherapy (CAV) versus CAV alone in limited stage Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:34">
                    <nciDocumentNumber>EST-4483</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-4483</localDocumentNumber>
                        <localDocumentNumber>INT-0037</localDocumentNumber>
                        <localDocumentNumber>SWOG-8592</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III low-dose Ara-c vs. supportive therapy alone in the treatment of Myelodysplastic Syndromes</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:34">
                    <nciDocumentNumber>EST-P-Z586</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-P-Z586</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of recombinant Interleukin 2 with and without recombinant beta Interferon in patients with advanced non-small cell Lung cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:35">
                    <nciDocumentNumber>EST-P-A987</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-P-A987</localDocumentNumber>
                        <localDocumentNumber>SEG-BMT-101</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I trial of high-dose Etoposide plus high-dose Melphalan and autologous bone marrow rescue for refractory malignancies</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:36">
                    <nciDocumentNumber>T86-0101</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CORN-8612</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of fludarabine phosphate in multiple myeloma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:36">
                    <nciDocumentNumber>T86-0109</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>8602-11</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of high dose chemotherapy with autologous bone marrow rescue in patients with refractory germinal neoplasms</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:36">
                    <nciDocumentNumber>SEG-HD-77-320</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-HD-77-320</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III study of combination chemotherapy with BVCPP with or without involved field radiotherapy in early stage Hodgkin's Disease with unfavorable prognostic indicators</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:37">
                    <nciDocumentNumber>T86-0001</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CO-8596</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of recombinant human tumor necrosis factor (rtnf) (product code g11038-01, genentech, inc.) on a three times weekly schedule</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:38">
                    <nciDocumentNumber>SEG-CML-83-215L</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-CML-83-215L</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II study of Syngeneic/Allogeneic BMT from genotypically HLA-identical siblings for Chronic Myelogenous Leukemia in chronic, accelerated or second chronic phase after blast crisis, phase STS-V, VYV, TBI.</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:41">
                    <nciDocumentNumber>SEG-BRE-82-297</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-BRE-82-297</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of multi-modality treatment of stage III and Non-Metastatic stage IV Breast Cancer with clinico-biological correlations</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:44">
                    <nciDocumentNumber>RTOG-87-04</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-87-04</localDocumentNumber>
                        <localDocumentNumber>EST-1289</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III randomized study employing 5FU and radiotherapy vs. 5FU, Mitomycin-C and Radiotherapy in Carcinoma of the Anal Canal</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:45">
                    <nciDocumentNumber>CCG-095</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCG-095</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I pediatric study of homoharringtonine (nsc 141633) in children with leukemia or solid tumors refractory to standard therapy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:47">
                    <nciDocumentNumber>RTOG-85-09</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-85-09</localDocumentNumber>
                        <localDocumentNumber>GOG-91</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II study of Intraoperative Radiotherapy in recurrent Carcinoma of the Cervix</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:47">
                    <nciDocumentNumber>RTOG-86-05</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>86-020</localDocumentNumber>
                        <localDocumentNumber>RTOG-86-05</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I trial of continuous infusion SR-2508 with Interstitial and Intracavity Radiation</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:47">
                    <nciDocumentNumber>RTOG-84-19</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-84-19</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A randomized Phase III study of Interstitial Thermoradiotherapy (43C) compared with Interstitial Radiotherapy alone in the treatment of recurrent or persistent Human Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:48">
                    <nciDocumentNumber>T85-0061</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>IRB-3008-5</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Echinomycin in the treatment of Multiple Myeloma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:48">
                    <nciDocumentNumber>T85-0063</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>OSU-8505</localDocumentNumber>
                        <localDocumentNumber>MAOP-3182</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III multicenter study of Amsacrine DMA/Lactate (CI-880) in combination with Thioguanine and Cytosine Arabinoside vs Daunorubicin, Thioguanine, &amp; ara-c in front line therapy of pts with acute non-lymphocytic leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:48">
                    <nciDocumentNumber>INT-0077</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-3185</localDocumentNumber>
                        <localDocumentNumber>SWOG-8697</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Combination chemotherapy of predominantly hormone insensitive metastatic Breast cancer:  Phase III</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:48">
                    <nciDocumentNumber>INT-0072</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-8616</localDocumentNumber>
                        <localDocumentNumber>CALGB-8692</localDocumentNumber>
                        <localDocumentNumber>ISS-4</localDocumentNumber>
                        <localDocumentNumber>S-676</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>An intergroup Phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:48">
                    <nciDocumentNumber>INT-0064</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-85-24</localDocumentNumber>
                        <localDocumentNumber>SWOG-8609</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Phase II study of neutron vs. photon radiation therapy after induction chemotherapy for inoperable, regional, non-small cell lung cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:49">
                    <nciDocumentNumber>INT-0005</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-3182</localDocumentNumber>
                        <localDocumentNumber>SEG-INT-BRE-83-332</localDocumentNumber>
                        <localDocumentNumber>SWOG-8293</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Intergroup Phase III protocol for the management of locally or regionally recurrent but surgically resectable Breast cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:51">
                    <nciDocumentNumber>T91-0030</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II trial of sequential active specific immunotherapy (Autologous Tumor Cell Vaccine) and Recombinant Interleukin-2 (RO 23-6019) for Metastatic Melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:51">
                    <nciDocumentNumber>T91-0037</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>91-006</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of Pala/MMPR/5-Fluorouracil in unresectable Adenocarcinoma of the Pancreas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:52">
                    <nciDocumentNumber>T91-0177</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UPCC-2591</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II evaluation of All-Trans-Retinoic Acid in extensive Small Cell Lung Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:52">
                    <nciDocumentNumber>GOG-76T</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-76T</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of Piroxantrone in patients with Advanced Squamous Cell Carcinoma of the Cervix</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:52">
                    <nciDocumentNumber>T92-0049</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>IDB-IL-6</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Interleukin-6 (IL-6) administered by one-hour continuous intravenous infusion</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:53">
                    <nciDocumentNumber>GOG-9202</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-9202</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I limited access study of Taxol (NSC #125973) and Carboplatin (NSC # 241240) in patients with suboptimal stage III and IV Epithelial Ovarian Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:53">
                    <nciDocumentNumber>T92-0184</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>93-C-0022</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Taxol in combination with Cyclophosphamide and Granulocyte-Colony stimulating factor (G-CSF) in metastatic Breast Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:54">
                    <nciDocumentNumber>T93-0040</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of Anti-B4-blocked Ricin Immunotoxin in patients with relapsed and refractory Hairy Cell Leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:54">
                    <nciDocumentNumber>T93-0063</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>93-C-0155</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Treatment of Thrombocytopenia with Dideoxynucleosides and Anti-RH Antibodies(Anti-D) in children with HIV infection: A Phase II Study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:54">
                    <nciDocumentNumber>NABTT-9301</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>T93-0065</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II clinical and pharmacologic study of pre-irradiation Taxol administered as a 96 hour infusion in adults with newly diagnosed Glioblastoma Multiforme</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:54">
                    <nciDocumentNumber>INT-0147</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-94-01</localDocumentNumber>
                        <localDocumentNumber>CALGB 9483</localDocumentNumber>
                        <localDocumentNumber>R9401</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III intergroup randomized trial of pre-operative vs. post-operative combined modality therapy for resectable rectal cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:54">
                    <nciDocumentNumber>T94-0036</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>94-C-0162</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I trial of Cisplatin and escalating dose tumor necrosis factor administered via continuous Hyperthermic Peritoneal Perfusion</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:55">
                    <nciDocumentNumber>T94-0095</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>94-C-0207</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I trial of Gallium Nitrate in patients with Androgen-resistant Prostate Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:55">
                    <nciDocumentNumber>T94-0121</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MCC CCHR 9408-2B</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of weekly IV Lometrexol with continuous oral folic acid supplementation</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:55">
                    <nciDocumentNumber>IND 41,824</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>6966</localDocumentNumber>
                        <localDocumentNumber>93-C-0090</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I  trial of phenylbutyrate administered to adults with cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:55">
                    <nciDocumentNumber>SWOG-8609</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-8609</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Vm-26 (Teniposide) single drug treatment for extensive Small Cell Lung Cancer: Phase II</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:56">
                    <nciDocumentNumber>T89-0174</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>90-C-95</localDocumentNumber>
                        <localDocumentNumber>90-C-95</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of Intrathecal Mafosfamide</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:56">
                    <nciDocumentNumber>T86-0045</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>86-C-08</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial and Biochemical and Pharmacokinetic study of sequential Methotrexate and 5-Fluorouracil with Leucovorin in children with refractory solid tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:56">
                    <nciDocumentNumber>T97-0095</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>98-42</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of BRYOSTATIN-1 in Patients with METASTATIC or RECURRENT SQUAMOUS CELL CARCINOMA of the HEAD and NECK</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-12-1999 16:46:00">
                    <nciDocumentNumber>GOG-0174</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-174</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III Trial of Weekly Parenteral Methotrexate Versus "Pulsed" Dactinomycin as Primary Management for Low Risk Gestational Trophoblastic Neoplasia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-18-1999 08:59:38">
                    <nciDocumentNumber>CALGB-39802</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-39802</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Video-Assisted Lobectomy for Peripheral (&lt; 3 cm), NO, Non-Small Cell Lung Cancer:  A Phase II Feasibility Study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:17">
                    <nciDocumentNumber>T98-0091</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Study of G3139, A Bcl-2 Antisense Oligonucleotide, Combined with Paclitacel for the Treatment of Recurrent Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:17">
                    <nciDocumentNumber>S9911</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S9911</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A phase II pilot rial of Chop followed by Iodine-131-labledd Monoclonal Anti-B1 Antibody for treatment of newly diagnosed Follicular Non-Hodgkin's Lymphomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:17">
                    <nciDocumentNumber>NCCTG-97-81-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-97-81-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Alternating Cycles of Fludarabine and Cyclophosphamide in Previously Untreated Patients with B-Cell CLL</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-29-1999 00:00:00">
                    <nciDocumentNumber>T99-0002</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>99-012</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of Bryostatin in Metastatic Renal Cell Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:18">
                    <nciDocumentNumber>E1298</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E1298</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of Gemcitabine and Docetaxel in Pancreatic Adenocarcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:18">
                    <nciDocumentNumber>AMC-013</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>AMC-013</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Randomized Placebo Controlled and Double Blinded Study of IM862 for Patients with Muco-Cutaneous AIDS Associated Kaposi's Sarcoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:18">
                    <nciDocumentNumber>T95-0032</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>99-C-0018</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>PHASE I Study in patients with Metastatic and Renal Cancer using NG-Monomethyl-L-Arginine for Iinterleukin 2 Induced Hypotention</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="03-29-1999 18:06:18">
                    <nciDocumentNumber>T91-0248</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>IOU 9224</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A phase ii study of topotecan in non-hodgkin's lymphoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-29-1999 18:06:18">
                    <nciDocumentNumber>SWOG-9003</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-9003</localDocumentNumber>
                        <localDocumentNumber>S9003</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Fludarabine for Waldenstrom's Macroglobulinemia (WM):  a Phase II Pilot Study for Untreated and Previously Treated Patients</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="03-29-1999 18:06:18">
                    <nciDocumentNumber>T93-0034</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study Of Taxol And Sdz PSC 833 In Patients With Refractory Malignancies</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:18">
                    <nciDocumentNumber>T93-0123</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>94-C-0119</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Infusional Paclitaxel with the P-Glycoprotein Antagonist PSC 833</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>T94-0150</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>94-507</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II clinical trial of isotretinoin in patients with advanced, hormone naive prostate cancer following combined androgen suppressive therapy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>NABTT-9602</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>T96-0027</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/Ii Study Of CI-980 In Adults With Newly Diagnosed Malignant Glioma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>T97-0083</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I and Pharmacologic Study of UCN-01 (NSC 638850)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>NABTT-9712</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTT-9712</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial to Evaluate Repetitive Intravenous Doses of Gadolinium-Texaphyrin as a Radiosensitizer in Patients with Glioblastoma Multiforme</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>NCCTG-98-24-53</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-98-24-53</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Irinotecan (CPT-11) and Doxetaxel (Taxotere) in Previously Treated Patients with Recurrent Non-Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>T99-0047</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>99-09</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Trial of PS-341 in Advanced Cancers</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-29-1999 18:06:20">
                    <nciDocumentNumber>T90-0129</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>91-C-14</localDocumentNumber>
                        <localDocumentNumber>CPB-262</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase 2 Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:21">
                    <nciDocumentNumber>T92-0183</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>92106</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Trial of Cyclophosphamide and Vp-16, Plus Fractionated Total Body Irradiation or Bcnu, and Interleukin-2-Activated Bone Marrow for Refractory Hematologic Malignancies</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:21">
                    <nciDocumentNumber>T93-0198</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>94-04</localDocumentNumber>
                        <localDocumentNumber>E2894</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Multicenter, Randomized Phase III Trial Of Interferon Alpha 2a (Roferon) With Or Without 13-Cis Retinoic Acid (Accutane) In Patients With Advanced Renal Cell Carcinoma.</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:21">
                    <nciDocumentNumber>T94-0007</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>94-C-0118</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Recombinant Vaccinia Virus that Expresses Prostate Specific Antigen in Adult Patients with Adenocarcinoma of the Prostate</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:22">
                    <nciDocumentNumber>T94-0078</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ICC 2994</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Trial Of Sequential TOPOTECAN (NSC 609699) and Etoposide For Patients With Relapsed, Refractory, Or High Risk Acute Myeloid Or Lymphoid Leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:22">
                    <nciDocumentNumber>NABTT-9403</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>T94-0088</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study Of Suramin In The Treatment Of Recurrent Or Progressive Malignant Glioma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:22">
                    <nciDocumentNumber>T94-0143</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial And Pharmacokinetic Study Of The Sequential Administration Of Carmustine (BCNU) And Temozolomide In Patients With Advanced Refractory Solid Tumors Or Refractory Lymphoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:22">
                    <nciDocumentNumber>T94-0187</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UPCC 4695</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A phase ii trial of hyperthermic isolated limb perfusion with tumor necrosis factor and melphalan in patients with unresectable extremity sarcoma and melanoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T96-0026</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>95-C-0032</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Trial in Patients with Metastatic Melanoma of Immunization with a Recombinant Fowlpox Virus Encoding the Mart-1 Melanoma Antigen</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T95-0042</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>96-C-0064</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of Anti-Tac(Fv)-PE38 (LMB-2), a Recombinant Single-Chain Immunotoxin for Treatment of Tac-Expressing Malignancies</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T96-0072</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>10M-96-1</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial Of A Tyrosinase/Gp100/Mart-1 Peptide-Pulsed Dendritic Cell Vaccine For Patients With Metastatic Melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>NABTC-9701</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>T96-0082</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Temozolomide and BCNU for Anaplastic Gliomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T96-0099</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>8548</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Flavopiridol (NSC 649890) Administered as a 72-Hour Continuous Infusion Every 2 Weeks in Patients with Previously Treated Intermediate and High Grade Non-Hodgkin's Lymphoma Including Mantle Cell Lymphoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T96-0119</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase II evaluation of  PYRAZOLOACRIDINE (NSC #366140) in Patients with  Metastatic RENAL CELL CANCER.</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T97-0024</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CWRU 1597</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of 9-AMINOCAMPTOTHECIN (9-AC) COLLOIDAL Dispersion (CD) 120-Hour Continuous Intravenous Infusion In Advanced NON-SMALL CELL LUNG CANCER</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T97-0033</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>97-118</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Study of Sequential Vaccinations with ALVAC-CEA  and Vaccinia-CEA with the Addition of IL-2 and GM-CSF in Patients with CEA Expressing Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>NABTC-9703</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTC 9703</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Trial of Adenovirus-Mediated Wild Type p53 Gene Therapy for Malignant Gliomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T97-0074</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Bryostatin 1 Therapy Followed by VAD for Multiple Myeloma a Randomized Phase II Study</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>NABTC-9705</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTC-9705</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II  trial  of THYMIDINE and CARBOPLATIN  Chemotherapy For Recurrent MALIGNANT  GLIOMA</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:24">
                    <nciDocumentNumber>T98-0075</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UNMC 170-04</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I and Pharmacologic Study of 17-(Allylamino)-17-Demethoxygeldanamycin (AAG, NSC 330507) in Adult Patients with Solid Tumors</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 00:00:00">
                    <nciDocumentNumber>T99-0008</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Oxaliplatin in Combination with Paclitaxel in Non-Small Cell  Lung  Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:24">
                    <nciDocumentNumber>T99-0042</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial of Photodynamic Therapy with Lutetium Texaphyrin in Patients with Locally Recurrent Prostate Carcinoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="04-06-1999 15:32:27">
                    <nciDocumentNumber>EORTC-30904</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EORTC-30904</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Prospective Randomized Phase III Study Comparing Radical Surgery to Elective Kidney Sparing Surgery for Low Stage Renal Cell Carcinoma:  An Intergroup Study</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="05-25-1999 09:50:15">
                    <nciDocumentNumber>GOG-0126K</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-126K</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Evaluation of Oxaliplatin in Recurrent Platinum Resistant  nd Refractory Ovarian Cancer and Primary Peritoneal Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="06-16-1999 13:39:09">
                    <nciDocumentNumber>T99-0071</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MAYO 98-01-11</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I and Pharmacologic Study of the Proteasome Inhibitor PS-341 in Patients with Advanced Solid Tumors and B-Cell Lymphoproliferative Disorders</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="08-02-1999 15:04:01">
                    <nciDocumentNumber>NABTC-99-02</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTC-99-02</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Trial  of SU5416 in Patients with  Recurrent  High Grade  Astrocytomas  or Mixed Gliomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="08-27-1999 07:57:21">
                    <nciDocumentNumber>51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Biologic Markers of Angiogenesis: A Companion Study to Phase II Trials of SU5416 (NSC #696819) in Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="09-02-1999 11:22:05">
                    <nciDocumentNumber>T99-0112</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>9940</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of Fenretinide (NSC-374551; IND-40,294) in Patients with Relapsed Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="09-10-1999 11:49:13">
                    <nciDocumentNumber>S9924</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S9924</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of R115777 (NSC #702818) in Patients with Advanced Pancreas Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="10-14-1999 09:24:40">
                    <nciDocumentNumber>ADVL0017</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>A0972</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Flavopiridol in Patients with Relapsed or Refractory Pediatric Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="10-20-1999 09:53:24">
                    <nciDocumentNumber>AAML0122</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>P9920</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Window Evaluation of the Farnesyl Transferase Inhibitor (R115777) Followed by 13-CIS Retinoic Acid, Cytosine Arabinoside and Fludarabine Plus Hematopoietic Stem Cell Transplantation in Children with Juvenile Myelomonocytic Leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="10-20-1999 13:43:58">
                    <nciDocumentNumber>290</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CWRU 4Y99</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of BMS-214662 and Paclitaxel in Patients with Advanced Malignancies</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="10-20-1999 13:55:08">
                    <nciDocumentNumber>ADVL0012</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCG-09802</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of Concurrent Cereport (Labradimil) and Carboplatin with Radiation Therapy for Children with Newly-Diagnosed Brain Stem Gliomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-28-2000 11:26:33">
                    <nciDocumentNumber>CALGB-89901</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-89901</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Study of Preoperative Oxaliplatin (NSC #266046), 5-Fluorouracil, and External Beam Radiation Therapy in Locally Advanced Rectal Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="02-02-2000 14:52:47">
                    <nciDocumentNumber>ADVL0023</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCG-09715</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Docetaxel (Taxotere) (NSC# 628503) in Children with Refractory Leukemias: A Groupwide Phase II Study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="02-09-2000 10:02:05">
                    <nciDocumentNumber>CALGB-59804</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-59804</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Study of Gemcitabine (Gemzar)/Vinorelbine (Navelbine)/Liposomal Doxorubicin (Doxil) in Relapsed/Refractory Hodgkin's Disease</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="02-16-2000 13:54:55">
                    <nciDocumentNumber>S0008</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0008</localDocumentNumber>
                        <localDocumentNumber>S0008</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Trial of High Dose Interferon Alpha-2b Versus Cisplatin, Vinblastine, DTIC Plus IL-2 and Interferon in Patients with High Risk Melanoma</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-08-2000 14:46:53">
                    <nciDocumentNumber>1653</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>00-102</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial of KRN5500 (NSC 650426) Given as a 72 Hour Continuous IV Infusion Every 21 Days in Patients with Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-16-2000 08:57:20">
                    <nciDocumentNumber>P9934</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>P9934</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Systemic Chemotherapy, Second Look Surgery and Conformal Radiation Therapy Limited to the Posterior Fossa and Primary Site for Children >/= to 8 months and &lt;3 Years with Non-metastatic Medulloblastoma: A Children's Oncology Group Phase III Study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-2000 13:57:40">
                    <nciDocumentNumber>ADVL0022</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>A0999</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Gemcitabine (NSC # 613327) in Children with Relapsed Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-29-2000 16:40:36">
                    <nciDocumentNumber>ANBL0032</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ANBL0032</localDocumentNumber>
                        <localDocumentNumber>ANBL0032</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="06-12-2000 09:41:23">
                    <nciDocumentNumber>S0001</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0001</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Study of Radiation Therapy (RT) and 06-Benzylguanine (O6-BG) Plus BCNU Versus RT and BCNU Alone for Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="07-05-2000 11:27:50">
                    <nciDocumentNumber>PBTC-005</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PBTC-005</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Trial of Temozolomide and O6-Benzylguanine in Pediatric Patients with Recurrent Brain Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="08-09-2000 10:30:36">
                    <nciDocumentNumber>3410</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ID00-156</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Prospective Randomized Phase III Trial Comparing Consolidation Therapy with or without Strontium-89 Following Induction Chemotherapy in Adrogen-Independent Prostate Cancer</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="08-29-2000 12:59:11">
                    <nciDocumentNumber>2310</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>2310</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Pilot Phase II Research Study of EF5 to Measure Tumor Hypoxia in Patients with Non-Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="09-12-2000 11:11:42">
                    <nciDocumentNumber>ADVL0015</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ADVL0015</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of  PS-341 in Pediatric Patients with Refractory Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="10-12-2000 15:29:19">
                    <nciDocumentNumber>1870</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UCLA IRB # 00-11-009-02D</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Trial of STI571 (NSC #716051) and High-Dose Cytarabine in Myeloid Blast Crisis of Chronic Myeloid Leukemia</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="10-12-2000 17:41:28">
                    <nciDocumentNumber>4292</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UCLA IRB #00-11-010-02D</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Trial of STI571 (NSC #716051) and Chemotherapy in Lymphoid Blast Crisis of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoid Leukemia</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="11-15-2000 10:53:09">
                    <nciDocumentNumber>AMC-024</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>AMC-024</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I-II Trial of BMS-275291 in Patients with HIV Related Kaposi's Sarcoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-19-2000 12:26:12">
                    <nciDocumentNumber>3852</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC007C</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of Epothilone B Analog (BMS-247550) in Advanced Soft Tissue Sarcomas</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="01-09-2001 10:19:22">
                    <nciDocumentNumber>2710</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>11046A</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Double Blind, Placebo Controlled Randomized Phase II Trial of Gemcitabine and Cisplatin with or without the VEGF Inhibitor Bevacizumab (NSC# 704865) in Patients with Malignant Mesothelioma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="02-26-2001 15:17:24">
                    <nciDocumentNumber>5340</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CWRU 1Y01</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Pharmacokinetic Study of STI571 in Patients with Advanced Malignancies and Varying Degrees of Renal Dysfunction for the CTEP-Sponsored Organ Dysfunction Working Group</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-07-2001 10:50:43">
                    <nciDocumentNumber>S0027</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0027</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of Sequential Vinorelbine and Docetaxel in Advanced Non-Small Cell Lung Cancer Patients Age Seventy and Older, or with Performance Status 2</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-14-2001 15:04:57">
                    <nciDocumentNumber>RTOG-BR-0118</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-BR-0118</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Study of Conventional Radiation Therapy Plus Thalidomide (NSC#66847) Versus Conventional Radiation Therapy for Multiple Brain Metastases</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-15-2001 07:58:43">
                    <nciDocumentNumber>GOG-0231B</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-0231-B</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Evaluation of  Thalidomide (NSC #66847, IND 48832) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-28-2001 11:58:59">
                    <nciDocumentNumber>EORTC-30987</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EORTC-30987</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Phase III Study Comparing Paclitaxel/Cisplatin/Gemcitabine and Cisplatin/Gemcitabine in Patients with Metastatic or Locally Advanced Urothelial Cancer without Prior Systemic Therapy</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-05-2001 16:09:51">
                    <nciDocumentNumber>ACRIN-6661</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ACRIN-6661</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Study of Percutaneous Radiofrequency Ablation of Bone Metastases Using CT Guidance</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="05-30-2001 14:53:00">
                    <nciDocumentNumber>1614</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>12157B</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of PV701 in Patients with Head and Neck Squamous Cell Carcinoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="06-26-2001 13:40:00">
                    <nciDocumentNumber>5643</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>04-C-0079</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Pediatric Phase I Trial of BL22 for Refractory CD22-Positive Leukemias and Lymphomas</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="07-20-2001 10:45:15">
                    <nciDocumentNumber>NCIC-149</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCIC-149</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of OSI-774 (NSC 718781) Given in Combination with Carboplatin in Patients with Recurrent Epithelial Ovarian Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="08-10-2001 11:00:35">
                    <nciDocumentNumber>GOG-0227D</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-0227-D</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Evaluation of OSI-774 (NSC #718781, IND #63383) in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="08-15-2001 10:51:17">
                    <nciDocumentNumber>N0186</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>N0186</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of CCI-779 in Previously Treated Patients with Mantle Cell Non-Hodgkin's Lymphoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="08-15-2001 11:32:44">
                    <nciDocumentNumber>5439</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>IDD #01-35</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study to Determine the Safety, Tolerance and Preliminary Antineoplastic Activity of Combined  EGFR (erbB1) and HER-2 (erbB2) Blockade, with OSI-774 and Trastuzumab, in Combination with Weekly Paclitaxel</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-10-2001 14:03:31">
                    <nciDocumentNumber>1951</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Hu1D10 in Recurrent Hodgkin's Disease</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-22-2001 13:55:00">
                    <nciDocumentNumber>5669</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Gleevec (Imatinib Mesylate Formerly Known as STI-571) in Patients with Myelofibrosis</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="11-01-2001 11:08:10">
                    <nciDocumentNumber>5684</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-008</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of STI571 (Gleevec) in Combination with Cisplatin/Irinotecan in Patients with Extensive Stage Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-11-2001 12:47:00">
                    <nciDocumentNumber>GOG-0131G</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-0131G</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Evaluation of Docetaxel and Gemcitabine Plus G-CSF in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-18-2001 15:15:12">
                    <nciDocumentNumber>S0202</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0202</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Gemcitabine (NSC-613327) and Capecitabine (NSC-712807) in Patients with Unresectable or Metastatic Gallbladder or Cholangiocarcinoma</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-27-2001 09:56:30">
                    <nciDocumentNumber>5715</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NANT 2001-01</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Investigation of IL-12 (NSC 672423)/Pulse IL-2 (Aldesleukin) in Children with Persistent and/or Refractory Neuroblastoma (13623)</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-24-2002 11:07:18">
                    <nciDocumentNumber>CALGB-80101</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-80101</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-25-2002 08:43:44">
                    <nciDocumentNumber>5270</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>02-C--0205A</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion with or without Concurrent Celecoxib in Subjects with Pulmonary and Pleural Malignancies</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="02-27-2002 11:10:22">
                    <nciDocumentNumber>5851</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>0216</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Study of Suramin in Combination with Paclitaxel in Advanced (Stage IIIB or IV) Metastatic Breast Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-28-2002 10:49:23">
                    <nciDocumentNumber>5330</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>5330</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Evaluation of the Efficacy and Safety of R115777 (NSC 702818), a Non-Peptidomimetic Farnesyl Transferase Inhibitor, and Trastuzumab in Patients with Advanced Breast Cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-12-2012 10:41:39" createdDate="04-18-2002 14:48:51">
                    <nciDocumentNumber>5808</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ID02-148</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of G3139 (Bcl-2 Antisense) and Rituximab in Patients with Recurrent B-Cell Non-Hodgkin's Lymphomas</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-25-2002 08:50:12">
                    <nciDocumentNumber>5798</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL 011</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of G3139 in Combination with Doxorubicin in Advanced Hepatocellular Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="05-17-2002 13:38:19">
                    <nciDocumentNumber>GOG-9912</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-9912</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Whole Pelvic Radiation Therapy with Concomitant Cisplatin and Gemcitabine Chemotherapy in Patients with Cervical Carcinoma (Stages I-IV) Limited to the Pelvis</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="05-20-2002 14:42:19">
                    <nciDocumentNumber>5761</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>02-119</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of OSI-774 in Combination with Bevacizumab in Patients with Stage IV Breast Cancer</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="06-26-2002 14:40:05">
                    <nciDocumentNumber>5890</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-012</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of PS-341 in Patients with Metastatic Colorectal Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="07-01-2002 09:45:20">
                    <nciDocumentNumber>5826</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC0285</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II Study of G3139 (Genasense) in Patients with Waldenstrom's Macroglobulinemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-12-2002 16:45:10">
                    <nciDocumentNumber>CALGB-90104</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-90104</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III Study Comparing Sequential Chemotherapy (AG-TP) to Cisplatin and Gemcitabine (GC) as Adjuvant Treatment After Cystectomy for Transitional Cell Carcinoma of the Bladder</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="10-18-2002 14:27:46">
                    <nciDocumentNumber>5961</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC0287</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Depsipeptide, a Histone Deacetylase Inhibitor, in Relapsed or Refractory Mantle Cell or Diffuse Large Cell Non-Hodgkin's Lymphoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="11-25-2002 08:42:29">
                    <nciDocumentNumber>6167</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>2003-0288</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Gemcitabine and Celecoxib as First-Line Treatment for Patients with Advanced Metastatic Pancreatic Cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-16-2002 12:01:42">
                    <nciDocumentNumber>6093</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHII-46</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of GTI-2040 (NSC 722929) in Combination with Capecitabine in Metastatic Breast Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-23-2002 14:11:30">
                    <nciDocumentNumber>6104</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-017</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 1/2 Study of GTI-2040 Combined with Docetaxel in Metastatic or Unresectable Locally Advanced Non-Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="02-06-2003 09:07:38">
                    <nciDocumentNumber>6090</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>IDD#03-06</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Pharmacokinetics and Pharmacodynamic Study of GTI2040 in Combination with Gemcitabine in Patients with Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="04-10-2003 13:39:52">
                    <nciDocumentNumber>CALGB-100101</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-100101</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Intravenous Pentostatin for the Treatment of Patients with Refractory Chronic Graft-Versus-Host Disease</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-21-2003 14:00:53">
                    <nciDocumentNumber>N0147</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>N0147</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) After Curative Resection for Patients with Stage III Colon Cancer</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="05-14-2003 13:32:14">
                    <nciDocumentNumber>6003</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>03-101</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Multicenter, Open-Label, Two-Stage, Phase II Study of PS-341 (LDP-341, NSC #681239) in Patients with Unresectable or Metastatic Gastric Adenocarcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="06-10-2003 16:13:02">
                    <nciDocumentNumber>E8802</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E8802</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of Doxorubicin and Gemcitabine in Metastatic Renal Cell Carcinoma with Sarcomatoid Features</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="06-11-2003 10:51:03">
                    <nciDocumentNumber>6262</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>10M-03-1</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of an Intradermally Administered MART-1/gp 100/Tyrosinase Peptide-Pulsed Dendritic Cell Vaccine Matured with a Cytokine Cocktail for Patients with Metastatic Melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="07-15-2003 15:49:19">
                    <nciDocumentNumber>6285</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>12765A</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Triapine in Combination with Cisplatin in Esophageal Carcinoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="07-17-2003 08:33:34">
                    <nciDocumentNumber>GOG-0230C</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-0230C</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Evaluation of Gleevec(TM) (NCI-Supplied Agent: STI571 [Imatinib Mesylate], IND #61135, NSC# 716051) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-30-2003 10:14:20">
                    <nciDocumentNumber>6246</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>LS038B</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Evaluation of FTI (R115777) in Treatment of Relapsed and Refractory Lymphoma</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-30-2003 17:14:30">
                    <nciDocumentNumber>6407</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial of the Farnesyltransferase Inhibitor, R115777 (NSC #702818) and Radiotherapy in Patients with Locally Advanced Pancreatic Cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-07-2003 10:42:52">
                    <nciDocumentNumber>PBTC-014</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PBTC-014</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II Trial of R115777 and XRT in Pediatric Patients with Newly Diagnosed Non-Disseminated Intrinsic Diffuse Brainstem Gliomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="11-12-2003 08:29:37">
                    <nciDocumentNumber>1990</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CASE 1503</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of XL119 (Rebeccamycin Analogue) in Relapsed "Sensitive" Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="11-12-2003 10:52:44">
                    <nciDocumentNumber>NABTC-03-02</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTC-03-02</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of EMD 121974 for Recurrent Glioblastoma:  A Clinical Trial with Tissue Correlates of Response</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="11-25-2003 12:56:14">
                    <nciDocumentNumber>6351</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>6075-04-7R0</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Single Agent Depsipeptide (FK228) in Gastric and Esophageal Cancers</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-23-2003 14:21:57">
                    <nciDocumentNumber>6432</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>C-2802</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Pharmacokinetic Study of PS-341 in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction for the CTEP-Sponsored Organ Dysfunction Working Group</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="02-23-2004 15:18:18">
                    <nciDocumentNumber>6576</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHII-50</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase II Study of BAY 43-9006 in Combination with Gemcitabine in Metastatic Pancreatic Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="02-23-2004 16:02:18">
                    <nciDocumentNumber>6565</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-025</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of BAY 43-9006 in Combination with Gemcitabine in Recurrent Epithelial Ovarian Cancer</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="02-25-2004 13:21:45">
                    <nciDocumentNumber>6557</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CASE 2804</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of BAY 43-9006, a Novel Raf Kinase Inhibitor, Plus Paclitaxel/Carboplatin in Women with Recurrent Platinum Sensitive Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-24-2004 10:10:19">
                    <nciDocumentNumber>S0420</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0420</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Evaluation of BAY 43-9006 (NSC-724772) in Patients with Recurrent or Metastatic Head and Neck Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-22-2004 11:16:17">
                    <nciDocumentNumber>E4A03</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E4A03</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III Study of CC-5013 Plus Dexamethasone Versus CC-5013 Plus Low Dose Dexamethasone in Multiple Myeloma with Thalidomide Plus Dexamethasone Salvage Therapy for Non-Responders</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-28-2004 11:42:04">
                    <nciDocumentNumber>6785</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>C-2818</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I, Open-Label, Dose-Escalation Study of SB-715992 Administered Days 1-3 of a 21-Day Cycle in Patients with Solid Tumors</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="07-27-2004 10:58:55">
                    <nciDocumentNumber>6972</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>C-2890</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Dose-Escalation Study of Intravenous 17-allylaminogeldanamycin (17-AAG) [NSC 330507, IND# 57,966] and Oral BAY 43-9006 [NSC 724772, IND #69,896] Administered in Patients with Pretreated Advanced Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-13-2004 10:31:09">
                    <nciDocumentNumber>6584</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>2004-251</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Trial of BAY 43-9006 (Sorafenib) in Combination with Anastrozole in Patients with Metastatic Breast Cancer</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-27-2004 13:49:39">
                    <nciDocumentNumber>7028</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>13780A</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of BAY 43-9006 for Patients with Imatinib and Sunitinib Resistant Gastrointestinal Stromal Tumor</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="11-29-2004 10:03:17">
                    <nciDocumentNumber>7062</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-036</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of BAY 43-9006 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter and Renal Pelvis)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-07-2004 14:18:39">
                    <nciDocumentNumber>E2104</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E2104</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Feasibility Trial Incorporating Bevacizumab into Dose Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Patients with Lymph Node Positive Breast Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-21-2004 09:30:23">
                    <nciDocumentNumber>7129</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-037</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of AZD2171 in Recurrent or Persistent Ovarian, Peritoneal, or Fallopian Tube Cancer</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-27-2004 12:56:00">
                    <nciDocumentNumber>ADVL0413</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ADVL0413</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Study of the RAF Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772 IND# 69896) in Children with Refractory Solid Tumors or Refractory Leukemias</documentTitle>
                    <currentStatus>Temporarily Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-13-2005 13:25:08">
                    <nciDocumentNumber>ADVL0416</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ADVL0416</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of SAHA (NSC# 701852 IND# 71976) in Pediatric Patients with Recurrent or Refractory Solid Tumors (Including Lymphomas) and Leukemia Followed by a Phase I Study of SAHA in Combination with 13-Cis-Retinoic Acid for Patients with Selected Recurrent/Refractory Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-19-2005 13:58:32">
                    <nciDocumentNumber>7216</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC047C</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of PS-341 in Combination with Paclitaxel and Carboplatin for the Treatment of Metastatic Melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="02-09-2005 10:21:48">
                    <nciDocumentNumber>7317</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>YALE HIC#27409</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 1 Study of 5-Azacitidine in Combination with Interferon-Alfa 2B in Unresectable or Metastatic Melanoma and Renal Cell Carcinoma</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-16-2005 16:25:33">
                    <nciDocumentNumber>6813</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>04-04</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Pharmacokinetic and Pharmacodynamic Study of Temsirolimus (CCI-779) in Patients with Advanced Malignancies and Normal and Impaired Liver Function: An NCI Organ Dysfunction Working Group Study</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-24-2005 09:09:50">
                    <nciDocumentNumber>7071</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>14194B</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of BAY 43-9006 in Relapsed Chronic Lymphocytic Leukemia</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-24-2005 13:12:29">
                    <nciDocumentNumber>7178</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-042</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of BAY 43-9006 (Sorafenib) in Combination with OSI-774 (Erlotinib; TarcevaTM ) in Advanced Solid Tumors</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-05-2005 16:33:13">
                    <nciDocumentNumber>7255</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHII 67</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of PXD101 (NSC 726630) as Second-Line Therapy for Treatment of Patients with Malignant Pleural Mesothelioma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-14-2005 10:08:41">
                    <nciDocumentNumber>7190</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MEL 47</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of CCI-779 in Combination with Bevacizumab in Stage III or IV Melanoma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="04-19-2005 15:05:00">
                    <nciDocumentNumber>7309</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>06-264</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Clinical Trial of AZD2171 Monotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Patients</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-06-2005 10:19:15">
                    <nciDocumentNumber>7024</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC044G</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Bevacizumab and Erlotinib in Patients with Advanced Biliary Tumors</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-17-2005 11:16:15">
                    <nciDocumentNumber>AAML0523</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>AAML0523</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Study of CLOLAR (Clofarabine, IND# 73,789) in Combination with Cytarabine in Pediatric Patients with Refractory/Relapsed Leukemia</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-19-2005 15:45:16">
                    <nciDocumentNumber>E1905</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E1905</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase II Trial of Azacitidine with or without the Histone Deacetylase Inhibitor Entinostat for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (Dysplastic Type), and Acute Myeloid Leukemia with Multilineage Dysplasia</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="10-21-2005 09:12:34">
                    <nciDocumentNumber>7341</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>2005-0839</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Gemcitabine, Paclitaxel, and Doxorubicin, with Pegfilgrastim for the Treatment of Patients with Metastatic Transitional Cell Carcinoma and Renal Insufficiency</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="11-22-2005 15:56:24">
                    <nciDocumentNumber>E1505</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E1505</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (>/= 4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC)</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="12-14-2005 11:24:17">
                    <nciDocumentNumber>7522</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHII-77</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study Evaluating the Efficacy of VEGF Trap in Patients with Recurrent Inoperable Stage III or Stage IV Melanoma</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="01-10-2006 14:13:00">
                    <nciDocumentNumber>7583</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHII-79</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of AZD0530 in Hormone Refractory Prostate Cancer (HRPC)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-18-2006 13:21:49">
                    <nciDocumentNumber>7703</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>06-05-291</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II Study of a Combination of Suberoylanilide Hydroxyamic Acid (Vorinostat) Plus Paclitaxel and Bevacizumab in Patients with Advanced Metastatic and/or Local Chest Wall Recurrent Breast Cancer</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="01-24-2006 11:53:24">
                    <nciDocumentNumber>7567</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>07-112</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of AZD0530 in Hormone Receptor-Negative, Metastatic or Unresectable, Locally Advanced Breast Cancer</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="01-27-2006 15:47:02">
                    <nciDocumentNumber>7521</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>0608008688</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of VEGF Trap (NSC 724770) in Relapsed and Progressive Multiple Myeloma (MedDRA10028228)</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="02-28-2006 14:02:02">
                    <nciDocumentNumber>7623</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCC-06-01</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of GW786034 (Pazopanib) in Asian Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="03-13-2006 14:59:56">
                    <nciDocumentNumber>7638</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-057</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of GW786034 (Pazopanib) in Patients with Recurrent and/or Metastatic Invasive Breast Carcinoma</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="03-29-2006 09:09:47">
                    <nciDocumentNumber>7659</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>14954A</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized, Phase II Study of GW786034 (Pazopanib) in Stage D0 Relapsed Androgen Sensitive Prostate Cancer Following Limited GnRH Agonist Therapy</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="04-05-2006 09:10:22">
                    <nciDocumentNumber>NABTC-06-02</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTC-06-02</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of GW786034 (Pazopanib) in Subjects with Recurrent Glioblastoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="04-10-2006 14:33:52">
                    <nciDocumentNumber>NCIC-PR.11</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCIC-PR.11</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Study of Active Surveillance Therapy Against Radical Treatment in Patients Diagnosed with Favourable Risk Prostate Cancer (START)</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-11-2006 10:24:59">
                    <nciDocumentNumber>NCIC-185</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCIC-185</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Sunitinib (SU11248; NSC 736511; IND 74019) in Patients with Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-12-2006 10:09:15">
                    <nciDocumentNumber>7358</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>07-C-0058D</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Sorafenib and Bevacizumab in Epithelial Ovarian, Fallopian, and Peritoneal Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="06-09-2006 11:15:21">
                    <nciDocumentNumber>E1305</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E1305</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="07-12-2006 14:06:01">
                    <nciDocumentNumber>7848</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC0672</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Intravenous Administration of Reovirus Serotype 3 - Dearing Strain (Reolysin) in Patients with Metastatic Melanoma</documentTitle>
                    <currentStatus>Temporarily Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="07-18-2006 12:01:05">
                    <nciDocumentNumber>7828</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CASE 5206</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Dasatinib (BMS-354825) in Patients with Metastatic Adenocarcinoma of the Pancreas</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="10-25-2006 13:45:22">
                    <nciDocumentNumber>E1A06</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E1A06</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>An Intergroup Phase III Randomized Controlled Trial Comparing Melphalan, Prednisone and Thalidomide (MPT) Versus Melphalan, Prednisone and Lenalidomide (Revlimid(TM))(MPR) in Newly Diagnosed Multiple Myeloma Patients who are not Candidates for High-Dose Therapy</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="11-16-2006 10:31:52">
                    <nciDocumentNumber>7080</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>3405</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II Multicenter Clinical Trial of O6Benzylguanine and Topical Carmustine in the Treatment of Refractory Early-Stage (IA-IIA) Cutaneous T-Cell Lymphoma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-19-2006 09:46:44">
                    <nciDocumentNumber>NCIC-MA.27 (NON-COMPANION)</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCIC-MA.27 (NON-COMPANION)</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III Trial of Exemestane versus Anastrozole in Postmenopausal Women with Receptor Positive Primary Breast Cancer</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="02-08-2007 09:21:18">
                    <nciDocumentNumber>8062</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CO 07901</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 1 Study of R-(-)-Gossypol (AT-101) in Combination with Cisplatin and Etoposide in Patients with Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="05-17-2007 11:29:08">
                    <nciDocumentNumber>7458</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>08-C-0007</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents, and Young Adults with Treatment Refractory Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="06-08-2007 12:48:45">
                    <nciDocumentNumber>S0777</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0777</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III Trial of CC-5013 (Lenalidomide, NSC-703813) and Low Dose Dexamethasone (LLD) Versus Bortezomib (PS-341, NSC-681239), Lenalidomide and Low Dose Dexamethasone (BLLD) for Induction, in Patients with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="09-06-2007 11:49:00">
                    <nciDocumentNumber>CALGB-10404</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-10404</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Genetic Risk-Stratified, Randomized Phase II Study of Four Fludarabine / Antibody Combinations for Patients with Symptomatic, Previously Untreated Chronic Lymphocytic Leukemia</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="10-03-2007 12:31:30">
                    <nciDocumentNumber>8174</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Multicenter Phase II Study of Belinostat (PXD101) in Previously Chemotherapy Treated Thymoma and Thymic Carcinoma</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="11-29-2007 13:55:45">
                    <nciDocumentNumber>8210</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>P07188</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 1, Single Center, Dose-Escalation Study of SS1(dsFv)PE38 Administered Concurrently with Pemetrexed and Cisplatin in Subjects with Unresectable Malignant Epithelial Pleural Mesothelioma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="01-18-2008 08:47:04">
                    <nciDocumentNumber>GOG-0240</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-0240</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III Trial of Cisplatin Plus Paclitaxel with and without NCI-Supplied Bevacizumab (NSC #704865, IND #7921) Versus the Non-Platinum Doublet, Topotecan Plus Paclitaxel, with and without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-12-2012 10:36:33" createdDate="04-23-2008 11:00:57">
                    <nciDocumentNumber>8054</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>09-C-0019F</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Dasatinib in Combination with Bevacizumab in Advanced Solid Tumors</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="05-20-2008 09:48:02">
                    <nciDocumentNumber>8237</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>J0856</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Phase II Study Comparing Two Administration Schedules of Flavopiridol (Alvocidib, NSC 649890, IND 46,211) Given in Timed Sequential Combination with Cytosine Arabinoside (ara-C) and Mitoxantrone for Adults with Newly Diagnosed, Previously Untreated, Poor-Risk Acute Myelogenous Leukemias (AML)</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="09-08-2008 15:54:36">
                    <nciDocumentNumber>8275</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>09-C-0048</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of ABT-888 in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="11-26-2008 10:13:48">
                    <nciDocumentNumber>8217</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>09C0195</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="12-30-2008 13:24:46">
                    <nciDocumentNumber>S0819</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0819</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="02-05-2009 15:44:04">
                    <nciDocumentNumber>E1208</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E1208</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Randomized, Double-Blind Trial of Chemoembolization with or without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients with and without Vascular Invasion</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:53:40" createdDate="02-18-2009 07:21:49">
                    <nciDocumentNumber>BMT-CTN 0701</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>BMT-CTN 0701</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients with Relapsed Follicular Non-Hodgkin's Lymphoma Beyond First Complete Response</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="03-06-2009 10:59:26">
                    <nciDocumentNumber>GOG-0261</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-0261</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients with Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus or Ovary</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="03-24-2009 11:20:15">
                    <nciDocumentNumber>8324</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of ABT-888 in Combination with Gemcitabine in Patients with Advanced Malignancies</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="04-21-2009 15:06:39">
                    <nciDocumentNumber>S0806</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0806</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Trial of Vorinostat (SAHA) (NSC-701852) in Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL)</documentTitle>
                    <currentStatus>Approved</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="05-07-2009 14:38:39">
                    <nciDocumentNumber>CALGB-30801</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB 30801</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="07-15-2009 09:23:46">
                    <nciDocumentNumber>ABTC-0904</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ABTC-0904</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Biomarker and Phase II Study of GDC-0449 in Patients with Recurrent Glioblastoma Multiforme</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="07-22-2009 12:23:34">
                    <nciDocumentNumber>8384</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>2009-0473</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase Ib/II Study of Preoperative GDC-0449 and Androgen Ablation Compared to Androgen Ablation Alone Followed by Radical Prostatectomy for Select Patients with Locally Advanced Adenocarcinoma of the Prostate</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-12-2012 10:41:39" createdDate="08-25-2009 10:22:50">
                    <nciDocumentNumber>8543</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>2009-0582</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Two Phase I Studies, Followed by a Randomized Phase 2 Study of RO4929097 Combined with CNS Radiotherapy in Patients with Brain Metastases from Breast Cancer Whose Tumors are Estrogen Receptor Negative</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="10-08-2009 08:42:12">
                    <nciDocumentNumber>S0916</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0916</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II, Window Trial of the Anti-CCR2 Antibody MLN1202 (NSC-751448) in Patients with Bone Metastases</documentTitle>
                    <currentStatus>Temporarily Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="11-12-2009 10:39:26">
                    <nciDocumentNumber>8475</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of ABT-888, PARP Inhibitor, and Pegylated Liposomal Doxorubicin (PLD) in Recurrent Gynecologic Cancer and Breast Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="11-18-2009 08:50:59">
                    <nciDocumentNumber>8264</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHII-96</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Phase II Trial of ABT-888 vs. ABT-888 in Combination with Carboplatin in Patients with Stage IV BRCA-associated Breast Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="12-11-2009 11:50:42">
                    <nciDocumentNumber>8444</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor with Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 with Erlotinib in Mutant KRAS Advanced NSCLC.</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="01-25-2010 08:53:34">
                    <nciDocumentNumber>8635</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-079</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of RO4929097 (IND 109291) in Advanced Platinum Resistant Ovarian Cancer</documentTitle>
                    <currentStatus>Temporarily Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="03-18-2010 12:00:56">
                    <nciDocumentNumber>NCIC CTG OV.21</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCIC CTG OV.21</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II/III Study of Intraperitoneal (IP) Plus Intravenous (IV) Chemotherapy Versus IV Carboplatin Plus Paclitaxel in Patients with Epithelial Ovarian Cancer Optimally Debulked at Surgery Following Neoadjuvant Intravenous Chemotherapy</documentTitle>
                    <currentStatus>Approved</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="03-29-2010 12:49:32">
                    <nciDocumentNumber>NCCTG-N08CB</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>N08CB</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium in Two Different Versions to Prevent Oxaliplatin-Induced Sensory Neurotoxicity</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="04-15-2010 08:11:40">
                    <nciDocumentNumber>8752</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHII-105</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of MK-2206 in Patients with Advanced Hepatocellular Carcinoma Who have Failed or are Intolerant of One Prior Line of Anti-Angiogenic Therapy</documentTitle>
                    <currentStatus>Approved</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:45">
                    <nciDocumentNumber>CCG-0903</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCG-0903</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of Taxol in refractory leukemia in children</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:45">
                    <nciDocumentNumber>RTOG-76-14</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-76-14</localDocumentNumber>
                        <localDocumentNumber>EST-4876</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase iii study of pelvic and abdominal radiotherapy and chemotherapy with l-pam for stage ii carcinoma of the ovary</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:45">
                    <nciDocumentNumber>S9628</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S9628</localDocumentNumber>
                        <localDocumentNumber>S9628</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Dexamethasone/Alpha-Interferon in AL  Amyloidosis</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:46">
                    <nciDocumentNumber>S9704</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S9704</localDocumentNumber>
                        <localDocumentNumber>S9704</localDocumentNumber>
                        <localDocumentNumber>S9704</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III Trial Comparing Early High Dose Chemoradiotherapy and an Autologous Stem Cell Transplant to Conventional Dose CHOP Chemotherapy Plus Rituximab for CD20 + B Cell Lymphomas (with Possible Late Autologous Stem Cell Transplant) for Patients with Diffuse Aggressive Non-Hodgkin's Lymphoma in the High-Intermediate and High Risk International Classification Prognostic Groups</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:46">
                    <nciDocumentNumber>E2196</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E2196</localDocumentNumber>
                        <localDocumentNumber>E2196</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A randomized Phase III trial of Marimastat versus placebo in patients with Metastatic Breast Cancer who have responding or stable disease after induction chemotherapy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:46">
                    <nciDocumentNumber>T92-0215</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DM 92-123</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study to Evaluate the Efficacy and Toxicity of RP56976 (Taxotere) Administered Intraveneously as a Single Infusion Every 21 Days to Women with Advanced or Recurrent Squamous Cell Cancer of the Cervix</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:46">
                    <nciDocumentNumber>T94-0087</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTC 9402</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of phenylacetic acid for recurrent malignant glioma and primitive neuroectodermal tumors: a clinical and pharmacokinetics study of the north0american brain tumor consortim</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:47">
                    <nciDocumentNumber>CALGB-9687</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-9687</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>The Role of Salvage Prostatectomy for Radiation Failure in Prostate Carcinoma:  A Phase II trial</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:47">
                    <nciDocumentNumber>NCCTG-90-70-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-90-70-51</localDocumentNumber>
                        <localDocumentNumber>90-70-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III study of Cisplatin, BCNU, DTIC +/- Tamoxifen in advanced malignant melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:50:48">
                    <nciDocumentNumber>SWOG-9430</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-9430</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Complete Surgical Resection for Stage IV Melanoma - Surgical Resection with Biological Evaluation and Clinical Follow-Up</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:48">
                    <nciDocumentNumber>CALGB-9481</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-9481</localDocumentNumber>
                        <localDocumentNumber>C9481</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>PHASE III STUDY OF HEPATIC ARTERY FLOXURIDINE (FDUR), LEUCOVORIN (LV), AND DEXAMETHASONE (DEX) VERSUS SYSTEMIC 5-FLURORURACIL (5-FU) AND LEUCOVORIN (LV) AS TREATMENT FOR HEPATIC METASTASES FROM COLORECTAL CANCER</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:48">
                    <nciDocumentNumber>POG-9530</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9530</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of chemotherapy/ XRT for primary malignant Germ Cel l Tumors of the Central Nervous System</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:48">
                    <nciDocumentNumber>POG-9425</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9425</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Advanced Stage Hodgkins Disease - A Pediatric Oncology Group Phase III Study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:48">
                    <nciDocumentNumber>SWOG-9133</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-9133</localDocumentNumber>
                        <localDocumentNumber>CALGB-9391</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized trial of subtotal NODAL IRRADIATION versus DOXORUBICIN plus VINBLASTINE and subtotal NODAL IRRADIATION for STAGE I-IIA HODGKIN'S DISEASE, PHASE III</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:49">
                    <nciDocumentNumber>INT-0097</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9049</localDocumentNumber>
                        <localDocumentNumber>CCG-8882</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A study of high-risk malignant germ cell tumors in children a Phase III study</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:49">
                    <nciDocumentNumber>POG-9330</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9330</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of Taxol in progessive or recurrent childhood BrainTumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:49">
                    <nciDocumentNumber>CALGB-9270</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-9270</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Colorectal adenoma chemoprevention trial using aspirin:  a Phase III study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:50:49">
                    <nciDocumentNumber>NCCTG-89-70-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-89-70-51</localDocumentNumber>
                        <localDocumentNumber>89-70-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized, Phase III Surgical Adjuvant Clinical Trial of Megestrol Acetate (Megace) in Selected Patients with Malignant Melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:49">
                    <nciDocumentNumber>NCCTG-87-50-01</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-87-50-01</localDocumentNumber>
                        <localDocumentNumber>87-50-01</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III: A randomized prospective assessment of recombinant Leukocyte a human Interferon with or without aspirin in advanced Renal Adenocarcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>E2394</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E2394</localDocumentNumber>
                        <localDocumentNumber>E2394</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III study comparing three cycles of infusional bcnu/cisplatin followed by radiation therapy with radiation therapy and concurrent bcnu for patients with newly diagnosed supratentorial glioblastoma multiforme</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>INT-0149</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-94-02</localDocumentNumber>
                        <localDocumentNumber>R9402</localDocumentNumber>
                        <localDocumentNumber>PENDING</localDocumentNumber>
                        <localDocumentNumber>92-72-52</localDocumentNumber>
                        <localDocumentNumber>NCIC CTG CE.2</localDocumentNumber>
                        <localDocumentNumber>SWOG-9402</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III intergroup randomized comparison of radiation alone vs pre-radiation chemotherapy for pure and mixed anaplastic oligodendrogliomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>INT-0148</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-9344</localDocumentNumber>
                        <localDocumentNumber>C9344</localDocumentNumber>
                        <localDocumentNumber>94-30-51</localDocumentNumber>
                        <localDocumentNumber>SWOG-9410</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Doxorubicin dose escalation, with or without Taxol, as part of the ca adjuvant chemotherapy regimen for node positive Breast cancer: a Phase III intergroup trial</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>RTOG-95-01</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-95-01</localDocumentNumber>
                        <localDocumentNumber>R9501</localDocumentNumber>
                        <localDocumentNumber>S9515</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III intergroup trial of surgery followed by (1) radiotherapy vs. (2) radiochemotherapy for resectable high risk Squamous Cell Carcinoma of the Head and Neck</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:50">
                    <nciDocumentNumber>INT-0075</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-8692</localDocumentNumber>
                        <localDocumentNumber>EST-8186</localDocumentNumber>
                        <localDocumentNumber>NCCTG-87-32-01</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Therapy in Premenopausal Women with Advanced, ER Positive or PGR Positive Breast Cancer: Surgical Oophorectomy vs. the LH-RH Analog, Zoladex: Phase III Intergroup</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:52">
                    <nciDocumentNumber>E1194</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E1194</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of Paclitaxel and Cisplatin in patients with advanced Breast cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:52">
                    <nciDocumentNumber>CCG-09709</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCG-09709</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Fenretinide (NSC #374551) in Children with High Risk Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:53">
                    <nciDocumentNumber>POG-9234</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9133/34</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Randomized Trial of Standard vs. Dose-Intensified Chemotherapy for Children &lt;3 Years of Age with a CNS Malignancy Treated with or without Radiation Therapy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:53">
                    <nciDocumentNumber>E4897</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E4897</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Trial of Methotrexate, Vinblastine, Doxorubicin and Cisplatin vs. Carboplatin and Paclitaxel in Advanced Carcinoma of the Urothelium</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:53">
                    <nciDocumentNumber>E1392</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E1392</localDocumentNumber>
                        <localDocumentNumber>SWOG-9059</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III comparison of standard Radiotherapy, vs. Radiotherapy + simultaneous Cisplatin vs. split-course Radiotherapy and simultaneous Cisplatin and 5-FU, in patients with unresectable squamous cell carcinoma of the Head and Neck.</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:53">
                    <nciDocumentNumber>E2491</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-2491</localDocumentNumber>
                        <localDocumentNumber>CALGB-9191</localDocumentNumber>
                        <localDocumentNumber>CCSG-2911</localDocumentNumber>
                        <localDocumentNumber>AL.2</localDocumentNumber>
                        <localDocumentNumber>POG-9220</localDocumentNumber>
                        <localDocumentNumber>SWOG-9129</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III randomized study of all-trans Retinoic Acid versus Cytosine Arabinoside and Daunorubicin as induction therapy for patients with previously untreated acute promyelocytic Leukemia, an intergroup trial</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:54">
                    <nciDocumentNumber>INT-0087</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-8791</localDocumentNumber>
                        <localDocumentNumber>CALGB-8895</localDocumentNumber>
                        <localDocumentNumber>EST-1788</localDocumentNumber>
                        <localDocumentNumber>RTOG-</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Adjuvant trial of soft tissue sarcomas: Phase III</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:56">
                    <nciDocumentNumber>NCCTG-91-62-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-91-62-51</localDocumentNumber>
                        <localDocumentNumber>91-62-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of Neoadjuvant MVAC + radical surgery + postoperative irradiation in locally advanced cervical cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:57">
                    <nciDocumentNumber>SWOG-9107</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-9107</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II pilot study of high-dose 24-hour continuous infusion of 5-fu and leucovorin and low-dose pala for patients with colorectal cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:57">
                    <nciDocumentNumber>S9717</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S9717</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Evaluation of Intravenously Administered Tirapazamine plus Cisplatin in Cervical Cancer,  Phase II</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:57">
                    <nciDocumentNumber>GOG-9804</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-9804</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Extended Field Radiation Therapy with Concomitant Paclitaxel and Cisplatin Chemotherapy in Patients with Cervical Carcinoma Metastatic to the Para-Aortic Lymph Nodes</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:57">
                    <nciDocumentNumber>CALGB-39801</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-39801</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Concurrent Carboplatin, Paclitaxel, and Radiation Therapy Versus Induction Carboplatin and Paclitaxel Followed by Concurrent Carboplatin, Paclitaxel and Radiation Therapy for Patients with Unresectable Stage III Non-Small Cell Lung Cancer: A Phase III Trial</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:57">
                    <nciDocumentNumber>GOG-0114</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-114</localDocumentNumber>
                        <localDocumentNumber>G0114</localDocumentNumber>
                        <localDocumentNumber>SWOG-9227</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III randomized study of intravenous CDDP and CPM vs. intravenous CDDP and Taxol vs. high dose intravenous CBDCA followed by intravenous Taxol and intraperitineal CDDP in patients with optimal stage III Epithelial Ovarian Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:58">
                    <nciDocumentNumber>GOG-0167</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-0167</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Two-part Study of the Treatment of Atypical Endometrial Hyperplasia.  Part A:  A Prospective Study of Immediate Hysterectomy; Part B: A Randomized Phase II Study of Medroxyprogesterone Acetate versus Deproprovera</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:50:59">
                    <nciDocumentNumber>GOG-0076U</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-76U</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of Topotecan in patients with Advanced Squamous Cell Carcinoma of the Cervix</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:50:59">
                    <nciDocumentNumber>G0134</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-134</localDocumentNumber>
                        <localDocumentNumber>G0134</localDocumentNumber>
                        <localDocumentNumber>92-61-51</localDocumentNumber>
                        <localDocumentNumber>9238</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III trial of Taxol at two dose levels and G-CSF at two dose levels in Platinum-Resistant Ovarian Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:50:59">
                    <nciDocumentNumber>T92-0207</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DM-92-109</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II randomized evaluation of cis-retinoic acid (isotretinoin) and recombinant interferon beta in patients with recurrent primary malignant brain tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:00">
                    <nciDocumentNumber>RTOG-98-02</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-98-02</localDocumentNumber>
                        <localDocumentNumber>RTOG-98-02</localDocumentNumber>
                        <localDocumentNumber>RTOG-98-02</localDocumentNumber>
                        <localDocumentNumber>RTOG-98-02</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase III Study of Radiation with or without PCV Chemotherapy in Unfavorable Low-Grade Glioma</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:01">
                    <nciDocumentNumber>T98-0019</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>D-1644</localDocumentNumber>
                        <localDocumentNumber>D-1644</localDocumentNumber>
                        <localDocumentNumber>D-1644</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Evaluation of Dolastatin-10 in Patients with Hormone Refractory Prostate Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:01">
                    <nciDocumentNumber>T89-0173</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>90-C-48</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I trial of poly iclc in combination with interferon-alpha</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:02">
                    <nciDocumentNumber>T84-0523</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>85-C-6</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of spirohydantoin mustard in pediatric malignancies</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:02">
                    <nciDocumentNumber>POG-8532</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-8532</localDocumentNumber>
                        <localDocumentNumber>RTOG-8532</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Treatment of intracranial Ependymomas-A Phase III study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:02">
                    <nciDocumentNumber>W83-0089</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>823-05-005</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II and pharmacokinetic study of hepatic artery infusion of bisantrene and mitoxantrone</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:02">
                    <nciDocumentNumber>POA-27183</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POA-27183</localDocumentNumber>
                        <localDocumentNumber>BGSM-27183</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>The treatment of Chronic Lymphocytic Leukemia with Levamisole and Lithium - A Phase II study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:03">
                    <nciDocumentNumber>N81-0507</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>81-C-116</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I and II trial of oral Aclacinomycin</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:03">
                    <nciDocumentNumber>N83-0518</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>83-C-127</localDocumentNumber>
                        <localDocumentNumber>T83-1187</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II single agent chemotherapy with CBDCA for metastatic breast Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:03">
                    <nciDocumentNumber>W81-0118</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>80-46-06</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Bisantrene straight Phase II advanced colorectal carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:04">
                    <nciDocumentNumber>T83-1339</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CO-8091</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II evaluation in man of human leukocyte interferon given by intramuscular injection and intraarterial tumor infusion</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:04">
                    <nciDocumentNumber>NCCTG-87-42-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-87-42-51</localDocumentNumber>
                        <localDocumentNumber>87-42-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of combined Doxorubicin and Alpha Interferon in the therapy of Advanced Hepatocellular Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:04">
                    <nciDocumentNumber>NCCTG-85-55-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-85-55-51</localDocumentNumber>
                        <localDocumentNumber>85-55-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of Menogaril (NSC 269148) in transitional carcinoma of the Urothelium after failure of frontline chemotherapy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:04">
                    <nciDocumentNumber>T89-0045</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>89-C-105</localDocumentNumber>
                        <localDocumentNumber>MB-241</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of ara-azacytidine(nsc 281272)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:05">
                    <nciDocumentNumber>SWOG-8824</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-8824</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of continuous infusion recombinant interleukin-2 (ril-2) in patients with advanced renal cell carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:05">
                    <nciDocumentNumber>T87-0091</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of echinomycin in advanced colorectal cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:05">
                    <nciDocumentNumber>T87-0094</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NYU-87-10</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of menogaril (nsc 269148) in aids related kaposi's sarcoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:06">
                    <nciDocumentNumber>T86-0163</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>86-06-169</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of Taxol (nsc 125973) in renal cell carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:06">
                    <nciDocumentNumber>T83-1078</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ICC-82X1</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of azq and abmt for refractory malignant diseases</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:06">
                    <nciDocumentNumber>T83-0965</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>82-C-150</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II study of 2-dcf in cutaneous t-cell lymphoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:07">
                    <nciDocumentNumber>SEG-MEL-P02</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-MEL-P02</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I pilot study of dtic (high dose), cyclophosphamide, and c parvum in melanoma patients</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="12-17-1998 16:51:07">
                    <nciDocumentNumber>EST-4587</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-4587</localDocumentNumber>
                        <localDocumentNumber>RTOG-8533</localDocumentNumber>
                        <localDocumentNumber>SEG-LUN-82-260</localDocumentNumber>
                        <localDocumentNumber>SWOG-8490</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of PAC (Cis-Platinum, Adriamycin, and Cyclophosphamide) in treatment of invasive Thymoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:08">
                    <nciDocumentNumber>T86-0017</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>85-C-201</localDocumentNumber>
                        <localDocumentNumber>WRAMC-8504</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I and pharmacokinetic study of flavone acetic acid</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:09">
                    <nciDocumentNumber>C78-0122</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>78-46-02</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of chlorozotocin in advanced large bowel carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:09">
                    <nciDocumentNumber>CCG-923</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCG-923</localDocumentNumber>
                        <localDocumentNumber>POG-8631</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Good prognosis medulloblastoma: a study of reduced neuraxis irradiation in newly-diagnosed children - a Phase III group-wide study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:09">
                    <nciDocumentNumber>RTOG-88-02</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-88-02</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II study of Neoadjuvant Combined Modality treatment with selective Bladder preservation for patients with invasive Bladder Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:10">
                    <nciDocumentNumber>RTOG-84-09</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-84-09</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Limited participation, Phase I/II study of radiation therapy and AZQ chemotherapy for Malignant Astrocytomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:10">
                    <nciDocumentNumber>T85-0090</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>85-C-48</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of methotrexate and 5-fluorocil administered as sequential intravenous infusions for the treatment of refractory lymphoma and chronic lymphocytic leukemia.</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:11">
                    <nciDocumentNumber>POG-8704</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-8704</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>T-Cell #3 protocol: a Pediatric Oncology Group Phase III study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:12">
                    <nciDocumentNumber>T92-0143</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UAB 2125</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of the murine monoclonal antibody d612 in patients with colorectal cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:12">
                    <nciDocumentNumber>T92-0149</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>92-C-0270</localDocumentNumber>
                        <localDocumentNumber>CCG-0926</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A pediatric Phase I trial and pharmacokinetic study of all-trans-retinoic acid in combination with interferon-alpha2a</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:12">
                    <nciDocumentNumber>T93-0068</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Irinotecan (CPT-11) in Advanced Carcinoma of the Uterine Cervix</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:12">
                    <nciDocumentNumber>T94-0130</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>IND.84</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of topotecan and etoposide in patients with refractory or relapsed acute myeloid leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:12">
                    <nciDocumentNumber>T94-0192</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of paclitaxel over three hours followed by topotecan (nsc#609699) administered daily for five days in patients with metastatic Breast cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:12">
                    <nciDocumentNumber>T96-0006</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>8184</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of ci-980 in advanced renal cell carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:12">
                    <nciDocumentNumber>NCCTG-89-46-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-89-46-51</localDocumentNumber>
                        <localDocumentNumber>89-46-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Controlled Phase III Evaluation of 5-FU Combined with Levamisole and Leucovorin as Adjuvant Treatment for Resectable Colon Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:13">
                    <nciDocumentNumber>102-30</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                        <localDocumentNumber>104/02</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Ifosfamide/prednisone Phase II therapy for pts with multiple myeloma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:14">
                    <nciDocumentNumber>POG-9171</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9171</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I trial of Taxol in children with refractory solid Tumors, a Pediatric Oncology Group study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:14">
                    <nciDocumentNumber>POG-7621</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-7621</localDocumentNumber>
                        <localDocumentNumber>SWOG-7621</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>MOPP versus OPP in the treatment of children with recurrent Brain Tumors - a Phase III study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:14">
                    <nciDocumentNumber>POG-7420/21</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-7420/21</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Evaluation of various systemic and prophylactic CNS regimens in the treatment of Acute Leukemia of childhood - Phase III</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:15">
                    <nciDocumentNumber>T84-0358</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ID-88-015</localDocumentNumber>
                        <localDocumentNumber>BTRC-8422/8522</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of tpdcv chemotherapy with hydroxyurea and irradiation for medulloblastoma, ependymoblastoma, primitive neuroectodermal tumors, pineoblastoma and childhood supratentorial malignant gliomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:16">
                    <nciDocumentNumber>N83-0519</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>83-C-132</localDocumentNumber>
                        <localDocumentNumber>T83-1188</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II and Pharmacokinetic study of CBDCA</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:19">
                    <nciDocumentNumber>T84-0324</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CIC-84-60A</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Proposal for a new clinical investigation project: Phase I/II trial of pala + methotrexate + 5-fluorouracil + leucovorin in the treatment of patients with metastatic colorectal cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:19">
                    <nciDocumentNumber>NWTS-3</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NWTS-3</localDocumentNumber>
                        <localDocumentNumber>CCG-491</localDocumentNumber>
                        <localDocumentNumber>POG-8000</localDocumentNumber>
                        <localDocumentNumber>SWOG-8000</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>National Wilms Tumor Study III, a Phase III group-wide study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:20">
                    <nciDocumentNumber>NCCTG-89-43-52</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-89-43-52</localDocumentNumber>
                        <localDocumentNumber>89-43-52</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>An evaluation of Sandostatin, 5-Fluorouracil, and 5-Fluorouracil/Leucovorin in the therapy of Advanced Non-Measurable Pancreatic Cancer:  A Phase III study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:21">
                    <nciDocumentNumber>T84-0301</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>0SU-8407</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I clinical - pharmacokinetic investigation pibenzimol</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:22">
                    <nciDocumentNumber>T89-0239</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>90-C-83</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II evaluation of interleukin-1 alpha plus indomethacin in the treatment of metastatic malignant melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:23">
                    <nciDocumentNumber>T89-0206</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>90-C-190</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I evaluation of intraarterial fudr/leucovorin administered by a modified hepatic artery catheter in combination with systemic 5fu/alfa interferon for patients with colon carcinoma metastatic to the liver</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:23">
                    <nciDocumentNumber>SWOG-8922</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-8922</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I trial of doxorubicin, dtic and ifosfamide with recombinant granulocyte-macrophage colony stimulating factor in advanced soft tissue sarcoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:24">
                    <nciDocumentNumber>T89-0142</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>89-C-121</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I safety study of recombinant cd4 (rcd4) in infants and children and in pregnant women and newborns with hiv infection</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:24">
                    <nciDocumentNumber>NCOG-5O-82-1J</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCOG-5O-82-1J</localDocumentNumber>
                        <localDocumentNumber>RTOG-84-10</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III study of pelvic and abdominal radiotherapy versus Cis-Platinum, Adriamycin, and Cyclophosphamide chemotherapy in Stages I, II and Optimal III Epithelial Carcinoma of the Ovary</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:25">
                    <nciDocumentNumber>CALGB-8912</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-8912</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>High dose melphalan (nsc #8806) and granulocyte macrophage-colony stimulating factor (rhgm-csf) in previously untreated stage iii multiple myeloma-a Phase I limited access study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:25">
                    <nciDocumentNumber>SWOG-8902</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-8902</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I trial of doxorubicin plus carboplatin with gm-csf in patients with advanced, previously treated cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:25">
                    <nciDocumentNumber>T89-0130</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>IL-2/ALPHA/MELANOMA</localDocumentNumber>
                        <localDocumentNumber>LU-2284</localDocumentNumber>
                        <localDocumentNumber>89-08-193</localDocumentNumber>
                        <localDocumentNumber>889-5011-438</localDocumentNumber>
                        <localDocumentNumber>89112-89-08-1</localDocumentNumber>
                        <localDocumentNumber>H6042-04705-01</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III randomized study of patients with metastatic malignant melanoma with high dose il-2 versus high dose il-2 in combination with alpha-interferon</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:25">
                    <nciDocumentNumber>T83-1346</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CO-8284</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I trial of high-dose prolonged intravesical infusion of 5-fu in refractory, superficial bladder cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-17-1998 16:51:25">
                    <nciDocumentNumber>T83-1347</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CO-8296</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I trial of recombinant human interferon beta in patients with cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:25">
                    <nciDocumentNumber>T83-1324</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>83-408</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>5-fu and cis-platinum chemotherapy for advanced pancreatic cancer: a Phase II trial</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:25">
                    <nciDocumentNumber>T83-1343</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CO-8241</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Vinzolidine: A Phase II study in patients with Hodgkin's and Non-Hodgkin's Lymphoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:25">
                    <nciDocumentNumber>T83-1268</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of Fludarabine Phosphate in patients with advanced Cancer of the Head and Neck</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:26">
                    <nciDocumentNumber>T83-1163</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>83H0125</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I evaluation pharmacokinetic study of acodazole</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:26">
                    <nciDocumentNumber>NCCTG-86-72-53</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-86-72-53</localDocumentNumber>
                        <localDocumentNumber>86-72-53</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II evaluation of Recombinant Interferon - Alpha and BCNU in recurrent primary central nervous system malignancy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:26">
                    <nciDocumentNumber>NCCTG-85-62-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-85-62-51</localDocumentNumber>
                        <localDocumentNumber>85-62-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of Menogaril (NSC 269148) in patients with Advanced Cancer of the Cervix.</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:26">
                    <nciDocumentNumber>T89-0055</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UMCC-8901</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I dose intensity trial of cyclophosphamide, doxorubicin, leucovorin,and 5-fluorouracil(calf) with granulocyte-macrophage colony stimulating factor(gm-csf)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:27">
                    <nciDocumentNumber>NBCCGA-9A</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NBCCGA-9A</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II master protocol: Evaluation of new agents for the treatment of patients with Advanced Urothelial cancer-- FAM combination chemotherapy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:27">
                    <nciDocumentNumber>T83-1141</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>1594</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I trial of thymidine and cisplatin in patients with advanced cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:27">
                    <nciDocumentNumber>NCCTG-89-81-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-89-81-51</localDocumentNumber>
                        <localDocumentNumber>89-81-52</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II attenuated intermediate high dose ARA-C in the treatment of Acute Nonlymphocytic Leukemia in patients older than 65</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:27">
                    <nciDocumentNumber>T88-0275</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>89-C-99</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of high-dose chemotherapy and autologous bone marrow transplant in metastatic carcinoma and lymphoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:27">
                    <nciDocumentNumber>T88-0249</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>89-C-27</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of the ability of granulocyte-macrophage colony stimulating factor (gm-csf) to moderate dose limiting granulocytopenia associated with escalating doses of thiotepa</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:29">
                    <nciDocumentNumber>T87-0181</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DM 87-071</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of high dose melphalan (hdm) and total body irradiation (tbi) with autologous rescue as consolidation therapy for multiple myeloma in second remission following vad or dexamethasone</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:29">
                    <nciDocumentNumber>T87-0168</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>IL2/RENAL</localDocumentNumber>
                        <localDocumentNumber>7/87-6D</localDocumentNumber>
                        <localDocumentNumber>87-08-193</localDocumentNumber>
                        <localDocumentNumber>867-5011-317</localDocumentNumber>
                        <localDocumentNumber>7089</localDocumentNumber>
                        <localDocumentNumber>804815-01</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II study of high dose continuous infusion il-2 and autologous lak cells in patients with metastatic or unresectable renal cell carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:30">
                    <nciDocumentNumber>T87-0101</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>OSU-8707</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I clinical and pharmacokinetic investigation of deoxycoformycin (nsc 218321) to determine a safe dose for patients with impaired renal function</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:30">
                    <nciDocumentNumber>T87-0014</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>OI-86-5</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of recombinant il-2 and recombinant gamma interferon combination regimen in advanced malignancies</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:30">
                    <nciDocumentNumber>T86-0169</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>IL-2-RENAL</localDocumentNumber>
                        <localDocumentNumber>EST-P-X888</localDocumentNumber>
                        <localDocumentNumber>CSU-412</localDocumentNumber>
                        <localDocumentNumber>804809-01</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of patients with metastatic or unresectable renal cell carcinoma with high dose il-2</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:31">
                    <nciDocumentNumber>T86-0151</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>86-C-105</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial with suramin in patients with surgically unresectable adrenal cortical carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:31">
                    <nciDocumentNumber>T83-1025</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>WRAMC-8304</localDocumentNumber>
                        <localDocumentNumber>CTEPIS-0208</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II single agent chemotherapy with cbdca for advanced colorectal carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:31">
                    <nciDocumentNumber>T83-0968</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>83-C-05</localDocumentNumber>
                        <localDocumentNumber>MOB-83-9</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of cis-platinum and vp-16,213 in patients with previously treated small cell carcinoma of the lung</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:32">
                    <nciDocumentNumber>SWOG-8305</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-8305</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II chemotherapy of metastatic colorectal carcinoma with 5-fu and folinic acid</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:33" createdDate="12-17-1998 16:51:32">
                    <nciDocumentNumber>SWOG-8273</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SWOG-8273</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Evaluation of Cis-Platinum and DTIC in Disseminated Melanoma, Phase II pilot</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:33">
                    <nciDocumentNumber>SEG-RLPD79-267</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-RLPD79-267</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Gallium Nitrate Phase II in Refractory HOD, NHL, and CLL</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:34">
                    <nciDocumentNumber>EST-4472</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-4472</localDocumentNumber>
                        <localDocumentNumber>SEG-343</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III study of intermittent BCNU, Cyclophosphamide and Prednisone vs intermittent Melphalan and Prednisone in Myeloma and of the addition of Fluoxymesterone, Sodium Fluoride and Calcium Gluconate vs placebo</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:34">
                    <nciDocumentNumber>EST-P-I883</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-P-I883</localDocumentNumber>
                        <localDocumentNumber>V85-0040</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II clinical trial of intraperitoneal Cisplatin with systemic Adriamycin and Cyclophosphamide(IP-CAC) Chemotherapy for stage III/IV adenocarcinoma of the Ovary</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:34">
                    <nciDocumentNumber>EST-P-Y586</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-P-Y586</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of combined recombinant beta and gamma Interferon in metastatic non-small cell Lung cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:35">
                    <nciDocumentNumber>EST-P-C680</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-P-C680</localDocumentNumber>
                        <localDocumentNumber>B83-0009</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I and II study of Poly Iclc (and interferon inducer) on the course of Melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:35">
                    <nciDocumentNumber>D82-001-0556</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CTEPIS-0064</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II study of melphalan in an isolated limb perfusion plus hyperthermia for stage i/ii/iii or recurrent malignant melanoma of the extremities in high risk patients</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:36">
                    <nciDocumentNumber>D80-048-0280</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Dibromodulcitol vs vindesine Phase II rand crossover chemo of metastatic malignant melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:36">
                    <nciDocumentNumber>D79-035-0229</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>79H0156</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Thc vs haloperidol Phase II randomized study of comparative effects of patients receiving chemotherapy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:36">
                    <nciDocumentNumber>T86-0078</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>WRAMC-8602</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Clinical pharmacologic and Phase I study of hexamethylene bisacetamide (hmba; nsc 95580) in patients with advanced solid tumors: a wramc-nci collaborative study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:37">
                    <nciDocumentNumber>C83-0271</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CIC-82-143</localDocumentNumber>
                        <localDocumentNumber>CORNELL-8290</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of vm-26 and gallium nitrate in non-hodgkin's lymphoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:37">
                    <nciDocumentNumber>T85-0282</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>85-C-193</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II protocol for the evaluation of alternating 2'deoxycoformycin and recombinant leukocyte interferon-alpha a in therapy of hairy cell leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:37">
                    <nciDocumentNumber>C82-0098</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DM-81-50</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III study of mime (methotrexate, ifosfamide, methyl gag and vp-16,213) for patients with relapsing lymphoma and myeloma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:37">
                    <nciDocumentNumber>C81-0167</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>TPN-2001</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Azq straight Phase II small cell bronchogenic ca</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:42">
                    <nciDocumentNumber>SEG-BRE-76-303</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-BRE-76-303</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III randomized comparison of Adjuvant short-term chemotherapy with Cyclophosphamide, Methotrexate &amp; 5-Fluorouracil + radiation RX vs long-term chemotherapy with Cyclophosphamide, MTX &amp; 5-FU in cancer of the Breast</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:43">
                    <nciDocumentNumber>CCG-8601</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCG-8601</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I trial of carboplatin in children with acute lymphocytic leukemia, acute non-lymphocytic leukemia, and chronic myelocytic leukemia in blast crisis in bone marrow relapse following therapy of highest priority</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:46">
                    <nciDocumentNumber>CALGB-8653</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-8653</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Recombinant Interleukin-2 and B-Interferon for Relapsed or Refractory Lymphoma: A limited access Phase II study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:47">
                    <nciDocumentNumber>T85-0099</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>OSU-8513</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II investigation of Fludarabine Phosphate in advanced Refractory Hodgkin's disease</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:47">
                    <nciDocumentNumber>B85-0007</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                        <localDocumentNumber>B83-0017</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of mouse monoclonal Anti-T suppressor cell (Anti-Leu 2A) antibody</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:48">
                    <nciDocumentNumber>RTOG-83-21</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-83-21</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III study of combined modality treatment by Thymosin and radiation therapy for Unresectable Non-Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:48">
                    <nciDocumentNumber>RTOG-84-01</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-84-01</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II study, combination of radiotherapy and Hyperthermia in patients with Deep-Seated Malignant Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:48">
                    <nciDocumentNumber>INT-0090</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Pilot Phase II study of selected high risk newly diagnosed patients with acute nonlymphocytic leukemia:a leukemia intergroup study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:49">
                    <nciDocumentNumber>POG-8692</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-8692</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II study of 5-Flourouracil, administered as a continuous 5-day intraveous infusion to Pediatric patients with recurrent Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-17-1998 16:51:49">
                    <nciDocumentNumber>GOG-81F</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-81F</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II trial of Tamoxifen Citrate in patients with Advanced or Recurrent Endometrial Carcinoma Responsive to Progestins</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:50">
                    <nciDocumentNumber>EST-1491</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>EST-1491</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of Fludarabine plus Cyclophosphamide in patients with low-grade Lymphoma previously untreated with Chemotherapy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:51">
                    <nciDocumentNumber>T91-0016</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PCI 92-37</localDocumentNumber>
                        <localDocumentNumber>DUGU-90-03</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of high dose intravenous Cyclophosphamide with GM-CSF in patients with Hormone-Refractory Metastatic Prostate Cancer and prior radiation therapy to the pelvis</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:51">
                    <nciDocumentNumber>T91-0018</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>91-C-122</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Cyclopentenyl Cytosine (NSC 375575) in adult patients with solid tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:51">
                    <nciDocumentNumber>T91-0021</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>BRMP-9101</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of IL-1Beta, G-CSF and Autologous Stem Cell Transplantation for patients with Refractory Intermediate Grade Lymphomas and Hodgkin's Disease</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:52">
                    <nciDocumentNumber>T91-0210</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>91-C-176</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of continuous infusion Immunotoxin IGG-RFB4-SMPT-DGA in refractory CD22-positive B-Cell Lymphoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:52">
                    <nciDocumentNumber>T91-0239</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>92-C-0077</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of resection and Intraoperative Photodynamic therapy for Intraperitoneal Sarcomatosis or recurrent Retroperitoneal Sarcoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:52">
                    <nciDocumentNumber>CALGB-9261</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-9261</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I study of Fixed Dose Topotecan and Escalating Dose Cisplatin</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:52">
                    <nciDocumentNumber>T92-0041</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>92-C-0228</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A pilot/Phase I Study of the toxicity, pharmacokinetics, and activity of TNP-470 to patients with HIV infection and Kaposi's Sarcoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:54">
                    <nciDocumentNumber>T93-0026</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DMS 9224</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I trial of IL-6 plus G-CSF in association with high dose chemotherapy and autologous stem cell transplantation in advanced Breast Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:54">
                    <nciDocumentNumber>CCG-0932</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCG-00057</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I study of Temozolomide in Pediatric and Adolescent Patients with Progressive Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:54">
                    <nciDocumentNumber>T93-0187</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase I trial of Interleukin-1 Alpha and Carboplatin in patients with solid tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:54">
                    <nciDocumentNumber>T94-0008</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>KU 3/94</localDocumentNumber>
                        <localDocumentNumber>SWOG-9435</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Evaluation of Pyrazoloacridine for advanced (Stage IV) Non-small cell carcinoma of the lung: Phase II</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:54">
                    <nciDocumentNumber>T94-0017</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PCI 92-80</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I trial of Interleukin-1 Alpha and Carboplatin in patients with metastatic disease to the lung: Effects on tumor blood flow evaluated by Positron Emission Tomography (PET)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:55">
                    <nciDocumentNumber>T94-0156</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>95-028</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A multicenter Phase II trial of 9-AC in patients with metastatic Breast Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:55">
                    <nciDocumentNumber>T95-0012</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>DM 95-010</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A randomized Phase II trial of Ketoconazole alone and Ketoconazole/Doxorubicin in hormone refractory Prostate Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:55">
                    <nciDocumentNumber>T95-0084</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>8013</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II study of Doxorubicin and Taxol given prior to Cisplatin and Etoposide in the treatment of patients with extensive-stage small cell Lung Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:55">
                    <nciDocumentNumber>T95-0088</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>9510-23</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Interleukin-2 in Patients with Myelodysplastic Syndromes</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:56">
                    <nciDocumentNumber>T96-0063</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Trial of Irinotecan and Tomudex in Combination on an Every Three Weeks Schedule</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:32" createdDate="12-17-1998 16:51:56">
                    <nciDocumentNumber>T97-0031</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>98-031</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Dose-Escalating Study of Recombinant Human Interleukin-12 (NSC #672423) Administered by Intraperitoneal Infusion in Refractory Advanced Stage Ovarian Cancer and Other Abdominal Carcinomatosis</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-17-1998 16:51:56">
                    <nciDocumentNumber>T97-0108</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>97-09-042-01</localDocumentNumber>
                        <localDocumentNumber>RP97-126</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Dose Escalating Study of the Safety and Tolerability of Gadolinium Texaphyrin as a Radiation Sensitizer in Patients with Primary Glioblastoma  Multiforme</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-12-1999 16:47:15">
                    <nciDocumentNumber>GOG-0177</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-177</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Study of Doxorubicin plus Cisplatin Versus Doxorubicin plus Cisplatin plus 3-hour Paclitaxel with G-CSF Support in Patients with Primary Stage III &amp; IV or Recurrent Endometrial Carcinoma (PHASE III)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-12-1999 17:10:54">
                    <nciDocumentNumber>T98-0003</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>98-80-03</localDocumentNumber>
                        <localDocumentNumber>98-80-03</localDocumentNumber>
                        <localDocumentNumber>98-80-03</localDocumentNumber>
                        <localDocumentNumber>98-80-03</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of 4'-IODO-4' Deoxydoxorubicin in Primary Amyloidosis (AL)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:17">
                    <nciDocumentNumber>T96-0075</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>96-158</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of CHOP and the IDEC-C2B8 Monoclonal Antibody in Patients with Previously Untreated Mantle Cell Lymphoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-29-1999 18:06:17">
                    <nciDocumentNumber>T97-0051</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>FCCC 98-026</localDocumentNumber>
                        <localDocumentNumber>DS94-23</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A PHASE I study of RAS PEPTIDE vaccination in patients with ADVANCED PANCREATIC or COLORECTAL  ADENOCARCINOMA</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:18">
                    <nciDocumentNumber>E2997</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E2997</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Randomized Trial of Fludarabine and Cyclophosphamide Versus Fludarabine for Previously Untreated Chronic Lymphocytic Leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>T96-0048</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>8254</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A phase ii trial of ci-980 in patients with stage d2, hormone refractory prostate cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>T96-0007</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>8183</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A phase ii trial of ci-980 in advanced melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>T96-0120</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Evaluation Of  PYRAZOLOACRIDINE (NSC #366140) in Patients with  METASTATIC BREAST  CANCER.</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>E7897</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E7897</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Randomized Study of  Vaccine Treatment of Advanced Prostate Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>T99-0018</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Bryostatin-1 in Combination with Paclitaxel for Non-Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-29-1999 18:06:19">
                    <nciDocumentNumber>NABTT-9808</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTT-9808</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of Suramin and Concurrent Radiation Therapy in Newly Diagnosed Glioblastoma Multiforme</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:34" createdDate="03-29-1999 18:06:20">
                    <nciDocumentNumber>SEG-78-BL-339</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>SEG-78-BL-339</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Adjuvant Study Of Combined Modality With Rt And Surgery In Transitional Cell Carcinoma Of The Bladder, Randomizing Pts To Post-Operative Chemotherapy With Cytoxan, Adriamycin &amp; Cisplatin Or To Control Arm</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:20">
                    <nciDocumentNumber>T90-0136</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase ii study of high-dose 24 hour continuous infusion of 5-fu and leucovorin and low-dose pala for patients with pancreatic cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:21">
                    <nciDocumentNumber>T94-0051</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>94-C-0159</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Protocol for the Evaluation of the Safety and Immunogenicity of Vaccination with Synthetic HIV Envelope Peptides in Patients with Early Human Immunodeficiency Virus Infection</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="03-29-1999 18:06:22">
                    <nciDocumentNumber>T94-0171</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UAB-9441</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of Bryostatin-1 for the Treatment of Patients with Metastatic Malignant Melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:22">
                    <nciDocumentNumber>T95-0073</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>95-131</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study Of Dx-52-1 In Refractory Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:22">
                    <nciDocumentNumber>T95-0086</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>96-079</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial of Recombinant Vaccinia Virus that Expresses PSA in Patients with Adenocarcinoma of the Prostate</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T96-0044</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                        <localDocumentNumber>97-C-0051</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I and Pharmacokinetic Trial of Phenylbutyrate Given as a Continuous Infusion in Pediatric Patients with Refractory Malignancy</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>T96-0121</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Pyrazoloacridine (NSC 366140) Administered as a 3-Hour Infusion Every 3 Weeks in Patients with Pancreatic Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:23">
                    <nciDocumentNumber>NABTT-9707</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTT-9707</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A phase II study to evaluate the efficacy and safety of repetitive daily intravenous doses of rsr13 administered to patients receiving cranial radiation therapy for glioblastoma multiforme</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:24">
                    <nciDocumentNumber>ACOSOG-Z0020</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ACOSOG-Z0020</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion and Melphalan with or without Tumor Necrosis Factor in the Patient with Localized, Advanced, Extremity Melanoma</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:24">
                    <nciDocumentNumber>T98-0057</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>97-050</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial of Recombinant Vaccinia Virus that Expresses DF3/MUC1 in Patients with Metastatic Adenocarcinoma of the Breast</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:24">
                    <nciDocumentNumber>NCCTG-98-72-52</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-98-72-52</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Pre-Irradiation Chemotherapy with BCNU, Cisplatin and Oral Etoposide Combined with Radiation Therapy in the Treatment of Grade 4 Astrocytoma (Glioblastoma)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:24">
                    <nciDocumentNumber>NCCTG-98-81-51</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCCTG-98-81-51</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of Theophylline in Asymptomatic Patients with B-Cell Chronic Lymphocytic Leukemia Previously Untreated with Chemotherapy</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:24">
                    <nciDocumentNumber>T99-0037</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of the Cyclin-Dependent Kinase (CDK) / Protein Kinase C (PKC) Inhibitor UCN-01 in Combination with 5-Fluorouracil in Patients with Advanced Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-29-1999 18:06:24">
                    <nciDocumentNumber>NABTT-9904</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTT-9904</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Clinical and Pharmacologic Study of Radiation Therapy and CAI (Carboxy-Amido Triazole) in Adults with Newly Diagnosed Glioblastoma Multiforme</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="05-24-1999 17:11:44">
                    <nciDocumentNumber>E1199</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E1199</localDocumentNumber>
                        <localDocumentNumber>E1199</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III study of Doxorubicin-Cyclophosphamide Therapy Followed by Paclitaxel or Docetaxel Given Weekly or Every 3 Weeks in Patients with Axillary Node-Positive or High Risk Node-Negative Breast Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="06-16-1999 15:09:24">
                    <nciDocumentNumber>AGCT0132</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>AGCT0132</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Study of Reduced Therapy in the Treatment of Children with Low and Intermediate Risk Extracranial Germ Cell Tumors</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="08-03-1999 14:01:40">
                    <nciDocumentNumber>T99-0085</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>T99-0085</localDocumentNumber>
                        <localDocumentNumber>T99-0085</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II trial of SU5416 and Interferon Alfa 2B in Unresectable or Metastatic Renal Cell Carcinoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="08-03-1999 14:26:05">
                    <nciDocumentNumber>T99-0086</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHI-30</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Trial of  SU5416 in Combination with Weekly Paclitaxel in Patients with Advanced Malignancies</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="08-03-1999 16:44:54">
                    <nciDocumentNumber>JPR.7</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>JPR.7</localDocumentNumber>
                        <localDocumentNumber>JPR.7</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Randomized Trial Comparing Intermittent  Versus Continuous Androgen Suppression for Patients with Prostate-Specific-Antigen Progression in the Clinical Absence of Distant Metastases Following Radiotherapy for Prostate Cancer</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="08-19-1999 16:38:32">
                    <nciDocumentNumber>NABTC-9901</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTC-9901</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II Trial of R115777 in Patients with Recurrent Malignant Glioma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="08-24-1999 13:36:14">
                    <nciDocumentNumber>T99-0109</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>T99-0109</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of Rebeccamycin Analogue NSC 655649 in Patients with Metastatic Colorectal Cancer  (IMT Codes 23988, 23989, 23993)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="08-25-1999 12:08:54">
                    <nciDocumentNumber>T99-0080</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>00-C-0070</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Trial and Pharmacokinetic Study of Arsenic Trioxide in Pediatric Patients with Refractory Leukemia or Lymphoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="08-26-1999 09:19:47">
                    <nciDocumentNumber>41</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>00-C-0121</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Investigation of  IL-12/Pulse IL-2 in Adults with Advanced Solid Tumors</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="08-31-1999 10:53:03">
                    <nciDocumentNumber>58</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of SU5416 as Treatment for Refractory/Relapsed Multiple Myeloma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="09-28-1999 20:15:49">
                    <nciDocumentNumber>104</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CCCWFU 57198</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of Adjuvant 2'2'-DIFLUORO-2'-DEOXYCYTIDINE (Gemcitabine) and External Beam Radiation for the Treatment of Resectable Pancreatic Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="09-30-1999 10:33:49">
                    <nciDocumentNumber>150</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>IDD99-32</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of BMS-247550 (NSC 710428) Given on a Continuous Weekly Schedule in Patients with Advanced Malignancies</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="10-21-1999 13:20:12">
                    <nciDocumentNumber>POG-9904</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>POG-9904</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>ALinC # 17 Treatment for Patients with Low Risk Acute Lymphoblastic Leukemia: A Phase III Study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="11-01-1999 14:26:20">
                    <nciDocumentNumber>CALGB-99813</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-99813</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A PHASE II study of ESTRAMUSTINE, DOCETAXEL, and CARBOPLATIN with G-CSF support in men with hormone refractory PROSTATE CANCER</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="11-09-1999 15:23:48">
                    <nciDocumentNumber>S9901</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S9901</localDocumentNumber>
                        <localDocumentNumber>S9901</localDocumentNumber>
                        <localDocumentNumber>S9901</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III Trial Comparing Early High Dose Chemotherapy and an Autologous Stem Cell Transplant  to Conventional Dose ABVD Chemotherapy for Patients with Advanced Stage Poor Prognosis Hodgkin's Disease as Defined by the International Prognostic Factors Project on Advanced Hodgkin's Disease</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="11-17-1999 15:23:17">
                    <nciDocumentNumber>NABTC-9907</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTC-9907</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II Trial of CPT-11 and Temozolomide (Temodar) in Patients with Recurrent Malignant Glioma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="11-24-1999 13:04:24">
                    <nciDocumentNumber>GOG-9904</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-9904</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A PHASE I open label assessment of the safety and pharmacokinetics of INTRAPERITONEAL PACLIMER MICROSPHERES (POLILACTOFATE/PACLITAXEL) in patients with OVARIAN CANCER</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-07-1999 14:11:40">
                    <nciDocumentNumber>29</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHII-27</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of CCI-779 (NSC 683864) in Metastatic Melanoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-10-1999 17:31:58">
                    <nciDocumentNumber>56</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of Chloroquinoxaline Sulfonamide (CQS) in Colorectal Cancer Stage STAGE IV</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-15-1999 13:43:04">
                    <nciDocumentNumber>43</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II Trial of Arsenic Trioxide (As2O3) with Ascorbic Acid in the Treatment of Relapsed/Refractory Multiple Myeloma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="02-02-2000 10:41:43">
                    <nciDocumentNumber>24</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>00-166</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Trial of Gemcitabine Followed by Flavopiridol in Patients with Solid Tumors</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-02-2000 10:48:03">
                    <nciDocumentNumber>GOG-0184</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-0184</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="05-23-2000 10:12:44">
                    <nciDocumentNumber>2530</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Fenretinide Combined with Paclitaxel and Cisplatin for the Treatment of Refractory Solid Tumors</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="06-01-2000 13:51:56">
                    <nciDocumentNumber>S0016</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0016</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Trial of CHOP + Rituximab vs CHOP + Iodine-131-Labeled Monoclonal Anti-B1 Antibody (Tositumomab) for Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphomas</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="06-08-2000 15:09:01">
                    <nciDocumentNumber>NABTC-9908</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTC-9908</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II Trial of STI571 in Patients with Recurrent Malignant Gliomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="06-23-2000 14:40:02">
                    <nciDocumentNumber>N9945</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>N9945</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial Evaluating Multiple Metastasectomy Combined with Hepatic Artery Infusion of Floxuridine (FUDR) and Dexamethasone (DXM), Alternating with Systemic Oxaliplatin (OXAL) and Capecitabine (CAPCIT) for Colorectal Carcinoma Metastatic to the Liver</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="06-29-2000 10:20:39">
                    <nciDocumentNumber>1639</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GCC 0044</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of ZD1839 (NSC#715055) in Renal Cell Carcinoma Stage IV and Renal Cell Carcinoma Recurrent</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="08-29-2000 09:50:19">
                    <nciDocumentNumber>E3200</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E3200</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Trial of Bevacizumab (NSC 704865), Oxaliplatin (NSC 266046), Fluorouracil and Leucovorin Versus Oxaliplatin, Fluorouracil and Leucovorin Versus Bevacizumab Alone in Previously Treated Patients with Advanced Colorectal Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="09-14-2000 11:07:03">
                    <nciDocumentNumber>1856</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>1856</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of PS-341 in Metastatic Neuroendocrine Tumors</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="09-15-2000 10:58:24">
                    <nciDocumentNumber>GOG-0182</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-0182</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Randomized Trial of Paclitaxel and Carboplatin Versus Triplet or Sequential Doublet Combinations in Patients with Epithelial Ovarian or Primary Peritoneal Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="11-21-2000 14:47:51">
                    <nciDocumentNumber>S0033</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCIC-CTG: SR.4</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Randomized, Intergroup Trial Assessing the Clinical Activity of STI-571 at Two Dose Levels in Patients with Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST) Expressing the Kit Receptor Tyrosine Kinase (CD117)</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-07-2000 14:19:49">
                    <nciDocumentNumber>NCIC-142</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCIC-142</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of SarCNU (NSC 364432) in Patients with Malignant Glioma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="12-14-2000 13:46:05">
                    <nciDocumentNumber>S0111</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0111</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Epothilone B Analogue BMS-247550 (NSC #710428) (IND 59699) Administered Every 21 Days in Patients with Hormone Refractory Prostate Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="01-24-2001 12:39:07">
                    <nciDocumentNumber>4653</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>STI571+ARA-C</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study to Determine the Anti-Leukemic Effects of STI571* in Combination with Ara-C in Patients with Chronic Myelogenous Leukemia in Chronic Phase</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:35" createdDate="03-21-2001 10:38:04">
                    <nciDocumentNumber>GOG-0129M</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-0129-M</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Evaluation of Flavopiridol (NSC# 649890) in the Treatment of Recurrent or Persistent Endometrial Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-28-2001 14:42:48">
                    <nciDocumentNumber>GOG-0170D</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-0170-D</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Evaluation of Bevacizumab (rhuMAB VEGF) (NSC #704865, IND #7921) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="05-29-2001 10:48:45">
                    <nciDocumentNumber>GOG-0229C</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-0229C</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of ZD1839 (IRESSA (TM) (NSC #715055, IND #61187) in the Treatment of Persistent or Recurrent Endometrial Carcinoma</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="06-05-2001 12:23:21">
                    <nciDocumentNumber>CALGB-90003</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-90003</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: A  Phase II Study</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="07-25-2001 08:34:25">
                    <nciDocumentNumber>5378</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-003</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of OSI-774 in Metastatic Colorectal Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="08-13-2001 12:33:45">
                    <nciDocumentNumber>5389</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CWRU 1301</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, OSI-774, in Combination with Docetaxel and Radiation in Locally Advanced Squamous Cell Cancer of the Head and Neck</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="08-14-2001 16:15:47">
                    <nciDocumentNumber>N0177</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>N0177</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Pilot and Phase II Study of OSI-774 and Temozolomide in Combination with Radiation Therapy in Glioblastoma Multiforme</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="08-21-2001 14:25:30">
                    <nciDocumentNumber>S0032</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0032</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Evaluation of Early Oral Estramustine, Oral Etoposide and Intravenous Paclitaxel in Combination With Hormone Therapy in Patients With High-Risk Metastatic Adenocarcinoma of the Prostate</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-10-2001 10:23:00">
                    <nciDocumentNumber>5747</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>02-310</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial of an Admixture of Recombinant Vaccinia Viruses that Express DF3/MUC1 and rV-TRICOM (B7.ICAM-1, and LFA-3) in Patients with  Metastatic Adenocarinoma of the Breast</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-12-2001 15:28:56">
                    <nciDocumentNumber>RTOG-0212</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-0212</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II/III Randomized Trial of Two Doses (Phase III-Standard vs. High) and Two High Dose Schedules (Phase II-Once vs. Twice Daily) for Delivering Prophylactic Cranial Irradiation for Patients with Limited Disease Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="11-23-2001 08:52:10">
                    <nciDocumentNumber>S0124</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0124</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Phase III Trial of Cisplatin and Irinotecan (NSC-616348) Versus Cisplatin and Etoposide in Patients with Extensive Stage Small Cell Lung Cancer (E-SCLC)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-05-2001 16:19:52">
                    <nciDocumentNumber>5791</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>02-C-0229</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Clinical Trial of Ixabepilone (BMS-247550, NSC 710428), an Epothilone B Analog, in Patients with Breast Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-28-2001 09:41:04">
                    <nciDocumentNumber>S0355</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>5707</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Pharmacokinetic Study of Epothilone B Analogue BMS-247550 (NSC-710428D) in Patients with Advanced Malignancies and Varying Levels of Liver Dysfunction</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-14-2002 11:03:22">
                    <nciDocumentNumber>ADVL0114</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ADVL0114</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Decitabine (DAC) (IND # 50733) in Children with Relapsed or Refractory Acute Leukemia</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-17-2002 16:21:32">
                    <nciDocumentNumber>5883</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>91102</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Whole-Brain Radiation Therapy with Thalidomide and Temozolomide in Patients with Newly Diagnosed Brain Metastases</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="02-12-2002 15:13:11">
                    <nciDocumentNumber>5585</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>4255</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of Intravesical Recombinant Fowlpox - GM-CSF (rF-GM-CSF) and/or Recombinant Fowlpox-TRICOM (rF-TRICOM) in Patients with Bladder Carcinoma Scheduled for Cystectomy</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-07-2002 18:32:53">
                    <nciDocumentNumber>S0114</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0114</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>An Early Phase Study of an EGFRVIII Peptide Based Vaccine in Patients with EGFRVIII Expressing Cancers</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-21-2002 12:30:36">
                    <nciDocumentNumber>5874</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CO 02903</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Pharmacokinetic Study of PS-341 in Patients with Advanced Malignancies and Varying Degrees of Renal Dysfunction for the CTEP-Sponsored Organ Dysfunction Working Group</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-03-2002 09:44:02">
                    <nciDocumentNumber>E6201</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E6201</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III, Randomized Study of Gemcitabine [Fixed-Dose Rate Infusion] and Oxaliplatin (NSC 266046) Versus Gemcitabine [Fixed-Dose Rate Infusion] Versus Gemcitabine [30-Minute Infusion] in Pancreatic Carcinoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-04-2002 10:20:43">
                    <nciDocumentNumber>E4201</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E4201</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III Study of Gemcitabine in Combination with Radiation Therapy Versus Gemcitabine Alone in Patients with Localized, Unresectable Pancreatic Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-19-2002 17:32:09">
                    <nciDocumentNumber>NCIC-MA.21</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NCIC-MA.21</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Adjuvant Trial of Sequenced EC + Filgrastim + Epoetin Alfa Followed by Paclitaxel Versus Sequenced AC Followed by Paclitaxel Versus CEF as Therapy  for Premenopausal Women and Early Postmenopausal Women Who have had Potentially Curative Surgery for Node Positive or High Risk Node Negative Breast Cancer</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="05-03-2002 11:46:35">
                    <nciDocumentNumber>CALGB-10102</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-10102</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Dose Escalation Study of Subcutaneous Campath-1H (NSC # 715969, IND # 10864) During Intensification Therapy in Adults with Untreated Acute Lymphoblastic Leukemia (ALL)</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="06-06-2002 07:38:28">
                    <nciDocumentNumber>IBCSG-24-02</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>IBCSG-24-02</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="06-26-2002 09:56:00">
                    <nciDocumentNumber>5922</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ICC 2402</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of Bryostatin 1 and Vincristine in Patients with Low or Intermediate Grade Non-Hodgkin's Lymphoma Progressing or Relapsing After a Prior Autologous Bone Marrow or Stem Cell Transplant</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="08-28-2002 12:53:25">
                    <nciDocumentNumber>RTOG-0241</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-0241</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of Irinotecan and Cisplatin in Combination with Twice Daily Thoracic Radiotherapy (45 Gy) or Once Daily Thoracic Radiotherapy (70 Gy) for Patients
                        with Limited Stage Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-21-2002 13:12:37">
                    <nciDocumentNumber>S0025</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0025</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of Irinotecan (Camptosar) for Patients with Platinum and Taxane Refractory Ovarian, Peritoneal or Fallopian Tube Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-10-2002 10:03:33">
                    <nciDocumentNumber>CALGB-10201</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-10201</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Study of Daunorubicin and Cytarabine +/- G3139 (Genasense, Oblimersen Sodium, NSC #683428, IND #58842), a BCL2 Antisense Oligodeoxynucleotide, in Previously Untreated Patients with Acute Myeloid Leukemia (AML) > / = 60 Years</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-24-2002 08:07:12">
                    <nciDocumentNumber>6052</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>03-082</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Clinical, Pharmacokinetic and Pharmacodynamic Study of Flavopiridol in Patients with Refractory Solid Tumors and Hematologic Malignancies</documentTitle>
                    <currentStatus>Temporarily Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-11-2003 14:35:01">
                    <nciDocumentNumber>6036</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II Trial of Low Dose Suramin (CI-1003, NSC #34936) and 5-Fluorouracil in Patients with Metastatic Renal Cell Carcinoma (RCC)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="05-01-2003 16:32:02">
                    <nciDocumentNumber>E4402</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E4402</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Phase III Trial Comparing Two Different Rituximab Dosing Regimens for Patients with Low Tumor Burden Indolent Non-Hodgkin's Lymphoma</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="05-02-2003 08:31:17">
                    <nciDocumentNumber>6216</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CII0301</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Bryostatin-1 in Combination with Rituximab in Rituximab-Refractory Indolent B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="05-13-2003 14:39:32">
                    <nciDocumentNumber>S0331</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0331</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of STI-571/Imatinib (Gleevec) (NSC-716051) in Neuroendocrine Carcinoma of the Skin (Merkel Cell Carcinoma)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="06-27-2003 14:39:35">
                    <nciDocumentNumber>S0325</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0325</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase IIb Study of Molecular Responses to Imatinib, at Standard or Increased Doses, or Dasatinib (BMS-354825) (NSC-732517) for Previously Untreated Patients with Chronic Myelogenous Leukemia (CML) in Chronic Phase</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-12-2012 10:41:39" createdDate="07-14-2003 09:40:18">
                    <nciDocumentNumber>6199</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>12983A</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of CCI-779 in B-Cell Lymphoma and CLL</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="07-18-2003 14:41:18">
                    <nciDocumentNumber>E2902</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E2902</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="08-05-2003 09:37:07">
                    <nciDocumentNumber>6205</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Tipifarnib (R115777, Zarnestra) in Combination with Fulvestrant (Faslodex) in Postmenopausal Hormone Receptor-Positive Breast Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="08-11-2003 13:58:43">
                    <nciDocumentNumber>ADVL0214</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ADVL0214</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Single Agent OSI-774 (Tarceva) (NSC# 718781, IND# 63383) Followed by OSI-774 with Temozolomide for Patients with Selected Recurrent/Refractory Solid Tumors, Including Brain Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-10-2003 14:02:32">
                    <nciDocumentNumber>ADVL0319</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ADVL0319</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of CC-5013 (Lenalidomide NSC# 703813, IND # 70116) in Pediatric Patients with Relapsed/Refractory Solid Tumors or Myelodysplastic Syndrome</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-17-2003 10:50:34">
                    <nciDocumentNumber>E1303</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E1303</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of PS-341 (NSC 681239) Followed by the Addition of Doxorubicin at Progression in Advanced Adenoid Cystic Carcinoma of the Head and Neck</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-29-2003 08:38:50">
                    <nciDocumentNumber>5876</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC0261</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of Flavopiridol and Cisplatin in Advanced Epithelial Ovarian and Primary Peritoneal Carcinomas</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="10-20-2003 12:43:56">
                    <nciDocumentNumber>6292</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC0333</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Gemcitabine and Triapine in Refractory Metastatic Breast Cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-27-2003 17:35:16">
                    <nciDocumentNumber>GOG-9917</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-9917</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Dose-Escalating Phase I Study with an Expanded Cohort to Assess the Feasibility of Intraperitoneal Carboplatin (NSC #214240) and Intravenous Paclitaxel (NSC # 673089) and Intravenous Paclitaxel, Intraperitoneal Carboplatin and NCI Supplied Intravenous Bevacizumab (NSC #704865, IND #7921) in Patients with Previously Untreated Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-04-2003 13:06:12">
                    <nciDocumentNumber>6542</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>04-053</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase 1 Study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG, NSC #707545) in Patients with Solid Tumors</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-24-2003 09:22:48">
                    <nciDocumentNumber>NABTT-0306</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTT 0306</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Safety Run-in/Randomized Phase II Trial of EMD 121974 in Conjunction with Concomitant and Adjuvant Temozolomide with Radiation Therapy in Patients with Newly Diagnosed Glioblastoma Multiforme</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="02-10-2004 14:27:25">
                    <nciDocumentNumber>6518</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>OSU 0429</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of 17-Allylamino-17-Demethoxygeldanamycin (17-AAG) (NSC 330507; IND 57,966) and Rituximab in Patients with Relapsed B-cell Chronic Lymphocytic Leukemia (CLL)</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-02-2004 12:02:03">
                    <nciDocumentNumber>6482</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC0476</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of 17-Allylaminogeldanamycin (17-AAG) in Advanced Medullary and Differentiated Thyroid Carcinoma</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-23-2004 13:46:53">
                    <nciDocumentNumber>NABTT-0401</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTT 0401</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial of BAY 43-9006 for Patients with Recurrent or Progressive Malignant Glioma</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-01-2004 10:20:22">
                    <nciDocumentNumber>6701</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-028</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of GW572016 in Recurrent and/or Metastatic Adenoid Cystic Carcinoma, and Other EGFR-and/or erbB2-expressing Malignant Tumors of the Salivary Glands</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-02-2004 12:23:02">
                    <nciDocumentNumber>6674</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHII-53</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of GW572016 (Lapatanib) in Locally Advanced or Metastatic Hepato-Biliary Cancers</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-08-2004 10:00:07">
                    <nciDocumentNumber>6706</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-030</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of GW572016 in Hormone Naive Recurrent or Metastatic Hormone Sensitive Prostate Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-12-2012 10:41:39" createdDate="04-29-2004 17:46:40">
                    <nciDocumentNumber>6484</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>2004-0342</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Phase II Trial of Idarubicin +  Ara-C +/- Bevacizumab in Patients Age &lt; 60 with Untreated Acute Myeloid Leukemia</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="06-09-2004 13:55:01">
                    <nciDocumentNumber>NABTC-04-01</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTC-04-01</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Biomarker and Phase II Study of GW 572016 in Recurrent Malignant Glioma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="06-23-2004 09:01:48">
                    <nciDocumentNumber>ADVL0415</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ADVL0415</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Oxaliplatin (NSC# 266046, IND #57004) and Irinotecan in Pediatric Patients with Refractory Solid Tumors and Lymphomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="07-06-2004 13:43:11">
                    <nciDocumentNumber>S0432</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0432</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Studies of Two Different Schedules and Two Different Doses of the Farnesyl Transferase Inhibitor R115777 (Tipifarnib, Zarnestra, NSC-702818) for Previously Untreated Acute Myeloid Leukemia (AML) in Patients of Age 70 or Older</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="07-28-2004 12:17:24">
                    <nciDocumentNumber>6948</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>05-033</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Clinical and Correlative Study of BAY 43-9006 (Sorafenib) IND 69,896 in Sarcoma</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="08-13-2004 15:05:03">
                    <nciDocumentNumber>E1304</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>E1304</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Two Arm Trial of the Proteasome Inhibitor, PS-341 (Velcade) in Combination with Irinotecan or PS-341 Alone Followed by the Addition of Irinotecan at Time of Progression in Patients with Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-22-2004 15:08:56">
                    <nciDocumentNumber>S0427</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0427</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Trial of Standard Fractionation Radiation and Concurrent Single Agent Cisplatin, with and without Docetaxel, Cisplatin, and 5-Fluorouracil Induction Chemotherapy, in Patients with Advanced Oropharyngeal Squamous Cell Cancer</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-30-2004 12:37:34">
                    <nciDocumentNumber>6745</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>J-0509</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Dose Escalation Trial of the Raf Kinase Inhibitor BAY 43-9006 (NSC # 724772) as Single Agent for Adults with Relapsed and Refractory Acute Leukemias and Chronic Myeloid Leukemia in Blast Crises</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-08-2004 08:41:08">
                    <nciDocumentNumber>7097</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHII-64</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Study of AZD2171 in Patients with Recurrent Small Cell Lung Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-13-2004 13:41:24">
                    <nciDocumentNumber>RTOG-0421</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-0421</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Trial for Locally Recurrent, Previously Irradiated Head and Neck Cancer: Concurrent Re-Irradiation and Chemotherapy versus Chemotherapy Alone</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-13-2004 15:18:22">
                    <nciDocumentNumber>7102</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>05-170</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of AZD2171 in Patients with Recurrent Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-15-2004 13:43:09">
                    <nciDocumentNumber>S0505</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0505</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of BAY 43-9006 (NSC #724772) in Advanced Soft Tissue Sarcomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-21-2004 15:32:04">
                    <nciDocumentNumber>7128</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-039</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of AZD2171 in Progressive Unresectable, Recurrent or Metastatic Renal Cell Carcinoma (RCC)</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-04-2005 14:22:54">
                    <nciDocumentNumber>7211</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MC048C</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Bevacizumab to Prevent or Delay Disease Progression in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-19-2005 14:21:56">
                    <nciDocumentNumber>7207</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>05-C-0167</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Trial of a PSA Based Vaccine and an Anti-CTLA-4 Antibody in Adults with Metastatic Androgen Independent Prostate Cancer</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-01-2005 19:11:03">
                    <nciDocumentNumber>7058</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GCC0508</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of BAY 43-9006 (IND 69896) in Chemosensitive Relapsed Aggressive Non-Hodgkin's Lymphomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-14-2005 08:02:24">
                    <nciDocumentNumber>RTOG-0524</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG 0524</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/II Trial of a Combination of Paclitaxel and Trastuzumab with Daily Irradiation or Paclitaxel Alone with Daily Irradiation Following Transurethral Surgery for Non-Cystectomy Candidates with Muscle-Invasive Bladder Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-19-2005 15:35:03">
                    <nciDocumentNumber>7265</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHII-68</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of PXD101 in Patients with Relapsed or Refractory Acute Myelogenous Leukemia or Patients Over 60 with Newly-Diagnosed Acute Myelogenous Leukemia</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="04-20-2005 10:44:30">
                    <nciDocumentNumber>ADVL0516</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ADVL0516</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of BMS-354825 (Dasatinib) in Children with Recurrent/Refractory Solid Tumors or Imatinib Resistant Ph+Leukemia (BMS Trial CA 180038)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="05-04-2005 12:39:46">
                    <nciDocumentNumber>PBTC-011C</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PBTC-011C</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II Trial of Intracerebral IL13-PE38QQR Infusion in Pediatric Patients with Recurrent Malignant Glioma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="05-11-2005 12:54:29">
                    <nciDocumentNumber>7296</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber xsi:nil="true" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"/>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of Sorafenib (BAY 43-9006) in Metastatic Renal Cell Cancer to the Brain</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="05-12-2005 08:20:36">
                    <nciDocumentNumber>NABTT-0502</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTT-0502</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Erlotinib (OSI-774) and Sorafenib (BAY 43-9006) for Patients with Progression or Recurrent Glioblastoma Multiforme</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="05-27-2005 12:34:00">
                    <nciDocumentNumber>7077</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHII-70</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Phase II Trial of Sequential Versus Concurrent Docetaxel and PS-341 (NSC 681239, IND 58,443) in Previously Treated Non-Small Cell Lung Cancer (NSCLC)</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="06-07-2005 11:19:11">
                    <nciDocumentNumber>RTOG-0525</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-0525</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-Intensive Temozolomide in Patients with Newly Diagnosed Glioblastoma</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-12-2012 10:41:39" createdDate="06-14-2005 10:39:32">
                    <nciDocumentNumber>7347</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>055513</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I/II Trial of Epothilone Analog BMS-247550 (Ixabepilone), Mitoxantrone, and Prednisone in Hormone Refractory Prostate Cancer Patients Previously Treated with Chemotherapy</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="07-18-2005 11:20:38">
                    <nciDocumentNumber>PBTC-020</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PBTC-020</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Clinical Trial of AZD2171 in Children with Recurrent or Progressive Central Nervous System (CNS) Tumors</documentTitle>
                    <currentStatus>Temporarily Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="08-03-2005 11:16:32">
                    <nciDocumentNumber>S0506</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0506</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Trial of PS-341 (Bortezomib, (NSC-681239) Followed by the Addition of Gemcitabine at Progression in Recurrent or Metastatic Nasopharyngeal Carcinoma</documentTitle>
                    <currentStatus>Administratively Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="08-22-2005 14:05:42">
                    <nciDocumentNumber>N027D</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>N027D</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of CCI-779 and Temozolomide in Combination with Radiation Therapy in Glioblastoma Multiforme</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="09-23-2005 08:11:53">
                    <nciDocumentNumber>7540</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHI-54</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients with Malignant Solid Tumors</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="10-26-2005 13:37:55">
                    <nciDocumentNumber>7440</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>05-087</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Cetuximab and Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="11-09-2005 15:17:49">
                    <nciDocumentNumber>7431</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>06-027</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Multi-Center Phase 2 Study of the Halichondrin B Analog E7389 in Recurrent Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="11-22-2005 14:59:47">
                    <nciDocumentNumber>RTOG-0415</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>RTOG-0415</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Randomized Study of Hypofractionated 3D-CRT/IMRT Versus Conventionally Fractionated 3D-CRT/IMRT in Patients with Favorable-Risk Prostate Cancer</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="12-02-2005 13:58:43">
                    <nciDocumentNumber>S0500</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0500</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell Levels at First Follow-Up Assessment</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="12-30-2005 10:19:27">
                    <nciDocumentNumber>7673</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>14577A</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of SB-715992 (NSC-727990, IND-70273) in Advanced Renal Cell Cancer</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-19-2006 08:45:57">
                    <nciDocumentNumber>7200</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>05-25</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II, Pharmacokinetic (PK), Pharmacodynamic (PD) and Biological Correlative Study of the Efficacy and Safety of Dual Antiangiogenic Inhibition Using  Bevacizumab and Sorafenib in Patients with Advanced Malignant Melanoma</documentTitle>
                    <currentStatus>Closed to Accrual &amp; Treatment</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="01-24-2006 08:45:33">
                    <nciDocumentNumber>7502</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-051</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Study of VEGF-Trap in Recurrent or Metastatic Gynecologic Soft-Tissue Sarcomas</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-12-2012 10:41:39" createdDate="02-22-2006 09:50:37">
                    <nciDocumentNumber>7650</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>MDACC 2006-0077</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="03-14-2006 09:42:49">
                    <nciDocumentNumber>7640</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHL-058</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 2 Study of GW786034 (Pazopanib) with or without Bicalutamide in Hormone Refractory Prostate Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:36" createdDate="03-24-2006 14:12:26">
                    <nciDocumentNumber>NABTC-06-01</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NABTC06-01</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase II Single Arm Trial of VEGF Trap in Patients with Recurrent Temozolomide-Resistant Malignant Gliomas</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:37" createdDate="04-28-2006 08:19:59">
                    <nciDocumentNumber>NCIC-179</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>IND.179</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of CCI-779 (NSC 683864, IND #61010) in Combination with Carboplatin and Paclitaxel in Patients with Advanced Solid Tumours</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-12-2012 10:36:33" createdDate="05-23-2006 13:43:21">
                    <nciDocumentNumber>ADVL0612</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ADVL0612</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Sunitinib (SU11248), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Children with Refractory Solid Tumors</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="07-20-2006 09:13:03">
                    <nciDocumentNumber>CALGB-10501</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-10501/CTSU C10501</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Intergroup CLL Study of Asymptomatic Patients with Untreated Chronic Lymphocytic Leukemia Randomized to Early Intervention Versus Observation with Later Treatment in the High Risk Genetic Subset with IGVH Unmutated Disease</documentTitle>
                    <currentStatus>Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="07-20-2006 11:08:30">
                    <nciDocumentNumber>7792</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHII-83</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Trial of Dasatinib (BMS-354825) in Advanced Hepatocellular Carcinoma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="02-09-2007 09:03:47">
                    <nciDocumentNumber>8030</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHS 398/2590</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase Ib/II Study of AZD2171 in Combination with Daily Temozolomide and Radiation in Patients with Newly Diagnosed Glioblastoma Not Taking Enzyme-Inducing Anti-Epileptic Drugs</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="04-05-2007 13:12:29">
                    <nciDocumentNumber>AAML07P1</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>AAML07P1</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase II Pilot Study of Bortezomib (PS-341, Velcade, IND #58,443) Combined with Reinduction Chemotherapy in Children and Young Adults with Recurrent, Refractory or Secondary Acute Myeloid Leukemia</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="06-12-2007 16:33:09">
                    <nciDocumentNumber>8077</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>J07109</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase II Trial of Tipifarnib (R115777, Zarnestra, NSC #702818, IND #58,359) in Combination with Oral Etoposide (VP-16) in Elderly Adults with Newly Diagnosed, Previously Untreated Acute Myelogenous Leukemia (AML)</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="07-10-2007 14:49:08">
                    <nciDocumentNumber>8063</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHI-60</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 1 and Pharmacokinetic Single Agent Study of Pazopanib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-12-2012 10:36:33" createdDate="09-25-2007 11:21:21">
                    <nciDocumentNumber>8178</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>08-C-0087</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Phase I Study of Vandetanib (ZD 6474) and Bevacizumab Combination Therapy Evaluating the VEGF and EGF Signal Transduction Pathways in Adults with Solid Tumors and Lymphomas</documentTitle>
                    <currentStatus>Complete</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="09-25-2007 14:37:51">
                    <nciDocumentNumber>8079</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UCIRB 16051B</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial of Concurrent Chemoradiation/Chemoreirradiation with Cetuximab (ERBITUX), Sunitinib, and Accelerated Radiation in Patients with Locally Advanced/High-Risk/Recurrent Poor Prognosis Head and Neck Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="10-02-2007 13:06:42">
                    <nciDocumentNumber>S0727</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>S0727</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I and Randomized Phase II Trial of Gemcitabine + Erlotinib (NSC-718781) + IMC-A12 (NSC-742460) vs. Gemcitabine + Erlotinib as First-Line Treatment in Patients with Metastatic Pancreatic Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="10-03-2007 09:01:52">
                    <nciDocumentNumber>8148</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>COMIRB 08-0044</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I/Randomized Phase II Study of the Anti-IGF-1R Monoclonal Antibody IMC-A12 in Combination with Erlotinib Compared with Erlotinib Alone in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="03-03-2008 15:27:35">
                    <nciDocumentNumber>CALGB-40603</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-40603</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="07-22-2008 08:29:11">
                    <nciDocumentNumber>CALGB-30506</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CALGB-30506</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III Trial of Adjuvant Chemotherapy in Patients with Early Stage Non-Small Cell Lung Cancer Associated with Banking of Frozen Tumor Specimens and Collection of Gene Expression Profile Data</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="08-18-2008 16:03:47">
                    <nciDocumentNumber>8213</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>09-089</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 1 Study of AZD2171 and WBRT in Patients with Brain Metastases</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="11-12-2008 14:11:40">
                    <nciDocumentNumber>8238</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>09-C-0173</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of Belinostat in Combination with Cisplatin and Etoposide in Adults with Small Cell Lung Carcinoma and Other Advanced Cancers</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="11-18-2008 15:51:57">
                    <nciDocumentNumber>8155</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>PHI-64</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Trial of Escalating Doses of the Anti-IGF-1R Monoclonal Antibody IMC-A12 and Standard Dose Sorafenib for Treatment of Advanced Hepatocellular Carcinoma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="02-27-2009 10:04:52">
                    <nciDocumentNumber>GOG-0258</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>GOG-0258</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="04-16-2009 13:07:45">
                    <nciDocumentNumber>8347</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>09-C-0212</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Multicenter Phase II Study of IMC-A12 in Patients with Thymoma and Thymic Carcinoma Who Have Been Previously Treated with Chemotherapy</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="05-04-2009 13:26:29">
                    <nciDocumentNumber>8443</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>10-053</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>Randomized Phase II Trial of Temozolomide Versus Hyd-sulfate AZD6244 [NSC 748727] in Patients with Metastatic Uveal Melanoma</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="09-01-2009 14:14:06">
                    <nciDocumentNumber>HLMCC-0803</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>HLMCC 0803</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Randomized, Phase II Placebo-controlled Study of the Use of Extended-Release Methylphenidate or Modafinil for the Treatment of Excessive Daytime Sleepiness in Children following Cancer Therapy</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="09-23-2009 13:28:12">
                    <nciDocumentNumber>8554</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>UPCI 09-080</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase Ib Neoadjuvant Study of the Gamma Secretase Inhibitor (RO4929097) in Combination with the Aromatase Inhibitor Letrozole in Post-Menopausal Women with Stage II/III Hormone Receptor-Positive Breast Cancer</documentTitle>
                    <currentStatus>Approved</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="10-21-2009 11:05:11">
                    <nciDocumentNumber>NSABP-C-11</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>NSABP-C-11</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase III Study Evaluating the Role of Perioperative Chemotherapy and Bevacizumab in Patients with Potentially Resectable Hepatic Colorectal Metastases</documentTitle>
                    <currentStatus>Temporarily Closed to Accrual</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="01-15-2010 15:58:10">
                    <nciDocumentNumber>8627</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>CO10901</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase 1 Study of AZD6244 in Combination with Cetuximab in Refractory Solid Tumors</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
                <document updatedDate="04-10-2012 14:17:38" createdDate="01-25-2010 10:49:15">
                    <nciDocumentNumber>ADVL1011</nciDocumentNumber>
                    <localDocumentNumberList>
                        <localDocumentNumber>ADVL1011</localDocumentNumber>
                    </localDocumentNumberList>
                    <documentTitle>A Phase I Study of JAK Inhibition (INCB018424) in Children with Relapsed or Refractory Solid Tumors, Leukemias, and Myeloproliferative Neoplasms</documentTitle>
                    <currentStatus>Active</currentStatus>
                </document>
            </Documents>
        </ns2:searchStudyResponse>
    </S:Body>
</S:Envelope>